id	sid	tid	token	lemma	pos
cord-021637-f5wwn45z	1	1	key	key	JJ
cord-021637-f5wwn45z	1	2	:	:	:
cord-021637-f5wwn45z	1	3	cord-021637-f5wwn45z	cord-021637-f5wwn45z	NNP
cord-021637-f5wwn45z	1	4	authors	author	NNS
cord-021637-f5wwn45z	1	5	:	:	:
cord-021637-f5wwn45z	1	6	Douglas	Douglas	NNP
cord-021637-f5wwn45z	1	7	,	,	,
cord-021637-f5wwn45z	1	8	R.	R.	NNP
cord-021637-f5wwn45z	1	9	Gordon	Gordon	NNP
cord-021637-f5wwn45z	1	10	;	;	:
cord-021637-f5wwn45z	1	11	Samant	Samant	NNP
cord-021637-f5wwn45z	1	12	,	,	,
cord-021637-f5wwn45z	1	13	Vijay	Vijay	NNP
cord-021637-f5wwn45z	1	14	B.	B.	NNP
cord-021637-f5wwn45z	1	15	title	title	NN
cord-021637-f5wwn45z	1	16	:	:	:
cord-021637-f5wwn45z	1	17	The	the	DT
cord-021637-f5wwn45z	1	18	Vaccine	Vaccine	NNP
cord-021637-f5wwn45z	1	19	Industry	Industry	NNP
cord-021637-f5wwn45z	1	20	date	date	NN
cord-021637-f5wwn45z	1	21	:	:	:
cord-021637-f5wwn45z	1	22	2017	2017	CD
cord-021637-f5wwn45z	1	23	-	-	HYPH
cord-021637-f5wwn45z	1	24	07	07	CD
cord-021637-f5wwn45z	1	25	-	-	SYM
cord-021637-f5wwn45z	1	26	17	17	CD
cord-021637-f5wwn45z	1	27	journal	journal	NN
cord-021637-f5wwn45z	1	28	:	:	:
cord-021637-f5wwn45z	2	1	Plotkin	Plotkin	NNP
cord-021637-f5wwn45z	2	2	's	's	POS
cord-021637-f5wwn45z	2	3	Vaccines	vaccine	NNS
cord-021637-f5wwn45z	2	4	DOI	DOI	NNP
cord-021637-f5wwn45z	2	5	:	:	:
cord-021637-f5wwn45z	3	1	10.1016	10.1016	CD
cord-021637-f5wwn45z	3	2	/	/	SYM
cord-021637-f5wwn45z	3	3	b978	b978	NNP
cord-021637-f5wwn45z	3	4	-	-	HYPH
cord-021637-f5wwn45z	3	5	0	0	CD
cord-021637-f5wwn45z	3	6	-	-	HYPH
cord-021637-f5wwn45z	3	7	323	323	CD
cord-021637-f5wwn45z	3	8	-	-	HYPH
cord-021637-f5wwn45z	3	9	35761	35761	CD
cord-021637-f5wwn45z	3	10	-	-	HYPH
cord-021637-f5wwn45z	3	11	6.00004	6.00004	CD
cord-021637-f5wwn45z	3	12	-	-	SYM
cord-021637-f5wwn45z	3	13	3	3	CD
cord-021637-f5wwn45z	3	14	sha	sha	NNP
cord-021637-f5wwn45z	3	15	:	:	:
cord-021637-f5wwn45z	4	1	325bd2461ab3081557f64a7767a1e8d1d9da1759	325bd2461ab3081557f64a7767a1e8d1d9da1759	NFP
cord-021637-f5wwn45z	4	2	doc_id	doc_id	CD
cord-021637-f5wwn45z	4	3	:	:	:
cord-021637-f5wwn45z	5	1	21637	21637	CD
cord-021637-f5wwn45z	5	2	cord_uid	cord_uid	NNS
cord-021637-f5wwn45z	5	3	:	:	:
cord-021637-f5wwn45z	6	1	f5wwn45z	f5wwn45z	NNP
cord-021637-f5wwn45z	6	2	nan	nan	NNP
cord-021637-f5wwn45z	7	1	The	the	DT
cord-021637-f5wwn45z	7	2	vaccine	vaccine	NN
cord-021637-f5wwn45z	7	3	industry	industry	NN
cord-021637-f5wwn45z	7	4	is	be	VBZ
cord-021637-f5wwn45z	7	5	composed	compose	VBN
cord-021637-f5wwn45z	7	6	of	of	IN
cord-021637-f5wwn45z	7	7	companies	company	NNS
cord-021637-f5wwn45z	7	8	that	that	WDT
cord-021637-f5wwn45z	7	9	are	be	VBP
cord-021637-f5wwn45z	7	10	engaged	engage	VBN
cord-021637-f5wwn45z	7	11	in	in	IN
cord-021637-f5wwn45z	7	12	any	any	DT
cord-021637-f5wwn45z	7	13	of	of	IN
cord-021637-f5wwn45z	7	14	the	the	DT
cord-021637-f5wwn45z	7	15	following	follow	VBG
cord-021637-f5wwn45z	7	16	activities	activity	NNS
cord-021637-f5wwn45z	7	17	:	:	:
cord-021637-f5wwn45z	7	18	research	research	NN
cord-021637-f5wwn45z	7	19	(	(	-LRB-
cord-021637-f5wwn45z	7	20	including	include	VBG
cord-021637-f5wwn45z	7	21	that	that	WDT
cord-021637-f5wwn45z	7	22	performed	perform	VBN
cord-021637-f5wwn45z	7	23	in	in	IN
cord-021637-f5wwn45z	7	24	industry	industry	NN
cord-021637-f5wwn45z	7	25	and	and	CC
cord-021637-f5wwn45z	7	26	biotech	biotech	NN
cord-021637-f5wwn45z	7	27	)	)	-RRB-
cord-021637-f5wwn45z	7	28	,	,	,
cord-021637-f5wwn45z	7	29	development	development	NN
cord-021637-f5wwn45z	7	30	,	,	,
cord-021637-f5wwn45z	7	31	manufacture	manufacture	NN
cord-021637-f5wwn45z	7	32	,	,	,
cord-021637-f5wwn45z	7	33	or	or	CC
cord-021637-f5wwn45z	7	34	sales	sale	NNS
cord-021637-f5wwn45z	7	35	,	,	,
cord-021637-f5wwn45z	7	36	marketing	marketing	NN
cord-021637-f5wwn45z	7	37	,	,	,
cord-021637-f5wwn45z	7	38	and	and	CC
cord-021637-f5wwn45z	7	39	distribution	distribution	NN
cord-021637-f5wwn45z	7	40	of	of	IN
cord-021637-f5wwn45z	7	41	vaccines	vaccine	NNS
cord-021637-f5wwn45z	7	42	.	.	.
cord-021637-f5wwn45z	8	1	They	-PRON-	PRP
cord-021637-f5wwn45z	8	2	receive	receive	VBP
cord-021637-f5wwn45z	8	3	their	-PRON-	PRP$
cord-021637-f5wwn45z	8	4	revenue	revenue	NN
cord-021637-f5wwn45z	8	5	chiefly	chiefly	RB
cord-021637-f5wwn45z	8	6	from	from	IN
cord-021637-f5wwn45z	8	7	sales	sale	NNS
cord-021637-f5wwn45z	8	8	of	of	IN
cord-021637-f5wwn45z	8	9	vaccine	vaccine	NN
cord-021637-f5wwn45z	8	10	products	product	NNS
cord-021637-f5wwn45z	8	11	or	or	CC
cord-021637-f5wwn45z	8	12	expectations	expectation	NNS
cord-021637-f5wwn45z	8	13	thereof	thereof	RB
cord-021637-f5wwn45z	8	14	.	.	.
cord-021637-f5wwn45z	9	1	The	the	DT
cord-021637-f5wwn45z	9	2	vaccine	vaccine	NN
cord-021637-f5wwn45z	9	3	industry	industry	NN
cord-021637-f5wwn45z	9	4	is	be	VBZ
cord-021637-f5wwn45z	9	5	relatively	relatively	RB
cord-021637-f5wwn45z	9	6	small	small	JJ
cord-021637-f5wwn45z	9	7	,	,	,
cord-021637-f5wwn45z	9	8	compared	compare	VBN
cord-021637-f5wwn45z	9	9	to	to	IN
cord-021637-f5wwn45z	9	10	the	the	DT
cord-021637-f5wwn45z	9	11	pharmaceutical	pharmaceutical	JJ
cord-021637-f5wwn45z	9	12	industry	industry	NN
cord-021637-f5wwn45z	9	13	,	,	,
cord-021637-f5wwn45z	9	14	but	but	CC
cord-021637-f5wwn45z	9	15	growing	grow	VBG
cord-021637-f5wwn45z	9	16	.	.	.
cord-021637-f5wwn45z	10	1	We	-PRON-	PRP
cord-021637-f5wwn45z	10	2	estimate	estimate	VBP
cord-021637-f5wwn45z	10	3	that	that	IN
cord-021637-f5wwn45z	10	4	total	total	JJ
cord-021637-f5wwn45z	10	5	infectious	infectious	JJ
cord-021637-f5wwn45z	10	6	disease	disease	NN
cord-021637-f5wwn45z	10	7	vaccine	vaccine	NN
cord-021637-f5wwn45z	10	8	sales	sale	NNS
cord-021637-f5wwn45z	10	9	in	in	IN
cord-021637-f5wwn45z	10	10	2013	2013	CD
cord-021637-f5wwn45z	10	11	were	be	VBD
cord-021637-f5wwn45z	10	12	more	more	JJR
cord-021637-f5wwn45z	10	13	than	than	IN
cord-021637-f5wwn45z	10	14	$	$	$
cord-021637-f5wwn45z	10	15	25	25	CD
cord-021637-f5wwn45z	10	16	billion	billion	CD
cord-021637-f5wwn45z	10	17	worldwide	worldwide	RB
cord-021637-f5wwn45z	10	18	and	and	CC
cord-021637-f5wwn45z	10	19	expected	expect	VBN
cord-021637-f5wwn45z	10	20	to	to	TO
cord-021637-f5wwn45z	10	21	grow	grow	VB
cord-021637-f5wwn45z	10	22	to	to	IN
cord-021637-f5wwn45z	10	23	about	about	RB
cord-021637-f5wwn45z	10	24	$	$	$
cord-021637-f5wwn45z	10	25	35	35	CD
cord-021637-f5wwn45z	10	26	billion	billion	CD
cord-021637-f5wwn45z	10	27	by	by	IN
cord-021637-f5wwn45z	10	28	2020	2020	CD
cord-021637-f5wwn45z	10	29	.	.	.
cord-021637-f5wwn45z	11	1	Although	although	IN
cord-021637-f5wwn45z	11	2	components	component	NNS
cord-021637-f5wwn45z	11	3	of	of	IN
cord-021637-f5wwn45z	11	4	the	the	DT
cord-021637-f5wwn45z	11	5	vaccine	vaccine	NN
cord-021637-f5wwn45z	11	6	industry	industry	NN
cord-021637-f5wwn45z	11	7	are	be	VBP
cord-021637-f5wwn45z	11	8	found	find	VBN
cord-021637-f5wwn45z	11	9	in	in	IN
cord-021637-f5wwn45z	11	10	50	50	CD
cord-021637-f5wwn45z	11	11	countries	country	NNS
cord-021637-f5wwn45z	11	12	worldwide	worldwide	RB
cord-021637-f5wwn45z	11	13	,	,	,
cord-021637-f5wwn45z	11	14	the	the	DT
cord-021637-f5wwn45z	11	15	large	large	JJ
cord-021637-f5wwn45z	11	16	vaccine	vaccine	NN
cord-021637-f5wwn45z	11	17	companies	company	NNS
cord-021637-f5wwn45z	11	18	are	be	VBP
cord-021637-f5wwn45z	11	19	primarily	primarily	RB
cord-021637-f5wwn45z	11	20	U.S.-or	u.s.-or	JJ
cord-021637-f5wwn45z	11	21	European	European	NNP
cord-021637-f5wwn45z	11	22	-	-	HYPH
cord-021637-f5wwn45z	11	23	based	base	VBN
cord-021637-f5wwn45z	11	24	and	and	CC
cord-021637-f5wwn45z	11	25	have	have	VB
cord-021637-f5wwn45z	11	26	the	the	DT
cord-021637-f5wwn45z	11	27	dominant	dominant	JJ
cord-021637-f5wwn45z	11	28	share	share	NN
cord-021637-f5wwn45z	11	29	of	of	IN
cord-021637-f5wwn45z	11	30	vaccine	vaccine	NN
cord-021637-f5wwn45z	11	31	business	business	NN
cord-021637-f5wwn45z	11	32	on	on	IN
cord-021637-f5wwn45z	11	33	a	a	DT
cord-021637-f5wwn45z	11	34	revenue	revenue	NN
cord-021637-f5wwn45z	11	35	basis	basis	NN
cord-021637-f5wwn45z	11	36	;	;	:
cord-021637-f5wwn45z	11	37	but	but	CC
cord-021637-f5wwn45z	11	38	regional	regional	JJ
cord-021637-f5wwn45z	11	39	companies	company	NNS
cord-021637-f5wwn45z	11	40	are	be	VBP
cord-021637-f5wwn45z	11	41	gradually	gradually	RB
cord-021637-f5wwn45z	11	42	growing	grow	VBG
cord-021637-f5wwn45z	11	43	their	-PRON-	PRP$
cord-021637-f5wwn45z	11	44	market	market	NN
cord-021637-f5wwn45z	11	45	share	share	NN
cord-021637-f5wwn45z	11	46	on	on	IN
cord-021637-f5wwn45z	11	47	a	a	DT
cord-021637-f5wwn45z	11	48	dose	dose	JJ
cord-021637-f5wwn45z	11	49	basis	basis	NN
cord-021637-f5wwn45z	11	50	(	(	-LRB-
cord-021637-f5wwn45z	11	51	Table	table	NN
cord-021637-f5wwn45z	11	52	4	4	CD
cord-021637-f5wwn45z	11	53	.1	.1	CD
cord-021637-f5wwn45z	11	54	)	)	-RRB-
cord-021637-f5wwn45z	11	55	.	.	.
cord-021637-f5wwn45z	12	1	1	1	LS
cord-021637-f5wwn45z	13	1	In	in	IN
cord-021637-f5wwn45z	13	2	the	the	DT
cord-021637-f5wwn45z	13	3	past	past	JJ
cord-021637-f5wwn45z	13	4	20	20	CD
cord-021637-f5wwn45z	13	5	years	year	NNS
cord-021637-f5wwn45z	13	6	,	,	,
cord-021637-f5wwn45z	13	7	the	the	DT
cord-021637-f5wwn45z	13	8	vaccine	vaccine	NN
cord-021637-f5wwn45z	13	9	business	business	NN
cord-021637-f5wwn45z	13	10	,	,	,
cord-021637-f5wwn45z	13	11	a	a	DT
cord-021637-f5wwn45z	13	12	former	former	JJ
cord-021637-f5wwn45z	13	13	laggard	laggard	NN
cord-021637-f5wwn45z	13	14	in	in	IN
cord-021637-f5wwn45z	13	15	the	the	DT
cord-021637-f5wwn45z	13	16	pharmaceutical	pharmaceutical	JJ
cord-021637-f5wwn45z	13	17	business	business	NN
cord-021637-f5wwn45z	13	18	,	,	,
cord-021637-f5wwn45z	13	19	has	have	VBZ
cord-021637-f5wwn45z	13	20	shown	show	VBN
cord-021637-f5wwn45z	13	21	remarkable	remarkable	JJ
cord-021637-f5wwn45z	13	22	growth	growth	NN
cord-021637-f5wwn45z	13	23	powered	power	VBN
cord-021637-f5wwn45z	13	24	by	by	IN
cord-021637-f5wwn45z	13	25	new	new	JJ
cord-021637-f5wwn45z	13	26	innovative	innovative	JJ
cord-021637-f5wwn45z	13	27	vaccines	vaccine	NNS
cord-021637-f5wwn45z	13	28	coupled	couple	VBN
cord-021637-f5wwn45z	13	29	with	with	IN
cord-021637-f5wwn45z	13	30	superior	superior	JJ
cord-021637-f5wwn45z	13	31	pricing	pricing	NN
cord-021637-f5wwn45z	13	32	strategies	strategy	NNS
cord-021637-f5wwn45z	13	33	(	(	-LRB-
cord-021637-f5wwn45z	13	34	Fig	Fig	NNP
cord-021637-f5wwn45z	13	35	.	.	NNP
cord-021637-f5wwn45z	13	36	4	4	CD
cord-021637-f5wwn45z	13	37	.1	.1	CD
cord-021637-f5wwn45z	13	38	)	)	-RRB-
cord-021637-f5wwn45z	13	39	.	.	.
cord-021637-f5wwn45z	14	1	2	2	LS
cord-021637-f5wwn45z	14	2	Specifically	specifically	RB
cord-021637-f5wwn45z	14	3	contributing	contribute	VBG
cord-021637-f5wwn45z	14	4	to	to	IN
cord-021637-f5wwn45z	14	5	this	this	DT
cord-021637-f5wwn45z	14	6	spectacular	spectacular	JJ
cord-021637-f5wwn45z	14	7	growth	growth	NN
cord-021637-f5wwn45z	14	8	were	be	VBD
cord-021637-f5wwn45z	14	9	the	the	DT
cord-021637-f5wwn45z	14	10	varicella	varicella	NN
cord-021637-f5wwn45z	14	11	,	,	,
cord-021637-f5wwn45z	14	12	hepatitis	hepatitis	NNP
cord-021637-f5wwn45z	14	13	A	A	NNP
cord-021637-f5wwn45z	14	14	,	,	,
cord-021637-f5wwn45z	14	15	pneumococcal	pneumococcal	JJ
cord-021637-f5wwn45z	14	16	conjugate	conjugate	NN
cord-021637-f5wwn45z	14	17	,	,	,
cord-021637-f5wwn45z	14	18	shingles	shingle	NNS
cord-021637-f5wwn45z	14	19	,	,	,
cord-021637-f5wwn45z	14	20	rotavirus	rotavirus	NN
cord-021637-f5wwn45z	14	21	,	,	,
cord-021637-f5wwn45z	14	22	meningococcal	meningococcal	JJ
cord-021637-f5wwn45z	14	23	conjugate	conjugate	NN
cord-021637-f5wwn45z	14	24	for	for	IN
cord-021637-f5wwn45z	14	25	A	A	NNP
cord-021637-f5wwn45z	14	26	,	,	,
cord-021637-f5wwn45z	14	27	C	C	NNP
cord-021637-f5wwn45z	14	28	,	,	,
cord-021637-f5wwn45z	14	29	Y	Y	NNP
cord-021637-f5wwn45z	14	30	,	,	,
cord-021637-f5wwn45z	14	31	W	W	NNP
cord-021637-f5wwn45z	14	32	,	,	,
cord-021637-f5wwn45z	14	33	and	and	CC
cord-021637-f5wwn45z	14	34	human	human	JJ
cord-021637-f5wwn45z	14	35	papillomavirus	papillomavirus	NN
cord-021637-f5wwn45z	14	36	(	(	-LRB-
cord-021637-f5wwn45z	14	37	HPV	hpv	NN
cord-021637-f5wwn45z	14	38	)	)	-RRB-
cord-021637-f5wwn45z	14	39	vaccines	vaccine	NNS
cord-021637-f5wwn45z	14	40	,	,	,
cord-021637-f5wwn45z	14	41	as	as	RB
cord-021637-f5wwn45z	14	42	well	well	RB
cord-021637-f5wwn45z	14	43	as	as	IN
cord-021637-f5wwn45z	14	44	myriad	myriad	JJ
cord-021637-f5wwn45z	14	45	combination	combination	NN
cord-021637-f5wwn45z	14	46	vaccines	vaccine	NNS
cord-021637-f5wwn45z	14	47	.	.	.
cord-021637-f5wwn45z	15	1	This	this	DT
cord-021637-f5wwn45z	15	2	projected	project	VBN
cord-021637-f5wwn45z	15	3	growth	growth	NN
cord-021637-f5wwn45z	15	4	may	may	MD
cord-021637-f5wwn45z	15	5	plateau	plateau	VB
cord-021637-f5wwn45z	15	6	in	in	IN
cord-021637-f5wwn45z	15	7	the	the	DT
cord-021637-f5wwn45z	15	8	early	early	JJ
cord-021637-f5wwn45z	15	9	2020s	2020s	CD
cord-021637-f5wwn45z	15	10	unless	unless	IN
cord-021637-f5wwn45z	15	11	the	the	DT
cord-021637-f5wwn45z	15	12	vaccine	vaccine	NN
cord-021637-f5wwn45z	15	13	industry	industry	NN
cord-021637-f5wwn45z	15	14	continues	continue	VBZ
cord-021637-f5wwn45z	15	15	to	to	TO
cord-021637-f5wwn45z	15	16	introduce	introduce	VB
cord-021637-f5wwn45z	15	17	new	new	JJ
cord-021637-f5wwn45z	15	18	innovative	innovative	JJ
cord-021637-f5wwn45z	15	19	products	product	NNS
cord-021637-f5wwn45z	15	20	targeting	target	VBG
cord-021637-f5wwn45z	15	21	diseases	disease	NNS
cord-021637-f5wwn45z	15	22	that	that	WDT
cord-021637-f5wwn45z	15	23	impact	impact	VBP
cord-021637-f5wwn45z	15	24	the	the	DT
cord-021637-f5wwn45z	15	25	Western	western	JJ
cord-021637-f5wwn45z	15	26	world	world	NN
cord-021637-f5wwn45z	15	27	.	.	.
cord-021637-f5wwn45z	16	1	Sustaining	sustain	VBG
cord-021637-f5wwn45z	16	2	this	this	DT
cord-021637-f5wwn45z	16	3	growth	growth	NN
cord-021637-f5wwn45z	16	4	will	will	MD
cord-021637-f5wwn45z	16	5	be	be	VB
cord-021637-f5wwn45z	16	6	a	a	DT
cord-021637-f5wwn45z	16	7	challenge	challenge	NN
cord-021637-f5wwn45z	16	8	because	because	IN
cord-021637-f5wwn45z	16	9	of	of	IN
cord-021637-f5wwn45z	16	10	dwindling	dwindle	VBG
cord-021637-f5wwn45z	16	11	numbers	number	NNS
cord-021637-f5wwn45z	16	12	of	of	IN
cord-021637-f5wwn45z	16	13	high	high	JJ
cord-021637-f5wwn45z	16	14	-	-	HYPH
cord-021637-f5wwn45z	16	15	value	value	NN
cord-021637-f5wwn45z	16	16	vaccine	vaccine	NN
cord-021637-f5wwn45z	16	17	targets	target	NNS
cord-021637-f5wwn45z	16	18	for	for	IN
cord-021637-f5wwn45z	16	19	which	which	WDT
cord-021637-f5wwn45z	16	20	the	the	DT
cord-021637-f5wwn45z	16	21	biology	biology	NN
cord-021637-f5wwn45z	16	22	of	of	IN
cord-021637-f5wwn45z	16	23	protection	protection	NN
cord-021637-f5wwn45z	16	24	is	be	VBZ
cord-021637-f5wwn45z	16	25	well	well	RB
cord-021637-f5wwn45z	16	26	understood	understand	VBN
cord-021637-f5wwn45z	16	27	(	(	-LRB-
cord-021637-f5wwn45z	16	28	see	see	VB
cord-021637-f5wwn45z	16	29	Table	table	NN
cord-021637-f5wwn45z	16	30	4	4	CD
cord-021637-f5wwn45z	16	31	.7	.7	NFP
cord-021637-f5wwn45z	16	32	)	)	-RRB-
cord-021637-f5wwn45z	16	33	.	.	.
cord-021637-f5wwn45z	17	1	The	the	DT
cord-021637-f5wwn45z	17	2	vaccine	vaccine	NN
cord-021637-f5wwn45z	17	3	business	business	NN
cord-021637-f5wwn45z	17	4	is	be	VBZ
cord-021637-f5wwn45z	17	5	a	a	DT
cord-021637-f5wwn45z	17	6	capital	capital	NN
cord-021637-f5wwn45z	17	7	-	-	HYPH
cord-021637-f5wwn45z	17	8	intensive	intensive	JJ
cord-021637-f5wwn45z	17	9	business	business	NN
cord-021637-f5wwn45z	17	10	that	that	WDT
cord-021637-f5wwn45z	17	11	requires	require	VBZ
cord-021637-f5wwn45z	17	12	considerable	considerable	JJ
cord-021637-f5wwn45z	17	13	ongoing	ongoing	JJ
cord-021637-f5wwn45z	17	14	investment	investment	NN
cord-021637-f5wwn45z	17	15	in	in	IN
cord-021637-f5wwn45z	17	16	manufacturing	manufacture	VBG
cord-021637-f5wwn45z	17	17	assets	asset	NNS
cord-021637-f5wwn45z	17	18	,	,	,
cord-021637-f5wwn45z	17	19	facilities	facility	NNS
cord-021637-f5wwn45z	17	20	,	,	,
cord-021637-f5wwn45z	17	21	and	and	CC
cord-021637-f5wwn45z	17	22	people	people	NNS
cord-021637-f5wwn45z	17	23	to	to	TO
cord-021637-f5wwn45z	17	24	maintain	maintain	VB
cord-021637-f5wwn45z	17	25	compliance	compliance	NN
cord-021637-f5wwn45z	17	26	with	with	IN
cord-021637-f5wwn45z	17	27	everincreasing	everincrease	VBG
cord-021637-f5wwn45z	17	28	regulatory	regulatory	JJ
cord-021637-f5wwn45z	17	29	directives	directive	NNS
cord-021637-f5wwn45z	17	30	.	.	.
cord-021637-f5wwn45z	18	1	The	the	DT
cord-021637-f5wwn45z	18	2	recent	recent	JJ
cord-021637-f5wwn45z	18	3	departure	departure	NN
cord-021637-f5wwn45z	18	4	of	of	IN
cord-021637-f5wwn45z	18	5	Baxter	Baxter	NNP
cord-021637-f5wwn45z	18	6	and	and	CC
cord-021637-f5wwn45z	18	7	Novartis	Novartis	NNP
cord-021637-f5wwn45z	18	8	from	from	IN
cord-021637-f5wwn45z	18	9	the	the	DT
cord-021637-f5wwn45z	18	10	vaccine	vaccine	NN
cord-021637-f5wwn45z	18	11	industry	industry	NN
cord-021637-f5wwn45z	18	12	is	be	VBZ
cord-021637-f5wwn45z	18	13	an	an	DT
cord-021637-f5wwn45z	18	14	ominous	ominous	JJ
cord-021637-f5wwn45z	18	15	sign	sign	NN
cord-021637-f5wwn45z	18	16	that	that	WDT
cord-021637-f5wwn45z	18	17	reflects	reflect	VBZ
cord-021637-f5wwn45z	18	18	the	the	DT
cord-021637-f5wwn45z	18	19	continued	continued	JJ
cord-021637-f5wwn45z	18	20	financial	financial	JJ
cord-021637-f5wwn45z	18	21	pressure	pressure	NN
cord-021637-f5wwn45z	18	22	on	on	IN
cord-021637-f5wwn45z	18	23	the	the	DT
cord-021637-f5wwn45z	18	24	remaining	remain	VBG
cord-021637-f5wwn45z	18	25	four	four	CD
cord-021637-f5wwn45z	18	26	major	major	JJ
cord-021637-f5wwn45z	18	27	vaccine	vaccine	NN
cord-021637-f5wwn45z	18	28	makers	maker	NNS
cord-021637-f5wwn45z	18	29	.	.	.
cord-021637-f5wwn45z	19	1	Further	further	JJ
cord-021637-f5wwn45z	19	2	consolidation	consolidation	NN
cord-021637-f5wwn45z	19	3	of	of	IN
cord-021637-f5wwn45z	19	4	this	this	DT
cord-021637-f5wwn45z	19	5	business	business	NN
cord-021637-f5wwn45z	19	6	is	be	VBZ
cord-021637-f5wwn45z	19	7	likely	likely	JJ
cord-021637-f5wwn45z	19	8	.	.	.
cord-021637-f5wwn45z	20	1	In	in	IN
cord-021637-f5wwn45z	20	2	addition	addition	NN
cord-021637-f5wwn45z	20	3	,	,	,
cord-021637-f5wwn45z	20	4	new	new	JJ
cord-021637-f5wwn45z	20	5	alliances	alliance	NNS
cord-021637-f5wwn45z	20	6	will	will	MD
cord-021637-f5wwn45z	20	7	be	be	VB
cord-021637-f5wwn45z	20	8	formed	form	VBN
cord-021637-f5wwn45z	20	9	between	between	IN
cord-021637-f5wwn45z	20	10	the	the	DT
cord-021637-f5wwn45z	20	11	big	big	JJ
cord-021637-f5wwn45z	20	12	four	four	CD
cord-021637-f5wwn45z	20	13	manufacturers	manufacturer	NNS
cord-021637-f5wwn45z	20	14	and	and	CC
cord-021637-f5wwn45z	20	15	emerging	emerge	VBG
cord-021637-f5wwn45z	20	16	companies	company	NNS
cord-021637-f5wwn45z	20	17	in	in	IN
cord-021637-f5wwn45z	20	18	India	India	NNP
cord-021637-f5wwn45z	20	19	,	,	,
cord-021637-f5wwn45z	20	20	China	China	NNP
cord-021637-f5wwn45z	20	21	,	,	,
cord-021637-f5wwn45z	20	22	and	and	CC
cord-021637-f5wwn45z	20	23	Brazil	Brazil	NNP
cord-021637-f5wwn45z	20	24	,	,	,
cord-021637-f5wwn45z	20	25	to	to	TO
cord-021637-f5wwn45z	20	26	take	take	VB
cord-021637-f5wwn45z	20	27	advantage	advantage	NN
cord-021637-f5wwn45z	20	28	of	of	IN
cord-021637-f5wwn45z	20	29	increasing	increase	VBG
cord-021637-f5wwn45z	20	30	immunization	immunization	NN
cord-021637-f5wwn45z	20	31	rates	rate	NNS
cord-021637-f5wwn45z	20	32	in	in	IN
cord-021637-f5wwn45z	20	33	those	those	DT
cord-021637-f5wwn45z	20	34	countries	country	NNS
cord-021637-f5wwn45z	20	35	as	as	RB
cord-021637-f5wwn45z	20	36	well	well	RB
cord-021637-f5wwn45z	20	37	as	as	IN
cord-021637-f5wwn45z	20	38	growth	growth	NN
cord-021637-f5wwn45z	20	39	of	of	IN
cord-021637-f5wwn45z	20	40	their	-PRON-	PRP$
cord-021637-f5wwn45z	20	41	private	private	JJ
cord-021637-f5wwn45z	20	42	markets	market	NNS
cord-021637-f5wwn45z	20	43	.	.	.
cord-021637-f5wwn45z	21	1	The	the	DT
cord-021637-f5wwn45z	21	2	United	United	NNP
cord-021637-f5wwn45z	21	3	States	States	NNP
cord-021637-f5wwn45z	21	4	has	have	VBZ
cord-021637-f5wwn45z	21	5	been	be	VBN
cord-021637-f5wwn45z	21	6	extraordinarily	extraordinarily	RB
cord-021637-f5wwn45z	21	7	successful	successful	JJ
cord-021637-f5wwn45z	21	8	in	in	IN
cord-021637-f5wwn45z	21	9	vaccine	vaccine	NN
cord-021637-f5wwn45z	21	10	research	research	NN
cord-021637-f5wwn45z	21	11	and	and	CC
cord-021637-f5wwn45z	21	12	development	development	NN
cord-021637-f5wwn45z	21	13	(	(	-LRB-
cord-021637-f5wwn45z	21	14	R&D	r&d	NN
cord-021637-f5wwn45z	21	15	)	)	-RRB-
cord-021637-f5wwn45z	21	16	.	.	.
cord-021637-f5wwn45z	22	1	3	3	CD
cord-021637-f5wwn45z	22	2	,	,	,
cord-021637-f5wwn45z	22	3	4	4	CD
cord-021637-f5wwn45z	23	1	In	in	IN
cord-021637-f5wwn45z	23	2	the	the	DT
cord-021637-f5wwn45z	23	3	past	past	JJ
cord-021637-f5wwn45z	23	4	20	20	CD
cord-021637-f5wwn45z	23	5	years	year	NNS
cord-021637-f5wwn45z	23	6	,	,	,
cord-021637-f5wwn45z	23	7	most	most	JJS
cord-021637-f5wwn45z	23	8	new	new	JJ
cord-021637-f5wwn45z	23	9	vaccines	vaccine	NNS
cord-021637-f5wwn45z	23	10	approved	approve	VBN
cord-021637-f5wwn45z	23	11	worldwide	worldwide	RB
cord-021637-f5wwn45z	23	12	were	be	VBD
cord-021637-f5wwn45z	23	13	developed	develop	VBN
cord-021637-f5wwn45z	23	14	in	in	IN
cord-021637-f5wwn45z	23	15	the	the	DT
cord-021637-f5wwn45z	23	16	United	United	NNP
cord-021637-f5wwn45z	23	17	States	States	NNP
cord-021637-f5wwn45z	23	18	.	.	.
cord-021637-f5wwn45z	24	1	Approximately	approximately	RB
cord-021637-f5wwn45z	24	2	15	15	CD
cord-021637-f5wwn45z	24	3	new	new	JJ
cord-021637-f5wwn45z	24	4	vaccines	vaccine	NNS
cord-021637-f5wwn45z	24	5	were	be	VBD
cord-021637-f5wwn45z	24	6	approved	approve	VBN
cord-021637-f5wwn45z	24	7	in	in	IN
cord-021637-f5wwn45z	24	8	the	the	DT
cord-021637-f5wwn45z	24	9	United	United	NNP
cord-021637-f5wwn45z	24	10	States	States	NNP
cord-021637-f5wwn45z	24	11	between	between	IN
cord-021637-f5wwn45z	24	12	1995	1995	CD
cord-021637-f5wwn45z	24	13	and	and	CC
cord-021637-f5wwn45z	24	14	2014	2014	CD
cord-021637-f5wwn45z	24	15	.	.	.
cord-021637-f5wwn45z	25	1	5	5	CD
cord-021637-f5wwn45z	25	2	,	,	,
cord-021637-f5wwn45z	25	3	6	6	CD
cord-021637-f5wwn45z	26	1	Since	since	IN
cord-021637-f5wwn45z	26	2	then	then	RB
cord-021637-f5wwn45z	26	3	,	,	,
cord-021637-f5wwn45z	26	4	combinations	combination	NNS
cord-021637-f5wwn45z	26	5	of	of	IN
cord-021637-f5wwn45z	26	6	existing	exist	VBG
cord-021637-f5wwn45z	26	7	vaccines	vaccine	NNS
cord-021637-f5wwn45z	26	8	have	have	VBP
cord-021637-f5wwn45z	26	9	been	be	VBN
cord-021637-f5wwn45z	26	10	introduced	introduce	VBN
cord-021637-f5wwn45z	26	11	for	for	IN
cord-021637-f5wwn45z	26	12	simplified	simplified	JJ
cord-021637-f5wwn45z	26	13	pediatric	pediatric	JJ
cord-021637-f5wwn45z	26	14	vaccination	vaccination	NN
cord-021637-f5wwn45z	26	15	resulting	result	VBG
cord-021637-f5wwn45z	26	16	in	in	IN
cord-021637-f5wwn45z	26	17	a	a	DT
cord-021637-f5wwn45z	26	18	wider	wide	JJR
cord-021637-f5wwn45z	26	19	adoption	adoption	NN
cord-021637-f5wwn45z	26	20	of	of	IN
cord-021637-f5wwn45z	26	21	acellular	acellular	JJ
cord-021637-f5wwn45z	26	22	pertussis	pertussis	NN
cord-021637-f5wwn45z	26	23	vaccination	vaccination	NN
cord-021637-f5wwn45z	26	24	.	.	.
cord-021637-f5wwn45z	27	1	A	a	DT
cord-021637-f5wwn45z	27	2	polyvalent	polyvalent	JJ
cord-021637-f5wwn45z	27	3	pneumococcal	pneumococcal	JJ
cord-021637-f5wwn45z	27	4	conjugate	conjugate	NN
cord-021637-f5wwn45z	27	5	vaccine	vaccine	NN
cord-021637-f5wwn45z	27	6	for	for	IN
cord-021637-f5wwn45z	27	7	infants	infant	NNS
cord-021637-f5wwn45z	27	8	introduced	introduce	VBN
cord-021637-f5wwn45z	27	9	by	by	IN
cord-021637-f5wwn45z	27	10	Wyeth	Wyeth	NNP
cord-021637-f5wwn45z	27	11	(	(	-LRB-
cord-021637-f5wwn45z	27	12	now	now	RB
cord-021637-f5wwn45z	27	13	a	a	DT
cord-021637-f5wwn45z	27	14	subsidiary	subsidiary	NN
cord-021637-f5wwn45z	27	15	of	of	IN
cord-021637-f5wwn45z	27	16	Pfizer	Pfizer	NNP
cord-021637-f5wwn45z	27	17	)	)	-RRB-
cord-021637-f5wwn45z	27	18	has	have	VBZ
cord-021637-f5wwn45z	27	19	been	be	VBN
cord-021637-f5wwn45z	27	20	widely	widely	RB
cord-021637-f5wwn45z	27	21	adopted	adopt	VBN
cord-021637-f5wwn45z	27	22	and	and	CC
cord-021637-f5wwn45z	27	23	has	have	VBZ
cord-021637-f5wwn45z	27	24	made	make	VBN
cord-021637-f5wwn45z	27	25	Pfizer	Pfizer	NNP
cord-021637-f5wwn45z	27	26	a	a	DT
cord-021637-f5wwn45z	27	27	major	major	JJ
cord-021637-f5wwn45z	27	28	force	force	NN
cord-021637-f5wwn45z	27	29	in	in	IN
cord-021637-f5wwn45z	27	30	the	the	DT
cord-021637-f5wwn45z	27	31	vaccine	vaccine	NN
cord-021637-f5wwn45z	27	32	business	business	NN
cord-021637-f5wwn45z	27	33	.	.	.
cord-021637-f5wwn45z	28	1	Since	since	IN
cord-021637-f5wwn45z	28	2	2006	2006	CD
cord-021637-f5wwn45z	28	3	,	,	,
cord-021637-f5wwn45z	28	4	several	several	JJ
cord-021637-f5wwn45z	28	5	new	new	JJ
cord-021637-f5wwn45z	28	6	vaccines	vaccine	NNS
cord-021637-f5wwn45z	28	7	have	have	VBP
cord-021637-f5wwn45z	28	8	been	be	VBN
cord-021637-f5wwn45z	28	9	licensed	license	VBN
cord-021637-f5wwn45z	28	10	,	,	,
cord-021637-f5wwn45z	28	11	including	include	VBG
cord-021637-f5wwn45z	28	12	a	a	DT
cord-021637-f5wwn45z	28	13	combination	combination	NN
cord-021637-f5wwn45z	28	14	of	of	IN
cord-021637-f5wwn45z	28	15	measles	measle	NNS
cord-021637-f5wwn45z	28	16	,	,	,
cord-021637-f5wwn45z	28	17	mumps	mumps	NN
cord-021637-f5wwn45z	28	18	,	,	,
cord-021637-f5wwn45z	28	19	and	and	CC
cord-021637-f5wwn45z	28	20	rubella	rubella	NN
cord-021637-f5wwn45z	28	21	(	(	-LRB-
cord-021637-f5wwn45z	28	22	MMR	MMR	NNP
cord-021637-f5wwn45z	28	23	)	)	-RRB-
cord-021637-f5wwn45z	28	24	and	and	CC
cord-021637-f5wwn45z	28	25	varicella	varicella	NN
cord-021637-f5wwn45z	28	26	,	,	,
cord-021637-f5wwn45z	28	27	as	as	RB
cord-021637-f5wwn45z	28	28	well	well	RB
cord-021637-f5wwn45z	28	29	as	as	IN
cord-021637-f5wwn45z	28	30	new	new	JJ
cord-021637-f5wwn45z	28	31	vaccines	vaccine	NNS
cord-021637-f5wwn45z	28	32	against	against	IN
cord-021637-f5wwn45z	28	33	rotavirus	rotavirus	NN
cord-021637-f5wwn45z	28	34	,	,	,
cord-021637-f5wwn45z	28	35	herpes	herpes	NNP
cord-021637-f5wwn45z	28	36	zoster	zoster	NN
cord-021637-f5wwn45z	28	37	,	,	,
cord-021637-f5wwn45z	28	38	HPV	HPV	NNP
cord-021637-f5wwn45z	28	39	,	,	,
cord-021637-f5wwn45z	28	40	meningococcus	meningococcus	NNP
cord-021637-f5wwn45z	28	41	,	,	,
cord-021637-f5wwn45z	28	42	influenza	influenza	NN
cord-021637-f5wwn45z	28	43	,	,	,
cord-021637-f5wwn45z	28	44	and	and	CC
cord-021637-f5wwn45z	28	45	others	other	NNS
cord-021637-f5wwn45z	28	46	.	.	.
cord-021637-f5wwn45z	29	1	The	the	DT
cord-021637-f5wwn45z	29	2	HPV	HPV	NNP
cord-021637-f5wwn45z	29	3	vaccines	vaccine	NNS
cord-021637-f5wwn45z	29	4	developed	develop	VBN
cord-021637-f5wwn45z	29	5	by	by	IN
cord-021637-f5wwn45z	29	6	Merck	Merck	NNP
cord-021637-f5wwn45z	29	7	and	and	CC
cord-021637-f5wwn45z	29	8	GlaxoSmithKline	GlaxoSmithKline	NNP
cord-021637-f5wwn45z	29	9	significantly	significantly	RB
cord-021637-f5wwn45z	29	10	expanded	expand	VBD
cord-021637-f5wwn45z	29	11	the	the	DT
cord-021637-f5wwn45z	29	12	field	field	NN
cord-021637-f5wwn45z	29	13	of	of	IN
cord-021637-f5wwn45z	29	14	adolescent	adolescent	JJ
cord-021637-f5wwn45z	29	15	vaccines	vaccine	NNS
cord-021637-f5wwn45z	29	16	and	and	CC
cord-021637-f5wwn45z	29	17	confirmed	confirm	VBD
cord-021637-f5wwn45z	29	18	market	market	NN
cord-021637-f5wwn45z	29	19	acceptance	acceptance	NN
cord-021637-f5wwn45z	29	20	of	of	IN
cord-021637-f5wwn45z	29	21	premium	premium	NN
cord-021637-f5wwn45z	29	22	pricing	pricing	NN
cord-021637-f5wwn45z	29	23	.	.	.
cord-021637-f5wwn45z	30	1	In	in	IN
cord-021637-f5wwn45z	30	2	the	the	DT
cord-021637-f5wwn45z	30	3	last	last	JJ
cord-021637-f5wwn45z	30	4	10	10	CD
cord-021637-f5wwn45z	30	5	years	year	NNS
cord-021637-f5wwn45z	30	6	,	,	,
cord-021637-f5wwn45z	30	7	the	the	DT
cord-021637-f5wwn45z	30	8	vaccine	vaccine	NN
cord-021637-f5wwn45z	30	9	industry	industry	NN
cord-021637-f5wwn45z	30	10	in	in	IN
cord-021637-f5wwn45z	30	11	the	the	DT
cord-021637-f5wwn45z	30	12	United	United	NNP
cord-021637-f5wwn45z	30	13	States	States	NNP
cord-021637-f5wwn45z	30	14	and	and	CC
cord-021637-f5wwn45z	30	15	Europe	Europe	NNP
cord-021637-f5wwn45z	30	16	has	have	VBZ
cord-021637-f5wwn45z	30	17	considerably	considerably	RB
cord-021637-f5wwn45z	30	18	improved	improve	VBN
cord-021637-f5wwn45z	30	19	its	-PRON-	PRP$
cord-021637-f5wwn45z	30	20	reliability	reliability	NN
cord-021637-f5wwn45z	30	21	as	as	IN
cord-021637-f5wwn45z	30	22	a	a	DT
cord-021637-f5wwn45z	30	23	supplier	supplier	NN
cord-021637-f5wwn45z	30	24	.	.	.
cord-021637-f5wwn45z	31	1	Chronic	chronic	JJ
cord-021637-f5wwn45z	31	2	shortages	shortage	NNS
cord-021637-f5wwn45z	31	3	are	be	VBP
cord-021637-f5wwn45z	31	4	a	a	DT
cord-021637-f5wwn45z	31	5	thing	thing	NN
cord-021637-f5wwn45z	31	6	of	of	IN
cord-021637-f5wwn45z	31	7	the	the	DT
cord-021637-f5wwn45z	31	8	past	past	NN
cord-021637-f5wwn45z	31	9	;	;	:
cord-021637-f5wwn45z	31	10	this	this	DT
cord-021637-f5wwn45z	31	11	turnaround	turnaround	NN
cord-021637-f5wwn45z	31	12	has	have	VBZ
cord-021637-f5wwn45z	31	13	primarily	primarily	RB
cord-021637-f5wwn45z	31	14	been	be	VBN
cord-021637-f5wwn45z	31	15	achieved	achieve	VBN
cord-021637-f5wwn45z	31	16	by	by	IN
cord-021637-f5wwn45z	31	17	modernization	modernization	NN
cord-021637-f5wwn45z	31	18	of	of	IN
cord-021637-f5wwn45z	31	19	vaccine	vaccine	NN
cord-021637-f5wwn45z	31	20	manufacturing	manufacturing	NN
cord-021637-f5wwn45z	31	21	and	and	CC
cord-021637-f5wwn45z	31	22	distribution	distribution	NN
cord-021637-f5wwn45z	31	23	infrastructure	infrastructure	NN
cord-021637-f5wwn45z	31	24	supported	support	VBN
cord-021637-f5wwn45z	31	25	and	and	CC
cord-021637-f5wwn45z	31	26	funded	fund	VBN
cord-021637-f5wwn45z	31	27	by	by	IN
cord-021637-f5wwn45z	31	28	the	the	DT
cord-021637-f5wwn45z	31	29	profitability	profitability	NN
cord-021637-f5wwn45z	31	30	of	of	IN
cord-021637-f5wwn45z	31	31	the	the	DT
cord-021637-f5wwn45z	31	32	vaccine	vaccine	NN
cord-021637-f5wwn45z	31	33	business	business	NN
cord-021637-f5wwn45z	31	34	.	.	.
cord-021637-f5wwn45z	32	1	The	the	DT
cord-021637-f5wwn45z	32	2	Centers	Centers	NNPS
cord-021637-f5wwn45z	32	3	for	for	IN
cord-021637-f5wwn45z	32	4	Disease	Disease	NNP
cord-021637-f5wwn45z	32	5	Control	Control	NNP
cord-021637-f5wwn45z	32	6	and	and	CC
cord-021637-f5wwn45z	32	7	Prevention	Prevention	NNP
cord-021637-f5wwn45z	32	8	(	(	-LRB-
cord-021637-f5wwn45z	32	9	CDC	CDC	NNP
cord-021637-f5wwn45z	32	10	)	)	-RRB-
cord-021637-f5wwn45z	32	11	stockpiling	stockpiling	NN
cord-021637-f5wwn45z	32	12	of	of	IN
cord-021637-f5wwn45z	32	13	pediatric	pediatric	JJ
cord-021637-f5wwn45z	32	14	vaccines	vaccine	NNS
cord-021637-f5wwn45z	32	15	has	have	VBZ
cord-021637-f5wwn45z	32	16	alleviated	alleviate	VBN
cord-021637-f5wwn45z	32	17	some	some	DT
cord-021637-f5wwn45z	32	18	concerns	concern	NNS
cord-021637-f5wwn45z	32	19	of	of	IN
cord-021637-f5wwn45z	32	20	critical	critical	JJ
cord-021637-f5wwn45z	32	21	shortages	shortage	NNS
cord-021637-f5wwn45z	32	22	in	in	IN
cord-021637-f5wwn45z	32	23	case	case	NN
cord-021637-f5wwn45z	32	24	of	of	IN
cord-021637-f5wwn45z	32	25	supply	supply	NN
cord-021637-f5wwn45z	32	26	interruptions	interruption	NNS
cord-021637-f5wwn45z	32	27	.	.	.
cord-021637-f5wwn45z	33	1	But	but	CC
cord-021637-f5wwn45z	33	2	the	the	DT
cord-021637-f5wwn45z	33	3	industry	industry	NN
cord-021637-f5wwn45z	33	4	's	's	POS
cord-021637-f5wwn45z	33	5	vulnerability	vulnerability	NN
cord-021637-f5wwn45z	33	6	because	because	IN
cord-021637-f5wwn45z	33	7	of	of	IN
cord-021637-f5wwn45z	33	8	dependence	dependence	NN
cord-021637-f5wwn45z	33	9	on	on	IN
cord-021637-f5wwn45z	33	10	singlesourced	singlesource	VBN
cord-021637-f5wwn45z	33	11	vaccines	vaccine	NNS
cord-021637-f5wwn45z	33	12	continues	continue	VBZ
cord-021637-f5wwn45z	33	13	to	to	TO
cord-021637-f5wwn45z	33	14	be	be	VB
cord-021637-f5wwn45z	33	15	an	an	DT
cord-021637-f5wwn45z	33	16	unresolved	unresolved	JJ
cord-021637-f5wwn45z	33	17	concern	concern	NN
cord-021637-f5wwn45z	33	18	.	.	.
cord-021637-f5wwn45z	34	1	The	the	DT
cord-021637-f5wwn45z	34	2	regulators	regulator	NNS
cord-021637-f5wwn45z	34	3	and	and	CC
cord-021637-f5wwn45z	34	4	the	the	DT
cord-021637-f5wwn45z	34	5	industry	industry	NN
cord-021637-f5wwn45z	34	6	must	must	MD
cord-021637-f5wwn45z	34	7	proactively	proactively	RB
cord-021637-f5wwn45z	34	8	develop	develop	VB
cord-021637-f5wwn45z	34	9	a	a	DT
cord-021637-f5wwn45z	34	10	solution	solution	NN
cord-021637-f5wwn45z	34	11	to	to	IN
cord-021637-f5wwn45z	34	12	this	this	DT
cord-021637-f5wwn45z	34	13	critical	critical	JJ
cord-021637-f5wwn45z	34	14	challenge	challenge	NN
cord-021637-f5wwn45z	34	15	and	and	CC
cord-021637-f5wwn45z	34	16	avoid	avoid	VB
cord-021637-f5wwn45z	34	17	any	any	DT
cord-021637-f5wwn45z	34	18	future	future	JJ
cord-021637-f5wwn45z	34	19	public	public	JJ
cord-021637-f5wwn45z	34	20	health	health	NN
cord-021637-f5wwn45z	34	21	crisis	crisis	NN
cord-021637-f5wwn45z	34	22	resulting	result	VBG
cord-021637-f5wwn45z	34	23	from	from	IN
cord-021637-f5wwn45z	34	24	vaccine	vaccine	NN
cord-021637-f5wwn45z	34	25	shortages	shortage	NNS
cord-021637-f5wwn45z	34	26	during	during	IN
cord-021637-f5wwn45z	34	27	a	a	DT
cord-021637-f5wwn45z	34	28	prolonged	prolonged	JJ
cord-021637-f5wwn45z	34	29	supply	supply	NN
cord-021637-f5wwn45z	34	30	interruption	interruption	NN
cord-021637-f5wwn45z	34	31	.	.	.
cord-021637-f5wwn45z	35	1	Vaccine	vaccine	NN
cord-021637-f5wwn45z	35	2	development	development	NN
cord-021637-f5wwn45z	35	3	is	be	VBZ
cord-021637-f5wwn45z	35	4	difficult	difficult	JJ
cord-021637-f5wwn45z	35	5	,	,	,
cord-021637-f5wwn45z	35	6	complex	complex	JJ
cord-021637-f5wwn45z	35	7	,	,	,
cord-021637-f5wwn45z	35	8	highly	highly	RB
cord-021637-f5wwn45z	35	9	risky	risky	JJ
cord-021637-f5wwn45z	35	10	,	,	,
cord-021637-f5wwn45z	35	11	and	and	CC
cord-021637-f5wwn45z	35	12	costly	costly	JJ
cord-021637-f5wwn45z	35	13	,	,	,
cord-021637-f5wwn45z	35	14	and	and	CC
cord-021637-f5wwn45z	35	15	includes	include	VBZ
cord-021637-f5wwn45z	35	16	clinical	clinical	JJ
cord-021637-f5wwn45z	35	17	development	development	NN
cord-021637-f5wwn45z	35	18	,	,	,
cord-021637-f5wwn45z	35	19	process	process	NN
cord-021637-f5wwn45z	35	20	development	development	NN
cord-021637-f5wwn45z	35	21	,	,	,
cord-021637-f5wwn45z	35	22	and	and	CC
cord-021637-f5wwn45z	35	23	assay	assay	NN
cord-021637-f5wwn45z	35	24	development	development	NN
cord-021637-f5wwn45z	35	25	.	.	.
cord-021637-f5wwn45z	36	1	The	the	DT
cord-021637-f5wwn45z	36	2	risk	risk	NN
cord-021637-f5wwn45z	36	3	is	be	VBZ
cord-021637-f5wwn45z	36	4	high	high	JJ
cord-021637-f5wwn45z	36	5	because	because	IN
cord-021637-f5wwn45z	36	6	most	most	JJS
cord-021637-f5wwn45z	36	7	vaccine	vaccine	NN
cord-021637-f5wwn45z	36	8	candidates	candidate	NNS
cord-021637-f5wwn45z	36	9	fail	fail	VBP
cord-021637-f5wwn45z	36	10	in	in	IN
cord-021637-f5wwn45z	36	11	preclinical	preclinical	JJ
cord-021637-f5wwn45z	36	12	or	or	CC
cord-021637-f5wwn45z	36	13	early	early	JJ
cord-021637-f5wwn45z	36	14	clinical	clinical	JJ
cord-021637-f5wwn45z	36	15	development	development	NN
cord-021637-f5wwn45z	36	16	and	and	CC
cord-021637-f5wwn45z	36	17	less	less	JJR
cord-021637-f5wwn45z	36	18	than	than	IN
cord-021637-f5wwn45z	36	19	1	1	CD
cord-021637-f5wwn45z	36	20	in	in	IN
cord-021637-f5wwn45z	36	21	15	15	CD
cord-021637-f5wwn45z	36	22	vaccine	vaccine	NN
cord-021637-f5wwn45z	36	23	candidates	candidate	NNS
cord-021637-f5wwn45z	36	24	entering	enter	VBG
cord-021637-f5wwn45z	36	25	Phase	Phase	NNP
cord-021637-f5wwn45z	36	26	II	II	NNP
cord-021637-f5wwn45z	36	27	achieves	achieve	VBZ
cord-021637-f5wwn45z	36	28	licensure	licensure	NN
cord-021637-f5wwn45z	36	29	.	.	.
cord-021637-f5wwn45z	37	1	The	the	DT
cord-021637-f5wwn45z	37	2	high	high	JJ
cord-021637-f5wwn45z	37	3	failure	failure	NN
cord-021637-f5wwn45z	37	4	rate	rate	NN
cord-021637-f5wwn45z	37	5	is	be	VBZ
cord-021637-f5wwn45z	37	6	the	the	DT
cord-021637-f5wwn45z	37	7	result	result	NN
cord-021637-f5wwn45z	37	8	of	of	IN
cord-021637-f5wwn45z	37	9	a	a	DT
cord-021637-f5wwn45z	37	10	variety	variety	NN
cord-021637-f5wwn45z	37	11	of	of	IN
cord-021637-f5wwn45z	37	12	reasons	reason	NNS
cord-021637-f5wwn45z	37	13	:	:	:
cord-021637-f5wwn45z	37	14	1	1	CD
cord-021637-f5wwn45z	37	15	.	.	.
cord-021637-f5wwn45z	38	1	Not	not	RB
cord-021637-f5wwn45z	38	2	fully	fully	RB
cord-021637-f5wwn45z	38	3	understanding	understand	VBG
cord-021637-f5wwn45z	38	4	the	the	DT
cord-021637-f5wwn45z	38	5	biology	biology	NN
cord-021637-f5wwn45z	38	6	of	of	IN
cord-021637-f5wwn45z	38	7	protection	protection	NN
cord-021637-f5wwn45z	38	8	.	.	.
cord-021637-f5wwn45z	39	1	2	2	LS
cord-021637-f5wwn45z	39	2	.	.	.
cord-021637-f5wwn45z	40	1	Lack	lack	NN
cord-021637-f5wwn45z	40	2	of	of	IN
cord-021637-f5wwn45z	40	3	good	good	JJ
cord-021637-f5wwn45z	40	4	animal	animal	NN
cord-021637-f5wwn45z	40	5	models	model	NNS
cord-021637-f5wwn45z	40	6	to	to	TO
cord-021637-f5wwn45z	40	7	predict	predict	VB
cord-021637-f5wwn45z	40	8	vaccine	vaccine	NN
cord-021637-f5wwn45z	40	9	behavior	behavior	NN
cord-021637-f5wwn45z	40	10	in	in	IN
cord-021637-f5wwn45z	40	11	humans	human	NNS
cord-021637-f5wwn45z	40	12	.	.	.
cord-021637-f5wwn45z	41	1	3	3	LS
cord-021637-f5wwn45z	41	2	.	.	.
cord-021637-f5wwn45z	42	1	Unpredictability	unpredictability	NN
cord-021637-f5wwn45z	42	2	of	of	IN
cord-021637-f5wwn45z	42	3	human	human	JJ
cord-021637-f5wwn45z	42	4	immune	immune	NN
cord-021637-f5wwn45z	42	5	system	system	NN
cord-021637-f5wwn45z	42	6	reactions	reaction	NNS
cord-021637-f5wwn45z	42	7	to	to	IN
cord-021637-f5wwn45z	42	8	antigens	antigen	NNS
cord-021637-f5wwn45z	42	9	as	as	IN
cord-021637-f5wwn45z	42	10	it	-PRON-	PRP
cord-021637-f5wwn45z	42	11	relates	relate	VBZ
cord-021637-f5wwn45z	42	12	to	to	IN
cord-021637-f5wwn45z	42	13	immunogenicity	immunogenicity	NN
cord-021637-f5wwn45z	42	14	or	or	CC
cord-021637-f5wwn45z	42	15	safety	safety	NN
cord-021637-f5wwn45z	42	16	.	.	.
cord-021637-f5wwn45z	43	1	4	4	LS
cord-021637-f5wwn45z	43	2	.	.	.
cord-021637-f5wwn45z	44	1	The	the	DT
cord-021637-f5wwn45z	44	2	unpredictability	unpredictability	NN
cord-021637-f5wwn45z	44	3	of	of	IN
cord-021637-f5wwn45z	44	4	the	the	DT
cord-021637-f5wwn45z	44	5	impact	impact	NN
cord-021637-f5wwn45z	44	6	of	of	IN
cord-021637-f5wwn45z	44	7	combining	combine	VBG
cord-021637-f5wwn45z	44	8	multiple	multiple	JJ
cord-021637-f5wwn45z	44	9	components	component	NNS
cord-021637-f5wwn45z	44	10	in	in	IN
cord-021637-f5wwn45z	44	11	a	a	DT
cord-021637-f5wwn45z	44	12	vaccine	vaccine	NN
cord-021637-f5wwn45z	44	13	.	.	.
cord-021637-f5wwn45z	45	1	Vaccine	vaccine	NN
cord-021637-f5wwn45z	45	2	development	development	NN
cord-021637-f5wwn45z	45	3	requires	require	VBZ
cord-021637-f5wwn45z	45	4	strong	strong	JJ
cord-021637-f5wwn45z	45	5	project	project	NN
cord-021637-f5wwn45z	45	6	management	management	NN
cord-021637-f5wwn45z	45	7	systems	system	NNS
cord-021637-f5wwn45z	45	8	and	and	CC
cord-021637-f5wwn45z	45	9	controls	control	NNS
cord-021637-f5wwn45z	45	10	and	and	CC
cord-021637-f5wwn45z	45	11	requisite	requisite	JJ
cord-021637-f5wwn45z	45	12	skill	skill	NN
cord-021637-f5wwn45z	45	13	sets	set	NNS
cord-021637-f5wwn45z	45	14	among	among	IN
cord-021637-f5wwn45z	45	15	scientists	scientist	NNS
cord-021637-f5wwn45z	45	16	and	and	CC
cord-021637-f5wwn45z	45	17	engineers	engineer	NNS
cord-021637-f5wwn45z	45	18	.	.	.
cord-021637-f5wwn45z	46	1	A	a	DT
cord-021637-f5wwn45z	46	2	key	key	JJ
cord-021637-f5wwn45z	46	3	strategic	strategic	JJ
cord-021637-f5wwn45z	46	4	document	document	NN
cord-021637-f5wwn45z	46	5	that	that	WDT
cord-021637-f5wwn45z	46	6	guides	guide	VBZ
cord-021637-f5wwn45z	46	7	the	the	DT
cord-021637-f5wwn45z	46	8	stakeholders	stakeholder	NNS
cord-021637-f5wwn45z	46	9	in	in	IN
cord-021637-f5wwn45z	46	10	vaccine	vaccine	NN
cord-021637-f5wwn45z	46	11	development	development	NN
cord-021637-f5wwn45z	46	12	is	be	VBZ
cord-021637-f5wwn45z	46	13	the	the	DT
cord-021637-f5wwn45z	46	14	"	"	``
cord-021637-f5wwn45z	46	15	target	target	NN
cord-021637-f5wwn45z	46	16	product	product	NN
cord-021637-f5wwn45z	46	17	profile	profile	NN
cord-021637-f5wwn45z	46	18	"	"	''
cord-021637-f5wwn45z	46	19	(	(	-LRB-
cord-021637-f5wwn45z	46	20	TPP	TPP	NNP
cord-021637-f5wwn45z	46	21	)	)	-RRB-
cord-021637-f5wwn45z	46	22	.	.	.
cord-021637-f5wwn45z	47	1	The	the	DT
cord-021637-f5wwn45z	47	2	TPP	TPP	NNP
cord-021637-f5wwn45z	47	3	summarizes	summarize	VBZ
cord-021637-f5wwn45z	47	4	the	the	DT
cord-021637-f5wwn45z	47	5	desired	desire	VBN
cord-021637-f5wwn45z	47	6	characteristics	characteristic	NNS
cord-021637-f5wwn45z	47	7	and	and	CC
cord-021637-f5wwn45z	47	8	features	feature	NNS
cord-021637-f5wwn45z	47	9	of	of	IN
cord-021637-f5wwn45z	47	10	the	the	DT
cord-021637-f5wwn45z	47	11	product	product	NN
cord-021637-f5wwn45z	47	12	under	under	IN
cord-021637-f5wwn45z	47	13	development	development	NN
cord-021637-f5wwn45z	47	14	,	,	,
cord-021637-f5wwn45z	47	15	the	the	DT
cord-021637-f5wwn45z	47	16	key	key	JJ
cord-021637-f5wwn45z	47	17	attributes	attribute	NNS
cord-021637-f5wwn45z	47	18	of	of	IN
cord-021637-f5wwn45z	47	19	the	the	DT
cord-021637-f5wwn45z	47	20	product	product	NN
cord-021637-f5wwn45z	47	21	that	that	WDT
cord-021637-f5wwn45z	47	22	provide	provide	VBP
cord-021637-f5wwn45z	47	23	competitive	competitive	JJ
cord-021637-f5wwn45z	47	24	advantage	advantage	NN
cord-021637-f5wwn45z	47	25	,	,	,
cord-021637-f5wwn45z	47	26	and	and	CC
cord-021637-f5wwn45z	47	27	,	,	,
cord-021637-f5wwn45z	47	28	finally	finally	RB
cord-021637-f5wwn45z	47	29	,	,	,
cord-021637-f5wwn45z	47	30	a	a	DT
cord-021637-f5wwn45z	47	31	topline	topline	NN
cord-021637-f5wwn45z	47	32	roadmap	roadmap	NN
cord-021637-f5wwn45z	47	33	of	of	IN
cord-021637-f5wwn45z	47	34	nonclinical	nonclinical	JJ
cord-021637-f5wwn45z	47	35	and	and	CC
cord-021637-f5wwn45z	47	36	clinical	clinical	JJ
cord-021637-f5wwn45z	47	37	studies	study	NNS
cord-021637-f5wwn45z	47	38	required	require	VBN
cord-021637-f5wwn45z	47	39	to	to	TO
cord-021637-f5wwn45z	47	40	evaluate	evaluate	VB
cord-021637-f5wwn45z	47	41	the	the	DT
cord-021637-f5wwn45z	47	42	products	product	NNS
cord-021637-f5wwn45z	47	43	efficacy	efficacy	NN
cord-021637-f5wwn45z	47	44	and	and	CC
cord-021637-f5wwn45z	47	45	safety	safety	NN
cord-021637-f5wwn45z	47	46	in	in	IN
cord-021637-f5wwn45z	47	47	the	the	DT
cord-021637-f5wwn45z	47	48	target	target	NN
cord-021637-f5wwn45z	47	49	population	population	NN
cord-021637-f5wwn45z	47	50	.	.	.
cord-021637-f5wwn45z	48	1	A	a	DT
cord-021637-f5wwn45z	48	2	well	well	RB
cord-021637-f5wwn45z	48	3	-	-	HYPH
cord-021637-f5wwn45z	48	4	defined	define	VBN
cord-021637-f5wwn45z	48	5	TPP	TPP	NNP
cord-021637-f5wwn45z	48	6	provides	provide	VBZ
cord-021637-f5wwn45z	48	7	all	all	PDT
cord-021637-f5wwn45z	48	8	the	the	DT
cord-021637-f5wwn45z	48	9	stakeholders	stakeholder	NNS
cord-021637-f5wwn45z	48	10	,	,	,
cord-021637-f5wwn45z	48	11	including	include	VBG
cord-021637-f5wwn45z	48	12	research	research	NN
cord-021637-f5wwn45z	48	13	,	,	,
cord-021637-f5wwn45z	48	14	process	process	NN
cord-021637-f5wwn45z	48	15	development	development	NN
cord-021637-f5wwn45z	48	16	,	,	,
cord-021637-f5wwn45z	48	17	manufacturing	manufacturing	NN
cord-021637-f5wwn45z	48	18	,	,	,
cord-021637-f5wwn45z	48	19	clinical	clinical	JJ
cord-021637-f5wwn45z	48	20	,	,	,
cord-021637-f5wwn45z	48	21	regulatory	regulatory	JJ
cord-021637-f5wwn45z	48	22	,	,	,
cord-021637-f5wwn45z	48	23	and	and	CC
cord-021637-f5wwn45z	48	24	senior	senior	JJ
cord-021637-f5wwn45z	48	25	management	management	NN
cord-021637-f5wwn45z	48	26	,	,	,
cord-021637-f5wwn45z	48	27	with	with	IN
cord-021637-f5wwn45z	48	28	a	a	DT
cord-021637-f5wwn45z	48	29	clear	clear	JJ
cord-021637-f5wwn45z	48	30	statement	statement	NN
cord-021637-f5wwn45z	48	31	of	of	IN
cord-021637-f5wwn45z	48	32	the	the	DT
cord-021637-f5wwn45z	48	33	desired	desire	VBN
cord-021637-f5wwn45z	48	34	outcome	outcome	NN
cord-021637-f5wwn45z	48	35	of	of	IN
cord-021637-f5wwn45z	48	36	the	the	DT
cord-021637-f5wwn45z	48	37	product	product	NN
cord-021637-f5wwn45z	48	38	development	development	NN
cord-021637-f5wwn45z	48	39	program	program	NN
cord-021637-f5wwn45z	48	40	.	.	.
cord-021637-f5wwn45z	49	1	Process	process	NN
cord-021637-f5wwn45z	49	2	development	development	NN
cord-021637-f5wwn45z	49	3	involves	involve	VBZ
cord-021637-f5wwn45z	49	4	making	make	VBG
cord-021637-f5wwn45z	49	5	preparations	preparation	NNS
cord-021637-f5wwn45z	49	6	of	of	IN
cord-021637-f5wwn45z	49	7	the	the	DT
cord-021637-f5wwn45z	49	8	test	test	NN
cord-021637-f5wwn45z	49	9	vaccine	vaccine	NN
cord-021637-f5wwn45z	49	10	that	that	WDT
cord-021637-f5wwn45z	49	11	satisfy	satisfy	VBP
cord-021637-f5wwn45z	49	12	regulatory	regulatory	JJ
cord-021637-f5wwn45z	49	13	requirements	requirement	NNS
cord-021637-f5wwn45z	49	14	for	for	IN
cord-021637-f5wwn45z	49	15	clinical	clinical	JJ
cord-021637-f5wwn45z	49	16	testing	testing	NN
cord-021637-f5wwn45z	49	17	including	include	VBG
cord-021637-f5wwn45z	49	18	clinical	clinical	JJ
cord-021637-f5wwn45z	49	19	lots	lot	NNS
cord-021637-f5wwn45z	49	20	,	,	,
cord-021637-f5wwn45z	49	21	preclinical	preclinical	JJ
cord-021637-f5wwn45z	49	22	toxicology	toxicology	NN
cord-021637-f5wwn45z	49	23	testing	testing	NN
cord-021637-f5wwn45z	49	24	,	,	,
cord-021637-f5wwn45z	49	25	and	and	CC
cord-021637-f5wwn45z	49	26	analytical	analytical	JJ
cord-021637-f5wwn45z	49	27	assessment	assessment	NN
cord-021637-f5wwn45z	49	28	,	,	,
cord-021637-f5wwn45z	49	29	and	and	CC
cord-021637-f5wwn45z	49	30	finally	finally	RB
cord-021637-f5wwn45z	49	31	,	,	,
cord-021637-f5wwn45z	49	32	scale	scale	NN
cord-021637-f5wwn45z	49	33	-	-	HYPH
cord-021637-f5wwn45z	49	34	up	up	RP
cord-021637-f5wwn45z	49	35	methods	method	NNS
cord-021637-f5wwn45z	49	36	that	that	WDT
cord-021637-f5wwn45z	49	37	lead	lead	VBP
cord-021637-f5wwn45z	49	38	to	to	IN
cord-021637-f5wwn45z	49	39	a	a	DT
cord-021637-f5wwn45z	49	40	consistent	consistent	JJ
cord-021637-f5wwn45z	49	41	manufacturing	manufacturing	NN
cord-021637-f5wwn45z	49	42	process	process	NN
cord-021637-f5wwn45z	49	43	at	at	IN
cord-021637-f5wwn45z	49	44	one	one	CD
cord-021637-f5wwn45z	49	45	-	-	HYPH
cord-021637-f5wwn45z	49	46	tenth	tenth	NN
cord-021637-f5wwn45z	49	47	of	of	IN
cord-021637-f5wwn45z	49	48	full	full	JJ
cord-021637-f5wwn45z	49	49	scale	scale	NN
cord-021637-f5wwn45z	49	50	.	.	.
cord-021637-f5wwn45z	50	1	Usually	usually	RB
cord-021637-f5wwn45z	50	2	three	three	CD
cord-021637-f5wwn45z	50	3	consecutive	consecutive	JJ
cord-021637-f5wwn45z	50	4	lots	lot	NNS
cord-021637-f5wwn45z	50	5	are	be	VBP
cord-021637-f5wwn45z	50	6	tested	test	VBN
cord-021637-f5wwn45z	50	7	in	in	IN
cord-021637-f5wwn45z	50	8	the	the	DT
cord-021637-f5wwn45z	50	9	clinic	clinic	NN
cord-021637-f5wwn45z	50	10	for	for	IN
cord-021637-f5wwn45z	50	11	immunogenicity	immunogenicity	NN
cord-021637-f5wwn45z	50	12	.	.	.
cord-021637-f5wwn45z	51	1	Assay	assay	NN
cord-021637-f5wwn45z	51	2	development	development	NN
cord-021637-f5wwn45z	51	3	involves	involve	VBZ
cord-021637-f5wwn45z	51	4	the	the	DT
cord-021637-f5wwn45z	51	5	definition	definition	NN
cord-021637-f5wwn45z	51	6	of	of	IN
cord-021637-f5wwn45z	51	7	specific	specific	JJ
cord-021637-f5wwn45z	51	8	methods	method	NNS
cord-021637-f5wwn45z	51	9	to	to	TO
cord-021637-f5wwn45z	51	10	test	test	VB
cord-021637-f5wwn45z	51	11	the	the	DT
cord-021637-f5wwn45z	51	12	purity	purity	NN
cord-021637-f5wwn45z	51	13	of	of	IN
cord-021637-f5wwn45z	51	14	raw	raw	JJ
cord-021637-f5wwn45z	51	15	materials	material	NNS
cord-021637-f5wwn45z	51	16	,	,	,
cord-021637-f5wwn45z	51	17	stability	stability	NN
cord-021637-f5wwn45z	51	18	and	and	CC
cord-021637-f5wwn45z	51	19	potency	potency	NN
cord-021637-f5wwn45z	51	20	of	of	IN
cord-021637-f5wwn45z	51	21	the	the	DT
cord-021637-f5wwn45z	51	22	vaccine	vaccine	NN
cord-021637-f5wwn45z	51	23	product	product	NN
cord-021637-f5wwn45z	51	24	,	,	,
cord-021637-f5wwn45z	51	25	and	and	CC
cord-021637-f5wwn45z	51	26	immunologic	immunologic	JJ
cord-021637-f5wwn45z	51	27	and	and	CC
cord-021637-f5wwn45z	51	28	other	other	JJ
cord-021637-f5wwn45z	51	29	criteria	criterion	NNS
cord-021637-f5wwn45z	51	30	to	to	TO
cord-021637-f5wwn45z	51	31	predict	predict	VB
cord-021637-f5wwn45z	51	32	vaccine	vaccine	NN
cord-021637-f5wwn45z	51	33	efficacy	efficacy	NN
cord-021637-f5wwn45z	51	34	.	.	.
cord-021637-f5wwn45z	52	1	Go	go	VB
cord-021637-f5wwn45z	52	2	/	/	SYM
cord-021637-f5wwn45z	52	3	no	no	DT
cord-021637-f5wwn45z	52	4	-	-	HYPH
cord-021637-f5wwn45z	52	5	go	go	JJ
cord-021637-f5wwn45z	52	6	decisions	decision	NNS
cord-021637-f5wwn45z	52	7	must	must	MD
cord-021637-f5wwn45z	52	8	be	be	VB
cord-021637-f5wwn45z	52	9	made	make	VBN
cord-021637-f5wwn45z	52	10	at	at	IN
cord-021637-f5wwn45z	52	11	each	each	DT
cord-021637-f5wwn45z	52	12	stage	stage	NN
cord-021637-f5wwn45z	52	13	of	of	IN
cord-021637-f5wwn45z	52	14	clinical	clinical	JJ
cord-021637-f5wwn45z	52	15	and	and	CC
cord-021637-f5wwn45z	52	16	process	process	NN
cord-021637-f5wwn45z	52	17	development	development	NN
cord-021637-f5wwn45z	52	18	and	and	CC
cord-021637-f5wwn45z	52	19	The	the	DT
cord-021637-f5wwn45z	52	20	Vaccine	Vaccine	NNP
cord-021637-f5wwn45z	52	21	Industry	Industry	NNP
cord-021637-f5wwn45z	52	22	R.	R.	NNP
cord-021637-f5wwn45z	52	23	Gordon	Gordon	NNP
cord-021637-f5wwn45z	52	24	Douglas	Douglas	NNP
cord-021637-f5wwn45z	52	25	and	and	CC
cord-021637-f5wwn45z	52	26	Vijay	Vijay	NNP
cord-021637-f5wwn45z	52	27	B.	B.	NNP
cord-021637-f5wwn45z	52	28	Samant	Samant	NNP
cord-021637-f5wwn45z	52	29	must	must	MD
cord-021637-f5wwn45z	52	30	be	be	VB
cord-021637-f5wwn45z	52	31	data	datum	NNS
cord-021637-f5wwn45z	52	32	driven	drive	VBN
cord-021637-f5wwn45z	52	33	.	.	.
cord-021637-f5wwn45z	53	1	Clinical	clinical	JJ
cord-021637-f5wwn45z	53	2	,	,	,
cord-021637-f5wwn45z	53	3	process	process	NN
cord-021637-f5wwn45z	53	4	,	,	,
cord-021637-f5wwn45z	53	5	and	and	CC
cord-021637-f5wwn45z	53	6	assay	assay	NN
cord-021637-f5wwn45z	53	7	development	development	NN
cord-021637-f5wwn45z	53	8	tasks	task	NNS
cord-021637-f5wwn45z	53	9	must	must	MD
cord-021637-f5wwn45z	53	10	be	be	VB
cord-021637-f5wwn45z	53	11	closely	closely	RB
cord-021637-f5wwn45z	53	12	integrated	integrate	VBN
cord-021637-f5wwn45z	53	13	.	.	.
cord-021637-f5wwn45z	54	1	Clinical	clinical	JJ
cord-021637-f5wwn45z	54	2	development	development	NN
cord-021637-f5wwn45z	54	3	involves	involve	VBZ
cord-021637-f5wwn45z	54	4	studies	study	NNS
cord-021637-f5wwn45z	54	5	of	of	IN
cord-021637-f5wwn45z	54	6	the	the	DT
cord-021637-f5wwn45z	54	7	effects	effect	NNS
cord-021637-f5wwn45z	54	8	of	of	IN
cord-021637-f5wwn45z	54	9	vaccines	vaccine	NNS
cord-021637-f5wwn45z	54	10	on	on	IN
cord-021637-f5wwn45z	54	11	patients	patient	NNS
cord-021637-f5wwn45z	54	12	for	for	IN
cord-021637-f5wwn45z	54	13	safety	safety	NN
cord-021637-f5wwn45z	54	14	,	,	,
cord-021637-f5wwn45z	54	15	immunogenicity	immunogenicity	NN
cord-021637-f5wwn45z	54	16	,	,	,
cord-021637-f5wwn45z	54	17	and	and	CC
cord-021637-f5wwn45z	54	18	efficacy	efficacy	NN
cord-021637-f5wwn45z	54	19	through	through	IN
cord-021637-f5wwn45z	54	20	a	a	DT
cord-021637-f5wwn45z	54	21	staged	stage	VBN
cord-021637-f5wwn45z	54	22	process	process	NN
cord-021637-f5wwn45z	54	23	:	:	:
cord-021637-f5wwn45z	54	24	phase	phase	NN
cord-021637-f5wwn45z	54	25	1	1	CD
cord-021637-f5wwn45z	54	26	,	,	,
cord-021637-f5wwn45z	54	27	early	early	JJ
cord-021637-f5wwn45z	54	28	safety	safety	NN
cord-021637-f5wwn45z	54	29	and	and	CC
cord-021637-f5wwn45z	54	30	immunogenicity	immunogenicity	NN
cord-021637-f5wwn45z	54	31	in	in	IN
cord-021637-f5wwn45z	54	32	small	small	JJ
cord-021637-f5wwn45z	54	33	numbers	number	NNS
cord-021637-f5wwn45z	54	34	;	;	:
cord-021637-f5wwn45z	54	35	phase	phase	NN
cord-021637-f5wwn45z	54	36	2	2	CD
cord-021637-f5wwn45z	54	37	,	,	,
cord-021637-f5wwn45z	54	38	safety	safety	NN
cord-021637-f5wwn45z	54	39	,	,	,
cord-021637-f5wwn45z	54	40	dose	dose	NN
cord-021637-f5wwn45z	54	41	ranging	ranging	NN
cord-021637-f5wwn45z	54	42	,	,	,
cord-021637-f5wwn45z	54	43	and	and	CC
cord-021637-f5wwn45z	54	44	immunogenicity	immunogenicity	NN
cord-021637-f5wwn45z	54	45	in	in	IN
cord-021637-f5wwn45z	54	46	200	200	CD
cord-021637-f5wwn45z	54	47	to	to	TO
cord-021637-f5wwn45z	54	48	400	400	CD
cord-021637-f5wwn45z	54	49	individuals	individual	NNS
cord-021637-f5wwn45z	54	50	;	;	:
cord-021637-f5wwn45z	54	51	sometimes	sometimes	RB
cord-021637-f5wwn45z	54	52	phase	phase	NN
cord-021637-f5wwn45z	54	53	2b	2b	CD
cord-021637-f5wwn45z	54	54	,	,	,
cord-021637-f5wwn45z	54	55	nonlicensure	nonlicensure	NNP
cord-021637-f5wwn45z	54	56	,	,	,
cord-021637-f5wwn45z	54	57	proof	proof	NN
cord-021637-f5wwn45z	54	58	-	-	HYPH
cord-021637-f5wwn45z	54	59	of	of	IN
cord-021637-f5wwn45z	54	60	-	-	HYPH
cord-021637-f5wwn45z	54	61	concept	concept	NN
cord-021637-f5wwn45z	54	62	trials	trial	NNS
cord-021637-f5wwn45z	54	63	for	for	IN
cord-021637-f5wwn45z	54	64	efficacy	efficacy	NN
cord-021637-f5wwn45z	54	65	;	;	:
cord-021637-f5wwn45z	54	66	and	and	CC
cord-021637-f5wwn45z	54	67	phase	phase	NN
cord-021637-f5wwn45z	54	68	3	3	CD
cord-021637-f5wwn45z	54	69	,	,	,
cord-021637-f5wwn45z	54	70	safety	safety	NN
cord-021637-f5wwn45z	54	71	and	and	CC
cord-021637-f5wwn45z	54	72	efficacy	efficacy	NN
cord-021637-f5wwn45z	54	73	trials	trial	NNS
cord-021637-f5wwn45z	54	74	that	that	WDT
cord-021637-f5wwn45z	54	75	permit	permit	VBP
cord-021637-f5wwn45z	54	76	licensure	licensure	NN
cord-021637-f5wwn45z	54	77	,	,	,
cord-021637-f5wwn45z	54	78	which	which	WDT
cord-021637-f5wwn45z	54	79	generally	generally	RB
cord-021637-f5wwn45z	54	80	require	require	VBP
cord-021637-f5wwn45z	54	81	thousands	thousand	NNS
cord-021637-f5wwn45z	54	82	of	of	IN
cord-021637-f5wwn45z	54	83	subjects	subject	NNS
cord-021637-f5wwn45z	54	84	.	.	.
cord-021637-f5wwn45z	55	1	"	"	``
cord-021637-f5wwn45z	55	2	Process	process	NN
cord-021637-f5wwn45z	55	3	"	"	''
cord-021637-f5wwn45z	55	4	can	can	MD
cord-021637-f5wwn45z	55	5	be	be	VB
cord-021637-f5wwn45z	55	6	broadly	broadly	RB
cord-021637-f5wwn45z	55	7	divided	divide	VBN
cord-021637-f5wwn45z	55	8	into	into	IN
cord-021637-f5wwn45z	55	9	two	two	CD
cord-021637-f5wwn45z	55	10	categories	category	NNS
cord-021637-f5wwn45z	55	11	:	:	:
cord-021637-f5wwn45z	55	12	bulk	bulk	NN
cord-021637-f5wwn45z	55	13	manufacturing	manufacturing	NN
cord-021637-f5wwn45z	55	14	and	and	CC
cord-021637-f5wwn45z	55	15	finishing	finish	VBG
cord-021637-f5wwn45z	55	16	operations	operation	NNS
cord-021637-f5wwn45z	55	17	.	.	.
cord-021637-f5wwn45z	56	1	Bulk	bulk	JJ
cord-021637-f5wwn45z	56	2	manufacturing	manufacturing	NN
cord-021637-f5wwn45z	56	3	includes	include	VBZ
cord-021637-f5wwn45z	56	4	cell	cell	NN
cord-021637-f5wwn45z	56	5	culture	culture	NN
cord-021637-f5wwn45z	56	6	and/or	and/or	CC
cord-021637-f5wwn45z	56	7	fermentation	fermentation	NN
cord-021637-f5wwn45z	56	8	-	-	HYPH
cord-021637-f5wwn45z	56	9	based	base	VBN
cord-021637-f5wwn45z	56	10	manufacturing	manufacturing	NN
cord-021637-f5wwn45z	56	11	followed	follow	VBN
cord-021637-f5wwn45z	56	12	by	by	IN
cord-021637-f5wwn45z	56	13	a	a	DT
cord-021637-f5wwn45z	56	14	variety	variety	NN
cord-021637-f5wwn45z	56	15	of	of	IN
cord-021637-f5wwn45z	56	16	separation	separation	NN
cord-021637-f5wwn45z	56	17	processes	process	NNS
cord-021637-f5wwn45z	56	18	to	to	TO
cord-021637-f5wwn45z	56	19	purify	purify	VB
cord-021637-f5wwn45z	56	20	the	the	DT
cord-021637-f5wwn45z	56	21	vaccine	vaccine	NN
cord-021637-f5wwn45z	56	22	.	.	.
cord-021637-f5wwn45z	57	1	The	the	DT
cord-021637-f5wwn45z	57	2	finishing	finishing	JJ
cord-021637-f5wwn45z	57	3	operations	operation	NNS
cord-021637-f5wwn45z	57	4	include	include	VBP
cord-021637-f5wwn45z	57	5	formulation	formulation	NN
cord-021637-f5wwn45z	57	6	with	with	IN
cord-021637-f5wwn45z	57	7	adjuvant	adjuvant	NN
cord-021637-f5wwn45z	57	8	/	/	SYM
cord-021637-f5wwn45z	57	9	stabilizer	stabilizer	NN
cord-021637-f5wwn45z	57	10	followed	follow	VBN
cord-021637-f5wwn45z	57	11	by	by	IN
cord-021637-f5wwn45z	57	12	vial	vial	NN
cord-021637-f5wwn45z	57	13	or	or	CC
cord-021637-f5wwn45z	57	14	syringe	syringe	NN
cord-021637-f5wwn45z	57	15	filling	filling	NN
cord-021637-f5wwn45z	57	16	(	(	-LRB-
cord-021637-f5wwn45z	57	17	including	include	VBG
cord-021637-f5wwn45z	57	18	lyophilization	lyophilization	NN
cord-021637-f5wwn45z	57	19	in	in	IN
cord-021637-f5wwn45z	57	20	the	the	DT
cord-021637-f5wwn45z	57	21	case	case	NN
cord-021637-f5wwn45z	57	22	of	of	IN
cord-021637-f5wwn45z	57	23	live	live	JJ
cord-021637-f5wwn45z	57	24	viral	viral	JJ
cord-021637-f5wwn45z	57	25	vaccines	vaccine	NNS
cord-021637-f5wwn45z	57	26	)	)	-RRB-
cord-021637-f5wwn45z	57	27	followed	follow	VBN
cord-021637-f5wwn45z	57	28	by	by	IN
cord-021637-f5wwn45z	57	29	labeling	labeling	NN
cord-021637-f5wwn45z	57	30	,	,	,
cord-021637-f5wwn45z	57	31	packaging	packaging	NN
cord-021637-f5wwn45z	57	32	,	,	,
cord-021637-f5wwn45z	57	33	and	and	CC
cord-021637-f5wwn45z	57	34	controlled	control	VBN
cord-021637-f5wwn45z	57	35	storage	storage	NN
cord-021637-f5wwn45z	57	36	.	.	.
cord-021637-f5wwn45z	58	1	Process	process	NN
cord-021637-f5wwn45z	58	2	development	development	NN
cord-021637-f5wwn45z	58	3	may	may	MD
cord-021637-f5wwn45z	58	4	be	be	VB
cord-021637-f5wwn45z	58	5	as	as	RB
cord-021637-f5wwn45z	58	6	costly	costly	JJ
cord-021637-f5wwn45z	58	7	as	as	IN
cord-021637-f5wwn45z	58	8	clinical	clinical	JJ
cord-021637-f5wwn45z	58	9	development	development	NN
cord-021637-f5wwn45z	58	10	and	and	CC
cord-021637-f5wwn45z	58	11	is	be	VBZ
cord-021637-f5wwn45z	58	12	critically	critically	RB
cord-021637-f5wwn45z	58	13	important	important	JJ
cord-021637-f5wwn45z	58	14	to	to	IN
cord-021637-f5wwn45z	58	15	the	the	DT
cord-021637-f5wwn45z	58	16	overall	overall	JJ
cord-021637-f5wwn45z	58	17	success	success	NN
cord-021637-f5wwn45z	58	18	of	of	IN
cord-021637-f5wwn45z	58	19	a	a	DT
cord-021637-f5wwn45z	58	20	vaccine	vaccine	NN
cord-021637-f5wwn45z	58	21	development	development	NN
cord-021637-f5wwn45z	58	22	program	program	NN
cord-021637-f5wwn45z	58	23	.	.	.
cord-021637-f5wwn45z	59	1	As	as	IN
cord-021637-f5wwn45z	59	2	development	development	NN
cord-021637-f5wwn45z	59	3	proceeds	proceed	VBZ
cord-021637-f5wwn45z	59	4	toward	toward	IN
cord-021637-f5wwn45z	59	5	licensure	licensure	NN
cord-021637-f5wwn45z	59	6	,	,	,
cord-021637-f5wwn45z	59	7	costs	cost	NNS
cord-021637-f5wwn45z	59	8	escalate	escalate	VBP
cord-021637-f5wwn45z	59	9	as	as	IN
cord-021637-f5wwn45z	59	10	clinical	clinical	JJ
cord-021637-f5wwn45z	59	11	studies	study	NNS
cord-021637-f5wwn45z	59	12	become	become	VBP
cord-021637-f5wwn45z	59	13	larger	large	JJR
cord-021637-f5wwn45z	59	14	,	,	,
cord-021637-f5wwn45z	59	15	manufacturing	manufacturing	NN
cord-021637-f5wwn45z	59	16	scales	scale	NNS
cord-021637-f5wwn45z	59	17	up	up	RP
cord-021637-f5wwn45z	59	18	,	,	,
cord-021637-f5wwn45z	59	19	and	and	CC
cord-021637-f5wwn45z	59	20	facilities	facility	NNS
cord-021637-f5wwn45z	59	21	must	must	MD
cord-021637-f5wwn45z	59	22	be	be	VB
cord-021637-f5wwn45z	59	23	built	build	VBN
cord-021637-f5wwn45z	59	24	.	.	.
cord-021637-f5wwn45z	60	1	Postlicensure	Postlicensure	NNP
cord-021637-f5wwn45z	60	2	studies	study	NNS
cord-021637-f5wwn45z	60	3	of	of	IN
cord-021637-f5wwn45z	60	4	safety	safety	NN
cord-021637-f5wwn45z	60	5	and	and	CC
cord-021637-f5wwn45z	60	6	efficacy	efficacy	NN
cord-021637-f5wwn45z	60	7	(	(	-LRB-
cord-021637-f5wwn45z	60	8	phase	phase	NN
cord-021637-f5wwn45z	60	9	4	4	CD
cord-021637-f5wwn45z	60	10	)	)	-RRB-
cord-021637-f5wwn45z	60	11	of	of	IN
cord-021637-f5wwn45z	60	12	vaccines	vaccine	NNS
cord-021637-f5wwn45z	60	13	are	be	VBP
cord-021637-f5wwn45z	60	14	essential	essential	JJ
cord-021637-f5wwn45z	60	15	and	and	CC
cord-021637-f5wwn45z	60	16	represent	represent	VBP
cord-021637-f5wwn45z	60	17	a	a	DT
cord-021637-f5wwn45z	60	18	large	large	JJ
cord-021637-f5wwn45z	60	19	additional	additional	JJ
cord-021637-f5wwn45z	60	20	cost	cost	NN
cord-021637-f5wwn45z	60	21	.	.	.
cord-021637-f5wwn45z	61	1	It	-PRON-	PRP
cord-021637-f5wwn45z	61	2	is	be	VBZ
cord-021637-f5wwn45z	61	3	important	important	JJ
cord-021637-f5wwn45z	61	4	to	to	TO
cord-021637-f5wwn45z	61	5	note	note	VB
cord-021637-f5wwn45z	61	6	that	that	IN
cord-021637-f5wwn45z	61	7	,	,	,
cord-021637-f5wwn45z	61	8	unlike	unlike	IN
cord-021637-f5wwn45z	61	9	pharmaceuticals	pharmaceutical	NNS
cord-021637-f5wwn45z	61	10	,	,	,
cord-021637-f5wwn45z	61	11	vaccines	vaccine	NNS
cord-021637-f5wwn45z	61	12	that	that	WDT
cord-021637-f5wwn45z	61	13	pass	pass	VBP
cord-021637-f5wwn45z	61	14	early	early	JJ
cord-021637-f5wwn45z	61	15	proof	proof	NN
cord-021637-f5wwn45z	61	16	-	-	HYPH
cord-021637-f5wwn45z	61	17	of	of	IN
cord-021637-f5wwn45z	61	18	-	-	HYPH
cord-021637-f5wwn45z	61	19	concept	concept	NN
cord-021637-f5wwn45z	61	20	studies	study	NNS
cord-021637-f5wwn45z	61	21	in	in	IN
cord-021637-f5wwn45z	61	22	humans	human	NNS
cord-021637-f5wwn45z	61	23	have	have	VBP
cord-021637-f5wwn45z	61	24	a	a	DT
cord-021637-f5wwn45z	61	25	very	very	RB
cord-021637-f5wwn45z	61	26	high	high	JJ
cord-021637-f5wwn45z	61	27	probability	probability	NN
cord-021637-f5wwn45z	61	28	of	of	IN
cord-021637-f5wwn45z	61	29	achieving	achieve	VBG
cord-021637-f5wwn45z	61	30	licensure	licensure	NN
cord-021637-f5wwn45z	61	31	.	.	.
cord-021637-f5wwn45z	62	1	Clinical	clinical	JJ
cord-021637-f5wwn45z	62	2	activities	activity	NNS
cord-021637-f5wwn45z	62	3	are	be	VBP
cord-021637-f5wwn45z	62	4	more	more	RBR
cord-021637-f5wwn45z	62	5	visible	visible	JJ
cord-021637-f5wwn45z	62	6	than	than	IN
cord-021637-f5wwn45z	62	7	bioprocess	bioprocess	NN
cord-021637-f5wwn45z	62	8	development	development	NN
cord-021637-f5wwn45z	62	9	and	and	CC
cord-021637-f5wwn45z	62	10	clearly	clearly	RB
cord-021637-f5wwn45z	62	11	drive	drive	VBP
cord-021637-f5wwn45z	62	12	the	the	DT
cord-021637-f5wwn45z	62	13	go	go	NN
cord-021637-f5wwn45z	62	14	/	/	SYM
cord-021637-f5wwn45z	62	15	no	no	DT
cord-021637-f5wwn45z	62	16	-	-	HYPH
cord-021637-f5wwn45z	62	17	go	go	JJ
cord-021637-f5wwn45z	62	18	decisions	decision	NNS
cord-021637-f5wwn45z	62	19	that	that	WDT
cord-021637-f5wwn45z	62	20	direct	direct	JJ
cord-021637-f5wwn45z	62	21	progress	progress	NN
cord-021637-f5wwn45z	62	22	.	.	.
cord-021637-f5wwn45z	63	1	The	the	DT
cord-021637-f5wwn45z	63	2	two	two	CD
cord-021637-f5wwn45z	63	3	are	be	VBP
cord-021637-f5wwn45z	63	4	interwoven	interwoven	JJ
cord-021637-f5wwn45z	63	5	and	and	CC
cord-021637-f5wwn45z	63	6	each	each	DT
cord-021637-f5wwn45z	63	7	has	have	VBZ
cord-021637-f5wwn45z	63	8	rate	rate	NN
cord-021637-f5wwn45z	63	9	-	-	HYPH
cord-021637-f5wwn45z	63	10	limiting	limit	VBG
cord-021637-f5wwn45z	63	11	steps	step	NNS
cord-021637-f5wwn45z	63	12	,	,	,
cord-021637-f5wwn45z	63	13	so	so	IN
cord-021637-f5wwn45z	63	14	they	-PRON-	PRP
cord-021637-f5wwn45z	63	15	must	must	MD
cord-021637-f5wwn45z	63	16	be	be	VB
cord-021637-f5wwn45z	63	17	done	do	VBN
cord-021637-f5wwn45z	63	18	in	in	IN
cord-021637-f5wwn45z	63	19	concert	concert	NN
cord-021637-f5wwn45z	63	20	.	.	.
cord-021637-f5wwn45z	64	1	The	the	DT
cord-021637-f5wwn45z	64	2	first	first	JJ
cord-021637-f5wwn45z	64	3	stage	stage	NN
cord-021637-f5wwn45z	64	4	of	of	IN
cord-021637-f5wwn45z	64	5	vaccine	vaccine	NN
cord-021637-f5wwn45z	64	6	development	development	NN
cord-021637-f5wwn45z	64	7	involves	involve	VBZ
cord-021637-f5wwn45z	64	8	acceptance	acceptance	NN
cord-021637-f5wwn45z	64	9	of	of	IN
cord-021637-f5wwn45z	64	10	a	a	DT
cord-021637-f5wwn45z	64	11	candidate	candidate	NN
cord-021637-f5wwn45z	64	12	from	from	IN
cord-021637-f5wwn45z	64	13	a	a	DT
cord-021637-f5wwn45z	64	14	basic	basic	JJ
cord-021637-f5wwn45z	64	15	research	research	NN
cord-021637-f5wwn45z	64	16	laboratory	laboratory	NN
cord-021637-f5wwn45z	64	17	and	and	CC
cord-021637-f5wwn45z	64	18	development	development	NN
cord-021637-f5wwn45z	64	19	of	of	IN
cord-021637-f5wwn45z	64	20	a	a	DT
cord-021637-f5wwn45z	64	21	small	small	JJ
cord-021637-f5wwn45z	64	22	-	-	HYPH
cord-021637-f5wwn45z	64	23	scale	scale	NN
cord-021637-f5wwn45z	64	24	process	process	NN
cord-021637-f5wwn45z	64	25	and	and	CC
cord-021637-f5wwn45z	64	26	formulation	formulation	NN
cord-021637-f5wwn45z	64	27	to	to	TO
cord-021637-f5wwn45z	64	28	make	make	VB
cord-021637-f5wwn45z	64	29	material	material	NN
cord-021637-f5wwn45z	64	30	for	for	IN
cord-021637-f5wwn45z	64	31	Phase	phase	NN
cord-021637-f5wwn45z	65	1	I	-PRON-	PRP
cord-021637-f5wwn45z	65	2	study	study	VBP
cord-021637-f5wwn45z	65	3	,	,	,
cord-021637-f5wwn45z	65	4	analytical	analytical	JJ
cord-021637-f5wwn45z	65	5	release	release	NN
cord-021637-f5wwn45z	65	6	assays	assay	NNS
cord-021637-f5wwn45z	65	7	,	,	,
cord-021637-f5wwn45z	65	8	preclinical	preclinical	JJ
cord-021637-f5wwn45z	65	9	toxicology	toxicology	NN
cord-021637-f5wwn45z	65	10	,	,	,
cord-021637-f5wwn45z	65	11	immunological	immunological	JJ
cord-021637-f5wwn45z	65	12	assays	assay	NNS
cord-021637-f5wwn45z	65	13	to	to	TO
cord-021637-f5wwn45z	65	14	evaluate	evaluate	VB
cord-021637-f5wwn45z	65	15	clinical	clinical	JJ
cord-021637-f5wwn45z	65	16	responses	response	NNS
cord-021637-f5wwn45z	65	17	,	,	,
cord-021637-f5wwn45z	65	18	an	an	DT
cord-021637-f5wwn45z	65	19	investigational	investigational	JJ
cord-021637-f5wwn45z	65	20	new	new	JJ
cord-021637-f5wwn45z	65	21	drug	drug	NN
cord-021637-f5wwn45z	65	22	(	(	-LRB-
cord-021637-f5wwn45z	65	23	IND	IND	NNP
cord-021637-f5wwn45z	65	24	)	)	-RRB-
cord-021637-f5wwn45z	65	25	filing	filing	NN
cord-021637-f5wwn45z	65	26	,	,	,
cord-021637-f5wwn45z	65	27	and	and	CC
cord-021637-f5wwn45z	65	28	well	well	RB
cord-021637-f5wwn45z	65	29	-	-	HYPH
cord-021637-f5wwn45z	65	30	designed	design	VBN
cord-021637-f5wwn45z	66	1	Phase	phase	NN
cord-021637-f5wwn45z	66	2	I	I	NNP
cord-021637-f5wwn45z	66	3	/	/	SYM
cord-021637-f5wwn45z	66	4	IIa	IIa	NNP
cord-021637-f5wwn45z	66	5	studies	study	NNS
cord-021637-f5wwn45z	66	6	.	.	.
cord-021637-f5wwn45z	67	1	The	the	DT
cord-021637-f5wwn45z	67	2	second	second	JJ
cord-021637-f5wwn45z	67	3	step	step	NN
cord-021637-f5wwn45z	67	4	is	be	VBZ
cord-021637-f5wwn45z	67	5	to	to	TO
cord-021637-f5wwn45z	67	6	complete	complete	VB
cord-021637-f5wwn45z	67	7	the	the	DT
cord-021637-f5wwn45z	67	8	definition	definition	NN
cord-021637-f5wwn45z	67	9	of	of	IN
cord-021637-f5wwn45z	67	10	product	product	NN
cord-021637-f5wwn45z	67	11	and	and	CC
cord-021637-f5wwn45z	67	12	process	process	NN
cord-021637-f5wwn45z	67	13	prior	prior	RB
cord-021637-f5wwn45z	67	14	to	to	IN
cord-021637-f5wwn45z	67	15	initiation	initiation	NN
cord-021637-f5wwn45z	67	16	of	of	IN
cord-021637-f5wwn45z	67	17	Phase	Phase	NNP
cord-021637-f5wwn45z	67	18	II	II	NNP
cord-021637-f5wwn45z	67	19	dose	dose	NN
cord-021637-f5wwn45z	67	20	-	-	HYPH
cord-021637-f5wwn45z	67	21	ranging	range	VBG
cord-021637-f5wwn45z	67	22	studies	study	NNS
cord-021637-f5wwn45z	67	23	,	,	,
cord-021637-f5wwn45z	67	24	which	which	WDT
cord-021637-f5wwn45z	67	25	may	may	MD
cord-021637-f5wwn45z	67	26	take	take	VB
cord-021637-f5wwn45z	67	27	a	a	DT
cord-021637-f5wwn45z	67	28	year	year	NN
cord-021637-f5wwn45z	67	29	or	or	CC
cord-021637-f5wwn45z	67	30	more	more	JJR
cord-021637-f5wwn45z	67	31	.	.	.
cord-021637-f5wwn45z	68	1	Product	product	NN
cord-021637-f5wwn45z	68	2	definition	definition	NN
cord-021637-f5wwn45z	68	3	includes	include	VBZ
cord-021637-f5wwn45z	68	4	methods	method	NNS
cord-021637-f5wwn45z	68	5	of	of	IN
cord-021637-f5wwn45z	68	6	synthesis	synthesis	NN
cord-021637-f5wwn45z	68	7	/	/	SYM
cord-021637-f5wwn45z	68	8	bioprocess	bioprocess	NN
cord-021637-f5wwn45z	68	9	steps	step	NNS
cord-021637-f5wwn45z	68	10	,	,	,
cord-021637-f5wwn45z	68	11	number	number	NN
cord-021637-f5wwn45z	68	12	of	of	IN
cord-021637-f5wwn45z	68	13	components	component	NNS
cord-021637-f5wwn45z	68	14	,	,	,
cord-021637-f5wwn45z	68	15	and	and	CC
cord-021637-f5wwn45z	68	16	stability	stability	NN
cord-021637-f5wwn45z	68	17	/	/	SYM
cord-021637-f5wwn45z	68	18	formulation	formulation	NN
cord-021637-f5wwn45z	68	19	.	.	.
cord-021637-f5wwn45z	69	1	Stability	stability	NN
cord-021637-f5wwn45z	69	2	,	,	,
cord-021637-f5wwn45z	69	3	release	release	NN
cord-021637-f5wwn45z	69	4	,	,	,
cord-021637-f5wwn45z	69	5	and	and	CC
cord-021637-f5wwn45z	69	6	raw	raw	JJ
cord-021637-f5wwn45z	69	7	material	material	NN
cord-021637-f5wwn45z	69	8	assays	assay	NNS
cord-021637-f5wwn45z	69	9	must	must	MD
cord-021637-f5wwn45z	69	10	be	be	VB
cord-021637-f5wwn45z	69	11	in	in	IN
cord-021637-f5wwn45z	69	12	place	place	NN
cord-021637-f5wwn45z	69	13	.	.	.
cord-021637-f5wwn45z	70	1	Immunologic	immunologic	JJ
cord-021637-f5wwn45z	70	2	and	and	CC
cord-021637-f5wwn45z	70	3	other	other	JJ
cord-021637-f5wwn45z	70	4	assays	assay	NNS
cord-021637-f5wwn45z	70	5	must	must	MD
cord-021637-f5wwn45z	70	6	be	be	VB
cord-021637-f5wwn45z	70	7	established	establish	VBN
cord-021637-f5wwn45z	70	8	to	to	TO
cord-021637-f5wwn45z	70	9	support	support	VB
cord-021637-f5wwn45z	70	10	dose	dose	NN
cord-021637-f5wwn45z	70	11	-	-	HYPH
cord-021637-f5wwn45z	70	12	ranging	range	VBG
cord-021637-f5wwn45z	70	13	studies	study	NNS
cord-021637-f5wwn45z	70	14	,	,	,
cord-021637-f5wwn45z	70	15	and	and	CC
cord-021637-f5wwn45z	70	16	a	a	DT
cord-021637-f5wwn45z	70	17	regulatory	regulatory	JJ
cord-021637-f5wwn45z	70	18	plan	plan	NN
cord-021637-f5wwn45z	70	19	for	for	IN
cord-021637-f5wwn45z	70	20	vaccine	vaccine	NN
cord-021637-f5wwn45z	70	21	process	process	NN
cord-021637-f5wwn45z	70	22	and	and	CC
cord-021637-f5wwn45z	70	23	product	product	NN
cord-021637-f5wwn45z	70	24	submissions	submission	NNS
cord-021637-f5wwn45z	70	25	must	must	MD
cord-021637-f5wwn45z	70	26	be	be	VB
cord-021637-f5wwn45z	70	27	written	write	VBN
cord-021637-f5wwn45z	70	28	.	.	.
cord-021637-f5wwn45z	71	1	The	the	DT
cord-021637-f5wwn45z	71	2	third	third	JJ
cord-021637-f5wwn45z	71	3	step	step	NN
cord-021637-f5wwn45z	71	4	is	be	VBZ
cord-021637-f5wwn45z	71	5	to	to	TO
cord-021637-f5wwn45z	71	6	define	define	VB
cord-021637-f5wwn45z	71	7	the	the	DT
cord-021637-f5wwn45z	71	8	clinical	clinical	JJ
cord-021637-f5wwn45z	71	9	dose	dose	NN
cord-021637-f5wwn45z	71	10	and	and	CC
cord-021637-f5wwn45z	71	11	arrive	arrive	VB
cord-021637-f5wwn45z	71	12	at	at	IN
cord-021637-f5wwn45z	71	13	the	the	DT
cord-021637-f5wwn45z	71	14	appropriate	appropriate	JJ
cord-021637-f5wwn45z	71	15	manufacturing	manufacturing	NN
cord-021637-f5wwn45z	71	16	scale	scale	NN
cord-021637-f5wwn45z	71	17	,	,	,
cord-021637-f5wwn45z	71	18	which	which	WDT
cord-021637-f5wwn45z	71	19	may	may	MD
cord-021637-f5wwn45z	71	20	take	take	VB
cord-021637-f5wwn45z	71	21	2	2	CD
cord-021637-f5wwn45z	71	22	years	year	NNS
cord-021637-f5wwn45z	71	23	or	or	CC
cord-021637-f5wwn45z	71	24	more	more	JJR
cord-021637-f5wwn45z	71	25	.	.	.
cord-021637-f5wwn45z	72	1	It	-PRON-	PRP
cord-021637-f5wwn45z	72	2	results	result	VBZ
cord-021637-f5wwn45z	72	3	in	in	IN
cord-021637-f5wwn45z	72	4	the	the	DT
cord-021637-f5wwn45z	72	5	identification	identification	NN
cord-021637-f5wwn45z	72	6	,	,	,
cord-021637-f5wwn45z	72	7	manufacture	manufacture	NN
cord-021637-f5wwn45z	72	8	,	,	,
cord-021637-f5wwn45z	72	9	filling	fill	VBG
cord-021637-f5wwn45z	72	10	,	,	,
cord-021637-f5wwn45z	72	11	and	and	CC
cord-021637-f5wwn45z	72	12	release	release	NN
cord-021637-f5wwn45z	72	13	of	of	IN
cord-021637-f5wwn45z	72	14	clinical	clinical	JJ
cord-021637-f5wwn45z	72	15	-	-	HYPH
cord-021637-f5wwn45z	72	16	grade	grade	NN
cord-021637-f5wwn45z	72	17	vaccine	vaccine	NN
cord-021637-f5wwn45z	72	18	-	-	:
cord-021637-f5wwn45z	72	19	usually	usually	RB
cord-021637-f5wwn45z	72	20	in	in	IN
cord-021637-f5wwn45z	72	21	a	a	DT
cord-021637-f5wwn45z	72	22	pilot	pilot	NN
cord-021637-f5wwn45z	72	23	plantdemonstration	plantdemonstration	NN
cord-021637-f5wwn45z	72	24	of	of	IN
cord-021637-f5wwn45z	72	25	safety	safety	NN
cord-021637-f5wwn45z	72	26	and	and	CC
cord-021637-f5wwn45z	72	27	a	a	DT
cord-021637-f5wwn45z	72	28	dose	dose	JJ
cord-021637-f5wwn45z	72	29	response	response	NN
cord-021637-f5wwn45z	72	30	in	in	IN
cord-021637-f5wwn45z	72	31	a	a	DT
cord-021637-f5wwn45z	72	32	Phase	Phase	NNP
cord-021637-f5wwn45z	72	33	II	II	NNP
cord-021637-f5wwn45z	72	34	clinical	clinical	JJ
cord-021637-f5wwn45z	72	35	study	study	NN
cord-021637-f5wwn45z	72	36	;	;	:
cord-021637-f5wwn45z	72	37	validation	validation	NN
cord-021637-f5wwn45z	72	38	of	of	IN
cord-021637-f5wwn45z	72	39	critical	critical	JJ
cord-021637-f5wwn45z	72	40	assays	assay	NNS
cord-021637-f5wwn45z	72	41	to	to	TO
cord-021637-f5wwn45z	72	42	support	support	VB
cord-021637-f5wwn45z	72	43	Phase	Phase	NNP
cord-021637-f5wwn45z	72	44	III	iii	CD
cord-021637-f5wwn45z	72	45	clinical	clinical	JJ
cord-021637-f5wwn45z	72	46	studies	study	NNS
cord-021637-f5wwn45z	72	47	;	;	:
cord-021637-f5wwn45z	72	48	consistency	consistency	NN
cord-021637-f5wwn45z	72	49	of	of	IN
cord-021637-f5wwn45z	72	50	lot	lot	NN
cord-021637-f5wwn45z	72	51	manufacture	manufacture	NN
cord-021637-f5wwn45z	72	52	(	(	-LRB-
cord-021637-f5wwn45z	72	53	ability	ability	NN
cord-021637-f5wwn45z	72	54	to	to	TO
cord-021637-f5wwn45z	72	55	produce	produce	VB
cord-021637-f5wwn45z	72	56	three	three	CD
cord-021637-f5wwn45z	72	57	or	or	CC
cord-021637-f5wwn45z	72	58	more	more	JJR
cord-021637-f5wwn45z	72	59	consecutive	consecutive	JJ
cord-021637-f5wwn45z	72	60	production	production	NN
cord-021637-f5wwn45z	72	61	-	-	HYPH
cord-021637-f5wwn45z	72	62	scale	scale	NN
cord-021637-f5wwn45z	72	63	lots	lot	NNS
cord-021637-f5wwn45z	72	64	that	that	WDT
cord-021637-f5wwn45z	72	65	meet	meet	VBP
cord-021637-f5wwn45z	72	66	all	all	DT
cord-021637-f5wwn45z	72	67	product	product	NN
cord-021637-f5wwn45z	72	68	specifications	specification	NNS
cord-021637-f5wwn45z	72	69	based	base	VBN
cord-021637-f5wwn45z	72	70	on	on	IN
cord-021637-f5wwn45z	72	71	validated	validate	VBN
cord-021637-f5wwn45z	72	72	analytical	analytical	JJ
cord-021637-f5wwn45z	72	73	methods	method	NNS
cord-021637-f5wwn45z	72	74	)	)	-RRB-
cord-021637-f5wwn45z	72	75	;	;	:
cord-021637-f5wwn45z	72	76	and	and	CC
cord-021637-f5wwn45z	72	77	completion	completion	NN
cord-021637-f5wwn45z	72	78	of	of	IN
cord-021637-f5wwn45z	72	79	technology	technology	NN
cord-021637-f5wwn45z	72	80	transfer	transfer	NN
cord-021637-f5wwn45z	72	81	to	to	IN
cord-021637-f5wwn45z	72	82	final	final	JJ
cord-021637-f5wwn45z	72	83	site	site	NN
cord-021637-f5wwn45z	72	84	material	material	NN
cord-021637-f5wwn45z	72	85	manufactured	manufacture	VBN
cord-021637-f5wwn45z	72	86	in	in	IN
cord-021637-f5wwn45z	72	87	the	the	DT
cord-021637-f5wwn45z	72	88	commercial	commercial	JJ
cord-021637-f5wwn45z	72	89	factory	factory	NN
cord-021637-f5wwn45z	72	90	.	.	.
cord-021637-f5wwn45z	73	1	This	this	DT
cord-021637-f5wwn45z	73	2	is	be	VBZ
cord-021637-f5wwn45z	73	3	especially	especially	RB
cord-021637-f5wwn45z	73	4	difficult	difficult	JJ
cord-021637-f5wwn45z	73	5	if	if	IN
cord-021637-f5wwn45z	73	6	immune	immune	JJ
cord-021637-f5wwn45z	73	7	studies	study	NNS
cord-021637-f5wwn45z	73	8	are	be	VBP
cord-021637-f5wwn45z	73	9	not	not	RB
cord-021637-f5wwn45z	73	10	highly	highly	RB
cord-021637-f5wwn45z	73	11	reproducible	reproducible	JJ
cord-021637-f5wwn45z	73	12	,	,	,
cord-021637-f5wwn45z	73	13	as	as	IN
cord-021637-f5wwn45z	73	14	is	be	VBZ
cord-021637-f5wwn45z	73	15	the	the	DT
cord-021637-f5wwn45z	73	16	case	case	NN
cord-021637-f5wwn45z	73	17	with	with	IN
cord-021637-f5wwn45z	73	18	most	most	JJS
cord-021637-f5wwn45z	73	19	cellular	cellular	JJ
cord-021637-f5wwn45z	73	20	immune	immune	JJ
cord-021637-f5wwn45z	73	21	assays	assay	NNS
cord-021637-f5wwn45z	73	22	.	.	.
cord-021637-f5wwn45z	74	1	Such	such	JJ
cord-021637-f5wwn45z	74	2	decisions	decision	NNS
cord-021637-f5wwn45z	74	3	pose	pose	VBP
cord-021637-f5wwn45z	74	4	large	large	JJ
cord-021637-f5wwn45z	74	5	financial	financial	JJ
cord-021637-f5wwn45z	74	6	risks	risk	NNS
cord-021637-f5wwn45z	74	7	if	if	IN
cord-021637-f5wwn45z	74	8	the	the	DT
cord-021637-f5wwn45z	74	9	product	product	NN
cord-021637-f5wwn45z	74	10	in	in	IN
cord-021637-f5wwn45z	74	11	development	development	NN
cord-021637-f5wwn45z	74	12	fails	fail	VBZ
cord-021637-f5wwn45z	74	13	and	and	CC
cord-021637-f5wwn45z	74	14	requires	require	VBZ
cord-021637-f5wwn45z	74	15	access	access	NN
cord-021637-f5wwn45z	74	16	to	to	IN
cord-021637-f5wwn45z	74	17	large	large	JJ
cord-021637-f5wwn45z	74	18	amounts	amount	NNS
cord-021637-f5wwn45z	74	19	of	of	IN
cord-021637-f5wwn45z	74	20	capital	capital	NN
cord-021637-f5wwn45z	74	21	,	,	,
cord-021637-f5wwn45z	74	22	an	an	DT
cord-021637-f5wwn45z	74	23	attribute	attribute	NN
cord-021637-f5wwn45z	74	24	usually	usually	RB
cord-021637-f5wwn45z	74	25	restricted	restrict	VBN
cord-021637-f5wwn45z	74	26	to	to	IN
cord-021637-f5wwn45z	74	27	large	large	JJ
cord-021637-f5wwn45z	74	28	pharmaceutical	pharmaceutical	JJ
cord-021637-f5wwn45z	74	29	companies	company	NNS
cord-021637-f5wwn45z	74	30	.	.	.
cord-021637-f5wwn45z	75	1	Estimates	estimate	NNS
cord-021637-f5wwn45z	75	2	of	of	IN
cord-021637-f5wwn45z	75	3	cost	cost	NN
cord-021637-f5wwn45z	75	4	of	of	IN
cord-021637-f5wwn45z	75	5	development	development	NN
cord-021637-f5wwn45z	75	6	of	of	IN
cord-021637-f5wwn45z	75	7	a	a	DT
cord-021637-f5wwn45z	75	8	new	new	JJ
cord-021637-f5wwn45z	75	9	drug	drug	NN
cord-021637-f5wwn45z	75	10	or	or	CC
cord-021637-f5wwn45z	75	11	vaccine	vaccine	NN
cord-021637-f5wwn45z	75	12	have	have	VBP
cord-021637-f5wwn45z	75	13	risen	rise	VBN
cord-021637-f5wwn45z	75	14	from	from	IN
cord-021637-f5wwn45z	75	15	$	$	$
cord-021637-f5wwn45z	75	16	231	231	CD
cord-021637-f5wwn45z	75	17	million	million	CD
cord-021637-f5wwn45z	75	18	in	in	IN
cord-021637-f5wwn45z	75	19	1991	1991	CD
cord-021637-f5wwn45z	75	20	,	,	,
cord-021637-f5wwn45z	75	21	to	to	IN
cord-021637-f5wwn45z	75	22	$	$	$
cord-021637-f5wwn45z	75	23	802	802	CD
cord-021637-f5wwn45z	75	24	million	million	CD
cord-021637-f5wwn45z	75	25	in	in	IN
cord-021637-f5wwn45z	75	26	2003	2003	CD
cord-021637-f5wwn45z	75	27	,	,	,
cord-021637-f5wwn45z	75	28	to	to	IN
cord-021637-f5wwn45z	75	29	$	$	$
cord-021637-f5wwn45z	75	30	1	1	CD
cord-021637-f5wwn45z	75	31	billion	billion	CD
cord-021637-f5wwn45z	75	32	in	in	IN
cord-021637-f5wwn45z	75	33	2010	2010	CD
cord-021637-f5wwn45z	75	34	.	.	.
cord-021637-f5wwn45z	76	1	[	[	-LRB-
cord-021637-f5wwn45z	76	2	7	7	CD
cord-021637-f5wwn45z	76	3	]	]	-RRB-
cord-021637-f5wwn45z	76	4	[	[	-LRB-
cord-021637-f5wwn45z	76	5	8	8	CD
cord-021637-f5wwn45z	76	6	]	]	-RRB-
cord-021637-f5wwn45z	76	7	[	[	-LRB-
cord-021637-f5wwn45z	76	8	9	9	CD
cord-021637-f5wwn45z	76	9	]	]	-RRB-
cord-021637-f5wwn45z	77	1	These	these	DT
cord-021637-f5wwn45z	77	2	estimates	estimate	NNS
cord-021637-f5wwn45z	77	3	take	take	VBP
cord-021637-f5wwn45z	77	4	into	into	IN
cord-021637-f5wwn45z	77	5	account	account	NN
cord-021637-f5wwn45z	77	6	all	all	DT
cord-021637-f5wwn45z	77	7	costs	cost	NNS
cord-021637-f5wwn45z	77	8	,	,	,
cord-021637-f5wwn45z	77	9	including	include	VBG
cord-021637-f5wwn45z	77	10	R&D	r&d	NN
cord-021637-f5wwn45z	77	11	costs	cost	NNS
cord-021637-f5wwn45z	77	12	of	of	IN
cord-021637-f5wwn45z	77	13	products	product	NNS
cord-021637-f5wwn45z	77	14	that	that	WDT
cord-021637-f5wwn45z	77	15	fail	fail	VBP
cord-021637-f5wwn45z	77	16	,	,	,
cord-021637-f5wwn45z	77	17	postlicensure	postlicensure	VB
cord-021637-f5wwn45z	77	18	clinical	clinical	JJ
cord-021637-f5wwn45z	77	19	studies	study	NNS
cord-021637-f5wwn45z	77	20	,	,	,
cord-021637-f5wwn45z	77	21	and	and	CC
cord-021637-f5wwn45z	77	22	improvements	improvement	NNS
cord-021637-f5wwn45z	77	23	in	in	IN
cord-021637-f5wwn45z	77	24	manufacturing	manufacturing	NN
cord-021637-f5wwn45z	77	25	processes	process	NNS
cord-021637-f5wwn45z	77	26	.	.	.
cord-021637-f5wwn45z	78	1	Approximately	approximately	RB
cord-021637-f5wwn45z	78	2	50	50	CD
cord-021637-f5wwn45z	78	3	%	%	NN
cord-021637-f5wwn45z	78	4	of	of	IN
cord-021637-f5wwn45z	78	5	the	the	DT
cord-021637-f5wwn45z	78	6	cost	cost	NN
cord-021637-f5wwn45z	78	7	is	be	VBZ
cord-021637-f5wwn45z	78	8	for	for	IN
cord-021637-f5wwn45z	78	9	construction	construction	NN
cord-021637-f5wwn45z	78	10	;	;	:
cord-021637-f5wwn45z	78	11	the	the	DT
cord-021637-f5wwn45z	78	12	remainder	remainder	NN
cord-021637-f5wwn45z	78	13	is	be	VBZ
cord-021637-f5wwn45z	78	14	the	the	DT
cord-021637-f5wwn45z	78	15	cost	cost	NN
cord-021637-f5wwn45z	78	16	of	of	IN
cord-021637-f5wwn45z	78	17	capital	capital	NN
cord-021637-f5wwn45z	78	18	interest	interest	NN
cord-021637-f5wwn45z	78	19	.	.	.
cord-021637-f5wwn45z	79	1	These	these	DT
cord-021637-f5wwn45z	79	2	numbers	number	NNS
cord-021637-f5wwn45z	79	3	have	have	VBP
cord-021637-f5wwn45z	79	4	been	be	VBN
cord-021637-f5wwn45z	79	5	debated	debate	VBN
cord-021637-f5wwn45z	79	6	(	(	-LRB-
cord-021637-f5wwn45z	79	7	others	other	NNS
cord-021637-f5wwn45z	79	8	estimate	estimate	VBP
cord-021637-f5wwn45z	79	9	$	$	$
cord-021637-f5wwn45z	79	10	100	100	CD
cord-021637-f5wwn45z	79	11	million	million	CD
cord-021637-f5wwn45z	79	12	to	to	TO
cord-021637-f5wwn45z	79	13	$	$	$
cord-021637-f5wwn45z	79	14	200	200	CD
cord-021637-f5wwn45z	79	15	million	million	CD
cord-021637-f5wwn45z	79	16	)	)	-RRB-
cord-021637-f5wwn45z	79	17	;	;	:
cord-021637-f5wwn45z	79	18	however	however	RB
cord-021637-f5wwn45z	79	19	,	,	,
cord-021637-f5wwn45z	79	20	the	the	DT
cord-021637-f5wwn45z	79	21	higher	high	JJR
cord-021637-f5wwn45z	79	22	estimates	estimate	NNS
cord-021637-f5wwn45z	79	23	have	have	VBP
cord-021637-f5wwn45z	79	24	been	be	VBN
cord-021637-f5wwn45z	79	25	validated	validate	VBN
cord-021637-f5wwn45z	79	26	in	in	IN
cord-021637-f5wwn45z	79	27	two	two	CD
cord-021637-f5wwn45z	79	28	ways	way	NNS
cord-021637-f5wwn45z	79	29	.	.	.
cord-021637-f5wwn45z	80	1	First	first	RB
cord-021637-f5wwn45z	80	2	,	,	,
cord-021637-f5wwn45z	80	3	the	the	DT
cord-021637-f5wwn45z	80	4	number	number	NN
cord-021637-f5wwn45z	80	5	of	of	IN
cord-021637-f5wwn45z	80	6	new	new	JJ
cord-021637-f5wwn45z	80	7	vaccines	vaccine	NNS
cord-021637-f5wwn45z	80	8	brought	bring	VBN
cord-021637-f5wwn45z	80	9	to	to	IN
cord-021637-f5wwn45z	80	10	licensure	licensure	NN
cord-021637-f5wwn45z	80	11	annually	annually	RB
cord-021637-f5wwn45z	80	12	by	by	IN
cord-021637-f5wwn45z	80	13	a	a	DT
cord-021637-f5wwn45z	80	14	company	company	NN
cord-021637-f5wwn45z	80	15	or	or	CC
cord-021637-f5wwn45z	80	16	the	the	DT
cord-021637-f5wwn45z	80	17	industry	industry	NN
cord-021637-f5wwn45z	80	18	is	be	VBZ
cord-021637-f5wwn45z	80	19	very	very	RB
cord-021637-f5wwn45z	80	20	small	small	JJ
cord-021637-f5wwn45z	80	21	compared	compare	VBN
cord-021637-f5wwn45z	80	22	with	with	IN
cord-021637-f5wwn45z	80	23	other	other	JJ
cord-021637-f5wwn45z	80	24	products	product	NNS
cord-021637-f5wwn45z	80	25	,	,	,
cord-021637-f5wwn45z	80	26	and	and	CC
cord-021637-f5wwn45z	80	27	correlates	correlate	VBZ
cord-021637-f5wwn45z	80	28	with	with	IN
cord-021637-f5wwn45z	80	29	R&D	r&d	NN
cord-021637-f5wwn45z	80	30	expenditures	expenditure	NNS
cord-021637-f5wwn45z	80	31	of	of	IN
cord-021637-f5wwn45z	80	32	$	$	$
cord-021637-f5wwn45z	80	33	600	600	CD
cord-021637-f5wwn45z	80	34	million	million	CD
cord-021637-f5wwn45z	80	35	to	to	TO
cord-021637-f5wwn45z	80	36	$	$	$
cord-021637-f5wwn45z	80	37	800	800	CD
cord-021637-f5wwn45z	80	38	million	million	CD
cord-021637-f5wwn45z	80	39	for	for	IN
cord-021637-f5wwn45z	80	40	each	each	DT
cord-021637-f5wwn45z	80	41	new	new	JJ
cord-021637-f5wwn45z	80	42	product	product	NN
cord-021637-f5wwn45z	80	43	.	.	.
cord-021637-f5wwn45z	81	1	Thus	thus	RB
cord-021637-f5wwn45z	81	2	,	,	,
cord-021637-f5wwn45z	81	3	if	if	IN
cord-021637-f5wwn45z	81	4	a	a	DT
cord-021637-f5wwn45z	81	5	company	company	NN
cord-021637-f5wwn45z	81	6	spends	spend	VBZ
cord-021637-f5wwn45z	81	7	$	$	$
cord-021637-f5wwn45z	81	8	100	100	CD
cord-021637-f5wwn45z	81	9	million	million	CD
cord-021637-f5wwn45z	81	10	annually	annually	RB
cord-021637-f5wwn45z	81	11	for	for	IN
cord-021637-f5wwn45z	81	12	vaccine	vaccine	NN
cord-021637-f5wwn45z	81	13	R&D	r&d	NN
cord-021637-f5wwn45z	81	14	,	,	,
cord-021637-f5wwn45z	81	15	one	one	PRP
cord-021637-f5wwn45z	81	16	might	may	MD
cord-021637-f5wwn45z	81	17	expect	expect	VB
cord-021637-f5wwn45z	81	18	one	one	CD
cord-021637-f5wwn45z	81	19	new	new	JJ
cord-021637-f5wwn45z	81	20	product	product	NN
cord-021637-f5wwn45z	81	21	every	every	DT
cord-021637-f5wwn45z	81	22	6	6	CD
cord-021637-f5wwn45z	81	23	to	to	TO
cord-021637-f5wwn45z	81	24	8	8	CD
cord-021637-f5wwn45z	81	25	years	year	NNS
cord-021637-f5wwn45z	81	26	,	,	,
cord-021637-f5wwn45z	81	27	and	and	CC
cord-021637-f5wwn45z	81	28	this	this	DT
cord-021637-f5wwn45z	81	29	appears	appear	VBZ
cord-021637-f5wwn45z	81	30	to	to	TO
cord-021637-f5wwn45z	81	31	hold	hold	VB
cord-021637-f5wwn45z	81	32	true	true	JJ
cord-021637-f5wwn45z	81	33	.	.	.
cord-021637-f5wwn45z	82	1	Second	second	JJ
cord-021637-f5wwn45z	82	2	,	,	,
cord-021637-f5wwn45z	82	3	biotechnology	biotechnology	NN
cord-021637-f5wwn45z	82	4	companies	company	NNS
cord-021637-f5wwn45z	82	5	that	that	WDT
cord-021637-f5wwn45z	82	6	are	be	VBP
cord-021637-f5wwn45z	82	7	focused	focus	VBN
cord-021637-f5wwn45z	82	8	on	on	IN
cord-021637-f5wwn45z	82	9	one	one	CD
cord-021637-f5wwn45z	82	10	vaccine	vaccine	NN
cord-021637-f5wwn45z	82	11	and	and	CC
cord-021637-f5wwn45z	82	12	have	have	VBP
cord-021637-f5wwn45z	82	13	successfully	successfully	RB
cord-021637-f5wwn45z	82	14	brought	bring	VBN
cord-021637-f5wwn45z	82	15	it	-PRON-	PRP
cord-021637-f5wwn45z	82	16	to	to	IN
cord-021637-f5wwn45z	82	17	market	market	NN
cord-021637-f5wwn45z	82	18	have	have	VBP
cord-021637-f5wwn45z	82	19	spent	spend	VBN
cord-021637-f5wwn45z	82	20	$	$	$
cord-021637-f5wwn45z	82	21	500	500	CD
cord-021637-f5wwn45z	82	22	million	million	CD
cord-021637-f5wwn45z	82	23	to	to	TO
cord-021637-f5wwn45z	82	24	$	$	$
cord-021637-f5wwn45z	82	25	700	700	CD
cord-021637-f5wwn45z	82	26	million	million	CD
cord-021637-f5wwn45z	82	27	on	on	IN
cord-021637-f5wwn45z	82	28	R&D	R&D	NNP
cord-021637-f5wwn45z	82	29	as	as	IN
cord-021637-f5wwn45z	82	30	exemplified	exemplify	VBN
cord-021637-f5wwn45z	82	31	by	by	IN
cord-021637-f5wwn45z	82	32	the	the	DT
cord-021637-f5wwn45z	82	33	development	development	NN
cord-021637-f5wwn45z	82	34	of	of	IN
cord-021637-f5wwn45z	82	35	the	the	DT
cord-021637-f5wwn45z	82	36	live	live	JJ
cord-021637-f5wwn45z	82	37	attenuated	attenuate	VBN
cord-021637-f5wwn45z	82	38	influenza	influenza	NN
cord-021637-f5wwn45z	82	39	vaccine	vaccine	NN
cord-021637-f5wwn45z	82	40	by	by	IN
cord-021637-f5wwn45z	82	41	Aviron	Aviron	NNP
cord-021637-f5wwn45z	82	42	,	,	,
cord-021637-f5wwn45z	82	43	now	now	RB
cord-021637-f5wwn45z	82	44	Medimmune	Medimmune	NNP
cord-021637-f5wwn45z	82	45	.	.	.
cord-021637-f5wwn45z	83	1	In	in	IN
cord-021637-f5wwn45z	83	2	summary	summary	NN
cord-021637-f5wwn45z	83	3	,	,	,
cord-021637-f5wwn45z	83	4	vaccine	vaccine	NN
cord-021637-f5wwn45z	83	5	development	development	NN
cord-021637-f5wwn45z	83	6	from	from	IN
cord-021637-f5wwn45z	83	7	concept	concept	NN
cord-021637-f5wwn45z	83	8	to	to	IN
cord-021637-f5wwn45z	83	9	licensure	licensure	NN
cord-021637-f5wwn45z	83	10	is	be	VBZ
cord-021637-f5wwn45z	83	11	a	a	DT
cord-021637-f5wwn45z	83	12	lengthy	lengthy	JJ
cord-021637-f5wwn45z	83	13	process	process	NN
cord-021637-f5wwn45z	83	14	as	as	IN
cord-021637-f5wwn45z	83	15	illustrated	illustrate	VBN
cord-021637-f5wwn45z	83	16	by	by	IN
cord-021637-f5wwn45z	83	17	timelines	timeline	NNS
cord-021637-f5wwn45z	83	18	for	for	IN
cord-021637-f5wwn45z	83	19	some	some	DT
cord-021637-f5wwn45z	83	20	of	of	IN
cord-021637-f5wwn45z	83	21	the	the	DT
cord-021637-f5wwn45z	83	22	currently	currently	RB
cord-021637-f5wwn45z	83	23	licensed	license	VBN
cord-021637-f5wwn45z	83	24	vaccines	vaccine	NNS
cord-021637-f5wwn45z	83	25	(	(	-LRB-
cord-021637-f5wwn45z	83	26	Table	table	NN
cord-021637-f5wwn45z	83	27	4	4	CD
cord-021637-f5wwn45z	83	28	.3	.3	CD
cord-021637-f5wwn45z	83	29	)	)	-RRB-
cord-021637-f5wwn45z	83	30	.	.	.
cord-021637-f5wwn45z	84	1	To	to	TO
cord-021637-f5wwn45z	84	2	understand	understand	VB
cord-021637-f5wwn45z	84	3	the	the	DT
cord-021637-f5wwn45z	84	4	predominant	predominant	JJ
cord-021637-f5wwn45z	84	5	role	role	NN
cord-021637-f5wwn45z	84	6	of	of	IN
cord-021637-f5wwn45z	84	7	major	major	JJ
cord-021637-f5wwn45z	84	8	pharmaceutical	pharmaceutical	JJ
cord-021637-f5wwn45z	84	9	companies	company	NNS
cord-021637-f5wwn45z	84	10	in	in	IN
cord-021637-f5wwn45z	84	11	the	the	DT
cord-021637-f5wwn45z	84	12	development	development	NN
cord-021637-f5wwn45z	84	13	of	of	IN
cord-021637-f5wwn45z	84	14	vaccines	vaccine	NNS
cord-021637-f5wwn45z	84	15	,	,	,
cord-021637-f5wwn45z	84	16	one	one	PRP
cord-021637-f5wwn45z	84	17	must	must	MD
cord-021637-f5wwn45z	84	18	examine	examine	VB
cord-021637-f5wwn45z	84	19	the	the	DT
cord-021637-f5wwn45z	84	20	role	role	NN
cord-021637-f5wwn45z	84	21	of	of	IN
cord-021637-f5wwn45z	84	22	a	a	DT
cord-021637-f5wwn45z	84	23	vaccine	vaccine	NN
cord-021637-f5wwn45z	84	24	development	development	NN
cord-021637-f5wwn45z	84	25	company	company	NN
cord-021637-f5wwn45z	84	26	in	in	IN
cord-021637-f5wwn45z	84	27	relation	relation	NN
cord-021637-f5wwn45z	84	28	to	to	IN
cord-021637-f5wwn45z	84	29	its	-PRON-	PRP$
cord-021637-f5wwn45z	84	30	of	of	IN
cord-021637-f5wwn45z	84	31	manufacture	manufacture	NN
cord-021637-f5wwn45z	84	32	of	of	IN
cord-021637-f5wwn45z	84	33	full	full	JJ
cord-021637-f5wwn45z	84	34	-	-	HYPH
cord-021637-f5wwn45z	84	35	scale	scale	NN
cord-021637-f5wwn45z	84	36	lots	lot	NNS
cord-021637-f5wwn45z	84	37	,	,	,
cord-021637-f5wwn45z	84	38	including	include	VBG
cord-021637-f5wwn45z	84	39	process	process	NN
cord-021637-f5wwn45z	84	40	and	and	CC
cord-021637-f5wwn45z	84	41	analytical	analytical	JJ
cord-021637-f5wwn45z	84	42	procedures	procedure	NNS
cord-021637-f5wwn45z	84	43	.	.	.
cord-021637-f5wwn45z	85	1	For	for	IN
cord-021637-f5wwn45z	85	2	vaccine	vaccine	NN
cord-021637-f5wwn45z	85	3	targets	target	NNS
cord-021637-f5wwn45z	85	4	for	for	IN
cord-021637-f5wwn45z	85	5	which	which	WDT
cord-021637-f5wwn45z	85	6	animal	animal	NN
cord-021637-f5wwn45z	85	7	studies	study	NNS
cord-021637-f5wwn45z	85	8	are	be	VBP
cord-021637-f5wwn45z	85	9	not	not	RB
cord-021637-f5wwn45z	85	10	predictive	predictive	JJ
cord-021637-f5wwn45z	85	11	of	of	IN
cord-021637-f5wwn45z	85	12	efficacy	efficacy	NN
cord-021637-f5wwn45z	85	13	in	in	IN
cord-021637-f5wwn45z	85	14	humans	human	NNS
cord-021637-f5wwn45z	85	15	,	,	,
cord-021637-f5wwn45z	85	16	such	such	JJ
cord-021637-f5wwn45z	85	17	as	as	IN
cord-021637-f5wwn45z	85	18	HIV	HIV	NNP
cord-021637-f5wwn45z	85	19	,	,	,
cord-021637-f5wwn45z	85	20	malaria	malaria	NN
cord-021637-f5wwn45z	85	21	,	,	,
cord-021637-f5wwn45z	85	22	and	and	CC
cord-021637-f5wwn45z	85	23	tuberculosis	tuberculosis	NN
cord-021637-f5wwn45z	85	24	(	(	-LRB-
cord-021637-f5wwn45z	85	25	TB	TB	NNP
cord-021637-f5wwn45z	85	26	)	)	-RRB-
cord-021637-f5wwn45z	85	27	,	,	,
cord-021637-f5wwn45z	85	28	small	small	JJ
cord-021637-f5wwn45z	85	29	Phase	Phase	NNP
cord-021637-f5wwn45z	85	30	IIb	iib	JJ
cord-021637-f5wwn45z	85	31	proof	proof	NN
cord-021637-f5wwn45z	85	32	-	-	HYPH
cord-021637-f5wwn45z	85	33	of	of	IN
cord-021637-f5wwn45z	85	34	-	-	HYPH
cord-021637-f5wwn45z	85	35	concept	concept	NN
cord-021637-f5wwn45z	85	36	studies	study	NNS
cord-021637-f5wwn45z	85	37	based	base	VBN
cord-021637-f5wwn45z	85	38	on	on	IN
cord-021637-f5wwn45z	85	39	adaptive	adaptive	JJ
cord-021637-f5wwn45z	85	40	clinical	clinical	JJ
cord-021637-f5wwn45z	85	41	trial	trial	NN
cord-021637-f5wwn45z	85	42	designs	design	NNS
cord-021637-f5wwn45z	85	43	may	may	MD
cord-021637-f5wwn45z	85	44	be	be	VB
cord-021637-f5wwn45z	85	45	used	use	VBN
cord-021637-f5wwn45z	85	46	to	to	TO
cord-021637-f5wwn45z	85	47	gain	gain	VB
cord-021637-f5wwn45z	85	48	confidence	confidence	NN
cord-021637-f5wwn45z	85	49	before	before	IN
cord-021637-f5wwn45z	85	50	committing	commit	VBG
cord-021637-f5wwn45z	85	51	significant	significant	JJ
cord-021637-f5wwn45z	85	52	resources	resource	NNS
cord-021637-f5wwn45z	85	53	for	for	IN
cord-021637-f5wwn45z	85	54	process	process	NN
cord-021637-f5wwn45z	85	55	development	development	NN
cord-021637-f5wwn45z	85	56	,	,	,
cord-021637-f5wwn45z	85	57	analytic	analytic	JJ
cord-021637-f5wwn45z	85	58	development	development	NN
cord-021637-f5wwn45z	85	59	,	,	,
cord-021637-f5wwn45z	85	60	and	and	CC
cord-021637-f5wwn45z	85	61	factory	factory	NN
cord-021637-f5wwn45z	85	62	construction	construction	NN
cord-021637-f5wwn45z	85	63	.	.	.
cord-021637-f5wwn45z	86	1	In	in	IN
cord-021637-f5wwn45z	86	2	general	general	JJ
cord-021637-f5wwn45z	86	3	,	,	,
cord-021637-f5wwn45z	86	4	the	the	DT
cord-021637-f5wwn45z	86	5	analytical	analytical	JJ
cord-021637-f5wwn45z	86	6	and	and	CC
cord-021637-f5wwn45z	86	7	release	release	NN
cord-021637-f5wwn45z	86	8	assays	assay	NNS
cord-021637-f5wwn45z	86	9	are	be	VBP
cord-021637-f5wwn45z	86	10	particularly	particularly	RB
cord-021637-f5wwn45z	86	11	difficult	difficult	JJ
cord-021637-f5wwn45z	86	12	to	to	TO
cord-021637-f5wwn45z	86	13	develop	develop	VB
cord-021637-f5wwn45z	86	14	because	because	IN
cord-021637-f5wwn45z	86	15	,	,	,
cord-021637-f5wwn45z	86	16	in	in	IN
cord-021637-f5wwn45z	86	17	most	most	JJS
cord-021637-f5wwn45z	86	18	cases	case	NNS
cord-021637-f5wwn45z	86	19	,	,	,
cord-021637-f5wwn45z	86	20	vaccines	vaccine	NNS
cord-021637-f5wwn45z	86	21	are	be	VBP
cord-021637-f5wwn45z	86	22	considered	consider	VBN
cord-021637-f5wwn45z	86	23	"	"	``
cord-021637-f5wwn45z	86	24	not	not	RB
cord-021637-f5wwn45z	86	25	well	well	RB
cord-021637-f5wwn45z	86	26	-	-	HYPH
cord-021637-f5wwn45z	86	27	characterized	characterize	VBN
cord-021637-f5wwn45z	86	28	"	"	``
cord-021637-f5wwn45z	86	29	biologicals	biological	NNS
cord-021637-f5wwn45z	86	30	by	by	IN
cord-021637-f5wwn45z	86	31	regulatory	regulatory	JJ
cord-021637-f5wwn45z	86	32	agencies	agency	NNS
cord-021637-f5wwn45z	86	33	.	.	.
cord-021637-f5wwn45z	87	1	The	the	DT
cord-021637-f5wwn45z	87	2	release	release	NN
cord-021637-f5wwn45z	87	3	assays	assay	NNS
cord-021637-f5wwn45z	87	4	initially	initially	RB
cord-021637-f5wwn45z	87	5	involve	involve	VBP
cord-021637-f5wwn45z	87	6	functional	functional	JJ
cord-021637-f5wwn45z	87	7	potency	potency	NN
cord-021637-f5wwn45z	87	8	assays	assay	NNS
cord-021637-f5wwn45z	87	9	such	such	JJ
cord-021637-f5wwn45z	87	10	as	as	IN
cord-021637-f5wwn45z	87	11	animal	animal	NN
cord-021637-f5wwn45z	87	12	immunogenicity	immunogenicity	NN
cord-021637-f5wwn45z	87	13	prior	prior	RB
cord-021637-f5wwn45z	87	14	to	to	IN
cord-021637-f5wwn45z	87	15	acceptance	acceptance	NN
cord-021637-f5wwn45z	87	16	of	of	IN
cord-021637-f5wwn45z	87	17	more	more	RBR
cord-021637-f5wwn45z	87	18	robust	robust	JJ
cord-021637-f5wwn45z	87	19	and	and	CC
cord-021637-f5wwn45z	87	20	precise	precise	JJ
cord-021637-f5wwn45z	88	1	in	in	FW
cord-021637-f5wwn45z	88	2	vitro	vitro	FW
cord-021637-f5wwn45z	88	3	assays	assay	NNS
cord-021637-f5wwn45z	88	4	that	that	WDT
cord-021637-f5wwn45z	88	5	correlate	correlate	VBP
cord-021637-f5wwn45z	88	6	with	with	IN
cord-021637-f5wwn45z	88	7	these	these	DT
cord-021637-f5wwn45z	88	8	functional	functional	JJ
cord-021637-f5wwn45z	88	9	potency	potency	NN
cord-021637-f5wwn45z	88	10	assays	assay	NNS
cord-021637-f5wwn45z	88	11	.	.	.
cord-021637-f5wwn45z	89	1	In	in	IN
cord-021637-f5wwn45z	89	2	general	general	JJ
cord-021637-f5wwn45z	89	3	,	,	,
cord-021637-f5wwn45z	89	4	variability	variability	NN
cord-021637-f5wwn45z	89	5	of	of	IN
cord-021637-f5wwn45z	89	6	biological	biological	JJ
cord-021637-f5wwn45z	89	7	assays	assay	NNS
cord-021637-f5wwn45z	89	8	is	be	VBZ
cord-021637-f5wwn45z	89	9	a	a	DT
cord-021637-f5wwn45z	89	10	major	major	JJ
cord-021637-f5wwn45z	89	11	hurdle	hurdle	NN
cord-021637-f5wwn45z	89	12	in	in	IN
cord-021637-f5wwn45z	89	13	achieving	achieve	VBG
cord-021637-f5wwn45z	89	14	process	process	NN
cord-021637-f5wwn45z	89	15	scale	scale	NN
cord-021637-f5wwn45z	89	16	-	-	HYPH
cord-021637-f5wwn45z	89	17	up	up	NN
cord-021637-f5wwn45z	89	18	and	and	CC
cord-021637-f5wwn45z	89	19	manufacturing	manufacture	VBG
cord-021637-f5wwn45z	89	20	consistency	consistency	NN
cord-021637-f5wwn45z	89	21	.	.	.
cord-021637-f5wwn45z	90	1	The	the	DT
cord-021637-f5wwn45z	90	2	fourth	fourth	JJ
cord-021637-f5wwn45z	90	3	stage	stage	NN
cord-021637-f5wwn45z	90	4	is	be	VBZ
cord-021637-f5wwn45z	90	5	the	the	DT
cord-021637-f5wwn45z	90	6	completion	completion	NN
cord-021637-f5wwn45z	90	7	of	of	IN
cord-021637-f5wwn45z	90	8	Phase	Phase	NNP
cord-021637-f5wwn45z	90	9	III	iii	CD
cord-021637-f5wwn45z	90	10	pivotal	pivotal	JJ
cord-021637-f5wwn45z	90	11	clinical	clinical	JJ
cord-021637-f5wwn45z	90	12	studies	study	NNS
cord-021637-f5wwn45z	90	13	and	and	CC
cord-021637-f5wwn45z	90	14	corresponding	correspond	VBG
cord-021637-f5wwn45z	90	15	consistency	consistency	NN
cord-021637-f5wwn45z	90	16	lot	lot	NN
cord-021637-f5wwn45z	90	17	studies	study	NNS
cord-021637-f5wwn45z	90	18	,	,	,
cord-021637-f5wwn45z	90	19	which	which	WDT
cord-021637-f5wwn45z	90	20	requires	require	VBZ
cord-021637-f5wwn45z	90	21	3	3	CD
cord-021637-f5wwn45z	90	22	to	to	TO
cord-021637-f5wwn45z	90	23	5	5	CD
cord-021637-f5wwn45z	90	24	years	year	NNS
cord-021637-f5wwn45z	90	25	.	.	.
cord-021637-f5wwn45z	91	1	Keys	key	NNS
cord-021637-f5wwn45z	91	2	to	to	IN
cord-021637-f5wwn45z	91	3	successful	successful	JJ
cord-021637-f5wwn45z	91	4	Phase	Phase	NNP
cord-021637-f5wwn45z	91	5	III	iii	CD
cord-021637-f5wwn45z	91	6	clinical	clinical	JJ
cord-021637-f5wwn45z	91	7	studies	study	NNS
cord-021637-f5wwn45z	91	8	are	be	VBP
cord-021637-f5wwn45z	91	9	an	an	DT
cord-021637-f5wwn45z	91	10	accurate	accurate	JJ
cord-021637-f5wwn45z	91	11	estimate	estimate	NN
cord-021637-f5wwn45z	91	12	of	of	IN
cord-021637-f5wwn45z	91	13	sample	sample	NN
cord-021637-f5wwn45z	91	14	size	size	NN
cord-021637-f5wwn45z	91	15	based	base	VBN
cord-021637-f5wwn45z	91	16	on	on	IN
cord-021637-f5wwn45z	91	17	disease	disease	NN
cord-021637-f5wwn45z	91	18	incidence	incidence	NN
cord-021637-f5wwn45z	91	19	,	,	,
cord-021637-f5wwn45z	91	20	low	low	JJ
cord-021637-f5wwn45z	91	21	dropout	dropout	NN
cord-021637-f5wwn45z	91	22	rates	rate	NNS
cord-021637-f5wwn45z	91	23	,	,	,
cord-021637-f5wwn45z	91	24	precise	precise	JJ
cord-021637-f5wwn45z	91	25	clinical	clinical	JJ
cord-021637-f5wwn45z	91	26	end	end	NN
cord-021637-f5wwn45z	91	27	point	point	NN
cord-021637-f5wwn45z	91	28	definitions	definition	NNS
cord-021637-f5wwn45z	91	29	related	relate	VBN
cord-021637-f5wwn45z	91	30	to	to	IN
cord-021637-f5wwn45z	91	31	future	future	JJ
cord-021637-f5wwn45z	91	32	label	label	NN
cord-021637-f5wwn45z	91	33	claims	claim	NNS
cord-021637-f5wwn45z	91	34	,	,	,
cord-021637-f5wwn45z	91	35	and	and	CC
cord-021637-f5wwn45z	91	36	rigorous	rigorous	JJ
cord-021637-f5wwn45z	91	37	data	datum	NNS
cord-021637-f5wwn45z	91	38	management	management	NN
cord-021637-f5wwn45z	91	39	to	to	IN
cord-021637-f5wwn45z	91	40	the	the	DT
cord-021637-f5wwn45z	91	41	highest	high	JJS
cord-021637-f5wwn45z	91	42	standards	standard	NNS
cord-021637-f5wwn45z	91	43	.	.	.
cord-021637-f5wwn45z	92	1	In	in	IN
cord-021637-f5wwn45z	92	2	addition	addition	NN
cord-021637-f5wwn45z	92	3	to	to	IN
cord-021637-f5wwn45z	92	4	clinical	clinical	JJ
cord-021637-f5wwn45z	92	5	studies	study	NNS
cord-021637-f5wwn45z	92	6	,	,	,
cord-021637-f5wwn45z	92	7	scale	scale	NN
cord-021637-f5wwn45z	92	8	-	-	HYPH
cord-021637-f5wwn45z	92	9	up	up	NN
cord-021637-f5wwn45z	92	10	and	and	CC
cord-021637-f5wwn45z	92	11	manufacture	manufacture	NN
cord-021637-f5wwn45z	92	12	of	of	IN
cord-021637-f5wwn45z	92	13	consistency	consistency	NN
cord-021637-f5wwn45z	92	14	lots	lot	NNS
cord-021637-f5wwn45z	92	15	,	,	,
cord-021637-f5wwn45z	92	16	including	include	VBG
cord-021637-f5wwn45z	92	17	transfer	transfer	NN
cord-021637-f5wwn45z	92	18	to	to	IN
cord-021637-f5wwn45z	92	19	the	the	DT
cord-021637-f5wwn45z	92	20	facility	facility	NN
cord-021637-f5wwn45z	92	21	of	of	IN
cord-021637-f5wwn45z	92	22	all	all	DT
cord-021637-f5wwn45z	92	23	assays	assay	NNS
cord-021637-f5wwn45z	92	24	,	,	,
cord-021637-f5wwn45z	92	25	facility	facility	NN
cord-021637-f5wwn45z	92	26	validation	validation	NN
cord-021637-f5wwn45z	92	27	,	,	,
cord-021637-f5wwn45z	92	28	demonstration	demonstration	NN
cord-021637-f5wwn45z	92	29	of	of	IN
cord-021637-f5wwn45z	92	30	consistency	consistency	NN
cord-021637-f5wwn45z	92	31	and	and	CC
cord-021637-f5wwn45z	92	32	real	real	JJ
cord-021637-f5wwn45z	92	33	-	-	HYPH
cord-021637-f5wwn45z	92	34	time	time	NN
cord-021637-f5wwn45z	92	35	stability	stability	NN
cord-021637-f5wwn45z	92	36	are	be	VBP
cord-021637-f5wwn45z	92	37	needed	need	VBN
cord-021637-f5wwn45z	92	38	to	to	TO
cord-021637-f5wwn45z	92	39	support	support	VB
cord-021637-f5wwn45z	92	40	adequate	adequate	JJ
cord-021637-f5wwn45z	92	41	shelf	shelf	NN
cord-021637-f5wwn45z	92	42	-	-	HYPH
cord-021637-f5wwn45z	92	43	life	life	NN
cord-021637-f5wwn45z	92	44	claims	claim	NNS
cord-021637-f5wwn45z	92	45	.	.	.
cord-021637-f5wwn45z	93	1	The	the	DT
cord-021637-f5wwn45z	93	2	final	final	JJ
cord-021637-f5wwn45z	93	3	stage	stage	NN
cord-021637-f5wwn45z	93	4	is	be	VBZ
cord-021637-f5wwn45z	93	5	Biologics	Biologics	NNP
cord-021637-f5wwn45z	93	6	License	License	NNP
cord-021637-f5wwn45z	93	7	Application	Application	NNP
cord-021637-f5wwn45z	93	8	(	(	-LRB-
cord-021637-f5wwn45z	93	9	BLA	BLA	NNP
cord-021637-f5wwn45z	93	10	)	)	-RRB-
cord-021637-f5wwn45z	93	11	preparation	preparation	NN
cord-021637-f5wwn45z	93	12	,	,	,
cord-021637-f5wwn45z	93	13	licensure	licensure	NN
cord-021637-f5wwn45z	93	14	,	,	,
cord-021637-f5wwn45z	93	15	and	and	CC
cord-021637-f5wwn45z	93	16	vaccine	vaccine	NN
cord-021637-f5wwn45z	93	17	launch	launch	NN
cord-021637-f5wwn45z	93	18	,	,	,
cord-021637-f5wwn45z	93	19	which	which	WDT
cord-021637-f5wwn45z	93	20	requires	require	VBZ
cord-021637-f5wwn45z	93	21	1.5	1.5	CD
cord-021637-f5wwn45z	93	22	to	to	TO
cord-021637-f5wwn45z	93	23	2	2	CD
cord-021637-f5wwn45z	93	24	years	year	NNS
cord-021637-f5wwn45z	93	25	.	.	.
cord-021637-f5wwn45z	94	1	Thus	thus	RB
cord-021637-f5wwn45z	94	2	the	the	DT
cord-021637-f5wwn45z	94	3	total	total	JJ
cord-021637-f5wwn45z	94	4	elapsed	elapsed	JJ
cord-021637-f5wwn45z	94	5	time	time	NN
cord-021637-f5wwn45z	94	6	for	for	IN
cord-021637-f5wwn45z	94	7	development	development	NN
cord-021637-f5wwn45z	94	8	is	be	VBZ
cord-021637-f5wwn45z	94	9	10	10	CD
cord-021637-f5wwn45z	94	10	to	to	TO
cord-021637-f5wwn45z	94	11	15	15	CD
cord-021637-f5wwn45z	94	12	years	year	NNS
cord-021637-f5wwn45z	94	13	,	,	,
cord-021637-f5wwn45z	94	14	assuming	assume	VBG
cord-021637-f5wwn45z	94	15	all	all	DT
cord-021637-f5wwn45z	94	16	activities	activity	NNS
cord-021637-f5wwn45z	94	17	proceed	proceed	VBP
cord-021637-f5wwn45z	94	18	as	as	IN
cord-021637-f5wwn45z	94	19	planned	plan	VBN
cord-021637-f5wwn45z	94	20	.	.	.
cord-021637-f5wwn45z	95	1	Manufacturing	manufacturing	NN
cord-021637-f5wwn45z	95	2	plants	plant	NNS
cord-021637-f5wwn45z	95	3	are	be	VBP
cord-021637-f5wwn45z	95	4	very	very	RB
cord-021637-f5wwn45z	95	5	expensive	expensive	JJ
cord-021637-f5wwn45z	95	6	to	to	TO
cord-021637-f5wwn45z	95	7	construct	construct	VB
cord-021637-f5wwn45z	95	8	,	,	,
cord-021637-f5wwn45z	95	9	ranging	range	VBG
cord-021637-f5wwn45z	95	10	from	from	IN
cord-021637-f5wwn45z	95	11	$	$	$
cord-021637-f5wwn45z	95	12	50	50	CD
cord-021637-f5wwn45z	95	13	million	million	CD
cord-021637-f5wwn45z	95	14	to	to	TO
cord-021637-f5wwn45z	95	15	$	$	$
cord-021637-f5wwn45z	95	16	300	300	CD
cord-021637-f5wwn45z	95	17	million	million	CD
cord-021637-f5wwn45z	95	18	depending	depend	VBG
cord-021637-f5wwn45z	95	19	on	on	IN
cord-021637-f5wwn45z	95	20	the	the	DT
cord-021637-f5wwn45z	95	21	size	size	NN
cord-021637-f5wwn45z	95	22	(	(	-LRB-
cord-021637-f5wwn45z	95	23	dose	dose	NN
cord-021637-f5wwn45z	95	24	requirements	requirement	NNS
cord-021637-f5wwn45z	95	25	)	)	-RRB-
cord-021637-f5wwn45z	95	26	and	and	CC
cord-021637-f5wwn45z	95	27	manufacturing	manufacture	VBG
cord-021637-f5wwn45z	95	28	complexity	complexity	NN
cord-021637-f5wwn45z	95	29	,	,	,
cord-021637-f5wwn45z	95	30	with	with	IN
cord-021637-f5wwn45z	95	31	an	an	DT
cord-021637-f5wwn45z	95	32	additional	additional	JJ
cord-021637-f5wwn45z	95	33	expenditure	expenditure	NN
cord-021637-f5wwn45z	95	34	of	of	IN
cord-021637-f5wwn45z	95	35	approximately	approximately	RB
cord-021637-f5wwn45z	95	36	20	20	CD
cord-021637-f5wwn45z	95	37	%	%	NN
cord-021637-f5wwn45z	95	38	of	of	IN
cord-021637-f5wwn45z	95	39	that	that	DT
cord-021637-f5wwn45z	95	40	cost	cost	NN
cord-021637-f5wwn45z	95	41	for	for	IN
cord-021637-f5wwn45z	95	42	cleaning	cleaning	NN
cord-021637-f5wwn45z	95	43	and	and	CC
cord-021637-f5wwn45z	95	44	process	process	NN
cord-021637-f5wwn45z	95	45	validation	validation	NN
cord-021637-f5wwn45z	95	46	activities	activity	NNS
cord-021637-f5wwn45z	95	47	that	that	WDT
cord-021637-f5wwn45z	95	48	are	be	VBP
cord-021637-f5wwn45z	95	49	now	now	RB
cord-021637-f5wwn45z	95	50	required	require	VBN
cord-021637-f5wwn45z	95	51	under	under	IN
cord-021637-f5wwn45z	95	52	the	the	DT
cord-021637-f5wwn45z	95	53	current	current	JJ
cord-021637-f5wwn45z	95	54	good	good	JJ
cord-021637-f5wwn45z	95	55	manufacturing	manufacturing	NN
cord-021637-f5wwn45z	95	56	practices	practice	NNS
cord-021637-f5wwn45z	95	57	regulations	regulation	NNS
cord-021637-f5wwn45z	95	58	.	.	.
cord-021637-f5wwn45z	96	1	With	with	IN
cord-021637-f5wwn45z	96	2	few	few	JJ
cord-021637-f5wwn45z	96	3	exceptions	exception	NNS
cord-021637-f5wwn45z	96	4	,	,	,
cord-021637-f5wwn45z	96	5	each	each	DT
cord-021637-f5wwn45z	96	6	vaccine	vaccine	NN
cord-021637-f5wwn45z	96	7	requires	require	VBZ
cord-021637-f5wwn45z	96	8	a	a	DT
cord-021637-f5wwn45z	96	9	different	different	JJ
cord-021637-f5wwn45z	96	10	plant	plant	NN
cord-021637-f5wwn45z	96	11	because	because	IN
cord-021637-f5wwn45z	96	12	of	of	IN
cord-021637-f5wwn45z	96	13	unique	unique	JJ
cord-021637-f5wwn45z	96	14	manufacturing	manufacturing	NN
cord-021637-f5wwn45z	96	15	requirements	requirement	NNS
cord-021637-f5wwn45z	96	16	and	and	CC
cord-021637-f5wwn45z	96	17	the	the	DT
cord-021637-f5wwn45z	96	18	regulatory	regulatory	JJ
cord-021637-f5wwn45z	96	19	difficulties	difficulty	NNS
cord-021637-f5wwn45z	96	20	associated	associate	VBN
cord-021637-f5wwn45z	96	21	with	with	IN
cord-021637-f5wwn45z	96	22	changing	change	VBG
cord-021637-f5wwn45z	96	23	over	over	RP
cord-021637-f5wwn45z	96	24	to	to	IN
cord-021637-f5wwn45z	96	25	a	a	DT
cord-021637-f5wwn45z	96	26	different	different	JJ
cord-021637-f5wwn45z	96	27	product	product	NN
cord-021637-f5wwn45z	96	28	.	.	.
cord-021637-f5wwn45z	97	1	Some	some	DT
cord-021637-f5wwn45z	97	2	processes	process	NNS
cord-021637-f5wwn45z	97	3	are	be	VBP
cord-021637-f5wwn45z	97	4	scalable	scalable	JJ
cord-021637-f5wwn45z	97	5	,	,	,
cord-021637-f5wwn45z	97	6	such	such	JJ
cord-021637-f5wwn45z	97	7	as	as	IN
cord-021637-f5wwn45z	97	8	bacterial	bacterial	JJ
cord-021637-f5wwn45z	97	9	or	or	CC
cord-021637-f5wwn45z	97	10	yeast	yeast	NN
cord-021637-f5wwn45z	97	11	fermentation	fermentation	NN
cord-021637-f5wwn45z	97	12	,	,	,
cord-021637-f5wwn45z	97	13	so	so	IN
cord-021637-f5wwn45z	97	14	that	that	IN
cord-021637-f5wwn45z	97	15	increasing	increase	VBG
cord-021637-f5wwn45z	97	16	the	the	DT
cord-021637-f5wwn45z	97	17	size	size	NN
cord-021637-f5wwn45z	97	18	of	of	IN
cord-021637-f5wwn45z	97	19	the	the	DT
cord-021637-f5wwn45z	97	20	manufacturing	manufacture	VBG
cord-021637-f5wwn45z	97	21	unit	unit	NN
cord-021637-f5wwn45z	97	22	(	(	-LRB-
cord-021637-f5wwn45z	97	23	i.e.	i.e.	FW
cord-021637-f5wwn45z	97	24	,	,	,
cord-021637-f5wwn45z	97	25	fermenter	fermenter	NN
cord-021637-f5wwn45z	97	26	)	)	-RRB-
cord-021637-f5wwn45z	97	27	will	will	MD
cord-021637-f5wwn45z	97	28	greatly	greatly	RB
cord-021637-f5wwn45z	97	29	increase	increase	VB
cord-021637-f5wwn45z	97	30	the	the	DT
cord-021637-f5wwn45z	97	31	yield	yield	NN
cord-021637-f5wwn45z	97	32	;	;	:
cord-021637-f5wwn45z	97	33	unit	unit	NN
cord-021637-f5wwn45z	97	34	cost	cost	NN
cord-021637-f5wwn45z	97	35	will	will	MD
cord-021637-f5wwn45z	97	36	decrease	decrease	VB
cord-021637-f5wwn45z	97	37	with	with	IN
cord-021637-f5wwn45z	97	38	volume	volume	NN
cord-021637-f5wwn45z	97	39	increase	increase	NN
cord-021637-f5wwn45z	97	40	.	.	.
cord-021637-f5wwn45z	98	1	Other	other	JJ
cord-021637-f5wwn45z	98	2	manufacturing	manufacturing	NN
cord-021637-f5wwn45z	98	3	processes	process	NNS
cord-021637-f5wwn45z	98	4	,	,	,
cord-021637-f5wwn45z	98	5	for	for	IN
cord-021637-f5wwn45z	98	6	example	example	NN
cord-021637-f5wwn45z	98	7	,	,	,
cord-021637-f5wwn45z	98	8	those	those	DT
cord-021637-f5wwn45z	98	9	dependent	dependent	JJ
cord-021637-f5wwn45z	98	10	on	on	IN
cord-021637-f5wwn45z	98	11	viral	viral	JJ
cord-021637-f5wwn45z	98	12	growth	growth	NN
cord-021637-f5wwn45z	98	13	in	in	IN
cord-021637-f5wwn45z	98	14	embryonated	embryonated	JJ
cord-021637-f5wwn45z	98	15	hen	hen	NN
cord-021637-f5wwn45z	98	16	eggs	egg	NNS
cord-021637-f5wwn45z	98	17	or	or	CC
cord-021637-f5wwn45z	98	18	cell	cell	NN
cord-021637-f5wwn45z	98	19	lines	line	NNS
cord-021637-f5wwn45z	98	20	,	,	,
cord-021637-f5wwn45z	98	21	are	be	VBP
cord-021637-f5wwn45z	98	22	not	not	RB
cord-021637-f5wwn45z	98	23	scalable	scalable	JJ
cord-021637-f5wwn45z	98	24	.	.	.
cord-021637-f5wwn45z	99	1	Additional	additional	JJ
cord-021637-f5wwn45z	99	2	plants	plant	NNS
cord-021637-f5wwn45z	99	3	or	or	CC
cord-021637-f5wwn45z	99	4	modules	module	NNS
cord-021637-f5wwn45z	99	5	within	within	IN
cord-021637-f5wwn45z	99	6	plants	plant	NNS
cord-021637-f5wwn45z	99	7	must	must	MD
cord-021637-f5wwn45z	99	8	be	be	VB
cord-021637-f5wwn45z	99	9	built	build	VBN
cord-021637-f5wwn45z	99	10	to	to	TO
cord-021637-f5wwn45z	99	11	increase	increase	VB
cord-021637-f5wwn45z	99	12	the	the	DT
cord-021637-f5wwn45z	99	13	throughput	throughput	NN
cord-021637-f5wwn45z	99	14	,	,	,
cord-021637-f5wwn45z	99	15	so	so	IN
cord-021637-f5wwn45z	99	16	unit	unit	NN
cord-021637-f5wwn45z	99	17	costs	cost	NNS
cord-021637-f5wwn45z	99	18	do	do	VBP
cord-021637-f5wwn45z	99	19	not	not	RB
cord-021637-f5wwn45z	99	20	appreciably	appreciably	RB
cord-021637-f5wwn45z	99	21	decrease	decrease	VB
cord-021637-f5wwn45z	99	22	with	with	IN
cord-021637-f5wwn45z	99	23	volume	volume	NN
cord-021637-f5wwn45z	99	24	increases	increase	NNS
cord-021637-f5wwn45z	99	25	.	.	.
cord-021637-f5wwn45z	100	1	Despite	despite	IN
cord-021637-f5wwn45z	100	2	the	the	DT
cord-021637-f5wwn45z	100	3	complexity	complexity	NN
cord-021637-f5wwn45z	100	4	of	of	IN
cord-021637-f5wwn45z	100	5	bulk	bulk	JJ
cord-021637-f5wwn45z	100	6	vaccine	vaccine	NN
cord-021637-f5wwn45z	100	7	manufacturing	manufacturing	NN
cord-021637-f5wwn45z	100	8	,	,	,
cord-021637-f5wwn45z	100	9	3	3	CD
cord-021637-f5wwn45z	100	10	to	to	TO
cord-021637-f5wwn45z	100	11	5	5	CD
cord-021637-f5wwn45z	100	12	years	year	NNS
cord-021637-f5wwn45z	100	13	post	post	JJ
cord-021637-f5wwn45z	100	14	-	-	JJ
cord-021637-f5wwn45z	100	15	product	product	JJ
cord-021637-f5wwn45z	100	16	launch	launch	NN
cord-021637-f5wwn45z	100	17	,	,	,
cord-021637-f5wwn45z	100	18	the	the	DT
cord-021637-f5wwn45z	100	19	fully	fully	RB
cord-021637-f5wwn45z	100	20	burdened	burden	VBN
cord-021637-f5wwn45z	100	21	bulk	bulk	JJ
cord-021637-f5wwn45z	100	22	cost	cost	NN
cord-021637-f5wwn45z	100	23	of	of	IN
cord-021637-f5wwn45z	100	24	production	production	NN
cord-021637-f5wwn45z	100	25	for	for	IN
cord-021637-f5wwn45z	100	26	most	most	JJS
cord-021637-f5wwn45z	100	27	of	of	IN
cord-021637-f5wwn45z	100	28	the	the	DT
cord-021637-f5wwn45z	100	29	older	old	JJR
cord-021637-f5wwn45z	100	30	vaccines	vaccine	NNS
cord-021637-f5wwn45z	100	31	declines	decline	VBZ
cord-021637-f5wwn45z	100	32	to	to	IN
cord-021637-f5wwn45z	100	33	as	as	RB
cord-021637-f5wwn45z	100	34	little	little	JJ
cord-021637-f5wwn45z	100	35	as	as	IN
cord-021637-f5wwn45z	100	36	$	$	$
cord-021637-f5wwn45z	100	37	0.50	0.50	CD
cord-021637-f5wwn45z	100	38	to	to	TO
cord-021637-f5wwn45z	100	39	$	$	$
cord-021637-f5wwn45z	100	40	1.00	1.00	CD
cord-021637-f5wwn45z	100	41	per	per	IN
cord-021637-f5wwn45z	100	42	dose	dose	NN
cord-021637-f5wwn45z	100	43	,	,	,
cord-021637-f5wwn45z	100	44	and	and	CC
cord-021637-f5wwn45z	100	45	significant	significant	JJ
cord-021637-f5wwn45z	100	46	elements	element	NNS
cord-021637-f5wwn45z	100	47	of	of	IN
cord-021637-f5wwn45z	100	48	product	product	NN
cord-021637-f5wwn45z	100	49	cost	cost	NN
cord-021637-f5wwn45z	100	50	are	be	VBP
cord-021637-f5wwn45z	100	51	primarily	primarily	RB
cord-021637-f5wwn45z	100	52	driven	drive	VBN
cord-021637-f5wwn45z	100	53	by	by	IN
cord-021637-f5wwn45z	100	54	activities	activity	NNS
cord-021637-f5wwn45z	100	55	related	relate	VBN
cord-021637-f5wwn45z	100	56	to	to	IN
cord-021637-f5wwn45z	100	57	filling	fill	VBG
cord-021637-f5wwn45z	100	58	,	,	,
cord-021637-f5wwn45z	100	59	vialing	vialing	NN
cord-021637-f5wwn45z	100	60	,	,	,
cord-021637-f5wwn45z	100	61	and	and	CC
cord-021637-f5wwn45z	100	62	packaging	packaging	NN
cord-021637-f5wwn45z	100	63	(	(	-LRB-
cord-021637-f5wwn45z	100	64	Table	Table	NNP
cord-021637-f5wwn45z	100	65	 	 	_SP
cord-021637-f5wwn45z	100	66	4	4	CD
cord-021637-f5wwn45z	100	67	.2	.2	CD
cord-021637-f5wwn45z	100	68	)	)	-RRB-
cord-021637-f5wwn45z	100	69	.	.	.
cord-021637-f5wwn45z	101	1	Established	establish	VBN
cord-021637-f5wwn45z	101	2	vaccines	vaccine	NNS
cord-021637-f5wwn45z	101	3	with	with	IN
cord-021637-f5wwn45z	101	4	a	a	DT
cord-021637-f5wwn45z	101	5	limited	limited	JJ
cord-021637-f5wwn45z	101	6	number	number	NN
cord-021637-f5wwn45z	101	7	of	of	IN
cord-021637-f5wwn45z	101	8	suppliers	supplier	NNS
cord-021637-f5wwn45z	101	9	can	can	MD
cord-021637-f5wwn45z	101	10	generate	generate	VB
cord-021637-f5wwn45z	101	11	very	very	RB
cord-021637-f5wwn45z	101	12	high	high	JJ
cord-021637-f5wwn45z	101	13	profit	profit	NN
cord-021637-f5wwn45z	101	14	margins	margin	NNS
cord-021637-f5wwn45z	101	15	over	over	IN
cord-021637-f5wwn45z	101	16	the	the	DT
cord-021637-f5wwn45z	101	17	product	product	NN
cord-021637-f5wwn45z	101	18	life	life	NN
cord-021637-f5wwn45z	101	19	cycle	cycle	NN
cord-021637-f5wwn45z	101	20	.	.	.
cord-021637-f5wwn45z	102	1	The	the	DT
cord-021637-f5wwn45z	102	2	commitment	commitment	NN
cord-021637-f5wwn45z	102	3	to	to	TO
cord-021637-f5wwn45z	102	4	build	build	VB
cord-021637-f5wwn45z	102	5	a	a	DT
cord-021637-f5wwn45z	102	6	plant	plant	NN
cord-021637-f5wwn45z	102	7	must	must	MD
cord-021637-f5wwn45z	102	8	be	be	VB
cord-021637-f5wwn45z	102	9	made	make	VBN
cord-021637-f5wwn45z	102	10	early	early	JJ
cord-021637-f5wwn45z	102	11	(	(	-LRB-
cord-021637-f5wwn45z	102	12	4	4	CD
cord-021637-f5wwn45z	102	13	to	to	TO
cord-021637-f5wwn45z	102	14	6	6	CD
cord-021637-f5wwn45z	102	15	years	year	NNS
cord-021637-f5wwn45z	102	16	before	before	IN
cord-021637-f5wwn45z	102	17	expected	expect	VBN
cord-021637-f5wwn45z	102	18	licensure	licensure	NN
cord-021637-f5wwn45z	102	19	)	)	-RRB-
cord-021637-f5wwn45z	102	20	including	include	VBG
cord-021637-f5wwn45z	102	21	a	a	DT
cord-021637-f5wwn45z	102	22	6-to	6-to	CD
cord-021637-f5wwn45z	102	23	12-month	12-month	JJ
cord-021637-f5wwn45z	102	24	finished	finished	JJ
cord-021637-f5wwn45z	102	25	goods	good	NNS
cord-021637-f5wwn45z	102	26	inventory	inventory	NN
cord-021637-f5wwn45z	102	27	build	build	NN
cord-021637-f5wwn45z	102	28	-	-	HYPH
cord-021637-f5wwn45z	102	29	up	up	NN
cord-021637-f5wwn45z	102	30	to	to	TO
cord-021637-f5wwn45z	102	31	expedite	expedite	VB
cord-021637-f5wwn45z	102	32	product	product	NN
cord-021637-f5wwn45z	102	33	to	to	IN
cord-021637-f5wwn45z	102	34	the	the	DT
cord-021637-f5wwn45z	102	35	market	market	NN
cord-021637-f5wwn45z	102	36	.	.	.
cord-021637-f5wwn45z	103	1	Otherwise	otherwise	RB
cord-021637-f5wwn45z	103	2	a	a	DT
cord-021637-f5wwn45z	103	3	gap	gap	NN
cord-021637-f5wwn45z	103	4	of	of	IN
cord-021637-f5wwn45z	103	5	1	1	CD
cord-021637-f5wwn45z	103	6	to	to	TO
cord-021637-f5wwn45z	103	7	5	5	CD
cord-021637-f5wwn45z	103	8	years	year	NNS
cord-021637-f5wwn45z	103	9	between	between	IN
cord-021637-f5wwn45z	103	10	licensure	licensure	NN
cord-021637-f5wwn45z	103	11	and	and	CC
cord-021637-f5wwn45z	103	12	product	product	NN
cord-021637-f5wwn45z	103	13	launch	launch	NN
cord-021637-f5wwn45z	103	14	will	will	MD
cord-021637-f5wwn45z	103	15	occur	occur	VB
cord-021637-f5wwn45z	103	16	.	.	.
cord-021637-f5wwn45z	104	1	Furthermore	furthermore	RB
cord-021637-f5wwn45z	104	2	,	,	,
cord-021637-f5wwn45z	104	3	it	-PRON-	PRP
cord-021637-f5wwn45z	104	4	is	be	VBZ
cord-021637-f5wwn45z	104	5	far	far	RB
cord-021637-f5wwn45z	104	6	better	well	JJR
cord-021637-f5wwn45z	104	7	to	to	TO
cord-021637-f5wwn45z	104	8	produce	produce	VB
cord-021637-f5wwn45z	104	9	consistency	consistency	NN
cord-021637-f5wwn45z	104	10	lots	lot	NNS
cord-021637-f5wwn45z	104	11	in	in	IN
cord-021637-f5wwn45z	104	12	the	the	DT
cord-021637-f5wwn45z	104	13	final	final	JJ
cord-021637-f5wwn45z	104	14	vaccine	vaccine	NN
cord-021637-f5wwn45z	104	15	production	production	NN
cord-021637-f5wwn45z	104	16	factory	factory	NN
cord-021637-f5wwn45z	104	17	to	to	TO
cord-021637-f5wwn45z	104	18	demonstrate	demonstrate	VB
cord-021637-f5wwn45z	104	19	the	the	DT
cord-021637-f5wwn45z	104	20	ability	ability	NN
cord-021637-f5wwn45z	104	21	to	to	TO
cord-021637-f5wwn45z	104	22	manufacture	manufacture	VB
cord-021637-f5wwn45z	104	23	the	the	DT
cord-021637-f5wwn45z	104	24	vaccine	vaccine	NN
cord-021637-f5wwn45z	104	25	reliably	reliably	RB
cord-021637-f5wwn45z	104	26	and	and	CC
cord-021637-f5wwn45z	104	27	to	to	TO
cord-021637-f5wwn45z	104	28	use	use	VB
cord-021637-f5wwn45z	104	29	those	those	DT
cord-021637-f5wwn45z	104	30	lots	lot	NNS
cord-021637-f5wwn45z	104	31	in	in	IN
cord-021637-f5wwn45z	104	32	the	the	DT
cord-021637-f5wwn45z	104	33	Phase	Phase	NNP
cord-021637-f5wwn45z	104	34	III	III	NNP
cord-021637-f5wwn45z	104	35	efficacy	efficacy	NN
cord-021637-f5wwn45z	104	36	trials	trial	NNS
cord-021637-f5wwn45z	104	37	.	.	.
cord-021637-f5wwn45z	105	1	Otherwise	otherwise	RB
cord-021637-f5wwn45z	105	2	,	,	,
cord-021637-f5wwn45z	105	3	immune	immune	JJ
cord-021637-f5wwn45z	105	4	studies	study	NNS
cord-021637-f5wwn45z	105	5	will	will	MD
cord-021637-f5wwn45z	105	6	be	be	VB
cord-021637-f5wwn45z	105	7	required	require	VBN
cord-021637-f5wwn45z	105	8	for	for	IN
cord-021637-f5wwn45z	105	9	"	"	``
cord-021637-f5wwn45z	105	10	bridging	bridge	VBG
cord-021637-f5wwn45z	105	11	"	"	''
cord-021637-f5wwn45z	105	12	the	the	DT
cord-021637-f5wwn45z	105	13	product	product	NN
cord-021637-f5wwn45z	105	14	used	use	VBN
cord-021637-f5wwn45z	105	15	in	in	IN
cord-021637-f5wwn45z	105	16	the	the	DT
cord-021637-f5wwn45z	105	17	efficacy	efficacy	NN
cord-021637-f5wwn45z	105	18	trial	trial	NN
cord-021637-f5wwn45z	105	19	to	to	IN
cord-021637-f5wwn45z	105	20	Bioshield	Bioshield	NNP
cord-021637-f5wwn45z	105	21	for	for	IN
cord-021637-f5wwn45z	105	22	the	the	DT
cord-021637-f5wwn45z	105	23	procurement	procurement	NN
cord-021637-f5wwn45z	105	24	of	of	IN
cord-021637-f5wwn45z	105	25	advanced	advanced	JJ
cord-021637-f5wwn45z	105	26	medical	medical	JJ
cord-021637-f5wwn45z	105	27	countermeasures	countermeasure	NNS
cord-021637-f5wwn45z	105	28	for	for	IN
cord-021637-f5wwn45z	105	29	biological	biological	JJ
cord-021637-f5wwn45z	105	30	as	as	RB
cord-021637-f5wwn45z	105	31	well	well	RB
cord-021637-f5wwn45z	105	32	as	as	IN
cord-021637-f5wwn45z	105	33	other	other	JJ
cord-021637-f5wwn45z	105	34	threats	threat	NNS
cord-021637-f5wwn45z	105	35	and	and	CC
cord-021637-f5wwn45z	105	36	has	have	VBZ
cord-021637-f5wwn45z	105	37	successfully	successfully	RB
cord-021637-f5wwn45z	105	38	developed	develop	VBN
cord-021637-f5wwn45z	105	39	medical	medical	JJ
cord-021637-f5wwn45z	105	40	countermeasures	countermeasure	NNS
cord-021637-f5wwn45z	105	41	against	against	IN
cord-021637-f5wwn45z	105	42	smallpox	smallpox	NN
cord-021637-f5wwn45z	105	43	,	,	,
cord-021637-f5wwn45z	105	44	anthrax	anthrax	NN
cord-021637-f5wwn45z	105	45	,	,	,
cord-021637-f5wwn45z	105	46	and	and	CC
cord-021637-f5wwn45z	105	47	botulinum	botulinum	NN
cord-021637-f5wwn45z	105	48	toxin	toxin	NN
cord-021637-f5wwn45z	105	49	.	.	.
cord-021637-f5wwn45z	106	1	In	in	IN
cord-021637-f5wwn45z	106	2	addition	addition	NN
cord-021637-f5wwn45z	106	3	,	,	,
cord-021637-f5wwn45z	106	4	BARDA	BARDA	NNP
cord-021637-f5wwn45z	106	5	is	be	VBZ
cord-021637-f5wwn45z	106	6	funding	fund	VBG
cord-021637-f5wwn45z	106	7	a	a	DT
cord-021637-f5wwn45z	106	8	variety	variety	NN
cord-021637-f5wwn45z	106	9	of	of	IN
cord-021637-f5wwn45z	106	10	early	early	JJ
cord-021637-f5wwn45z	106	11	stage	stage	NN
cord-021637-f5wwn45z	106	12	novel	novel	NN
cord-021637-f5wwn45z	106	13	vaccine	vaccine	NN
cord-021637-f5wwn45z	106	14	approaches	approach	NNS
cord-021637-f5wwn45z	106	15	for	for	IN
cord-021637-f5wwn45z	106	16	pandemic	pandemic	NN
cord-021637-f5wwn45z	106	17	influenza	influenza	NN
cord-021637-f5wwn45z	106	18	.	.	.
cord-021637-f5wwn45z	107	1	BARDA	BARDA	NNP
cord-021637-f5wwn45z	107	2	essentially	essentially	RB
cord-021637-f5wwn45z	107	3	is	be	VBZ
cord-021637-f5wwn45z	107	4	intended	intend	VBN
cord-021637-f5wwn45z	107	5	to	to	TO
cord-021637-f5wwn45z	107	6	overlap	overlap	VB
cord-021637-f5wwn45z	107	7	with	with	IN
cord-021637-f5wwn45z	107	8	and	and	CC
cord-021637-f5wwn45z	107	9	close	close	VB
cord-021637-f5wwn45z	107	10	the	the	DT
cord-021637-f5wwn45z	107	11	gap	gap	NN
cord-021637-f5wwn45z	107	12	between	between	IN
cord-021637-f5wwn45z	107	13	NIH	NIH	NNP
cord-021637-f5wwn45z	107	14	-	-	HYPH
cord-021637-f5wwn45z	107	15	funded	fund	VBN
cord-021637-f5wwn45z	107	16	preclinical	preclinical	JJ
cord-021637-f5wwn45z	107	17	or	or	CC
cord-021637-f5wwn45z	107	18	initial	initial	JJ
cord-021637-f5wwn45z	107	19	Phase	phase	NN
cord-021637-f5wwn45z	108	1	I	-PRON-	PRP
cord-021637-f5wwn45z	108	2	trials	trial	NNS
cord-021637-f5wwn45z	108	3	and	and	CC
cord-021637-f5wwn45z	108	4	the	the	DT
cord-021637-f5wwn45z	108	5	more	more	RBR
cord-021637-f5wwn45z	108	6	advanced	advanced	JJ
cord-021637-f5wwn45z	108	7	Project	Project	NNP
cord-021637-f5wwn45z	108	8	Bioshield	Bioshield	NNP
cord-021637-f5wwn45z	108	9	programs	program	NNS
cord-021637-f5wwn45z	108	10	that	that	WDT
cord-021637-f5wwn45z	108	11	are	be	VBP
cord-021637-f5wwn45z	108	12	in	in	IN
cord-021637-f5wwn45z	108	13	late	late	JJ
cord-021637-f5wwn45z	108	14	stage	stage	NN
cord-021637-f5wwn45z	108	15	Phase	Phase	NNP
cord-021637-f5wwn45z	108	16	III	III	NNP
cord-021637-f5wwn45z	108	17	or	or	CC
cord-021637-f5wwn45z	108	18	licensure	licensure	NN
cord-021637-f5wwn45z	108	19	stages	stage	NNS
cord-021637-f5wwn45z	108	20	of	of	IN
cord-021637-f5wwn45z	108	21	development	development	NN
cord-021637-f5wwn45z	108	22	.	.	.
cord-021637-f5wwn45z	109	1	The	the	DT
cord-021637-f5wwn45z	109	2	U.S.	U.S.	NNP
cord-021637-f5wwn45z	109	3	Agency	Agency	NNP
cord-021637-f5wwn45z	109	4	for	for	IN
cord-021637-f5wwn45z	109	5	International	International	NNP
cord-021637-f5wwn45z	109	6	Development	Development	NNP
cord-021637-f5wwn45z	109	7	(	(	-LRB-
cord-021637-f5wwn45z	109	8	USAID	USAID	NNP
cord-021637-f5wwn45z	109	9	)	)	-RRB-
cord-021637-f5wwn45z	109	10	supports	support	VBZ
cord-021637-f5wwn45z	109	11	limited	limited	JJ
cord-021637-f5wwn45z	109	12	R&D	r&d	NN
cord-021637-f5wwn45z	109	13	targeted	target	VBD
cord-021637-f5wwn45z	109	14	toward	toward	IN
cord-021637-f5wwn45z	109	15	those	those	DT
cord-021637-f5wwn45z	109	16	vaccines	vaccine	NNS
cord-021637-f5wwn45z	109	17	that	that	WDT
cord-021637-f5wwn45z	109	18	potentially	potentially	RB
cord-021637-f5wwn45z	109	19	will	will	MD
cord-021637-f5wwn45z	109	20	have	have	VB
cord-021637-f5wwn45z	109	21	the	the	DT
cord-021637-f5wwn45z	109	22	greatest	great	JJS
cord-021637-f5wwn45z	109	23	impact	impact	NN
cord-021637-f5wwn45z	109	24	on	on	IN
cord-021637-f5wwn45z	109	25	children	child	NNS
cord-021637-f5wwn45z	109	26	younger	young	JJR
cord-021637-f5wwn45z	109	27	than	than	IN
cord-021637-f5wwn45z	109	28	age	age	NN
cord-021637-f5wwn45z	109	29	5	5	CD
cord-021637-f5wwn45z	109	30	years	year	NNS
cord-021637-f5wwn45z	109	31	in	in	IN
cord-021637-f5wwn45z	109	32	developing	develop	VBG
cord-021637-f5wwn45z	109	33	countries	country	NNS
cord-021637-f5wwn45z	109	34	.	.	.
cord-021637-f5wwn45z	110	1	The	the	DT
cord-021637-f5wwn45z	110	2	Center	Center	NNP
cord-021637-f5wwn45z	110	3	for	for	IN
cord-021637-f5wwn45z	110	4	Biologics	Biologics	NNP
cord-021637-f5wwn45z	110	5	Evaluation	Evaluation	NNP
cord-021637-f5wwn45z	110	6	and	and	CC
cord-021637-f5wwn45z	110	7	Research	Research	NNP
cord-021637-f5wwn45z	110	8	(	(	-LRB-
cord-021637-f5wwn45z	110	9	CBER	CBER	NNP
cord-021637-f5wwn45z	110	10	)	)	-RRB-
cord-021637-f5wwn45z	110	11	,	,	,
cord-021637-f5wwn45z	110	12	a	a	DT
cord-021637-f5wwn45z	110	13	division	division	NN
cord-021637-f5wwn45z	110	14	of	of	IN
cord-021637-f5wwn45z	110	15	the	the	DT
cord-021637-f5wwn45z	110	16	U.S.	U.S.	NNP
cord-021637-f5wwn45z	110	17	Food	Food	NNP
cord-021637-f5wwn45z	110	18	and	and	CC
cord-021637-f5wwn45z	110	19	Drug	Drug	NNP
cord-021637-f5wwn45z	110	20	Administration	Administration	NNP
cord-021637-f5wwn45z	110	21	(	(	-LRB-
cord-021637-f5wwn45z	110	22	FDA	FDA	NNP
cord-021637-f5wwn45z	110	23	)	)	-RRB-
cord-021637-f5wwn45z	110	24	,	,	,
cord-021637-f5wwn45z	110	25	is	be	VBZ
cord-021637-f5wwn45z	110	26	responsible	responsible	JJ
cord-021637-f5wwn45z	110	27	for	for	IN
cord-021637-f5wwn45z	110	28	licensing	license	VBG
cord-021637-f5wwn45z	110	29	new	new	JJ
cord-021637-f5wwn45z	110	30	vaccines	vaccine	NNS
cord-021637-f5wwn45z	110	31	.	.	.
cord-021637-f5wwn45z	111	1	CBER	CBER	NNP
cord-021637-f5wwn45z	111	2	establishes	establish	VBZ
cord-021637-f5wwn45z	111	3	standards	standard	NNS
cord-021637-f5wwn45z	111	4	for	for	IN
cord-021637-f5wwn45z	111	5	manufacturing	manufacturing	NN
cord-021637-f5wwn45z	111	6	processes	process	NNS
cord-021637-f5wwn45z	111	7	,	,	,
cord-021637-f5wwn45z	111	8	facilities	facility	NNS
cord-021637-f5wwn45z	111	9	,	,	,
cord-021637-f5wwn45z	111	10	and	and	CC
cord-021637-f5wwn45z	111	11	pre	pre	JJ
cord-021637-f5wwn45z	111	12	-	-	JJ
cord-021637-f5wwn45z	111	13	and	and	CC
cord-021637-f5wwn45z	111	14	postlicensing	postlicense	VBG
cord-021637-f5wwn45z	111	15	clinical	clinical	JJ
cord-021637-f5wwn45z	111	16	studies	study	NNS
cord-021637-f5wwn45z	111	17	to	to	TO
cord-021637-f5wwn45z	111	18	ensure	ensure	VB
cord-021637-f5wwn45z	111	19	that	that	IN
cord-021637-f5wwn45z	111	20	licensed	license	VBN
cord-021637-f5wwn45z	111	21	vaccines	vaccine	NNS
cord-021637-f5wwn45z	111	22	are	be	VBP
cord-021637-f5wwn45z	111	23	safe	safe	JJ
cord-021637-f5wwn45z	111	24	and	and	CC
cord-021637-f5wwn45z	111	25	effective	effective	JJ
cord-021637-f5wwn45z	111	26	(	(	-LRB-
cord-021637-f5wwn45z	111	27	see	see	VB
cord-021637-f5wwn45z	111	28	Table	table	NN
cord-021637-f5wwn45z	111	29	4	4	CD
cord-021637-f5wwn45z	111	30	.4	.4	CD
cord-021637-f5wwn45z	111	31	)	)	-RRB-
cord-021637-f5wwn45z	111	32	.	.	.
cord-021637-f5wwn45z	112	1	These	these	DT
cord-021637-f5wwn45z	112	2	standards	standard	NNS
cord-021637-f5wwn45z	112	3	have	have	VBP
cord-021637-f5wwn45z	112	4	a	a	DT
cord-021637-f5wwn45z	112	5	profound	profound	JJ
cord-021637-f5wwn45z	112	6	partners	partner	NNS
cord-021637-f5wwn45z	112	7	.	.	.
cord-021637-f5wwn45z	113	1	The	the	DT
cord-021637-f5wwn45z	113	2	relative	relative	JJ
cord-021637-f5wwn45z	113	3	contributions	contribution	NNS
cord-021637-f5wwn45z	113	4	of	of	IN
cord-021637-f5wwn45z	113	5	the	the	DT
cord-021637-f5wwn45z	113	6	various	various	JJ
cord-021637-f5wwn45z	113	7	partners	partner	NNS
cord-021637-f5wwn45z	113	8	to	to	IN
cord-021637-f5wwn45z	113	9	the	the	DT
cord-021637-f5wwn45z	113	10	delicate	delicate	JJ
cord-021637-f5wwn45z	113	11	fabric	fabric	NN
cord-021637-f5wwn45z	113	12	of	of	IN
cord-021637-f5wwn45z	113	13	vaccine	vaccine	NN
cord-021637-f5wwn45z	113	14	R&D	r&d	NN
cord-021637-f5wwn45z	113	15	is	be	VBZ
cord-021637-f5wwn45z	113	16	shown	show	VBN
cord-021637-f5wwn45z	113	17	in	in	IN
cord-021637-f5wwn45z	113	18	Table	Table	NNP
cord-021637-f5wwn45z	113	19	4	4	CD
cord-021637-f5wwn45z	113	20	.4	.4	NFP
cord-021637-f5wwn45z	113	21	.	.	.
cord-021637-f5wwn45z	114	1	10	10	CD
cord-021637-f5wwn45z	115	1	Several	several	JJ
cord-021637-f5wwn45z	115	2	branches	branch	NNS
cord-021637-f5wwn45z	115	3	of	of	IN
cord-021637-f5wwn45z	115	4	the	the	DT
cord-021637-f5wwn45z	115	5	U.S.	U.S.	NNP
cord-021637-f5wwn45z	115	6	government	government	NN
cord-021637-f5wwn45z	115	7	play	play	VB
cord-021637-f5wwn45z	115	8	major	major	JJ
cord-021637-f5wwn45z	115	9	roles	role	NNS
cord-021637-f5wwn45z	115	10	in	in	IN
cord-021637-f5wwn45z	116	1	vaccine	vaccine	NN
cord-021637-f5wwn45z	116	2	R&D.	R&D.	NNP
cord-021637-f5wwn45z	117	1	The	the	DT
cord-021637-f5wwn45z	117	2	U.S.	U.S.	NNP
cord-021637-f5wwn45z	117	3	National	National	NNP
cord-021637-f5wwn45z	117	4	Institutes	Institutes	NNPS
cord-021637-f5wwn45z	117	5	of	of	IN
cord-021637-f5wwn45z	117	6	Health	Health	NNP
cord-021637-f5wwn45z	117	7	(	(	-LRB-
cord-021637-f5wwn45z	117	8	NIH	NIH	NNP
cord-021637-f5wwn45z	117	9	)	)	-RRB-
cord-021637-f5wwn45z	117	10	is	be	VBZ
cord-021637-f5wwn45z	117	11	the	the	DT
cord-021637-f5wwn45z	117	12	major	major	JJ
cord-021637-f5wwn45z	117	13	funding	funding	NN
cord-021637-f5wwn45z	117	14	source	source	NN
cord-021637-f5wwn45z	117	15	via	via	IN
cord-021637-f5wwn45z	117	16	intramural	intramural	JJ
cord-021637-f5wwn45z	117	17	and	and	CC
cord-021637-f5wwn45z	117	18	extramural	extramural	JJ
cord-021637-f5wwn45z	117	19	(	(	-LRB-
cord-021637-f5wwn45z	117	20	largely	largely	RB
cord-021637-f5wwn45z	117	21	academic	academic	JJ
cord-021637-f5wwn45z	117	22	)	)	-RRB-
cord-021637-f5wwn45z	117	23	programs	program	NNS
cord-021637-f5wwn45z	117	24	of	of	IN
cord-021637-f5wwn45z	117	25	fundamental	fundamental	JJ
cord-021637-f5wwn45z	117	26	research	research	NN
cord-021637-f5wwn45z	117	27	(	(	-LRB-
cord-021637-f5wwn45z	117	28	e.g.	e.g.	RB
cord-021637-f5wwn45z	117	29	,	,	,
cord-021637-f5wwn45z	117	30	gene	gene	NN
cord-021637-f5wwn45z	117	31	-	-	HYPH
cord-021637-f5wwn45z	117	32	based	base	VBN
cord-021637-f5wwn45z	117	33	vaccines	vaccine	NNS
cord-021637-f5wwn45z	117	34	or	or	CC
cord-021637-f5wwn45z	117	35	T	t	NN
cord-021637-f5wwn45z	117	36	-	-	HYPH
cord-021637-f5wwn45z	117	37	cell	cell	NN
cord-021637-f5wwn45z	117	38	memory	memory	NN
cord-021637-f5wwn45z	117	39	studies	study	NNS
cord-021637-f5wwn45z	117	40	)	)	-RRB-
cord-021637-f5wwn45z	117	41	and	and	CC
cord-021637-f5wwn45z	117	42	directed	direct	VBD
cord-021637-f5wwn45z	117	43	research	research	NN
cord-021637-f5wwn45z	117	44	on	on	IN
cord-021637-f5wwn45z	117	45	pathogens	pathogen	NNS
cord-021637-f5wwn45z	117	46	(	(	-LRB-
cord-021637-f5wwn45z	117	47	e.g.	e.g.	RB
cord-021637-f5wwn45z	117	48	,	,	,
cord-021637-f5wwn45z	117	49	HIV	HIV	NNP
cord-021637-f5wwn45z	117	50	)	)	-RRB-
cord-021637-f5wwn45z	117	51	,	,	,
cord-021637-f5wwn45z	117	52	which	which	WDT
cord-021637-f5wwn45z	117	53	may	may	MD
cord-021637-f5wwn45z	117	54	lead	lead	VB
cord-021637-f5wwn45z	117	55	to	to	IN
cord-021637-f5wwn45z	117	56	new	new	JJ
cord-021637-f5wwn45z	117	57	vaccine	vaccine	NN
cord-021637-f5wwn45z	117	58	candidates	candidate	NNS
cord-021637-f5wwn45z	117	59	.	.	.
cord-021637-f5wwn45z	118	1	The	the	DT
cord-021637-f5wwn45z	118	2	NIH	NIH	NNP
cord-021637-f5wwn45z	118	3	,	,	,
cord-021637-f5wwn45z	118	4	through	through	IN
cord-021637-f5wwn45z	118	5	its	-PRON-	PRP$
cord-021637-f5wwn45z	118	6	vaccine	vaccine	NN
cord-021637-f5wwn45z	118	7	trials	trial	NNS
cord-021637-f5wwn45z	118	8	network	network	NN
cord-021637-f5wwn45z	118	9	,	,	,
cord-021637-f5wwn45z	118	10	has	have	VBZ
cord-021637-f5wwn45z	118	11	increased	increase	VBN
cord-021637-f5wwn45z	118	12	its	-PRON-	PRP$
cord-021637-f5wwn45z	118	13	role	role	NN
cord-021637-f5wwn45z	118	14	in	in	IN
cord-021637-f5wwn45z	118	15	clinical	clinical	JJ
cord-021637-f5wwn45z	118	16	development	development	NN
cord-021637-f5wwn45z	118	17	domestically	domestically	RB
cord-021637-f5wwn45z	118	18	and	and	CC
cord-021637-f5wwn45z	118	19	internationally	internationally	RB
cord-021637-f5wwn45z	118	20	.	.	.
cord-021637-f5wwn45z	119	1	In	in	IN
cord-021637-f5wwn45z	119	2	addition	addition	NN
cord-021637-f5wwn45z	119	3	,	,	,
cord-021637-f5wwn45z	119	4	the	the	DT
cord-021637-f5wwn45z	119	5	Dale	Dale	NNP
cord-021637-f5wwn45z	119	6	and	and	CC
cord-021637-f5wwn45z	119	7	Betty	Betty	NNP
cord-021637-f5wwn45z	119	8	Bumpers	Bumpers	NNP
cord-021637-f5wwn45z	119	9	Vaccine	Vaccine	NNP
cord-021637-f5wwn45z	119	10	Research	Research	NNP
cord-021637-f5wwn45z	119	11	Center	Center	NNP
cord-021637-f5wwn45z	119	12	at	at	IN
cord-021637-f5wwn45z	119	13	the	the	DT
cord-021637-f5wwn45z	119	14	NIH	NIH	NNP
cord-021637-f5wwn45z	119	15	was	be	VBD
cord-021637-f5wwn45z	119	16	established	establish	VBN
cord-021637-f5wwn45z	119	17	in	in	IN
cord-021637-f5wwn45z	119	18	1999	1999	CD
cord-021637-f5wwn45z	119	19	primarily	primarily	RB
cord-021637-f5wwn45z	119	20	to	to	TO
cord-021637-f5wwn45z	119	21	pursue	pursue	VB
cord-021637-f5wwn45z	119	22	the	the	DT
cord-021637-f5wwn45z	119	23	development	development	NN
cord-021637-f5wwn45z	119	24	of	of	IN
cord-021637-f5wwn45z	119	25	HIV	HIV	NNP
cord-021637-f5wwn45z	119	26	vaccines	vaccine	NNS
cord-021637-f5wwn45z	119	27	.	.	.
cord-021637-f5wwn45z	120	1	The	the	DT
cord-021637-f5wwn45z	120	2	Centers	Centers	NNPS
cord-021637-f5wwn45z	120	3	for	for	IN
cord-021637-f5wwn45z	120	4	Disease	Disease	NNP
cord-021637-f5wwn45z	120	5	Control	Control	NNP
cord-021637-f5wwn45z	120	6	and	and	CC
cord-021637-f5wwn45z	120	7	Prevention	Prevention	NNP
cord-021637-f5wwn45z	120	8	(	(	-LRB-
cord-021637-f5wwn45z	120	9	CDC	CDC	NNP
cord-021637-f5wwn45z	120	10	)	)	-RRB-
cord-021637-f5wwn45z	120	11	is	be	VBZ
cord-021637-f5wwn45z	120	12	the	the	DT
cord-021637-f5wwn45z	120	13	primary	primary	JJ
cord-021637-f5wwn45z	120	14	government	government	NN
cord-021637-f5wwn45z	120	15	agency	agency	NN
cord-021637-f5wwn45z	120	16	responsible	responsible	JJ
cord-021637-f5wwn45z	120	17	for	for	IN
cord-021637-f5wwn45z	120	18	epidemiological	epidemiological	JJ
cord-021637-f5wwn45z	120	19	monitoring	monitoring	NN
cord-021637-f5wwn45z	120	20	of	of	IN
cord-021637-f5wwn45z	120	21	disease	disease	NN
cord-021637-f5wwn45z	120	22	trends	trend	NNS
cord-021637-f5wwn45z	120	23	.	.	.
cord-021637-f5wwn45z	121	1	The	the	DT
cord-021637-f5wwn45z	121	2	CDC	CDC	NNP
cord-021637-f5wwn45z	121	3	conducts	conduct	VBZ
cord-021637-f5wwn45z	121	4	disease	disease	NN
cord-021637-f5wwn45z	121	5	surveillance	surveillance	NN
cord-021637-f5wwn45z	121	6	and	and	CC
cord-021637-f5wwn45z	121	7	epidemiological	epidemiological	JJ
cord-021637-f5wwn45z	121	8	studies	study	NNS
cord-021637-f5wwn45z	121	9	to	to	TO
cord-021637-f5wwn45z	121	10	ascertain	ascertain	VB
cord-021637-f5wwn45z	121	11	the	the	DT
cord-021637-f5wwn45z	121	12	prevalence	prevalence	NN
cord-021637-f5wwn45z	121	13	and	and	CC
cord-021637-f5wwn45z	121	14	incidence	incidence	NN
cord-021637-f5wwn45z	121	15	of	of	IN
cord-021637-f5wwn45z	121	16	specific	specific	JJ
cord-021637-f5wwn45z	121	17	diseases	disease	NNS
cord-021637-f5wwn45z	121	18	;	;	:
cord-021637-f5wwn45z	121	19	this	this	DT
cord-021637-f5wwn45z	121	20	information	information	NN
cord-021637-f5wwn45z	121	21	provides	provide	VBZ
cord-021637-f5wwn45z	121	22	a	a	DT
cord-021637-f5wwn45z	121	23	rationale	rationale	NN
cord-021637-f5wwn45z	121	24	for	for	IN
cord-021637-f5wwn45z	121	25	prioritizing	prioritize	VBG
cord-021637-f5wwn45z	121	26	vaccine	vaccine	NN
cord-021637-f5wwn45z	121	27	development	development	NN
cord-021637-f5wwn45z	121	28	.	.	.
cord-021637-f5wwn45z	122	1	These	these	DT
cord-021637-f5wwn45z	122	2	studies	study	NNS
cord-021637-f5wwn45z	122	3	by	by	IN
cord-021637-f5wwn45z	122	4	the	the	DT
cord-021637-f5wwn45z	122	5	CDC	CDC	NNP
cord-021637-f5wwn45z	122	6	are	be	VBP
cord-021637-f5wwn45z	122	7	performed	perform	VBN
cord-021637-f5wwn45z	122	8	in	in	IN
cord-021637-f5wwn45z	122	9	addition	addition	NN
cord-021637-f5wwn45z	122	10	to	to	IN
cord-021637-f5wwn45z	122	11	studies	study	NNS
cord-021637-f5wwn45z	122	12	conducted	conduct	VBN
cord-021637-f5wwn45z	122	13	by	by	IN
cord-021637-f5wwn45z	122	14	the	the	DT
cord-021637-f5wwn45z	122	15	vaccine	vaccine	NN
cord-021637-f5wwn45z	122	16	companies	company	NNS
cord-021637-f5wwn45z	122	17	,	,	,
cord-021637-f5wwn45z	122	18	such	such	JJ
cord-021637-f5wwn45z	122	19	as	as	IN
cord-021637-f5wwn45z	122	20	Phase	Phase	NNP
cord-021637-f5wwn45z	122	21	IV	IV	NNP
cord-021637-f5wwn45z	122	22	studies	study	NNS
cord-021637-f5wwn45z	122	23	.	.	.
cord-021637-f5wwn45z	123	1	Through	through	IN
cord-021637-f5wwn45z	123	2	the	the	DT
cord-021637-f5wwn45z	123	3	Advisory	Advisory	NNP
cord-021637-f5wwn45z	123	4	Committee	Committee	NNP
cord-021637-f5wwn45z	123	5	on	on	IN
cord-021637-f5wwn45z	123	6	Immunization	Immunization	NNP
cord-021637-f5wwn45z	123	7	Practices	Practices	NNPS
cord-021637-f5wwn45z	123	8	(	(	-LRB-
cord-021637-f5wwn45z	123	9	ACIP	ACIP	NNP
cord-021637-f5wwn45z	123	10	)	)	-RRB-
cord-021637-f5wwn45z	123	11	,	,	,
cord-021637-f5wwn45z	123	12	the	the	DT
cord-021637-f5wwn45z	123	13	CDC	CDC	NNP
cord-021637-f5wwn45z	123	14	recommends	recommend	VBZ
cord-021637-f5wwn45z	123	15	usage	usage	NN
cord-021637-f5wwn45z	123	16	of	of	IN
cord-021637-f5wwn45z	123	17	vaccines	vaccine	NNS
cord-021637-f5wwn45z	123	18	,	,	,
cord-021637-f5wwn45z	123	19	and	and	CC
cord-021637-f5wwn45z	123	20	is	be	VBZ
cord-021637-f5wwn45z	123	21	responsible	responsible	JJ
cord-021637-f5wwn45z	123	22	for	for	IN
cord-021637-f5wwn45z	123	23	most	most	JJS
cord-021637-f5wwn45z	123	24	of	of	IN
cord-021637-f5wwn45z	123	25	the	the	DT
cord-021637-f5wwn45z	123	26	public	public	JJ
cord-021637-f5wwn45z	123	27	purchases	purchase	NNS
cord-021637-f5wwn45z	123	28	(	(	-LRB-
cord-021637-f5wwn45z	123	29	directly	directly	RB
cord-021637-f5wwn45z	123	30	through	through	IN
cord-021637-f5wwn45z	123	31	the	the	DT
cord-021637-f5wwn45z	123	32	Vaccines	Vaccines	NNPS
cord-021637-f5wwn45z	123	33	for	for	IN
cord-021637-f5wwn45z	123	34	Children	Children	NNP
cord-021637-f5wwn45z	123	35	program	program	NN
cord-021637-f5wwn45z	123	36	for	for	IN
cord-021637-f5wwn45z	123	37	approximately	approximately	RB
cord-021637-f5wwn45z	123	38	41	41	CD
cord-021637-f5wwn45z	123	39	%	%	NN
cord-021637-f5wwn45z	123	40	,	,	,
cord-021637-f5wwn45z	123	41	and	and	CC
cord-021637-f5wwn45z	123	42	indirectly	indirectly	RB
cord-021637-f5wwn45z	123	43	through	through	IN
cord-021637-f5wwn45z	123	44	other	other	JJ
cord-021637-f5wwn45z	123	45	federal	federal	JJ
cord-021637-f5wwn45z	123	46	,	,	,
cord-021637-f5wwn45z	123	47	state	state	NN
cord-021637-f5wwn45z	123	48	,	,	,
cord-021637-f5wwn45z	123	49	and	and	CC
cord-021637-f5wwn45z	123	50	local	local	JJ
cord-021637-f5wwn45z	123	51	government	government	NN
cord-021637-f5wwn45z	123	52	purchases	purchase	NNS
cord-021637-f5wwn45z	123	53	for	for	IN
cord-021637-f5wwn45z	123	54	approximately	approximately	RB
cord-021637-f5wwn45z	123	55	16	16	CD
cord-021637-f5wwn45z	123	56	%	%	NN
cord-021637-f5wwn45z	123	57	,	,	,
cord-021637-f5wwn45z	123	58	together	together	RB
cord-021637-f5wwn45z	123	59	totaling	total	VBG
cord-021637-f5wwn45z	123	60	approximately	approximately	RB
cord-021637-f5wwn45z	123	61	57	57	CD
cord-021637-f5wwn45z	123	62	%	%	NN
cord-021637-f5wwn45z	123	63	of	of	IN
cord-021637-f5wwn45z	123	64	all	all	DT
cord-021637-f5wwn45z	123	65	childhood	childhood	NN
cord-021637-f5wwn45z	123	66	vaccines	vaccine	NNS
cord-021637-f5wwn45z	123	67	in	in	IN
cord-021637-f5wwn45z	123	68	the	the	DT
cord-021637-f5wwn45z	123	69	United	United	NNP
cord-021637-f5wwn45z	123	70	States	States	NNP
cord-021637-f5wwn45z	123	71	)	)	-RRB-
cord-021637-f5wwn45z	123	72	,	,	,
cord-021637-f5wwn45z	123	73	thereby	thereby	RB
cord-021637-f5wwn45z	123	74	playing	play	VBG
cord-021637-f5wwn45z	123	75	a	a	DT
cord-021637-f5wwn45z	123	76	major	major	JJ
cord-021637-f5wwn45z	123	77	role	role	NN
cord-021637-f5wwn45z	123	78	in	in	IN
cord-021637-f5wwn45z	123	79	determining	determine	VBG
cord-021637-f5wwn45z	123	80	the	the	DT
cord-021637-f5wwn45z	123	81	demand	demand	NN
cord-021637-f5wwn45z	123	82	and	and	CC
cord-021637-f5wwn45z	123	83	potential	potential	JJ
cord-021637-f5wwn45z	123	84	profit	profit	NN
cord-021637-f5wwn45z	123	85	associated	associate	VBN
cord-021637-f5wwn45z	123	86	with	with	IN
cord-021637-f5wwn45z	123	87	vaccines	vaccine	NNS
cord-021637-f5wwn45z	123	88	.	.	.
cord-021637-f5wwn45z	124	1	Professional	professional	JJ
cord-021637-f5wwn45z	124	2	organizations	organization	NNS
cord-021637-f5wwn45z	124	3	such	such	JJ
cord-021637-f5wwn45z	124	4	as	as	IN
cord-021637-f5wwn45z	124	5	the	the	DT
cord-021637-f5wwn45z	124	6	American	American	NNP
cord-021637-f5wwn45z	124	7	Academy	Academy	NNP
cord-021637-f5wwn45z	124	8	of	of	IN
cord-021637-f5wwn45z	124	9	Pediatrics	Pediatrics	NNP
cord-021637-f5wwn45z	124	10	and	and	CC
cord-021637-f5wwn45z	124	11	the	the	DT
cord-021637-f5wwn45z	124	12	American	American	NNP
cord-021637-f5wwn45z	124	13	Academy	Academy	NNP
cord-021637-f5wwn45z	124	14	of	of	IN
cord-021637-f5wwn45z	124	15	Family	Family	NNP
cord-021637-f5wwn45z	124	16	Physicians	Physicians	NNPS
cord-021637-f5wwn45z	124	17	also	also	RB
cord-021637-f5wwn45z	124	18	make	make	VBP
cord-021637-f5wwn45z	124	19	recommendations	recommendation	NNS
cord-021637-f5wwn45z	124	20	for	for	IN
cord-021637-f5wwn45z	124	21	vaccine	vaccine	NN
cord-021637-f5wwn45z	124	22	usage	usage	NN
cord-021637-f5wwn45z	124	23	.	.	.
cord-021637-f5wwn45z	125	1	There	there	EX
cord-021637-f5wwn45z	125	2	is	be	VBZ
cord-021637-f5wwn45z	125	3	no	no	DT
cord-021637-f5wwn45z	125	4	federal	federal	JJ
cord-021637-f5wwn45z	125	5	vaccine	vaccine	NN
cord-021637-f5wwn45z	125	6	program	program	NN
cord-021637-f5wwn45z	125	7	for	for	IN
cord-021637-f5wwn45z	125	8	adults	adult	NNS
cord-021637-f5wwn45z	125	9	,	,	,
cord-021637-f5wwn45z	125	10	although	although	IN
cord-021637-f5wwn45z	125	11	Medicare	Medicare	NNP
cord-021637-f5wwn45z	125	12	does	do	VBZ
cord-021637-f5wwn45z	125	13	reimburse	reimburse	VB
cord-021637-f5wwn45z	125	14	for	for	IN
cord-021637-f5wwn45z	125	15	influenza	influenza	NN
cord-021637-f5wwn45z	125	16	and	and	CC
cord-021637-f5wwn45z	125	17	pneumococcal	pneumococcal	JJ
cord-021637-f5wwn45z	125	18	conjugate	conjugate	NN
cord-021637-f5wwn45z	125	19	vaccines	vaccine	NNS
cord-021637-f5wwn45z	125	20	.	.	.
cord-021637-f5wwn45z	126	1	Historically	historically	RB
cord-021637-f5wwn45z	126	2	,	,	,
cord-021637-f5wwn45z	126	3	many	many	JJ
cord-021637-f5wwn45z	126	4	adults	adult	NNS
cord-021637-f5wwn45z	126	5	with	with	IN
cord-021637-f5wwn45z	126	6	private	private	JJ
cord-021637-f5wwn45z	126	7	insurance	insurance	NN
cord-021637-f5wwn45z	126	8	were	be	VBD
cord-021637-f5wwn45z	126	9	not	not	RB
cord-021637-f5wwn45z	126	10	covered	cover	VBN
cord-021637-f5wwn45z	126	11	for	for	IN
cord-021637-f5wwn45z	126	12	immunizations	immunization	NNS
cord-021637-f5wwn45z	126	13	.	.	.
cord-021637-f5wwn45z	127	1	However	however	RB
cord-021637-f5wwn45z	127	2	,	,	,
cord-021637-f5wwn45z	127	3	the	the	DT
cord-021637-f5wwn45z	127	4	Affordable	Affordable	NNP
cord-021637-f5wwn45z	127	5	Care	Care	NNP
cord-021637-f5wwn45z	127	6	Act	Act	NNP
cord-021637-f5wwn45z	127	7	of	of	IN
cord-021637-f5wwn45z	127	8	2010	2010	CD
cord-021637-f5wwn45z	127	9	requires	require	VBZ
cord-021637-f5wwn45z	127	10	health	health	NN
cord-021637-f5wwn45z	127	11	plans	plan	NNS
cord-021637-f5wwn45z	127	12	to	to	TO
cord-021637-f5wwn45z	127	13	cover	cover	VB
cord-021637-f5wwn45z	127	14	vaccines	vaccine	NNS
cord-021637-f5wwn45z	127	15	recommended	recommend	VBN
cord-021637-f5wwn45z	127	16	by	by	IN
cord-021637-f5wwn45z	127	17	the	the	DT
cord-021637-f5wwn45z	127	18	ACIP	ACIP	NNP
cord-021637-f5wwn45z	127	19	prior	prior	RB
cord-021637-f5wwn45z	127	20	to	to	IN
cord-021637-f5wwn45z	127	21	September	September	NNP
cord-021637-f5wwn45z	127	22	2009	2009	CD
cord-021637-f5wwn45z	127	23	with	with	IN
cord-021637-f5wwn45z	127	24	no	no	DT
cord-021637-f5wwn45z	127	25	copayments	copayment	NNS
cord-021637-f5wwn45z	127	26	or	or	CC
cord-021637-f5wwn45z	127	27	other	other	JJ
cord-021637-f5wwn45z	127	28	cost	cost	NN
cord-021637-f5wwn45z	127	29	-	-	HYPH
cord-021637-f5wwn45z	127	30	sharing	sharing	NN
cord-021637-f5wwn45z	127	31	requirements	requirement	NNS
cord-021637-f5wwn45z	127	32	when	when	WRB
cord-021637-f5wwn45z	127	33	those	those	DT
cord-021637-f5wwn45z	127	34	services	service	NNS
cord-021637-f5wwn45z	127	35	are	be	VBP
cord-021637-f5wwn45z	127	36	delivered	deliver	VBN
cord-021637-f5wwn45z	127	37	by	by	IN
cord-021637-f5wwn45z	127	38	an	an	DT
cord-021637-f5wwn45z	127	39	in	in	IN
cord-021637-f5wwn45z	127	40	-	-	HYPH
cord-021637-f5wwn45z	127	41	network	network	NN
cord-021637-f5wwn45z	127	42	provider	provider	NN
cord-021637-f5wwn45z	127	43	.	.	.
cord-021637-f5wwn45z	128	1	The	the	DT
cord-021637-f5wwn45z	128	2	Department	Department	NNP
cord-021637-f5wwn45z	128	3	of	of	IN
cord-021637-f5wwn45z	128	4	Defense	Defense	NNP
cord-021637-f5wwn45z	128	5	(	(	-LRB-
cord-021637-f5wwn45z	128	6	DOD	DOD	NNP
cord-021637-f5wwn45z	128	7	)	)	-RRB-
cord-021637-f5wwn45z	128	8	does	do	VBZ
cord-021637-f5wwn45z	128	9	targeted	target	VBN
cord-021637-f5wwn45z	128	10	vaccine	vaccine	NN
cord-021637-f5wwn45z	128	11	R&D	r&d	NN
cord-021637-f5wwn45z	128	12	to	to	TO
cord-021637-f5wwn45z	128	13	help	help	VB
cord-021637-f5wwn45z	128	14	it	-PRON-	PRP
cord-021637-f5wwn45z	128	15	perform	perform	VB
cord-021637-f5wwn45z	128	16	its	-PRON-	PRP$
cord-021637-f5wwn45z	128	17	mission	mission	NN
cord-021637-f5wwn45z	128	18	of	of	IN
cord-021637-f5wwn45z	128	19	protecting	protect	VBG
cord-021637-f5wwn45z	128	20	deployable	deployable	JJ
cord-021637-f5wwn45z	128	21	impact	impact	NN
cord-021637-f5wwn45z	128	22	on	on	IN
cord-021637-f5wwn45z	128	23	the	the	DT
cord-021637-f5wwn45z	128	24	nature	nature	NN
cord-021637-f5wwn45z	128	25	and	and	CC
cord-021637-f5wwn45z	128	26	direction	direction	NN
cord-021637-f5wwn45z	128	27	of	of	IN
cord-021637-f5wwn45z	128	28	vaccine	vaccine	NN
cord-021637-f5wwn45z	128	29	development	development	NN
cord-021637-f5wwn45z	128	30	and	and	CC
cord-021637-f5wwn45z	128	31	its	-PRON-	PRP$
cord-021637-f5wwn45z	128	32	costs	cost	NNS
cord-021637-f5wwn45z	128	33	.	.	.
cord-021637-f5wwn45z	129	1	In	in	IN
cord-021637-f5wwn45z	129	2	addition	addition	NN
cord-021637-f5wwn45z	129	3	,	,	,
cord-021637-f5wwn45z	129	4	CBER	CBER	NNP
cord-021637-f5wwn45z	129	5	maintains	maintain	VBZ
cord-021637-f5wwn45z	129	6	a	a	DT
cord-021637-f5wwn45z	129	7	strong	strong	JJ
cord-021637-f5wwn45z	129	8	research	research	NN
cord-021637-f5wwn45z	129	9	base	base	NN
cord-021637-f5wwn45z	129	10	internally	internally	RB
cord-021637-f5wwn45z	129	11	,	,	,
cord-021637-f5wwn45z	129	12	so	so	CC
cord-021637-f5wwn45z	129	13	it	-PRON-	PRP
cord-021637-f5wwn45z	129	14	is	be	VBZ
cord-021637-f5wwn45z	129	15	better	well	RBR
cord-021637-f5wwn45z	129	16	positioned	position	VBN
cord-021637-f5wwn45z	129	17	to	to	TO
cord-021637-f5wwn45z	129	18	evaluate	evaluate	VB
cord-021637-f5wwn45z	129	19	data	datum	NNS
cord-021637-f5wwn45z	129	20	from	from	IN
cord-021637-f5wwn45z	129	21	various	various	JJ
cord-021637-f5wwn45z	129	22	studies	study	NNS
cord-021637-f5wwn45z	129	23	.	.	.
cord-021637-f5wwn45z	130	1	CBER	CBER	NNP
cord-021637-f5wwn45z	130	2	remains	remain	VBZ
cord-021637-f5wwn45z	130	3	the	the	DT
cord-021637-f5wwn45z	130	4	premier	premier	JJ
cord-021637-f5wwn45z	130	5	vaccine	vaccine	NN
cord-021637-f5wwn45z	130	6	regulatory	regulatory	JJ
cord-021637-f5wwn45z	130	7	agency	agency	NN
cord-021637-f5wwn45z	130	8	in	in	IN
cord-021637-f5wwn45z	130	9	the	the	DT
cord-021637-f5wwn45z	130	10	world	world	NN
cord-021637-f5wwn45z	130	11	.	.	.
cord-021637-f5wwn45z	131	1	Nongovernmental	nongovernmental	JJ
cord-021637-f5wwn45z	131	2	organizations	organization	NNS
cord-021637-f5wwn45z	131	3	(	(	-LRB-
cord-021637-f5wwn45z	131	4	NGOs	NGOs	NNPS
cord-021637-f5wwn45z	131	5	)	)	-RRB-
cord-021637-f5wwn45z	131	6	are	be	VBP
cord-021637-f5wwn45z	131	7	playing	play	VBG
cord-021637-f5wwn45z	131	8	an	an	DT
cord-021637-f5wwn45z	131	9	increasing	increase	VBG
cord-021637-f5wwn45z	131	10	role	role	NN
cord-021637-f5wwn45z	131	11	in	in	IN
cord-021637-f5wwn45z	131	12	vaccine	vaccine	NN
cord-021637-f5wwn45z	131	13	research	research	NN
cord-021637-f5wwn45z	131	14	.	.	.
cord-021637-f5wwn45z	132	1	The	the	DT
cord-021637-f5wwn45z	132	2	Bill	Bill	NNP
cord-021637-f5wwn45z	132	3	and	and	CC
cord-021637-f5wwn45z	132	4	Melinda	Melinda	NNP
cord-021637-f5wwn45z	132	5	Gates	Gates	NNP
cord-021637-f5wwn45z	132	6	Foundation	Foundation	NNP
cord-021637-f5wwn45z	132	7	supports	support	VBZ
cord-021637-f5wwn45z	132	8	several	several	JJ
cord-021637-f5wwn45z	132	9	organizations	organization	NNS
cord-021637-f5wwn45z	132	10	including	include	VBG
cord-021637-f5wwn45z	132	11	the	the	DT
cord-021637-f5wwn45z	132	12	International	International	NNP
cord-021637-f5wwn45z	132	13	AIDS	AIDS	NNP
cord-021637-f5wwn45z	132	14	Vaccine	Vaccine	NNP
cord-021637-f5wwn45z	132	15	Initiative	Initiative	NNP
cord-021637-f5wwn45z	132	16	,	,	,
cord-021637-f5wwn45z	132	17	the	the	DT
cord-021637-f5wwn45z	132	18	Malaria	Malaria	NNP
cord-021637-f5wwn45z	132	19	Vaccine	Vaccine	NNP
cord-021637-f5wwn45z	132	20	Initiative	Initiative	NNP
cord-021637-f5wwn45z	132	21	,	,	,
cord-021637-f5wwn45z	132	22	Aeras	Aeras	NNP
cord-021637-f5wwn45z	132	23	(	(	-LRB-
cord-021637-f5wwn45z	132	24	dedicated	dedicate	VBN
cord-021637-f5wwn45z	132	25	to	to	IN
cord-021637-f5wwn45z	132	26	developing	develop	VBG
cord-021637-f5wwn45z	132	27	TB	TB	NNP
cord-021637-f5wwn45z	132	28	vaccines	vaccine	NNS
cord-021637-f5wwn45z	132	29	)	)	-RRB-
cord-021637-f5wwn45z	132	30	,	,	,
cord-021637-f5wwn45z	132	31	and	and	CC
cord-021637-f5wwn45z	132	32	others	other	NNS
cord-021637-f5wwn45z	132	33	with	with	IN
cord-021637-f5wwn45z	132	34	significant	significant	JJ
cord-021637-f5wwn45z	132	35	funding	funding	NN
cord-021637-f5wwn45z	132	36	for	for	IN
cord-021637-f5wwn45z	132	37	development	development	NN
cord-021637-f5wwn45z	132	38	of	of	IN
cord-021637-f5wwn45z	132	39	vaccines	vaccine	NNS
cord-021637-f5wwn45z	132	40	that	that	WDT
cord-021637-f5wwn45z	132	41	would	would	MD
cord-021637-f5wwn45z	132	42	have	have	VB
cord-021637-f5wwn45z	132	43	the	the	DT
cord-021637-f5wwn45z	132	44	greatest	great	JJS
cord-021637-f5wwn45z	132	45	impact	impact	NN
cord-021637-f5wwn45z	132	46	on	on	IN
cord-021637-f5wwn45z	132	47	diseases	disease	NNS
cord-021637-f5wwn45z	132	48	of	of	IN
cord-021637-f5wwn45z	132	49	developing	develop	VBG
cord-021637-f5wwn45z	132	50	countries	country	NNS
cord-021637-f5wwn45z	132	51	.	.	.
cord-021637-f5wwn45z	133	1	In	in	IN
cord-021637-f5wwn45z	133	2	addition	addition	NN
cord-021637-f5wwn45z	133	3	,	,	,
cord-021637-f5wwn45z	133	4	a	a	DT
cord-021637-f5wwn45z	133	5	related	related	JJ
cord-021637-f5wwn45z	133	6	organization	organization	NN
cord-021637-f5wwn45z	133	7	,	,	,
cord-021637-f5wwn45z	133	8	Programs	Programs	NNP
cord-021637-f5wwn45z	133	9	for	for	IN
cord-021637-f5wwn45z	133	10	Appropriate	Appropriate	NNP
cord-021637-f5wwn45z	133	11	Technology	Technology	NNP
cord-021637-f5wwn45z	133	12	in	in	IN
cord-021637-f5wwn45z	133	13	Health	Health	NNP
cord-021637-f5wwn45z	133	14	(	(	-LRB-
cord-021637-f5wwn45z	133	15	PATH	path	NN
cord-021637-f5wwn45z	133	16	)	)	-RRB-
cord-021637-f5wwn45z	133	17	,	,	,
cord-021637-f5wwn45z	133	18	is	be	VBZ
cord-021637-f5wwn45z	133	19	a	a	DT
cord-021637-f5wwn45z	133	20	nonprofit	nonprofit	JJ
cord-021637-f5wwn45z	133	21	group	group	NN
cord-021637-f5wwn45z	133	22	that	that	WDT
cord-021637-f5wwn45z	133	23	forges	forge	VBZ
cord-021637-f5wwn45z	133	24	private	private	JJ
cord-021637-f5wwn45z	133	25	sector	sector	NN
cord-021637-f5wwn45z	133	26	partnerships	partnership	NNS
cord-021637-f5wwn45z	133	27	to	to	TO
cord-021637-f5wwn45z	133	28	develop	develop	VB
cord-021637-f5wwn45z	133	29	vaccine	vaccine	NN
cord-021637-f5wwn45z	133	30	technologies	technology	NNS
cord-021637-f5wwn45z	133	31	suitable	suitable	JJ
cord-021637-f5wwn45z	133	32	for	for	IN
cord-021637-f5wwn45z	133	33	the	the	DT
cord-021637-f5wwn45z	133	34	developing	develop	VBG
cord-021637-f5wwn45z	133	35	world	world	NN
cord-021637-f5wwn45z	133	36	.	.	.
cord-021637-f5wwn45z	134	1	These	these	DT
cord-021637-f5wwn45z	134	2	product	product	NN
cord-021637-f5wwn45z	134	3	development	development	NN
cord-021637-f5wwn45z	134	4	partnership	partnership	NN
cord-021637-f5wwn45z	134	5	organizations	organization	NNS
cord-021637-f5wwn45z	134	6	(	(	-LRB-
cord-021637-f5wwn45z	134	7	PDPs	pdp	NNS
cord-021637-f5wwn45z	134	8	;	;	:
cord-021637-f5wwn45z	134	9	essentially	essentially	RB
cord-021637-f5wwn45z	134	10	not	not	RB
cord-021637-f5wwn45z	134	11	-	-	HYPH
cord-021637-f5wwn45z	134	12	for	for	IN
cord-021637-f5wwn45z	134	13	-	-	HYPH
cord-021637-f5wwn45z	134	14	profit	profit	NN
cord-021637-f5wwn45z	134	15	biotech	biotech	NN
cord-021637-f5wwn45z	134	16	companies	company	NNS
cord-021637-f5wwn45z	134	17	)	)	-RRB-
cord-021637-f5wwn45z	134	18	bring	bring	VBP
cord-021637-f5wwn45z	134	19	together	together	RB
cord-021637-f5wwn45z	134	20	specialized	specialized	JJ
cord-021637-f5wwn45z	134	21	knowledge	knowledge	NN
cord-021637-f5wwn45z	134	22	,	,	,
cord-021637-f5wwn45z	134	23	animal	animal	NN
cord-021637-f5wwn45z	134	24	models	model	NNS
cord-021637-f5wwn45z	134	25	,	,	,
cord-021637-f5wwn45z	134	26	immunologic	immunologic	JJ
cord-021637-f5wwn45z	134	27	assays	assay	NNS
cord-021637-f5wwn45z	134	28	,	,	,
cord-021637-f5wwn45z	134	29	and	and	CC
cord-021637-f5wwn45z	134	30	field	field	NN
cord-021637-f5wwn45z	134	31	sites	site	NNS
cord-021637-f5wwn45z	134	32	for	for	IN
cord-021637-f5wwn45z	134	33	vaccine	vaccine	NN
cord-021637-f5wwn45z	134	34	testing	testing	NN
cord-021637-f5wwn45z	134	35	as	as	RB
cord-021637-f5wwn45z	134	36	well	well	RB
cord-021637-f5wwn45z	134	37	as	as	IN
cord-021637-f5wwn45z	134	38	early	early	JJ
cord-021637-f5wwn45z	134	39	capital	capital	NN
cord-021637-f5wwn45z	134	40	investment	investment	NN
cord-021637-f5wwn45z	134	41	to	to	TO
cord-021637-f5wwn45z	134	42	reduce	reduce	VB
cord-021637-f5wwn45z	134	43	the	the	DT
cord-021637-f5wwn45z	134	44	scientific	scientific	JJ
cord-021637-f5wwn45z	134	45	technical	technical	JJ
cord-021637-f5wwn45z	134	46	risks	risk	NNS
cord-021637-f5wwn45z	134	47	,	,	,
cord-021637-f5wwn45z	134	48	opportunity	opportunity	NN
cord-021637-f5wwn45z	134	49	costs	cost	NNS
cord-021637-f5wwn45z	134	50	,	,	,
cord-021637-f5wwn45z	134	51	and	and	CC
cord-021637-f5wwn45z	134	52	financial	financial	JJ
cord-021637-f5wwn45z	134	53	risk	risk	NN
cord-021637-f5wwn45z	134	54	to	to	IN
cord-021637-f5wwn45z	134	55	their	-PRON-	PRP$
cord-021637-f5wwn45z	134	56	biotech	biotech	JJ
cord-021637-f5wwn45z	134	57	and	and	CC
cord-021637-f5wwn45z	134	58	large	large	JJ
cord-021637-f5wwn45z	134	59	pharma	pharma	NNS
cord-021637-f5wwn45z	134	60	industrial	industrial	JJ
cord-021637-f5wwn45z	134	61	partners	partner	NNS
cord-021637-f5wwn45z	134	62	.	.	.
cord-021637-f5wwn45z	135	1	They	-PRON-	PRP
cord-021637-f5wwn45z	135	2	also	also	RB
cord-021637-f5wwn45z	135	3	provide	provide	VBP
cord-021637-f5wwn45z	135	4	opportunities	opportunity	NNS
cord-021637-f5wwn45z	135	5	for	for	IN
cord-021637-f5wwn45z	135	6	validation	validation	NN
cord-021637-f5wwn45z	135	7	of	of	IN
cord-021637-f5wwn45z	135	8	novel	novel	JJ
cord-021637-f5wwn45z	135	9	vaccine	vaccine	NN
cord-021637-f5wwn45z	135	10	technologies	technology	NNS
cord-021637-f5wwn45z	135	11	and	and	CC
cord-021637-f5wwn45z	135	12	platforms	platform	NNS
cord-021637-f5wwn45z	135	13	.	.	.
cord-021637-f5wwn45z	136	1	The	the	DT
cord-021637-f5wwn45z	136	2	role	role	NN
cord-021637-f5wwn45z	136	3	of	of	IN
cord-021637-f5wwn45z	136	4	large	large	JJ
cord-021637-f5wwn45z	136	5	,	,	,
cord-021637-f5wwn45z	136	6	full	full	JJ
cord-021637-f5wwn45z	136	7	-	-	HYPH
cord-021637-f5wwn45z	136	8	service	service	NN
cord-021637-f5wwn45z	136	9	vaccine	vaccine	NN
cord-021637-f5wwn45z	136	10	companies	company	NNS
cord-021637-f5wwn45z	136	11	(	(	-LRB-
cord-021637-f5wwn45z	136	12	in	in	IN
cord-021637-f5wwn45z	136	13	some	some	DT
cord-021637-f5wwn45z	136	14	limited	limited	JJ
cord-021637-f5wwn45z	136	15	basic	basic	JJ
cord-021637-f5wwn45z	136	16	research	research	NN
cord-021637-f5wwn45z	136	17	and	and	CC
cord-021637-f5wwn45z	136	18	significant	significant	JJ
cord-021637-f5wwn45z	136	19	amounts	amount	NNS
cord-021637-f5wwn45z	136	20	of	of	IN
cord-021637-f5wwn45z	136	21	targeted	target	VBN
cord-021637-f5wwn45z	136	22	research	research	NN
cord-021637-f5wwn45z	136	23	regarding	regard	VBG
cord-021637-f5wwn45z	136	24	specific	specific	JJ
cord-021637-f5wwn45z	136	25	organisms	organism	NNS
cord-021637-f5wwn45z	136	26	,	,	,
cord-021637-f5wwn45z	136	27	but	but	CC
cord-021637-f5wwn45z	136	28	the	the	DT
cord-021637-f5wwn45z	136	29	preponderance	preponderance	NN
cord-021637-f5wwn45z	136	30	of	of	IN
cord-021637-f5wwn45z	136	31	activity	activity	NN
cord-021637-f5wwn45z	136	32	is	be	VBZ
cord-021637-f5wwn45z	136	33	in	in	IN
cord-021637-f5wwn45z	136	34	clinical	clinical	JJ
cord-021637-f5wwn45z	136	35	and	and	CC
cord-021637-f5wwn45z	136	36	process	process	NN
cord-021637-f5wwn45z	136	37	development	development	NN
cord-021637-f5wwn45z	136	38	.	.	.
cord-021637-f5wwn45z	137	1	Sufficient	sufficient	JJ
cord-021637-f5wwn45z	137	2	personnel	personnel	NNS
cord-021637-f5wwn45z	137	3	and	and	CC
cord-021637-f5wwn45z	137	4	expertise	expertise	NN
cord-021637-f5wwn45z	137	5	in	in	IN
cord-021637-f5wwn45z	137	6	process	process	NN
cord-021637-f5wwn45z	137	7	development	development	NN
cord-021637-f5wwn45z	137	8	and	and	CC
cord-021637-f5wwn45z	137	9	chemical	chemical	NN
cord-021637-f5wwn45z	137	10	engineering	engineering	NN
cord-021637-f5wwn45z	137	11	reside	reside	VBP
cord-021637-f5wwn45z	137	12	almost	almost	RB
cord-021637-f5wwn45z	137	13	exclusively	exclusively	RB
cord-021637-f5wwn45z	137	14	in	in	IN
cord-021637-f5wwn45z	137	15	these	these	DT
cord-021637-f5wwn45z	137	16	companies	company	NNS
cord-021637-f5wwn45z	137	17	;	;	:
cord-021637-f5wwn45z	137	18	there	there	EX
cord-021637-f5wwn45z	137	19	is	be	VBZ
cord-021637-f5wwn45z	137	20	no	no	DT
cord-021637-f5wwn45z	137	21	other	other	JJ
cord-021637-f5wwn45z	137	22	resource	resource	NN
cord-021637-f5wwn45z	137	23	for	for	IN
cord-021637-f5wwn45z	137	24	such	such	JJ
cord-021637-f5wwn45z	137	25	development	development	NN
cord-021637-f5wwn45z	137	26	.	.	.
cord-021637-f5wwn45z	138	1	Clinical	clinical	JJ
cord-021637-f5wwn45z	138	2	development	development	NN
cord-021637-f5wwn45z	138	3	that	that	WDT
cord-021637-f5wwn45z	138	4	will	will	MD
cord-021637-f5wwn45z	138	5	satisfy	satisfy	VB
cord-021637-f5wwn45z	138	6	FDA	FDA	NNP
cord-021637-f5wwn45z	138	7	standards	standard	NNS
cord-021637-f5wwn45z	138	8	is	be	VBZ
cord-021637-f5wwn45z	138	9	also	also	RB
cord-021637-f5wwn45z	138	10	done	do	VBN
cord-021637-f5wwn45z	138	11	mostly	mostly	RB
cord-021637-f5wwn45z	138	12	by	by	IN
cord-021637-f5wwn45z	138	13	the	the	DT
cord-021637-f5wwn45z	138	14	large	large	JJ
cord-021637-f5wwn45z	138	15	companies	company	NNS
cord-021637-f5wwn45z	138	16	,	,	,
cord-021637-f5wwn45z	138	17	performed	perform	VBN
cord-021637-f5wwn45z	138	18	by	by	IN
cord-021637-f5wwn45z	138	19	academia	academia	NN
cord-021637-f5wwn45z	138	20	and	and	CC
cord-021637-f5wwn45z	138	21	contract	contract	NN
cord-021637-f5wwn45z	138	22	research	research	NN
cord-021637-f5wwn45z	138	23	organizations	organization	NNS
cord-021637-f5wwn45z	138	24	.	.	.
cord-021637-f5wwn45z	139	1	Personnel	Personnel	NNS
cord-021637-f5wwn45z	139	2	and	and	CC
cord-021637-f5wwn45z	139	3	expertise	expertise	NN
cord-021637-f5wwn45z	139	4	in	in	IN
cord-021637-f5wwn45z	139	5	clinical	clinical	JJ
cord-021637-f5wwn45z	139	6	research	research	NN
cord-021637-f5wwn45z	139	7	,	,	,
cord-021637-f5wwn45z	139	8	regulatory	regulatory	JJ
cord-021637-f5wwn45z	139	9	affairs	affair	NNS
cord-021637-f5wwn45z	139	10	,	,	,
cord-021637-f5wwn45z	139	11	data	datum	NNS
cord-021637-f5wwn45z	139	12	management	management	NN
cord-021637-f5wwn45z	139	13	,	,	,
cord-021637-f5wwn45z	139	14	statistics	statistic	NNS
cord-021637-f5wwn45z	139	15	,	,	,
cord-021637-f5wwn45z	139	16	project	project	NN
cord-021637-f5wwn45z	139	17	management	management	NN
cord-021637-f5wwn45z	139	18	,	,	,
cord-021637-f5wwn45z	139	19	and	and	CC
cord-021637-f5wwn45z	139	20	all	all	DT
cord-021637-f5wwn45z	139	21	other	other	JJ
cord-021637-f5wwn45z	139	22	required	require	VBN
cord-021637-f5wwn45z	139	23	disciplines	discipline	NNS
cord-021637-f5wwn45z	139	24	also	also	RB
cord-021637-f5wwn45z	139	25	exist	exist	VBP
cord-021637-f5wwn45z	139	26	within	within	IN
cord-021637-f5wwn45z	139	27	the	the	DT
cord-021637-f5wwn45z	139	28	large	large	JJ
cord-021637-f5wwn45z	139	29	companies	company	NNS
cord-021637-f5wwn45z	139	30	.	.	.
cord-021637-f5wwn45z	140	1	Perhaps	perhaps	RB
cord-021637-f5wwn45z	140	2	most	most	RBS
cord-021637-f5wwn45z	140	3	importantly	importantly	RB
cord-021637-f5wwn45z	140	4	,	,	,
cord-021637-f5wwn45z	140	5	their	-PRON-	PRP$
cord-021637-f5wwn45z	140	6	management	management	NN
cord-021637-f5wwn45z	140	7	is	be	VBZ
cord-021637-f5wwn45z	140	8	structured	structure	VBN
cord-021637-f5wwn45z	140	9	to	to	TO
cord-021637-f5wwn45z	140	10	make	make	VB
cord-021637-f5wwn45z	140	11	rapid	rapid	JJ
cord-021637-f5wwn45z	140	12	go	go	NN
cord-021637-f5wwn45z	141	1	/no	/no	LS
cord-021637-f5wwn45z	141	2	-	-	HYPH
cord-021637-f5wwn45z	141	3	go	go	VB
cord-021637-f5wwn45z	141	4	decisions	decision	NNS
cord-021637-f5wwn45z	141	5	required	require	VBN
cord-021637-f5wwn45z	141	6	to	to	TO
cord-021637-f5wwn45z	141	7	minimize	minimize	VB
cord-021637-f5wwn45z	141	8	risk	risk	NN
cord-021637-f5wwn45z	141	9	and	and	CC
cord-021637-f5wwn45z	141	10	assess	assess	VB
cord-021637-f5wwn45z	141	11	efficient	efficient	JJ
cord-021637-f5wwn45z	141	12	vaccine	vaccine	NN
cord-021637-f5wwn45z	141	13	development	development	NN
cord-021637-f5wwn45z	141	14	.	.	.
cord-021637-f5wwn45z	142	1	Many	many	JJ
cord-021637-f5wwn45z	142	2	smaller	small	JJR
cord-021637-f5wwn45z	142	3	organizations	organization	NNS
cord-021637-f5wwn45z	142	4	,	,	,
cord-021637-f5wwn45z	142	5	often	often	RB
cord-021637-f5wwn45z	142	6	referred	refer	VBD
cord-021637-f5wwn45z	142	7	to	to	IN
cord-021637-f5wwn45z	142	8	as	as	IN
cord-021637-f5wwn45z	142	9	biotechnology	biotechnology	NN
cord-021637-f5wwn45z	142	10	companies	company	NNS
cord-021637-f5wwn45z	142	11	,	,	,
cord-021637-f5wwn45z	142	12	are	be	VBP
cord-021637-f5wwn45z	142	13	engaged	engage	VBN
cord-021637-f5wwn45z	142	14	in	in	IN
cord-021637-f5wwn45z	142	15	vaccine	vaccine	NN
cord-021637-f5wwn45z	142	16	research	research	NN
cord-021637-f5wwn45z	142	17	.	.	.
cord-021637-f5wwn45z	143	1	They	-PRON-	PRP
cord-021637-f5wwn45z	143	2	are	be	VBP
cord-021637-f5wwn45z	143	3	often	often	RB
cord-021637-f5wwn45z	143	4	started	start	VBN
cord-021637-f5wwn45z	143	5	by	by	IN
cord-021637-f5wwn45z	143	6	university	university	NN
cord-021637-f5wwn45z	143	7	scientists	scientist	NNS
cord-021637-f5wwn45z	143	8	,	,	,
cord-021637-f5wwn45z	143	9	supported	support	VBN
cord-021637-f5wwn45z	143	10	by	by	IN
cord-021637-f5wwn45z	143	11	venture	venture	NN
cord-021637-f5wwn45z	143	12	capitalists	capitalist	NNS
cord-021637-f5wwn45z	143	13	,	,	,
cord-021637-f5wwn45z	143	14	and	and	CC
cord-021637-f5wwn45z	143	15	are	be	VBP
cord-021637-f5wwn45z	143	16	capable	capable	JJ
cord-021637-f5wwn45z	143	17	of	of	IN
cord-021637-f5wwn45z	143	18	basic	basic	JJ
cord-021637-f5wwn45z	143	19	research	research	NN
cord-021637-f5wwn45z	143	20	on	on	IN
cord-021637-f5wwn45z	143	21	a	a	DT
cord-021637-f5wwn45z	143	22	vaccine	vaccine	NN
cord-021637-f5wwn45z	143	23	idea	idea	NN
cord-021637-f5wwn45z	143	24	.	.	.
cord-021637-f5wwn45z	144	1	At	at	IN
cord-021637-f5wwn45z	144	2	this	this	DT
cord-021637-f5wwn45z	144	3	early	early	JJ
cord-021637-f5wwn45z	144	4	stage	stage	NN
cord-021637-f5wwn45z	144	5	,	,	,
cord-021637-f5wwn45z	144	6	they	-PRON-	PRP
cord-021637-f5wwn45z	144	7	usually	usually	RB
cord-021637-f5wwn45z	144	8	have	have	VBP
cord-021637-f5wwn45z	144	9	limited	limit	VBN
cord-021637-f5wwn45z	144	10	capacity	capacity	NN
cord-021637-f5wwn45z	144	11	in	in	IN
cord-021637-f5wwn45z	144	12	process	process	NN
cord-021637-f5wwn45z	144	13	development	development	NN
cord-021637-f5wwn45z	144	14	,	,	,
cord-021637-f5wwn45z	144	15	manufacturing	manufacturing	NN
cord-021637-f5wwn45z	144	16	,	,	,
cord-021637-f5wwn45z	144	17	and	and	CC
cord-021637-f5wwn45z	144	18	clinical	clinical	JJ
cord-021637-f5wwn45z	144	19	development	development	NN
cord-021637-f5wwn45z	144	20	,	,	,
cord-021637-f5wwn45z	144	21	and	and	CC
cord-021637-f5wwn45z	144	22	none	none	NN
cord-021637-f5wwn45z	144	23	in	in	IN
cord-021637-f5wwn45z	144	24	distribution	distribution	NN
cord-021637-f5wwn45z	144	25	,	,	,
cord-021637-f5wwn45z	144	26	sales	sale	NNS
cord-021637-f5wwn45z	144	27	,	,	,
cord-021637-f5wwn45z	144	28	or	or	CC
cord-021637-f5wwn45z	144	29	marketing	marketing	NN
cord-021637-f5wwn45z	144	30	.	.	.
cord-021637-f5wwn45z	145	1	If	if	IN
cord-021637-f5wwn45z	145	2	research	research	NN
cord-021637-f5wwn45z	145	3	results	result	NNS
cord-021637-f5wwn45z	145	4	are	be	VBP
cord-021637-f5wwn45z	145	5	favorable	favorable	JJ
cord-021637-f5wwn45z	145	6	,	,	,
cord-021637-f5wwn45z	145	7	capacity	capacity	NN
cord-021637-f5wwn45z	145	8	in	in	IN
cord-021637-f5wwn45z	145	9	process	process	NN
cord-021637-f5wwn45z	145	10	engineering	engineering	NN
cord-021637-f5wwn45z	145	11	,	,	,
cord-021637-f5wwn45z	145	12	clinical	clinical	JJ
cord-021637-f5wwn45z	145	13	studies	study	NNS
cord-021637-f5wwn45z	145	14	,	,	,
cord-021637-f5wwn45z	145	15	and	and	CC
cord-021637-f5wwn45z	145	16	manufacturing	manufacturing	NN
cord-021637-f5wwn45z	145	17	must	must	MD
cord-021637-f5wwn45z	145	18	be	be	VB
cord-021637-f5wwn45z	145	19	enhanced	enhance	VBN
cord-021637-f5wwn45z	145	20	or	or	CC
cord-021637-f5wwn45z	145	21	obtained	obtain	VBN
cord-021637-f5wwn45z	145	22	by	by	IN
cord-021637-f5wwn45z	145	23	partnering	partner	VBG
cord-021637-f5wwn45z	145	24	.	.	.
cord-021637-f5wwn45z	146	1	Because	because	IN
cord-021637-f5wwn45z	146	2	of	of	IN
cord-021637-f5wwn45z	146	3	the	the	DT
cord-021637-f5wwn45z	146	4	large	large	JJ
cord-021637-f5wwn45z	146	5	cost	cost	NN
cord-021637-f5wwn45z	146	6	of	of	IN
cord-021637-f5wwn45z	146	7	adding	add	VBG
cord-021637-f5wwn45z	146	8	new	new	JJ
cord-021637-f5wwn45z	146	9	capacities	capacity	NNS
cord-021637-f5wwn45z	146	10	and	and	CC
cord-021637-f5wwn45z	146	11	expertise	expertise	NN
cord-021637-f5wwn45z	146	12	,	,	,
cord-021637-f5wwn45z	146	13	many	many	JJ
cord-021637-f5wwn45z	146	14	biotech	biotech	JJ
cord-021637-f5wwn45z	146	15	companies	company	NNS
cord-021637-f5wwn45z	146	16	in	in	IN
cord-021637-f5wwn45z	146	17	advanced	advanced	JJ
cord-021637-f5wwn45z	146	18	product	product	NN
cord-021637-f5wwn45z	146	19	development	development	NN
cord-021637-f5wwn45z	146	20	will	will	MD
cord-021637-f5wwn45z	146	21	opt	opt	VB
cord-021637-f5wwn45z	146	22	to	to	TO
cord-021637-f5wwn45z	146	23	partner	partner	VB
cord-021637-f5wwn45z	146	24	with	with	IN
cord-021637-f5wwn45z	146	25	large	large	JJ
cord-021637-f5wwn45z	146	26	,	,	,
cord-021637-f5wwn45z	146	27	full	full	JJ
cord-021637-f5wwn45z	146	28	-	-	HYPH
cord-021637-f5wwn45z	146	29	scale	scale	NN
cord-021637-f5wwn45z	146	30	companies	company	NNS
cord-021637-f5wwn45z	146	31	.	.	.
cord-021637-f5wwn45z	147	1	Although	although	IN
cord-021637-f5wwn45z	147	2	60	60	CD
cord-021637-f5wwn45z	147	3	or	or	CC
cord-021637-f5wwn45z	147	4	so	so	RB
cord-021637-f5wwn45z	147	5	small	small	JJ
cord-021637-f5wwn45z	147	6	companies	company	NNS
cord-021637-f5wwn45z	147	7	claim	claim	VBP
cord-021637-f5wwn45z	147	8	engagement	engagement	NN
cord-021637-f5wwn45z	147	9	in	in	IN
cord-021637-f5wwn45z	147	10	vaccine	vaccine	NN
cord-021637-f5wwn45z	147	11	R&D	r&d	NN
cord-021637-f5wwn45z	147	12	,	,	,
cord-021637-f5wwn45z	147	13	only	only	RB
cord-021637-f5wwn45z	147	14	about	about	RB
cord-021637-f5wwn45z	147	15	a	a	DT
cord-021637-f5wwn45z	147	16	dozen	dozen	NN
cord-021637-f5wwn45z	147	17	or	or	CC
cord-021637-f5wwn45z	147	18	so	so	RB
cord-021637-f5wwn45z	147	19	consider	consider	VB
cord-021637-f5wwn45z	147	20	it	-PRON-	PRP
cord-021637-f5wwn45z	147	21	a	a	DT
cord-021637-f5wwn45z	147	22	major	major	JJ
cord-021637-f5wwn45z	147	23	activity	activity	NN
cord-021637-f5wwn45z	147	24	,	,	,
cord-021637-f5wwn45z	147	25	and	and	CC
cord-021637-f5wwn45z	147	26	only	only	RB
cord-021637-f5wwn45z	147	27	a	a	DT
cord-021637-f5wwn45z	147	28	very	very	RB
cord-021637-f5wwn45z	147	29	few	few	JJ
cord-021637-f5wwn45z	147	30	,	,	,
cord-021637-f5wwn45z	147	31	such	such	JJ
cord-021637-f5wwn45z	147	32	as	as	IN
cord-021637-f5wwn45z	147	33	MedImmune	MedImmune	NNP
cord-021637-f5wwn45z	147	34	,	,	,
cord-021637-f5wwn45z	147	35	have	have	VBP
cord-021637-f5wwn45z	147	36	made	make	VBN
cord-021637-f5wwn45z	147	37	it	-PRON-	PRP
cord-021637-f5wwn45z	147	38	to	to	IN
cord-021637-f5wwn45z	147	39	the	the	DT
cord-021637-f5wwn45z	147	40	market	market	NN
cord-021637-f5wwn45z	147	41	or	or	CC
cord-021637-f5wwn45z	147	42	close	close	RB
cord-021637-f5wwn45z	147	43	to	to	IN
cord-021637-f5wwn45z	147	44	the	the	DT
cord-021637-f5wwn45z	147	45	market	market	NN
cord-021637-f5wwn45z	147	46	on	on	IN
cord-021637-f5wwn45z	147	47	their	-PRON-	PRP$
cord-021637-f5wwn45z	147	48	own	own	JJ
cord-021637-f5wwn45z	147	49	.	.	.
cord-021637-f5wwn45z	148	1	More	More	JJR
cord-021637-f5wwn45z	148	2	have	have	VBP
cord-021637-f5wwn45z	148	3	licensed	license	VBN
cord-021637-f5wwn45z	148	4	their	-PRON-	PRP$
cord-021637-f5wwn45z	148	5	products	product	NNS
cord-021637-f5wwn45z	148	6	or	or	CC
cord-021637-f5wwn45z	148	7	technology	technology	NN
cord-021637-f5wwn45z	148	8	platforms	platform	NNS
cord-021637-f5wwn45z	148	9	to	to	IN
cord-021637-f5wwn45z	148	10	larger	large	JJR
cord-021637-f5wwn45z	148	11	companies	company	NNS
cord-021637-f5wwn45z	148	12	that	that	WDT
cord-021637-f5wwn45z	148	13	have	have	VBP
cord-021637-f5wwn45z	148	14	then	then	RB
cord-021637-f5wwn45z	148	15	completed	complete	VBN
cord-021637-f5wwn45z	148	16	development	development	NN
cord-021637-f5wwn45z	148	17	,	,	,
cord-021637-f5wwn45z	148	18	yielding	yield	VBG
cord-021637-f5wwn45z	148	19	new	new	JJ
cord-021637-f5wwn45z	148	20	vaccines	vaccine	NNS
cord-021637-f5wwn45z	148	21	such	such	JJ
cord-021637-f5wwn45z	148	22	as	as	IN
cord-021637-f5wwn45z	148	23	those	those	DT
cord-021637-f5wwn45z	148	24	for	for	IN
cord-021637-f5wwn45z	148	25	hepatitis	hepatitis	NN
cord-021637-f5wwn45z	148	26	B	B	NNP
cord-021637-f5wwn45z	148	27	and	and	CC
cord-021637-f5wwn45z	149	1	Haemophilus	haemophilus	JJ
cord-021637-f5wwn45z	149	2	influenzae	influenzae	NN
cord-021637-f5wwn45z	149	3	type	type	NN
cord-021637-f5wwn45z	149	4	b.	b.	NN
cord-021637-f5wwn45z	150	1	For	for	IN
cord-021637-f5wwn45z	150	2	example	example	NN
cord-021637-f5wwn45z	150	3	,	,	,
cord-021637-f5wwn45z	150	4	the	the	DT
cord-021637-f5wwn45z	150	5	hepatitis	hepatitis	NN
cord-021637-f5wwn45z	150	6	B	B	NNP
cord-021637-f5wwn45z	150	7	innovation	innovation	NN
cord-021637-f5wwn45z	150	8	came	come	VBD
cord-021637-f5wwn45z	150	9	from	from	IN
cord-021637-f5wwn45z	150	10	the	the	DT
cord-021637-f5wwn45z	150	11	research	research	NN
cord-021637-f5wwn45z	150	12	laboratories	laboratory	NNS
cord-021637-f5wwn45z	150	13	of	of	IN
cord-021637-f5wwn45z	150	14	Chiron	Chiron	NNP
cord-021637-f5wwn45z	150	15	Corporation	Corporation	NNP
cord-021637-f5wwn45z	150	16	that	that	WDT
cord-021637-f5wwn45z	150	17	succeeded	succeed	VBD
cord-021637-f5wwn45z	150	18	in	in	IN
cord-021637-f5wwn45z	150	19	making	make	VBG
cord-021637-f5wwn45z	150	20	hepatitis	hepatitis	NNP
cord-021637-f5wwn45z	150	21	B	B	NNP
cord-021637-f5wwn45z	150	22	surface	surface	NN
cord-021637-f5wwn45z	150	23	antigen	antigen	NN
cord-021637-f5wwn45z	150	24	in	in	IN
cord-021637-f5wwn45z	150	25	yeast	yeast	NN
cord-021637-f5wwn45z	150	26	,	,	,
cord-021637-f5wwn45z	150	27	and	and	CC
cord-021637-f5wwn45z	150	28	thus	thus	RB
cord-021637-f5wwn45z	150	29	enabling	enable	VBG
cord-021637-f5wwn45z	150	30	Merck	Merck	NNP
cord-021637-f5wwn45z	150	31	and	and	CC
cord-021637-f5wwn45z	150	32	GlaxoSmith	GlaxoSmith	NNP
cord-021637-f5wwn45z	150	33	-	-	HYPH
cord-021637-f5wwn45z	150	34	Kline	Kline	NNP
cord-021637-f5wwn45z	150	35	to	to	TO
cord-021637-f5wwn45z	150	36	commercialize	commercialize	VB
cord-021637-f5wwn45z	150	37	the	the	DT
cord-021637-f5wwn45z	150	38	modern	modern	JJ
cord-021637-f5wwn45z	150	39	hepatitis	hepatitis	NN
cord-021637-f5wwn45z	150	40	B	B	NNP
cord-021637-f5wwn45z	150	41	vaccines	vaccine	NNS
cord-021637-f5wwn45z	150	42	.	.	.
cord-021637-f5wwn45z	151	1	In	in	IN
cord-021637-f5wwn45z	151	2	the	the	DT
cord-021637-f5wwn45z	151	3	case	case	NN
cord-021637-f5wwn45z	151	4	of	of	IN
cord-021637-f5wwn45z	151	5	H.	H.	NNP
cord-021637-f5wwn45z	151	6	influenzae	influenzae	NN
cord-021637-f5wwn45z	151	7	type	type	NN
cord-021637-f5wwn45z	151	8	b	b	NN
cord-021637-f5wwn45z	151	9	(	(	-LRB-
cord-021637-f5wwn45z	151	10	Hib	Hib	NNP
cord-021637-f5wwn45z	151	11	)	)	-RRB-
cord-021637-f5wwn45z	151	12	,	,	,
cord-021637-f5wwn45z	151	13	Praxis	Praxis	NNP
cord-021637-f5wwn45z	151	14	Biologics	Biologics	NNP
cord-021637-f5wwn45z	151	15	and	and	CC
cord-021637-f5wwn45z	151	16	Connaught	Connaught	NNP
cord-021637-f5wwn45z	151	17	Laboratories	Laboratories	NNP
cord-021637-f5wwn45z	151	18	pioneered	pioneer	VBD
cord-021637-f5wwn45z	151	19	the	the	DT
cord-021637-f5wwn45z	151	20	development	development	NN
cord-021637-f5wwn45z	151	21	of	of	IN
cord-021637-f5wwn45z	151	22	Hib	Hib	NNP
cord-021637-f5wwn45z	151	23	polysaccharide	polysaccharide	NN
cord-021637-f5wwn45z	151	24	and	and	CC
cord-021637-f5wwn45z	151	25	conjugate	conjugate	VB
cord-021637-f5wwn45z	151	26	vaccines	vaccine	NNS
cord-021637-f5wwn45z	151	27	.	.	.
cord-021637-f5wwn45z	152	1	These	these	DT
cord-021637-f5wwn45z	152	2	companies	company	NNS
cord-021637-f5wwn45z	152	3	were	be	VBD
cord-021637-f5wwn45z	152	4	eventually	eventually	RB
cord-021637-f5wwn45z	152	5	acquired	acquire	VBN
cord-021637-f5wwn45z	152	6	by	by	IN
cord-021637-f5wwn45z	152	7	Sanofi	Sanofi	NNP
cord-021637-f5wwn45z	152	8	and	and	CC
cord-021637-f5wwn45z	152	9	Wyeth	Wyeth	NNP
cord-021637-f5wwn45z	152	10	-	-	HYPH
cord-021637-f5wwn45z	152	11	Lederle	Lederle	NNP
cord-021637-f5wwn45z	152	12	,	,	,
cord-021637-f5wwn45z	152	13	respectively	respectively	RB
cord-021637-f5wwn45z	152	14	.	.	.
cord-021637-f5wwn45z	153	1	The	the	DT
cord-021637-f5wwn45z	153	2	greatest	great	JJS
cord-021637-f5wwn45z	153	3	contributions	contribution	NNS
cord-021637-f5wwn45z	153	4	of	of	IN
cord-021637-f5wwn45z	153	5	the	the	DT
cord-021637-f5wwn45z	153	6	biotechnology	biotechnology	NN
cord-021637-f5wwn45z	153	7	companies	company	NNS
cord-021637-f5wwn45z	153	8	have	have	VBP
cord-021637-f5wwn45z	153	9	been	be	VBN
cord-021637-f5wwn45z	153	10	the	the	DT
cord-021637-f5wwn45z	153	11	introduction	introduction	NN
cord-021637-f5wwn45z	153	12	of	of	IN
cord-021637-f5wwn45z	153	13	multiple	multiple	JJ
cord-021637-f5wwn45z	153	14	ideas	idea	NNS
cord-021637-f5wwn45z	153	15	into	into	IN
cord-021637-f5wwn45z	153	16	early	early	JJ
cord-021637-f5wwn45z	153	17	vaccine	vaccine	NN
cord-021637-f5wwn45z	153	18	development	development	NN
cord-021637-f5wwn45z	153	19	,	,	,
cord-021637-f5wwn45z	153	20	and	and	CC
cord-021637-f5wwn45z	153	21	testing	test	VBG
cord-021637-f5wwn45z	153	22	them	-PRON-	PRP
cord-021637-f5wwn45z	153	23	to	to	TO
cord-021637-f5wwn45z	153	24	determine	determine	VB
cord-021637-f5wwn45z	153	25	if	if	IN
cord-021637-f5wwn45z	153	26	they	-PRON-	PRP
cord-021637-f5wwn45z	153	27	should	should	MD
cord-021637-f5wwn45z	153	28	be	be	VB
cord-021637-f5wwn45z	153	29	rejected	reject	VBN
cord-021637-f5wwn45z	153	30	or	or	CC
cord-021637-f5wwn45z	153	31	carried	carry	VBN
cord-021637-f5wwn45z	153	32	forward	forward	RB
cord-021637-f5wwn45z	153	33	.	.	.
cord-021637-f5wwn45z	154	1	These	these	DT
cord-021637-f5wwn45z	154	2	small	small	JJ
cord-021637-f5wwn45z	154	3	companies	company	NNS
cord-021637-f5wwn45z	154	4	are	be	VBP
cord-021637-f5wwn45z	154	5	dependent	dependent	JJ
cord-021637-f5wwn45z	154	6	on	on	IN
cord-021637-f5wwn45z	154	7	several	several	JJ
cord-021637-f5wwn45z	154	8	factors	factor	NNS
cord-021637-f5wwn45z	154	9	for	for	IN
cord-021637-f5wwn45z	154	10	their	-PRON-	PRP$
cord-021637-f5wwn45z	154	11	success	success	NN
cord-021637-f5wwn45z	154	12	:	:	:
cord-021637-f5wwn45z	154	13	1	1	CD
cord-021637-f5wwn45z	154	14	.	.	.
cord-021637-f5wwn45z	155	1	A	a	DT
cord-021637-f5wwn45z	155	2	vibrant	vibrant	JJ
cord-021637-f5wwn45z	155	3	basic	basic	JJ
cord-021637-f5wwn45z	155	4	research	research	NN
cord-021637-f5wwn45z	155	5	environment	environment	NN
cord-021637-f5wwn45z	155	6	that	that	WDT
cord-021637-f5wwn45z	155	7	allows	allow	VBZ
cord-021637-f5wwn45z	155	8	for	for	IN
cord-021637-f5wwn45z	155	9	creation	creation	NN
cord-021637-f5wwn45z	155	10	of	of	IN
cord-021637-f5wwn45z	155	11	new	new	JJ
cord-021637-f5wwn45z	155	12	ideas	idea	NNS
cord-021637-f5wwn45z	155	13	,	,	,
cord-021637-f5wwn45z	155	14	an	an	DT
cord-021637-f5wwn45z	155	15	environment	environment	NN
cord-021637-f5wwn45z	155	16	that	that	WDT
cord-021637-f5wwn45z	155	17	exists	exist	VBZ
cord-021637-f5wwn45z	155	18	in	in	IN
cord-021637-f5wwn45z	155	19	wellfunded	wellfunde	VBN
cord-021637-f5wwn45z	155	20	(	(	-LRB-
cord-021637-f5wwn45z	155	21	NIH	NIH	NNP
cord-021637-f5wwn45z	155	22	)	)	-RRB-
cord-021637-f5wwn45z	155	23	academic	academic	JJ
cord-021637-f5wwn45z	155	24	research	research	NN
cord-021637-f5wwn45z	155	25	programs	program	NNS
cord-021637-f5wwn45z	155	26	.	.	.
cord-021637-f5wwn45z	156	1	2	2	LS
cord-021637-f5wwn45z	156	2	.	.	.
cord-021637-f5wwn45z	157	1	A	a	DT
cord-021637-f5wwn45z	157	2	strong	strong	JJ
cord-021637-f5wwn45z	157	3	venture	venture	NN
cord-021637-f5wwn45z	157	4	capital	capital	NN
cord-021637-f5wwn45z	157	5	and	and	CC
cord-021637-f5wwn45z	157	6	investment	investment	NN
cord-021637-f5wwn45z	157	7	community	community	NN
cord-021637-f5wwn45z	157	8	that	that	WDT
cord-021637-f5wwn45z	157	9	views	view	VBZ
cord-021637-f5wwn45z	157	10	vaccine	vaccine	NN
cord-021637-f5wwn45z	157	11	companies	company	NNS
cord-021637-f5wwn45z	157	12	as	as	IN
cord-021637-f5wwn45z	157	13	potentially	potentially	RB
cord-021637-f5wwn45z	157	14	financially	financially	RB
cord-021637-f5wwn45z	157	15	rewarding	rewarding	JJ
cord-021637-f5wwn45z	157	16	as	as	IN
cord-021637-f5wwn45z	157	17	other	other	JJ
cord-021637-f5wwn45z	157	18	investment	investment	NN
cord-021637-f5wwn45z	157	19	opportunities	opportunity	NNS
cord-021637-f5wwn45z	157	20	.	.	.
cord-021637-f5wwn45z	158	1	3	3	LS
cord-021637-f5wwn45z	158	2	.	.	.
cord-021637-f5wwn45z	159	1	Strong	strong	JJ
cord-021637-f5wwn45z	159	2	patent	patent	NN
cord-021637-f5wwn45z	159	3	laws	law	NNS
cord-021637-f5wwn45z	159	4	providing	provide	VBG
cord-021637-f5wwn45z	159	5	the	the	DT
cord-021637-f5wwn45z	159	6	intellectual	intellectual	JJ
cord-021637-f5wwn45z	159	7	property	property	NN
cord-021637-f5wwn45z	159	8	protection	protection	NN
cord-021637-f5wwn45z	159	9	that	that	WDT
cord-021637-f5wwn45z	159	10	is	be	VBZ
cord-021637-f5wwn45z	159	11	essential	essential	JJ
cord-021637-f5wwn45z	159	12	for	for	IN
cord-021637-f5wwn45z	159	13	commercial	commercial	JJ
cord-021637-f5wwn45z	159	14	success	success	NN
cord-021637-f5wwn45z	159	15	.	.	.
cord-021637-f5wwn45z	160	1	Funding	funding	NN
cord-021637-f5wwn45z	160	2	sources	source	NNS
cord-021637-f5wwn45z	160	3	for	for	IN
cord-021637-f5wwn45z	160	4	vaccine	vaccine	NN
cord-021637-f5wwn45z	160	5	R&D	r&d	NN
cord-021637-f5wwn45z	160	6	include	include	VBP
cord-021637-f5wwn45z	160	7	government	government	NN
cord-021637-f5wwn45z	160	8	,	,	,
cord-021637-f5wwn45z	160	9	profits	profit	NNS
cord-021637-f5wwn45z	160	10	from	from	IN
cord-021637-f5wwn45z	160	11	sales	sale	NNS
cord-021637-f5wwn45z	160	12	of	of	IN
cord-021637-f5wwn45z	160	13	product	product	NN
cord-021637-f5wwn45z	160	14	,	,	,
cord-021637-f5wwn45z	160	15	risk	risk	NN
cord-021637-f5wwn45z	160	16	capital	capital	NN
cord-021637-f5wwn45z	160	17	,	,	,
cord-021637-f5wwn45z	160	18	and	and	CC
cord-021637-f5wwn45z	160	19	charitable	charitable	JJ
cord-021637-f5wwn45z	160	20	foundations	foundation	NNS
cord-021637-f5wwn45z	160	21	.	.	.
cord-021637-f5wwn45z	161	1	The	the	DT
cord-021637-f5wwn45z	161	2	NIH	NIH	NNP
cord-021637-f5wwn45z	161	3	competes	compete	VBZ
cord-021637-f5wwn45z	161	4	with	with	IN
cord-021637-f5wwn45z	161	5	other	other	JJ
cord-021637-f5wwn45z	161	6	federal	federal	JJ
cord-021637-f5wwn45z	161	7	agencies	agency	NNS
cord-021637-f5wwn45z	161	8	and	and	CC
cord-021637-f5wwn45z	161	9	programs	program	NNS
cord-021637-f5wwn45z	161	10	for	for	IN
cord-021637-f5wwn45z	161	11	taxpayer	taxpayer	NN
cord-021637-f5wwn45z	161	12	support	support	NN
cord-021637-f5wwn45z	161	13	,	,	,
cord-021637-f5wwn45z	161	14	and	and	CC
cord-021637-f5wwn45z	161	15	,	,	,
cord-021637-f5wwn45z	161	16	in	in	IN
cord-021637-f5wwn45z	161	17	general	general	JJ
cord-021637-f5wwn45z	161	18	,	,	,
cord-021637-f5wwn45z	161	19	has	have	VBZ
cord-021637-f5wwn45z	161	20	been	be	VBN
cord-021637-f5wwn45z	161	21	more	more	RBR
cord-021637-f5wwn45z	161	22	successful	successful	JJ
cord-021637-f5wwn45z	161	23	than	than	IN
cord-021637-f5wwn45z	161	24	most	most	JJS
cord-021637-f5wwn45z	161	25	.	.	.
cord-021637-f5wwn45z	162	1	Similarly	similarly	RB
cord-021637-f5wwn45z	162	2	,	,	,
cord-021637-f5wwn45z	162	3	vaccine	vaccine	NN
cord-021637-f5wwn45z	162	4	R&D	r&d	NN
cord-021637-f5wwn45z	162	5	sponsored	sponsor	VBN
cord-021637-f5wwn45z	162	6	through	through	IN
cord-021637-f5wwn45z	162	7	the	the	DT
cord-021637-f5wwn45z	162	8	DOD	DOD	NNP
cord-021637-f5wwn45z	162	9	,	,	,
cord-021637-f5wwn45z	162	10	FDA	FDA	NNP
cord-021637-f5wwn45z	162	11	,	,	,
cord-021637-f5wwn45z	162	12	CDC	CDC	NNP
cord-021637-f5wwn45z	162	13	,	,	,
cord-021637-f5wwn45z	162	14	and	and	CC
cord-021637-f5wwn45z	162	15	USAID	USAID	NNP
cord-021637-f5wwn45z	162	16	is	be	VBZ
cord-021637-f5wwn45z	162	17	competitive	competitive	JJ
cord-021637-f5wwn45z	162	18	with	with	IN
cord-021637-f5wwn45z	162	19	other	other	JJ
cord-021637-f5wwn45z	162	20	public	public	JJ
cord-021637-f5wwn45z	162	21	needs	need	NNS
cord-021637-f5wwn45z	162	22	as	as	IN
cord-021637-f5wwn45z	162	23	determined	determine	VBN
cord-021637-f5wwn45z	162	24	by	by	IN
cord-021637-f5wwn45z	162	25	the	the	DT
cord-021637-f5wwn45z	162	26	executive	executive	JJ
cord-021637-f5wwn45z	162	27	and	and	CC
cord-021637-f5wwn45z	162	28	legislative	legislative	JJ
cord-021637-f5wwn45z	162	29	branches	branch	NNS
cord-021637-f5wwn45z	162	30	of	of	IN
cord-021637-f5wwn45z	162	31	government	government	NN
cord-021637-f5wwn45z	162	32	.	.	.
cord-021637-f5wwn45z	163	1	Risk	risk	NN
cord-021637-f5wwn45z	163	2	capital	capital	NN
cord-021637-f5wwn45z	163	3	from	from	IN
cord-021637-f5wwn45z	163	4	private	private	JJ
cord-021637-f5wwn45z	163	5	investors	investor	NNS
cord-021637-f5wwn45z	163	6	is	be	VBZ
cord-021637-f5wwn45z	163	7	the	the	DT
cord-021637-f5wwn45z	163	8	primary	primary	JJ
cord-021637-f5wwn45z	163	9	source	source	NN
cord-021637-f5wwn45z	163	10	of	of	IN
cord-021637-f5wwn45z	163	11	funds	fund	NNS
cord-021637-f5wwn45z	163	12	for	for	IN
cord-021637-f5wwn45z	163	13	small	small	JJ
cord-021637-f5wwn45z	163	14	companies	company	NNS
cord-021637-f5wwn45z	163	15	.	.	.
cord-021637-f5wwn45z	164	1	Investors	investor	NNS
cord-021637-f5wwn45z	164	2	are	be	VBP
cord-021637-f5wwn45z	164	3	attracted	attract	VBN
cord-021637-f5wwn45z	164	4	to	to	IN
cord-021637-f5wwn45z	164	5	the	the	DT
cord-021637-f5wwn45z	164	6	potential	potential	JJ
cord-021637-f5wwn45z	164	7	profits	profit	NNS
cord-021637-f5wwn45z	164	8	of	of	IN
cord-021637-f5wwn45z	164	9	a	a	DT
cord-021637-f5wwn45z	164	10	new	new	JJ
cord-021637-f5wwn45z	164	11	vaccine	vaccine	NN
cord-021637-f5wwn45z	164	12	,	,	,
cord-021637-f5wwn45z	164	13	a	a	DT
cord-021637-f5wwn45z	164	14	forecast	forecast	NN
cord-021637-f5wwn45z	164	15	determined	determine	VBN
cord-021637-f5wwn45z	164	16	in	in	IN
cord-021637-f5wwn45z	164	17	part	part	NN
cord-021637-f5wwn45z	164	18	by	by	IN
cord-021637-f5wwn45z	164	19	sales	sale	NNS
cord-021637-f5wwn45z	164	20	of	of	IN
cord-021637-f5wwn45z	164	21	current	current	JJ
cord-021637-f5wwn45z	164	22	vaccines	vaccine	NNS
cord-021637-f5wwn45z	164	23	.	.	.
cord-021637-f5wwn45z	165	1	Large	large	JJ
cord-021637-f5wwn45z	165	2	vaccine	vaccine	NN
cord-021637-f5wwn45z	165	3	companies	company	NNS
cord-021637-f5wwn45z	165	4	,	,	,
cord-021637-f5wwn45z	165	5	which	which	WDT
cord-021637-f5wwn45z	165	6	are	be	VBP
cord-021637-f5wwn45z	165	7	divisions	division	NNS
cord-021637-f5wwn45z	165	8	of	of	IN
cord-021637-f5wwn45z	165	9	much	much	RB
cord-021637-f5wwn45z	165	10	larger	large	JJR
cord-021637-f5wwn45z	165	11	pharmaceutical	pharmaceutical	NN
cord-021637-f5wwn45z	165	12	companies	company	NNS
cord-021637-f5wwn45z	165	13	,	,	,
cord-021637-f5wwn45z	165	14	seek	seek	VB
cord-021637-f5wwn45z	165	15	a	a	DT
cord-021637-f5wwn45z	165	16	profit	profit	NN
cord-021637-f5wwn45z	165	17	by	by	IN
cord-021637-f5wwn45z	165	18	selling	sell	VBG
cord-021637-f5wwn45z	165	19	products	product	NNS
cord-021637-f5wwn45z	165	20	.	.	.
cord-021637-f5wwn45z	166	1	On	on	IN
cord-021637-f5wwn45z	166	2	average	average	JJ
cord-021637-f5wwn45z	166	3	,	,	,
cord-021637-f5wwn45z	166	4	pharmaceutical	pharmaceutical	NN
cord-021637-f5wwn45z	166	5	companies	company	NNS
cord-021637-f5wwn45z	166	6	reinvest	reinvest	VBP
cord-021637-f5wwn45z	166	7	approximately	approximately	RB
cord-021637-f5wwn45z	166	8	18	18	CD
cord-021637-f5wwn45z	166	9	%	%	NN
cord-021637-f5wwn45z	166	10	of	of	IN
cord-021637-f5wwn45z	166	11	their	-PRON-	PRP$
cord-021637-f5wwn45z	166	12	profits	profit	NNS
cord-021637-f5wwn45z	166	13	from	from	IN
cord-021637-f5wwn45z	166	14	product	product	NN
cord-021637-f5wwn45z	166	15	sales	sale	NNS
cord-021637-f5wwn45z	166	16	into	into	IN
cord-021637-f5wwn45z	166	17	R&D	r&d	NN
cord-021637-f5wwn45z	166	18	,	,	,
cord-021637-f5wwn45z	166	19	and	and	CC
cord-021637-f5wwn45z	166	20	this	this	DT
cord-021637-f5wwn45z	166	21	proportion	proportion	NN
cord-021637-f5wwn45z	166	22	applies	apply	VBZ
cord-021637-f5wwn45z	166	23	to	to	IN
cord-021637-f5wwn45z	166	24	vaccine	vaccine	NN
cord-021637-f5wwn45z	166	25	sales	sale	NNS
cord-021637-f5wwn45z	166	26	as	as	RB
cord-021637-f5wwn45z	166	27	well	well	RB
cord-021637-f5wwn45z	166	28	as	as	IN
cord-021637-f5wwn45z	166	29	other	other	JJ
cord-021637-f5wwn45z	166	30	pharmaceutical	pharmaceutical	JJ
cord-021637-f5wwn45z	166	31	products	product	NNS
cord-021637-f5wwn45z	166	32	(	(	-LRB-
cord-021637-f5wwn45z	166	33	Pharmaceutical	Pharmaceutical	NNP
cord-021637-f5wwn45z	166	34	Research	Research	NNP
cord-021637-f5wwn45z	166	35	Manufacturers	Manufacturers	NNPS
cord-021637-f5wwn45z	166	36	Association	Association	NNP
cord-021637-f5wwn45z	166	37	,	,	,
cord-021637-f5wwn45z	166	38	personal	personal	JJ
cord-021637-f5wwn45z	166	39	communication	communication	NN
cord-021637-f5wwn45z	166	40	,	,	,
cord-021637-f5wwn45z	166	41	2001	2001	CD
cord-021637-f5wwn45z	166	42	)	)	-RRB-
cord-021637-f5wwn45z	166	43	.	.	.
cord-021637-f5wwn45z	167	1	Because	because	IN
cord-021637-f5wwn45z	167	2	vaccine	vaccine	NN
cord-021637-f5wwn45z	167	3	companies	company	NNS
cord-021637-f5wwn45z	167	4	are	be	VBP
cord-021637-f5wwn45z	167	5	subsidiaries	subsidiary	NNS
cord-021637-f5wwn45z	167	6	of	of	IN
cord-021637-f5wwn45z	167	7	large	large	JJ
cord-021637-f5wwn45z	167	8	companies	company	NNS
cord-021637-f5wwn45z	167	9	,	,	,
cord-021637-f5wwn45z	167	10	vaccine	vaccine	NN
cord-021637-f5wwn45z	167	11	R&D	r&d	NN
cord-021637-f5wwn45z	167	12	and	and	CC
cord-021637-f5wwn45z	167	13	manufacturing	manufacturing	NN
cord-021637-f5wwn45z	167	14	must	must	MD
cord-021637-f5wwn45z	167	15	compete	compete	VB
cord-021637-f5wwn45z	167	16	with	with	IN
cord-021637-f5wwn45z	167	17	other	other	JJ
cord-021637-f5wwn45z	167	18	product	product	NN
cord-021637-f5wwn45z	167	19	areas	area	NNS
cord-021637-f5wwn45z	167	20	for	for	IN
cord-021637-f5wwn45z	167	21	resources	resource	NNS
cord-021637-f5wwn45z	167	22	.	.	.
cord-021637-f5wwn45z	168	1	Comparisons	comparison	NNS
cord-021637-f5wwn45z	168	2	of	of	IN
cord-021637-f5wwn45z	168	3	the	the	DT
cord-021637-f5wwn45z	168	4	economics	economic	NNS
cord-021637-f5wwn45z	168	5	of	of	IN
cord-021637-f5wwn45z	168	6	the	the	DT
cord-021637-f5wwn45z	168	7	vaccine	vaccine	NN
cord-021637-f5wwn45z	168	8	industry	industry	NN
cord-021637-f5wwn45z	168	9	with	with	IN
cord-021637-f5wwn45z	168	10	the	the	DT
cord-021637-f5wwn45z	168	11	pharmaceutical	pharmaceutical	JJ
cord-021637-f5wwn45z	168	12	industry	industry	NN
cord-021637-f5wwn45z	168	13	in	in	IN
cord-021637-f5wwn45z	168	14	Europe	Europe	NNP
cord-021637-f5wwn45z	168	15	,	,	,
cord-021637-f5wwn45z	168	16	and	and	CC
cord-021637-f5wwn45z	168	17	separately	separately	RB
cord-021637-f5wwn45z	168	18	in	in	IN
cord-021637-f5wwn45z	168	19	the	the	DT
cord-021637-f5wwn45z	168	20	United	United	NNP
cord-021637-f5wwn45z	168	21	States	States	NNP
cord-021637-f5wwn45z	168	22	,	,	,
cord-021637-f5wwn45z	168	23	were	be	VBD
cord-021637-f5wwn45z	168	24	performed	perform	VBN
cord-021637-f5wwn45z	168	25	by	by	IN
cord-021637-f5wwn45z	168	26	the	the	DT
cord-021637-f5wwn45z	168	27	Mercer	Mercer	NNP
cord-021637-f5wwn45z	168	28	Consulting	Consulting	NNP
cord-021637-f5wwn45z	168	29	Company	Company	NNP
cord-021637-f5wwn45z	168	30	in	in	IN
cord-021637-f5wwn45z	168	31	1995	1995	CD
cord-021637-f5wwn45z	168	32	(	(	-LRB-
cord-021637-f5wwn45z	168	33	Fig	Fig	NNP
cord-021637-f5wwn45z	168	34	.	.	.
cord-021637-f5wwn45z	168	35	 	 	_SP
cord-021637-f5wwn45z	168	36	4.2	4.2	CD
cord-021637-f5wwn45z	168	37	)	)	-RRB-
cord-021637-f5wwn45z	168	38	.	.	.
cord-021637-f5wwn45z	169	1	13	13	CD
cord-021637-f5wwn45z	170	1	These	these	DT
cord-021637-f5wwn45z	170	2	studies	study	NNS
cord-021637-f5wwn45z	170	3	in	in	IN
cord-021637-f5wwn45z	170	4	the	the	DT
cord-021637-f5wwn45z	170	5	United	United	NNP
cord-021637-f5wwn45z	170	6	States	States	NNP
cord-021637-f5wwn45z	170	7	showed	show	VBD
cord-021637-f5wwn45z	170	8	that	that	IN
cord-021637-f5wwn45z	170	9	the	the	DT
cord-021637-f5wwn45z	170	10	 	 	_SP
cord-021637-f5wwn45z	170	11	in	in	IN
cord-021637-f5wwn45z	170	12	terms	term	NNS
cord-021637-f5wwn45z	170	13	of	of	IN
cord-021637-f5wwn45z	170	14	technical	technical	JJ
cord-021637-f5wwn45z	170	15	feasibility	feasibility	NN
cord-021637-f5wwn45z	170	16	,	,	,
cord-021637-f5wwn45z	170	17	strong	strong	JJ
cord-021637-f5wwn45z	170	18	patent	patent	NN
cord-021637-f5wwn45z	170	19	protection	protection	NN
cord-021637-f5wwn45z	170	20	,	,	,
cord-021637-f5wwn45z	170	21	and	and	CC
cord-021637-f5wwn45z	170	22	potential	potential	JJ
cord-021637-f5wwn45z	170	23	market	market	NN
cord-021637-f5wwn45z	170	24	size	size	NN
cord-021637-f5wwn45z	170	25	will	will	MD
cord-021637-f5wwn45z	170	26	be	be	VB
cord-021637-f5wwn45z	170	27	taken	take	VBN
cord-021637-f5wwn45z	170	28	forward	forward	RB
cord-021637-f5wwn45z	170	29	into	into	IN
cord-021637-f5wwn45z	170	30	development	development	NN
cord-021637-f5wwn45z	170	31	(	(	-LRB-
cord-021637-f5wwn45z	170	32	post	post	JJ
cord-021637-f5wwn45z	170	33	-	-	NN
cord-021637-f5wwn45z	170	34	Phase	phase	NN
cord-021637-f5wwn45z	170	35	I	i	CD
cord-021637-f5wwn45z	170	36	)	)	-RRB-
cord-021637-f5wwn45z	170	37	.	.	.
cord-021637-f5wwn45z	171	1	In	in	IN
cord-021637-f5wwn45z	171	2	addition	addition	NN
cord-021637-f5wwn45z	171	3	,	,	,
cord-021637-f5wwn45z	171	4	other	other	JJ
cord-021637-f5wwn45z	171	5	candidate	candidate	NN
cord-021637-f5wwn45z	171	6	vaccines	vaccine	NNS
cord-021637-f5wwn45z	171	7	might	may	MD
cord-021637-f5wwn45z	171	8	be	be	VB
cord-021637-f5wwn45z	171	9	licensed	license	VBN
cord-021637-f5wwn45z	171	10	from	from	IN
cord-021637-f5wwn45z	171	11	small	small	JJ
cord-021637-f5wwn45z	171	12	companies	company	NNS
cord-021637-f5wwn45z	171	13	.	.	.
cord-021637-f5wwn45z	172	1	Even	even	RB
cord-021637-f5wwn45z	172	2	in	in	IN
cord-021637-f5wwn45z	172	3	the	the	DT
cord-021637-f5wwn45z	172	4	largest	large	JJS
cord-021637-f5wwn45z	172	5	companies	company	NNS
cord-021637-f5wwn45z	172	6	,	,	,
cord-021637-f5wwn45z	172	7	only	only	RB
cord-021637-f5wwn45z	172	8	a	a	DT
cord-021637-f5wwn45z	172	9	few	few	JJ
cord-021637-f5wwn45z	172	10	products	product	NNS
cord-021637-f5wwn45z	172	11	can	can	MD
cord-021637-f5wwn45z	172	12	be	be	VB
cord-021637-f5wwn45z	172	13	in	in	IN
cord-021637-f5wwn45z	172	14	development	development	NN
cord-021637-f5wwn45z	172	15	at	at	IN
cord-021637-f5wwn45z	172	16	the	the	DT
cord-021637-f5wwn45z	172	17	same	same	JJ
cord-021637-f5wwn45z	172	18	time	time	NN
cord-021637-f5wwn45z	172	19	.	.	.
cord-021637-f5wwn45z	173	1	Thus	thus	RB
cord-021637-f5wwn45z	173	2	,	,	,
cord-021637-f5wwn45z	173	3	go	go	VB
cord-021637-f5wwn45z	173	4	/	/	SYM
cord-021637-f5wwn45z	173	5	no	no	DT
cord-021637-f5wwn45z	173	6	-	-	HYPH
cord-021637-f5wwn45z	173	7	go	go	JJ
cord-021637-f5wwn45z	173	8	decisions	decision	NNS
cord-021637-f5wwn45z	173	9	must	must	MD
cord-021637-f5wwn45z	173	10	be	be	VB
cord-021637-f5wwn45z	173	11	made	make	VBN
cord-021637-f5wwn45z	173	12	and	and	CC
cord-021637-f5wwn45z	173	13	market	market	NN
cord-021637-f5wwn45z	173	14	size	size	NN
cord-021637-f5wwn45z	173	15	is	be	VBZ
cord-021637-f5wwn45z	173	16	a	a	DT
cord-021637-f5wwn45z	173	17	major	major	JJ
cord-021637-f5wwn45z	173	18	determinant	determinant	NN
cord-021637-f5wwn45z	173	19	of	of	IN
cord-021637-f5wwn45z	173	20	the	the	DT
cord-021637-f5wwn45z	173	21	choice	choice	NN
cord-021637-f5wwn45z	173	22	between	between	IN
cord-021637-f5wwn45z	173	23	two	two	CD
cord-021637-f5wwn45z	173	24	candidate	candidate	NN
cord-021637-f5wwn45z	173	25	vaccines	vaccine	NNS
cord-021637-f5wwn45z	173	26	,	,	,
cord-021637-f5wwn45z	173	27	otherwise	otherwise	RB
cord-021637-f5wwn45z	173	28	equal	equal	JJ
cord-021637-f5wwn45z	173	29	in	in	IN
cord-021637-f5wwn45z	173	30	technical	technical	JJ
cord-021637-f5wwn45z	173	31	feasibility	feasibility	NN
cord-021637-f5wwn45z	173	32	and	and	CC
cord-021637-f5wwn45z	173	33	likelihood	likelihood	NN
cord-021637-f5wwn45z	173	34	of	of	IN
cord-021637-f5wwn45z	173	35	success	success	NN
cord-021637-f5wwn45z	174	1	(	(	-LRB-
cord-021637-f5wwn45z	174	2	Table	table	NN
cord-021637-f5wwn45z	174	3	4	4	CD
cord-021637-f5wwn45z	174	4	.7	.7	NFP
cord-021637-f5wwn45z	174	5	)	)	-RRB-
cord-021637-f5wwn45z	174	6	.	.	.
cord-021637-f5wwn45z	175	1	This	this	DT
cord-021637-f5wwn45z	175	2	system	system	NN
cord-021637-f5wwn45z	175	3	works	work	VBZ
cord-021637-f5wwn45z	175	4	extremely	extremely	RB
cord-021637-f5wwn45z	175	5	well	well	RB
cord-021637-f5wwn45z	175	6	for	for	IN
cord-021637-f5wwn45z	175	7	vaccines	vaccine	NNS
cord-021637-f5wwn45z	175	8	with	with	IN
cord-021637-f5wwn45z	175	9	large	large	JJ
cord-021637-f5wwn45z	175	10	potential	potential	JJ
cord-021637-f5wwn45z	175	11	markets	market	NNS
cord-021637-f5wwn45z	175	12	in	in	IN
cord-021637-f5wwn45z	175	13	the	the	DT
cord-021637-f5wwn45z	175	14	developed	developed	JJ
cord-021637-f5wwn45z	175	15	world	world	NN
cord-021637-f5wwn45z	175	16	when	when	WRB
cord-021637-f5wwn45z	175	17	technical	technical	JJ
cord-021637-f5wwn45z	175	18	feasibility	feasibility	NN
cord-021637-f5wwn45z	175	19	is	be	VBZ
cord-021637-f5wwn45z	175	20	demonstrated	demonstrate	VBN
cord-021637-f5wwn45z	175	21	.	.	.
cord-021637-f5wwn45z	176	1	It	-PRON-	PRP
cord-021637-f5wwn45z	176	2	does	do	VBZ
cord-021637-f5wwn45z	176	3	not	not	RB
cord-021637-f5wwn45z	176	4	work	work	VB
cord-021637-f5wwn45z	176	5	for	for	IN
cord-021637-f5wwn45z	176	6	vaccines	vaccine	NNS
cord-021637-f5wwn45z	176	7	for	for	IN
cord-021637-f5wwn45z	176	8	diseases	disease	NNS
cord-021637-f5wwn45z	176	9	that	that	WDT
cord-021637-f5wwn45z	176	10	exist	exist	VBP
cord-021637-f5wwn45z	176	11	predominantly	predominantly	RB
cord-021637-f5wwn45z	176	12	in	in	IN
cord-021637-f5wwn45z	176	13	the	the	DT
cord-021637-f5wwn45z	176	14	poorer	poor	JJR
cord-021637-f5wwn45z	176	15	regions	region	NNS
cord-021637-f5wwn45z	176	16	of	of	IN
cord-021637-f5wwn45z	176	17	the	the	DT
cord-021637-f5wwn45z	176	18	world	world	NN
cord-021637-f5wwn45z	176	19	(	(	-LRB-
cord-021637-f5wwn45z	176	20	e.g.	e.g.	RB
cord-021637-f5wwn45z	176	21	,	,	,
cord-021637-f5wwn45z	176	22	TB	TB	NNP
cord-021637-f5wwn45z	176	23	)	)	-RRB-
cord-021637-f5wwn45z	176	24	;	;	:
cord-021637-f5wwn45z	176	25	it	-PRON-	PRP
cord-021637-f5wwn45z	176	26	works	work	VBZ
cord-021637-f5wwn45z	176	27	imperfectly	imperfectly	RB
cord-021637-f5wwn45z	176	28	for	for	IN
cord-021637-f5wwn45z	176	29	diseases	disease	NNS
cord-021637-f5wwn45z	176	30	of	of	IN
cord-021637-f5wwn45z	176	31	the	the	DT
cord-021637-f5wwn45z	176	32	developed	developed	JJ
cord-021637-f5wwn45z	176	33	world	world	NN
cord-021637-f5wwn45z	176	34	that	that	WDT
cord-021637-f5wwn45z	176	35	affect	affect	VBP
cord-021637-f5wwn45z	176	36	relatively	relatively	RB
cord-021637-f5wwn45z	176	37	few	few	JJ
cord-021637-f5wwn45z	176	38	persons	person	NNS
cord-021637-f5wwn45z	176	39	because	because	IN
cord-021637-f5wwn45z	176	40	of	of	IN
cord-021637-f5wwn45z	176	41	geographic	geographic	JJ
cord-021637-f5wwn45z	176	42	restriction	restriction	NN
cord-021637-f5wwn45z	176	43	(	(	-LRB-
cord-021637-f5wwn45z	176	44	e.g.	e.g.	RB
cord-021637-f5wwn45z	176	45	,	,	,
cord-021637-f5wwn45z	176	46	Lyme	Lyme	NNP
cord-021637-f5wwn45z	176	47	disease	disease	NN
cord-021637-f5wwn45z	176	48	)	)	-RRB-
cord-021637-f5wwn45z	176	49	or	or	CC
cord-021637-f5wwn45z	176	50	diseases	disease	NNS
cord-021637-f5wwn45z	176	51	limited	limit	VBN
cord-021637-f5wwn45z	176	52	to	to	IN
cord-021637-f5wwn45z	176	53	specific	specific	JJ
cord-021637-f5wwn45z	176	54	risk	risk	NN
cord-021637-f5wwn45z	176	55	groups	group	NNS
cord-021637-f5wwn45z	176	56	(	(	-LRB-
cord-021637-f5wwn45z	176	57	e.g.	e.g.	RB
cord-021637-f5wwn45z	176	58	,	,	,
cord-021637-f5wwn45z	176	59	cytomegalovirus	cytomegalovirus	JJ
cord-021637-f5wwn45z	176	60	[	[	-LRB-
cord-021637-f5wwn45z	176	61	CMV	CMV	NNP
cord-021637-f5wwn45z	176	62	]	]	-RRB-
cord-021637-f5wwn45z	176	63	in	in	IN
cord-021637-f5wwn45z	176	64	transplant	transplant	NN
cord-021637-f5wwn45z	176	65	recipients	recipient	NNS
cord-021637-f5wwn45z	176	66	)	)	-RRB-
cord-021637-f5wwn45z	176	67	,	,	,
cord-021637-f5wwn45z	176	68	and	and	CC
cord-021637-f5wwn45z	176	69	it	-PRON-	PRP
cord-021637-f5wwn45z	176	70	does	do	VBZ
cord-021637-f5wwn45z	176	71	not	not	RB
cord-021637-f5wwn45z	176	72	work	work	VB
cord-021637-f5wwn45z	176	73	when	when	WRB
cord-021637-f5wwn45z	176	74	technical	technical	JJ
cord-021637-f5wwn45z	176	75	feasibility	feasibility	NN
cord-021637-f5wwn45z	176	76	has	have	VBZ
cord-021637-f5wwn45z	176	77	not	not	RB
cord-021637-f5wwn45z	176	78	been	be	VBN
cord-021637-f5wwn45z	176	79	demonstrated	demonstrate	VBN
cord-021637-f5wwn45z	176	80	(	(	-LRB-
cord-021637-f5wwn45z	176	81	e.g.	e.g.	RB
cord-021637-f5wwn45z	176	82	,	,	,
cord-021637-f5wwn45z	176	83	HIV	HIV	NNP
cord-021637-f5wwn45z	176	84	)	)	-RRB-
cord-021637-f5wwn45z	176	85	.	.	.
cord-021637-f5wwn45z	177	1	The	the	DT
cord-021637-f5wwn45z	177	2	last	last	JJ
cord-021637-f5wwn45z	177	3	problem	problem	NN
cord-021637-f5wwn45z	177	4	has	have	VBZ
cord-021637-f5wwn45z	177	5	to	to	TO
cord-021637-f5wwn45z	177	6	be	be	VB
cord-021637-f5wwn45z	177	7	solved	solve	VBN
cord-021637-f5wwn45z	177	8	by	by	IN
cord-021637-f5wwn45z	177	9	a	a	DT
cord-021637-f5wwn45z	177	10	strong	strong	JJ
cord-021637-f5wwn45z	177	11	basic	basic	JJ
cord-021637-f5wwn45z	177	12	program	program	NN
cord-021637-f5wwn45z	177	13	in	in	IN
cord-021637-f5wwn45z	177	14	vaccine	vaccine	NN
cord-021637-f5wwn45z	177	15	-	-	HYPH
cord-021637-f5wwn45z	177	16	related	relate	VBN
cord-021637-f5wwn45z	177	17	sciences	science	NNS
cord-021637-f5wwn45z	177	18	,	,	,
cord-021637-f5wwn45z	177	19	particularly	particularly	RB
cord-021637-f5wwn45z	177	20	for	for	IN
cord-021637-f5wwn45z	177	21	HIV	HIV	NNP
cord-021637-f5wwn45z	177	22	,	,	,
cord-021637-f5wwn45z	177	23	Staphylococcus	Staphylococcus	NNP
cord-021637-f5wwn45z	177	24	aureus	aureus	NN
cord-021637-f5wwn45z	177	25	,	,	,
cord-021637-f5wwn45z	177	26	malaria	malaria	NN
cord-021637-f5wwn45z	177	27	,	,	,
cord-021637-f5wwn45z	177	28	and	and	CC
cord-021637-f5wwn45z	177	29	other	other	JJ
cord-021637-f5wwn45z	177	30	challenging	challenging	JJ
cord-021637-f5wwn45z	177	31	targets	target	NNS
cord-021637-f5wwn45z	177	32	.	.	.
cord-021637-f5wwn45z	178	1	Niche	niche	NN
cord-021637-f5wwn45z	178	2	vaccines	vaccine	NNS
cord-021637-f5wwn45z	178	3	for	for	IN
cord-021637-f5wwn45z	178	4	developed	develop	VBN
cord-021637-f5wwn45z	178	5	-	-	HYPH
cord-021637-f5wwn45z	178	6	world	world	NN
cord-021637-f5wwn45z	178	7	markets	market	NNS
cord-021637-f5wwn45z	178	8	are	be	VBP
cord-021637-f5wwn45z	178	9	much	much	RB
cord-021637-f5wwn45z	178	10	more	more	RBR
cord-021637-f5wwn45z	178	11	attractive	attractive	JJ
cord-021637-f5wwn45z	178	12	to	to	IN
cord-021637-f5wwn45z	178	13	biotech	biotech	NN
cord-021637-f5wwn45z	178	14	than	than	IN
cord-021637-f5wwn45z	178	15	to	to	IN
cord-021637-f5wwn45z	178	16	large	large	JJ
cord-021637-f5wwn45z	178	17	pharmaceutical	pharmaceutical	JJ
cord-021637-f5wwn45z	178	18	companies	company	NNS
cord-021637-f5wwn45z	178	19	as	as	IN
cord-021637-f5wwn45z	178	20	evidenced	evidence	VBN
cord-021637-f5wwn45z	178	21	by	by	IN
cord-021637-f5wwn45z	178	22	recent	recent	JJ
cord-021637-f5wwn45z	178	23	biotech	biotech	JJ
cord-021637-f5wwn45z	178	24	vaccine	vaccine	NN
cord-021637-f5wwn45z	178	25	efforts	effort	NNS
cord-021637-f5wwn45z	178	26	for	for	IN
cord-021637-f5wwn45z	178	27	West	West	NNP
cord-021637-f5wwn45z	178	28	Nile	Nile	NNP
cord-021637-f5wwn45z	178	29	virus	virus	NN
cord-021637-f5wwn45z	178	30	,	,	,
cord-021637-f5wwn45z	178	31	Japanese	japanese	JJ
cord-021637-f5wwn45z	178	32	encephalitis	encephalitis	RB
cord-021637-f5wwn45z	178	33	virus	virus	NN
cord-021637-f5wwn45z	178	34	,	,	,
cord-021637-f5wwn45z	178	35	the	the	DT
cord-021637-f5wwn45z	178	36	CMV	CMV	NNP
cord-021637-f5wwn45z	178	37	-	-	HYPH
cord-021637-f5wwn45z	178	38	transplant	transplant	NN
cord-021637-f5wwn45z	178	39	indication	indication	NN
cord-021637-f5wwn45z	178	40	,	,	,
cord-021637-f5wwn45z	178	41	and	and	CC
cord-021637-f5wwn45z	178	42	dengue	dengue	NN
cord-021637-f5wwn45z	178	43	.	.	.
cord-021637-f5wwn45z	179	1	To	to	TO
cord-021637-f5wwn45z	179	2	involve	involve	VB
cord-021637-f5wwn45z	179	3	large	large	JJ
cord-021637-f5wwn45z	179	4	companies	company	NNS
cord-021637-f5wwn45z	179	5	in	in	IN
cord-021637-f5wwn45z	179	6	development	development	NN
cord-021637-f5wwn45z	179	7	and	and	CC
cord-021637-f5wwn45z	179	8	manufacturing	manufacturing	NN
cord-021637-f5wwn45z	179	9	of	of	IN
cord-021637-f5wwn45z	179	10	vaccines	vaccine	NNS
cord-021637-f5wwn45z	179	11	to	to	TO
cord-021637-f5wwn45z	179	12	meet	meet	VB
cord-021637-f5wwn45z	179	13	needs	need	NNS
cord-021637-f5wwn45z	179	14	such	such	JJ
cord-021637-f5wwn45z	179	15	as	as	IN
cord-021637-f5wwn45z	179	16	biodefense	biodefense	NN
cord-021637-f5wwn45z	179	17	or	or	CC
cord-021637-f5wwn45z	179	18	health	health	NN
cord-021637-f5wwn45z	179	19	needs	need	NNS
cord-021637-f5wwn45z	179	20	of	of	IN
cord-021637-f5wwn45z	179	21	poorer	poor	JJR
cord-021637-f5wwn45z	179	22	countries	country	NNS
cord-021637-f5wwn45z	179	23	,	,	,
cord-021637-f5wwn45z	179	24	incentives	incentive	NNS
cord-021637-f5wwn45z	179	25	must	must	MD
cord-021637-f5wwn45z	179	26	be	be	VB
cord-021637-f5wwn45z	179	27	established	establish	VBN
cord-021637-f5wwn45z	179	28	to	to	TO
cord-021637-f5wwn45z	179	29	convince	convince	VB
cord-021637-f5wwn45z	179	30	these	these	DT
cord-021637-f5wwn45z	179	31	companies	company	NNS
cord-021637-f5wwn45z	179	32	that	that	IN
cord-021637-f5wwn45z	179	33	they	-PRON-	PRP
cord-021637-f5wwn45z	179	34	should	should	MD
cord-021637-f5wwn45z	179	35	develop	develop	VB
cord-021637-f5wwn45z	179	36	and	and	CC
cord-021637-f5wwn45z	179	37	manufacture	manufacture	VB
cord-021637-f5wwn45z	179	38	such	such	JJ
cord-021637-f5wwn45z	179	39	products	product	NNS
cord-021637-f5wwn45z	179	40	.	.	.
cord-021637-f5wwn45z	180	1	Such	such	JJ
cord-021637-f5wwn45z	180	2	incentives	incentive	NNS
cord-021637-f5wwn45z	180	3	might	may	MD
cord-021637-f5wwn45z	180	4	take	take	VB
cord-021637-f5wwn45z	180	5	the	the	DT
cord-021637-f5wwn45z	180	6	form	form	NN
cord-021637-f5wwn45z	180	7	of	of	IN
cord-021637-f5wwn45z	180	8	guaranteed	guarantee	VBN
cord-021637-f5wwn45z	180	9	purchase	purchase	NN
cord-021637-f5wwn45z	180	10	of	of	IN
cord-021637-f5wwn45z	180	11	certain	certain	JJ
cord-021637-f5wwn45z	180	12	volumes	volume	NNS
cord-021637-f5wwn45z	180	13	of	of	IN
cord-021637-f5wwn45z	180	14	a	a	DT
cord-021637-f5wwn45z	180	15	vaccine	vaccine	NN
cord-021637-f5wwn45z	180	16	if	if	IN
cord-021637-f5wwn45z	180	17	specified	specify	VBN
cord-021637-f5wwn45z	180	18	standards	standard	NNS
cord-021637-f5wwn45z	180	19	are	be	VBP
cord-021637-f5wwn45z	180	20	met	meet	VBN
cord-021637-f5wwn45z	180	21	,	,	,
cord-021637-f5wwn45z	180	22	direct	direct	JJ
cord-021637-f5wwn45z	180	23	contracting	contracting	NN
cord-021637-f5wwn45z	180	24	by	by	IN
cord-021637-f5wwn45z	180	25	a	a	DT
cord-021637-f5wwn45z	180	26	government	government	NN
cord-021637-f5wwn45z	180	27	agency	agency	NN
cord-021637-f5wwn45z	180	28	,	,	,
cord-021637-f5wwn45z	180	29	or	or	CC
cord-021637-f5wwn45z	180	30	some	some	DT
cord-021637-f5wwn45z	180	31	other	other	JJ
cord-021637-f5wwn45z	180	32	publicly	publicly	RB
cord-021637-f5wwn45z	180	33	funded	fund	VBN
cord-021637-f5wwn45z	180	34	mechanism	mechanism	NN
cord-021637-f5wwn45z	180	35	.	.	.
cord-021637-f5wwn45z	181	1	18	18	CD
cord-021637-f5wwn45z	181	2	,	,	,
cord-021637-f5wwn45z	181	3	19	19	CD
cord-021637-f5wwn45z	182	1	The	the	DT
cord-021637-f5wwn45z	182	2	use	use	NN
cord-021637-f5wwn45z	182	3	of	of	IN
cord-021637-f5wwn45z	182	4	Advanced	Advanced	NNP
cord-021637-f5wwn45z	182	5	Market	Market	NNP
cord-021637-f5wwn45z	182	6	Commitments	commitment	NNS
cord-021637-f5wwn45z	182	7	to	to	TO
cord-021637-f5wwn45z	182	8	create	create	VB
cord-021637-f5wwn45z	182	9	a	a	DT
cord-021637-f5wwn45z	182	10	funding	funding	NN
cord-021637-f5wwn45z	182	11	mechanism	mechanism	NN
cord-021637-f5wwn45z	182	12	for	for	IN
cord-021637-f5wwn45z	182	13	vaccines	vaccine	NNS
cord-021637-f5wwn45z	182	14	needed	need	VBN
cord-021637-f5wwn45z	182	15	in	in	IN
cord-021637-f5wwn45z	182	16	the	the	DT
cord-021637-f5wwn45z	182	17	developing	develop	VBG
cord-021637-f5wwn45z	182	18	world	world	NN
cord-021637-f5wwn45z	182	19	has	have	VBZ
cord-021637-f5wwn45z	182	20	been	be	VBN
cord-021637-f5wwn45z	182	21	endorsed	endorse	VBN
cord-021637-f5wwn45z	182	22	by	by	IN
cord-021637-f5wwn45z	182	23	the	the	DT
cord-021637-f5wwn45z	182	24	G8	G8	NNP
cord-021637-f5wwn45z	182	25	and	and	CC
cord-021637-f5wwn45z	182	26	pilot	pilot	NN
cord-021637-f5wwn45z	182	27	projects	project	NNS
cord-021637-f5wwn45z	182	28	may	may	MD
cord-021637-f5wwn45z	182	29	be	be	VB
cord-021637-f5wwn45z	182	30	starting	start	VBG
cord-021637-f5wwn45z	182	31	soon	soon	RB
cord-021637-f5wwn45z	182	32	.	.	.
cord-021637-f5wwn45z	183	1	This	this	DT
cord-021637-f5wwn45z	183	2	will	will	MD
cord-021637-f5wwn45z	183	3	not	not	RB
cord-021637-f5wwn45z	183	4	solve	solve	VB
cord-021637-f5wwn45z	183	5	the	the	DT
cord-021637-f5wwn45z	183	6	problem	problem	NN
cord-021637-f5wwn45z	183	7	of	of	IN
cord-021637-f5wwn45z	183	8	the	the	DT
cord-021637-f5wwn45z	183	9	high	high	JJ
cord-021637-f5wwn45z	183	10	technical	technical	JJ
cord-021637-f5wwn45z	183	11	risk	risk	NN
cord-021637-f5wwn45z	183	12	and	and	CC
cord-021637-f5wwn45z	183	13	opportunity	opportunity	NN
cord-021637-f5wwn45z	183	14	costs	cost	NNS
cord-021637-f5wwn45z	183	15	associated	associate	VBN
cord-021637-f5wwn45z	183	16	with	with	IN
cord-021637-f5wwn45z	183	17	such	such	JJ
cord-021637-f5wwn45z	183	18	vaccines	vaccine	NNS
cord-021637-f5wwn45z	183	19	,	,	,
cord-021637-f5wwn45z	183	20	but	but	CC
cord-021637-f5wwn45z	183	21	it	-PRON-	PRP
cord-021637-f5wwn45z	183	22	may	may	MD
cord-021637-f5wwn45z	183	23	contribute	contribute	VB
cord-021637-f5wwn45z	183	24	to	to	IN
cord-021637-f5wwn45z	183	25	the	the	DT
cord-021637-f5wwn45z	183	26	solution	solution	NN
cord-021637-f5wwn45z	183	27	if	if	IN
cord-021637-f5wwn45z	183	28	combined	combine	VBN
cord-021637-f5wwn45z	183	29	with	with	IN
cord-021637-f5wwn45z	183	30	early	early	JJ
cord-021637-f5wwn45z	183	31	investment	investment	NN
cord-021637-f5wwn45z	183	32	.	.	.
cord-021637-f5wwn45z	184	1	Companies	company	NNS
cord-021637-f5wwn45z	184	2	may	may	MD
cord-021637-f5wwn45z	184	3	be	be	VB
cord-021637-f5wwn45z	184	4	willing	willing	JJ
cord-021637-f5wwn45z	184	5	to	to	TO
cord-021637-f5wwn45z	184	6	engage	engage	VB
cord-021637-f5wwn45z	184	7	in	in	IN
cord-021637-f5wwn45z	184	8	such	such	JJ
cord-021637-f5wwn45z	184	9	work	work	NN
cord-021637-f5wwn45z	184	10	.	.	.
cord-021637-f5wwn45z	185	1	Indeed	indeed	RB
cord-021637-f5wwn45z	185	2	,	,	,
cord-021637-f5wwn45z	185	3	they	-PRON-	PRP
cord-021637-f5wwn45z	185	4	may	may	MD
cord-021637-f5wwn45z	185	5	already	already	RB
cord-021637-f5wwn45z	185	6	have	have	VB
cord-021637-f5wwn45z	185	7	donated	donate	VBN
cord-021637-f5wwn45z	185	8	or	or	CC
cord-021637-f5wwn45z	185	9	sold	sell	VBN
cord-021637-f5wwn45z	185	10	vaccines	vaccine	NNS
cord-021637-f5wwn45z	185	11	at	at	IN
cord-021637-f5wwn45z	185	12	very	very	RB
cord-021637-f5wwn45z	185	13	low	low	JJ
cord-021637-f5wwn45z	185	14	prices	price	NNS
cord-021637-f5wwn45z	185	15	to	to	IN
cord-021637-f5wwn45z	185	16	poorer	poor	JJR
cord-021637-f5wwn45z	185	17	countries	country	NNS
cord-021637-f5wwn45z	185	18	.	.	.
cord-021637-f5wwn45z	186	1	However	however	RB
cord-021637-f5wwn45z	186	2	,	,	,
cord-021637-f5wwn45z	186	3	such	such	JJ
cord-021637-f5wwn45z	186	4	practices	practice	NNS
cord-021637-f5wwn45z	186	5	alone	alone	RB
cord-021637-f5wwn45z	186	6	will	will	MD
cord-021637-f5wwn45z	186	7	not	not	RB
cord-021637-f5wwn45z	186	8	solve	solve	VB
cord-021637-f5wwn45z	186	9	the	the	DT
cord-021637-f5wwn45z	186	10	enormity	enormity	NN
cord-021637-f5wwn45z	186	11	of	of	IN
cord-021637-f5wwn45z	186	12	the	the	DT
cord-021637-f5wwn45z	186	13	health	health	NN
cord-021637-f5wwn45z	186	14	problems	problem	NNS
cord-021637-f5wwn45z	186	15	worldwide	worldwide	RB
cord-021637-f5wwn45z	186	16	.	.	.
cord-021637-f5wwn45z	187	1	Without	without	IN
cord-021637-f5wwn45z	187	2	special	special	JJ
cord-021637-f5wwn45z	187	3	incentives	incentive	NNS
cord-021637-f5wwn45z	187	4	,	,	,
cord-021637-f5wwn45z	187	5	it	-PRON-	PRP
cord-021637-f5wwn45z	187	6	is	be	VBZ
cord-021637-f5wwn45z	187	7	unrealistic	unrealistic	JJ
cord-021637-f5wwn45z	187	8	to	to	TO
cord-021637-f5wwn45z	187	9	expect	expect	VB
cord-021637-f5wwn45z	187	10	companies	company	NNS
cord-021637-f5wwn45z	187	11	to	to	TO
cord-021637-f5wwn45z	187	12	engage	engage	VB
cord-021637-f5wwn45z	187	13	in	in	IN
cord-021637-f5wwn45z	187	14	R&D	r&d	NN
cord-021637-f5wwn45z	187	15	on	on	IN
cord-021637-f5wwn45z	187	16	diseases	disease	NNS
cord-021637-f5wwn45z	187	17	that	that	WDT
cord-021637-f5wwn45z	187	18	only	only	RB
cord-021637-f5wwn45z	187	19	,	,	,
cord-021637-f5wwn45z	187	20	or	or	CC
cord-021637-f5wwn45z	187	21	predominantly	predominantly	RB
cord-021637-f5wwn45z	187	22	,	,	,
cord-021637-f5wwn45z	187	23	affect	affect	VB
cord-021637-f5wwn45z	187	24	the	the	DT
cord-021637-f5wwn45z	187	25	poorer	poor	JJR
cord-021637-f5wwn45z	187	26	regions	region	NNS
cord-021637-f5wwn45z	187	27	of	of	IN
cord-021637-f5wwn45z	187	28	the	the	DT
cord-021637-f5wwn45z	187	29	world	world	NN
cord-021637-f5wwn45z	187	30	.	.	.
cord-021637-f5wwn45z	188	1	13	13	CD
cord-021637-f5wwn45z	188	2	Manufacturers	manufacturer	NNS
cord-021637-f5wwn45z	188	3	in	in	IN
cord-021637-f5wwn45z	188	4	developing	develop	VBG
cord-021637-f5wwn45z	188	5	countries	country	NNS
cord-021637-f5wwn45z	188	6	(	(	-LRB-
cord-021637-f5wwn45z	188	7	initially	initially	RB
cord-021637-f5wwn45z	188	8	in	in	IN
cord-021637-f5wwn45z	188	9	India	India	NNP
cord-021637-f5wwn45z	188	10	and	and	CC
cord-021637-f5wwn45z	188	11	China	China	NNP
cord-021637-f5wwn45z	188	12	,	,	,
cord-021637-f5wwn45z	188	13	and	and	CC
cord-021637-f5wwn45z	188	14	more	more	RBR
cord-021637-f5wwn45z	188	15	recently	recently	RB
cord-021637-f5wwn45z	188	16	in	in	IN
cord-021637-f5wwn45z	188	17	Brazil	Brazil	NNP
cord-021637-f5wwn45z	188	18	)	)	-RRB-
cord-021637-f5wwn45z	188	19	are	be	VBP
cord-021637-f5wwn45z	188	20	playing	play	VBG
cord-021637-f5wwn45z	188	21	an	an	DT
cord-021637-f5wwn45z	188	22	increasing	increase	VBG
cord-021637-f5wwn45z	188	23	role	role	NN
cord-021637-f5wwn45z	188	24	in	in	IN
cord-021637-f5wwn45z	188	25	meeting	meet	VBG
cord-021637-f5wwn45z	188	26	these	these	DT
cord-021637-f5wwn45z	188	27	needs	need	NNS
cord-021637-f5wwn45z	188	28	.	.	.
cord-021637-f5wwn45z	189	1	Indeed	indeed	RB
cord-021637-f5wwn45z	189	2	,	,	,
cord-021637-f5wwn45z	189	3	they	-PRON-	PRP
cord-021637-f5wwn45z	189	4	already	already	RB
cord-021637-f5wwn45z	189	5	supply	supply	VBP
cord-021637-f5wwn45z	189	6	the	the	DT
cord-021637-f5wwn45z	189	7	majority	majority	NN
cord-021637-f5wwn45z	189	8	of	of	IN
cord-021637-f5wwn45z	189	9	doses	dose	NNS
cord-021637-f5wwn45z	189	10	of	of	IN
cord-021637-f5wwn45z	189	11	older	old	JJR
cord-021637-f5wwn45z	189	12	vaccines	vaccine	NNS
cord-021637-f5wwn45z	189	13	for	for	IN
cord-021637-f5wwn45z	189	14	such	such	JJ
cord-021637-f5wwn45z	189	15	countries	country	NNS
cord-021637-f5wwn45z	189	16	.	.	.
cord-021637-f5wwn45z	190	1	As	as	IN
cord-021637-f5wwn45z	190	2	their	-PRON-	PRP$
cord-021637-f5wwn45z	190	3	expertise	expertise	NN
cord-021637-f5wwn45z	190	4	and	and	CC
cord-021637-f5wwn45z	190	5	capacity	capacity	NN
cord-021637-f5wwn45z	190	6	in	in	IN
cord-021637-f5wwn45z	190	7	vaccine	vaccine	NN
cord-021637-f5wwn45z	190	8	R&D	r&d	NN
cord-021637-f5wwn45z	190	9	increases	increase	VBZ
cord-021637-f5wwn45z	190	10	they	-PRON-	PRP
cord-021637-f5wwn45z	190	11	will	will	MD
cord-021637-f5wwn45z	190	12	perhaps	perhaps	RB
cord-021637-f5wwn45z	190	13	evolve	evolve	VB
cord-021637-f5wwn45z	190	14	into	into	IN
cord-021637-f5wwn45z	190	15	major	major	JJ
cord-021637-f5wwn45z	190	16	participants	participant	NNS
cord-021637-f5wwn45z	190	17	in	in	IN
cord-021637-f5wwn45z	190	18	supplying	supply	VBG
cord-021637-f5wwn45z	190	19	new	new	JJ
cord-021637-f5wwn45z	190	20	vaccines	vaccine	NNS
cord-021637-f5wwn45z	190	21	to	to	IN
cord-021637-f5wwn45z	190	22	the	the	DT
cord-021637-f5wwn45z	190	23	developing	develop	VBG
cord-021637-f5wwn45z	190	24	world	world	NN
cord-021637-f5wwn45z	190	25	.	.	.
cord-021637-f5wwn45z	191	1	There	there	EX
cord-021637-f5wwn45z	191	2	are	be	VBP
cord-021637-f5wwn45z	191	3	numerous	numerous	JJ
cord-021637-f5wwn45z	191	4	manufacturers	manufacturer	NNS
cord-021637-f5wwn45z	191	5	in	in	IN
cord-021637-f5wwn45z	191	6	these	these	DT
cord-021637-f5wwn45z	191	7	emerging	emerge	VBG
cord-021637-f5wwn45z	191	8	countries	country	NNS
cord-021637-f5wwn45z	191	9	,	,	,
cord-021637-f5wwn45z	191	10	but	but	CC
cord-021637-f5wwn45z	191	11	a	a	DT
cord-021637-f5wwn45z	191	12	few	few	JJ
cord-021637-f5wwn45z	191	13	truly	truly	RB
cord-021637-f5wwn45z	191	14	stand	stand	VBP
cord-021637-f5wwn45z	191	15	out	out	RP
cord-021637-f5wwn45z	191	16	.	.	.
cord-021637-f5wwn45z	192	1	The	the	DT
cord-021637-f5wwn45z	192	2	vaccine	vaccine	NN
cord-021637-f5wwn45z	192	3	industry	industry	NN
cord-021637-f5wwn45z	192	4	has	have	VBZ
cord-021637-f5wwn45z	192	5	slowly	slowly	RB
cord-021637-f5wwn45z	192	6	mushroomed	mushroom	VBN
cord-021637-f5wwn45z	192	7	in	in	IN
cord-021637-f5wwn45z	192	8	India	India	NNP
cord-021637-f5wwn45z	192	9	with	with	IN
cord-021637-f5wwn45z	192	10	several	several	JJ
cord-021637-f5wwn45z	192	11	key	key	JJ
cord-021637-f5wwn45z	192	12	companies	company	NNS
cord-021637-f5wwn45z	192	13	emerging	emerge	VBG
cord-021637-f5wwn45z	192	14	including	include	VBG
cord-021637-f5wwn45z	192	15	Bharat	Bharat	NNP
cord-021637-f5wwn45z	192	16	Biotech	Biotech	NNP
cord-021637-f5wwn45z	192	17	,	,	,
cord-021637-f5wwn45z	192	18	Biological	Biological	NNP
cord-021637-f5wwn45z	192	19	E.	E.	NNP
cord-021637-f5wwn45z	192	20	,	,	,
cord-021637-f5wwn45z	192	21	Panacea	Panacea	NNP
cord-021637-f5wwn45z	192	22	Biotec	Biotec	NNP
cord-021637-f5wwn45z	192	23	,	,	,
cord-021637-f5wwn45z	192	24	and	and	CC
cord-021637-f5wwn45z	192	25	others	other	NNS
cord-021637-f5wwn45z	192	26	,	,	,
cord-021637-f5wwn45z	192	27	but	but	CC
cord-021637-f5wwn45z	192	28	the	the	DT
cord-021637-f5wwn45z	192	29	largest	large	JJS
cord-021637-f5wwn45z	192	30	one	one	CD
cord-021637-f5wwn45z	192	31	is	be	VBZ
cord-021637-f5wwn45z	192	32	the	the	DT
cord-021637-f5wwn45z	192	33	privately	privately	RB
cord-021637-f5wwn45z	192	34	held	hold	VBN
cord-021637-f5wwn45z	192	35	Serum	Serum	NNP
cord-021637-f5wwn45z	192	36	Institute	Institute	NNP
cord-021637-f5wwn45z	192	37	of	of	IN
cord-021637-f5wwn45z	192	38	India	India	NNP
cord-021637-f5wwn45z	192	39	.	.	.
cord-021637-f5wwn45z	193	1	The	the	DT
cord-021637-f5wwn45z	193	2	Indian	indian	JJ
cord-021637-f5wwn45z	193	3	vaccine	vaccine	NN
cord-021637-f5wwn45z	193	4	industry	industry	NN
cord-021637-f5wwn45z	193	5	has	have	VBZ
cord-021637-f5wwn45z	193	6	significantly	significantly	RB
cord-021637-f5wwn45z	193	7	benefited	benefit	VBN
cord-021637-f5wwn45z	193	8	from	from	IN
cord-021637-f5wwn45z	193	9	technology	technology	NN
cord-021637-f5wwn45z	193	10	transfer	transfer	NN
cord-021637-f5wwn45z	193	11	from	from	IN
cord-021637-f5wwn45z	193	12	the	the	DT
cord-021637-f5wwn45z	193	13	West	West	NNP
cord-021637-f5wwn45z	193	14	.	.	.
cord-021637-f5wwn45z	194	1	Despite	despite	IN
cord-021637-f5wwn45z	194	2	the	the	DT
cord-021637-f5wwn45z	194	3	industry	industry	NN
cord-021637-f5wwn45z	194	4	's	's	POS
cord-021637-f5wwn45z	194	5	success	success	NN
cord-021637-f5wwn45z	194	6	,	,	,
cord-021637-f5wwn45z	194	7	the	the	DT
cord-021637-f5wwn45z	194	8	available	available	JJ
cord-021637-f5wwn45z	194	9	estimates	estimate	NNS
cord-021637-f5wwn45z	194	10	suggest	suggest	VBP
cord-021637-f5wwn45z	194	11	that	that	IN
cord-021637-f5wwn45z	194	12	R&D	r&d	NN
cord-021637-f5wwn45z	194	13	spending	spending	NN
cord-021637-f5wwn45z	194	14	remains	remain	VBZ
cord-021637-f5wwn45z	194	15	relatively	relatively	RB
cord-021637-f5wwn45z	194	16	low	low	JJ
cord-021637-f5wwn45z	194	17	as	as	IN
cord-021637-f5wwn45z	194	18	a	a	DT
cord-021637-f5wwn45z	194	19	percentage	percentage	NN
cord-021637-f5wwn45z	194	20	of	of	IN
cord-021637-f5wwn45z	194	21	sales	sale	NNS
cord-021637-f5wwn45z	194	22	.	.	.
cord-021637-f5wwn45z	195	1	20	20	CD
cord-021637-f5wwn45z	195	2	Serum	Serum	NNP
cord-021637-f5wwn45z	195	3	Institute	Institute	NNP
cord-021637-f5wwn45z	195	4	of	of	IN
cord-021637-f5wwn45z	195	5	India	India	NNP
cord-021637-f5wwn45z	195	6	is	be	VBZ
cord-021637-f5wwn45z	195	7	the	the	DT
cord-021637-f5wwn45z	195	8	world	world	NN
cord-021637-f5wwn45z	195	9	's	's	POS
cord-021637-f5wwn45z	195	10	largest	large	JJS
cord-021637-f5wwn45z	195	11	producer	producer	NN
cord-021637-f5wwn45z	195	12	of	of	IN
cord-021637-f5wwn45z	195	13	vaccines	vaccine	NNS
cord-021637-f5wwn45z	195	14	by	by	IN
cord-021637-f5wwn45z	195	15	number	number	NN
cord-021637-f5wwn45z	195	16	of	of	IN
cord-021637-f5wwn45z	195	17	doses	dose	NNS
cord-021637-f5wwn45z	195	18	,	,	,
cord-021637-f5wwn45z	195	19	producing	produce	VBG
cord-021637-f5wwn45z	195	20	1.3	1.3	CD
cord-021637-f5wwn45z	195	21	billion	billion	CD
cord-021637-f5wwn45z	195	22	doses	dose	NNS
cord-021637-f5wwn45z	195	23	contributions	contribution	NNS
cord-021637-f5wwn45z	195	24	to	to	IN
cord-021637-f5wwn45z	195	25	R&D	r&d	NN
cord-021637-f5wwn45z	195	26	,	,	,
cord-021637-f5wwn45z	195	27	interest	interest	NN
cord-021637-f5wwn45z	195	28	,	,	,
cord-021637-f5wwn45z	195	29	taxes	taxis	NNS
cord-021637-f5wwn45z	195	30	,	,	,
cord-021637-f5wwn45z	195	31	and	and	CC
cord-021637-f5wwn45z	195	32	earnings	earning	NNS
cord-021637-f5wwn45z	195	33	after	after	IN
cord-021637-f5wwn45z	195	34	expenses	expense	NNS
cord-021637-f5wwn45z	195	35	were	be	VBD
cord-021637-f5wwn45z	195	36	similar	similar	JJ
cord-021637-f5wwn45z	195	37	for	for	IN
cord-021637-f5wwn45z	195	38	the	the	DT
cord-021637-f5wwn45z	195	39	two	two	CD
cord-021637-f5wwn45z	195	40	industries	industry	NNS
cord-021637-f5wwn45z	195	41	(	(	-LRB-
cord-021637-f5wwn45z	195	42	44	44	CD
cord-021637-f5wwn45z	195	43	%	%	NN
cord-021637-f5wwn45z	195	44	vs.	vs.	IN
cord-021637-f5wwn45z	195	45	46	46	CD
cord-021637-f5wwn45z	195	46	%	%	NN
cord-021637-f5wwn45z	195	47	,	,	,
cord-021637-f5wwn45z	195	48	respectively	respectively	RB
cord-021637-f5wwn45z	195	49	)	)	-RRB-
cord-021637-f5wwn45z	195	50	.	.	.
cord-021637-f5wwn45z	196	1	However	however	RB
cord-021637-f5wwn45z	196	2	,	,	,
cord-021637-f5wwn45z	196	3	the	the	DT
cord-021637-f5wwn45z	196	4	expenses	expense	NNS
cord-021637-f5wwn45z	196	5	were	be	VBD
cord-021637-f5wwn45z	196	6	quite	quite	RB
cord-021637-f5wwn45z	196	7	different	different	JJ
cord-021637-f5wwn45z	196	8	.	.	.
cord-021637-f5wwn45z	197	1	Significantly	significantly	RB
cord-021637-f5wwn45z	197	2	more	more	RBR
cord-021637-f5wwn45z	197	3	was	be	VBD
cord-021637-f5wwn45z	197	4	spent	spend	VBN
cord-021637-f5wwn45z	197	5	on	on	IN
cord-021637-f5wwn45z	197	6	production	production	NN
cord-021637-f5wwn45z	197	7	and	and	CC
cord-021637-f5wwn45z	197	8	distribution	distribution	NN
cord-021637-f5wwn45z	197	9	(	(	-LRB-
cord-021637-f5wwn45z	197	10	32	32	CD
cord-021637-f5wwn45z	197	11	%	%	NN
cord-021637-f5wwn45z	197	12	,	,	,
cord-021637-f5wwn45z	197	13	which	which	WDT
cord-021637-f5wwn45z	197	14	includes	include	VBZ
cord-021637-f5wwn45z	197	15	production	production	NN
cord-021637-f5wwn45z	197	16	,	,	,
cord-021637-f5wwn45z	197	17	distribution	distribution	NN
cord-021637-f5wwn45z	197	18	,	,	,
cord-021637-f5wwn45z	197	19	and	and	CC
cord-021637-f5wwn45z	197	20	returns	return	NNS
cord-021637-f5wwn45z	197	21	of	of	IN
cord-021637-f5wwn45z	197	22	product	product	NN
cord-021637-f5wwn45z	197	23	)	)	-RRB-
cord-021637-f5wwn45z	197	24	in	in	IN
cord-021637-f5wwn45z	197	25	the	the	DT
cord-021637-f5wwn45z	197	26	vaccine	vaccine	NN
cord-021637-f5wwn45z	197	27	industry	industry	NN
cord-021637-f5wwn45z	197	28	compared	compare	VBN
cord-021637-f5wwn45z	197	29	with	with	IN
cord-021637-f5wwn45z	197	30	the	the	DT
cord-021637-f5wwn45z	197	31	pharmaceutical	pharmaceutical	NN
cord-021637-f5wwn45z	197	32	industry	industry	NN
cord-021637-f5wwn45z	197	33	(	(	-LRB-
cord-021637-f5wwn45z	197	34	19	19	CD
cord-021637-f5wwn45z	197	35	%	%	NN
cord-021637-f5wwn45z	197	36	)	)	-RRB-
cord-021637-f5wwn45z	197	37	,	,	,
cord-021637-f5wwn45z	197	38	whereas	whereas	IN
cord-021637-f5wwn45z	197	39	the	the	DT
cord-021637-f5wwn45z	197	40	pharmaceutical	pharmaceutical	NN
cord-021637-f5wwn45z	197	41	industry	industry	NN
cord-021637-f5wwn45z	197	42	spent	spend	VBD
cord-021637-f5wwn45z	197	43	more	more	JJR
cord-021637-f5wwn45z	197	44	than	than	IN
cord-021637-f5wwn45z	197	45	the	the	DT
cord-021637-f5wwn45z	197	46	vaccine	vaccine	NN
cord-021637-f5wwn45z	197	47	industry	industry	NN
cord-021637-f5wwn45z	197	48	on	on	IN
cord-021637-f5wwn45z	197	49	sales	sale	NNS
cord-021637-f5wwn45z	197	50	,	,	,
cord-021637-f5wwn45z	197	51	marketing	marketing	NN
cord-021637-f5wwn45z	197	52	,	,	,
cord-021637-f5wwn45z	197	53	and	and	CC
cord-021637-f5wwn45z	197	54	administrative	administrative	JJ
cord-021637-f5wwn45z	197	55	expenses	expense	NNS
cord-021637-f5wwn45z	197	56	(	(	-LRB-
cord-021637-f5wwn45z	197	57	35	35	CD
cord-021637-f5wwn45z	197	58	%	%	NN
cord-021637-f5wwn45z	197	59	vs.	vs.	CC
cord-021637-f5wwn45z	197	60	24	24	CD
cord-021637-f5wwn45z	197	61	%	%	NN
cord-021637-f5wwn45z	197	62	,	,	,
cord-021637-f5wwn45z	197	63	respectively	respectively	RB
cord-021637-f5wwn45z	197	64	)	)	-RRB-
cord-021637-f5wwn45z	197	65	.	.	.
cord-021637-f5wwn45z	198	1	Consequently	consequently	RB
cord-021637-f5wwn45z	198	2	,	,	,
cord-021637-f5wwn45z	198	3	within	within	IN
cord-021637-f5wwn45z	198	4	companies	company	NNS
cord-021637-f5wwn45z	198	5	,	,	,
cord-021637-f5wwn45z	198	6	there	there	EX
cord-021637-f5wwn45z	198	7	is	be	VBZ
cord-021637-f5wwn45z	198	8	an	an	DT
cord-021637-f5wwn45z	198	9	expectation	expectation	NN
cord-021637-f5wwn45z	198	10	that	that	IN
cord-021637-f5wwn45z	198	11	sales	sale	NNS
cord-021637-f5wwn45z	198	12	-	-	HYPH
cord-021637-f5wwn45z	198	13	to	to	IN
cord-021637-f5wwn45z	198	14	-	-	HYPH
cord-021637-f5wwn45z	198	15	expense	expense	NN
cord-021637-f5wwn45z	198	16	ratios	ratio	NNS
cord-021637-f5wwn45z	198	17	for	for	IN
cord-021637-f5wwn45z	198	18	vaccines	vaccine	NNS
cord-021637-f5wwn45z	198	19	will	will	MD
cord-021637-f5wwn45z	198	20	be	be	VB
cord-021637-f5wwn45z	198	21	similar	similar	JJ
cord-021637-f5wwn45z	198	22	to	to	IN
cord-021637-f5wwn45z	198	23	those	those	DT
cord-021637-f5wwn45z	198	24	of	of	IN
cord-021637-f5wwn45z	198	25	other	other	JJ
cord-021637-f5wwn45z	198	26	pharmaceutical	pharmaceutical	JJ
cord-021637-f5wwn45z	198	27	products	product	NNS
cord-021637-f5wwn45z	198	28	,	,	,
cord-021637-f5wwn45z	198	29	and	and	CC
cord-021637-f5wwn45z	198	30	that	that	IN
cord-021637-f5wwn45z	198	31	revenues	revenue	NNS
cord-021637-f5wwn45z	198	32	will	will	MD
cord-021637-f5wwn45z	198	33	increase	increase	VB
cord-021637-f5wwn45z	198	34	every	every	DT
cord-021637-f5wwn45z	198	35	year	year	NN
cord-021637-f5wwn45z	198	36	.	.	.
cord-021637-f5wwn45z	199	1	Although	although	IN
cord-021637-f5wwn45z	199	2	some	some	DT
cord-021637-f5wwn45z	199	3	of	of	IN
cord-021637-f5wwn45z	199	4	this	this	DT
cord-021637-f5wwn45z	199	5	increase	increase	NN
cord-021637-f5wwn45z	199	6	may	may	MD
cord-021637-f5wwn45z	199	7	be	be	VB
cord-021637-f5wwn45z	199	8	accomplished	accomplish	VBN
cord-021637-f5wwn45z	199	9	with	with	IN
cord-021637-f5wwn45z	199	10	sales	sale	NNS
cord-021637-f5wwn45z	199	11	volume	volume	NN
cord-021637-f5wwn45z	199	12	,	,	,
cord-021637-f5wwn45z	199	13	prices	price	NNS
cord-021637-f5wwn45z	199	14	stabilize	stabilize	VBP
cord-021637-f5wwn45z	199	15	as	as	IN
cord-021637-f5wwn45z	199	16	vaccine	vaccine	NN
cord-021637-f5wwn45z	199	17	products	product	NNS
cord-021637-f5wwn45z	199	18	mature	mature	VBP
cord-021637-f5wwn45z	199	19	,	,	,
cord-021637-f5wwn45z	199	20	and	and	CC
cord-021637-f5wwn45z	199	21	increased	increase	VBN
cord-021637-f5wwn45z	199	22	revenues	revenue	NNS
cord-021637-f5wwn45z	199	23	are	be	VBP
cord-021637-f5wwn45z	199	24	no	no	RB
cord-021637-f5wwn45z	199	25	longer	long	RBR
cord-021637-f5wwn45z	199	26	possible	possible	JJ
cord-021637-f5wwn45z	199	27	;	;	:
cord-021637-f5wwn45z	199	28	hence	hence	RB
cord-021637-f5wwn45z	199	29	,	,	,
cord-021637-f5wwn45z	199	30	the	the	DT
cord-021637-f5wwn45z	199	31	requirement	requirement	NN
cord-021637-f5wwn45z	199	32	for	for	IN
cord-021637-f5wwn45z	199	33	a	a	DT
cord-021637-f5wwn45z	199	34	steady	steady	JJ
cord-021637-f5wwn45z	199	35	rollout	rollout	NN
cord-021637-f5wwn45z	199	36	of	of	IN
cord-021637-f5wwn45z	199	37	new	new	JJ
cord-021637-f5wwn45z	199	38	products	product	NNS
cord-021637-f5wwn45z	199	39	.	.	.
cord-021637-f5wwn45z	200	1	However	however	RB
cord-021637-f5wwn45z	200	2	,	,	,
cord-021637-f5wwn45z	200	3	unlike	unlike	IN
cord-021637-f5wwn45z	200	4	pharmaceuticals	pharmaceutical	NNS
cord-021637-f5wwn45z	200	5	,	,	,
cord-021637-f5wwn45z	200	6	old	old	JJ
cord-021637-f5wwn45z	200	7	vaccines	vaccine	NNS
cord-021637-f5wwn45z	200	8	continue	continue	VBP
cord-021637-f5wwn45z	200	9	to	to	TO
cord-021637-f5wwn45z	200	10	be	be	VB
cord-021637-f5wwn45z	200	11	profitable	profitable	JJ
cord-021637-f5wwn45z	200	12	for	for	IN
cord-021637-f5wwn45z	200	13	a	a	DT
cord-021637-f5wwn45z	200	14	variety	variety	NN
cord-021637-f5wwn45z	200	15	of	of	IN
cord-021637-f5wwn45z	200	16	reasons	reason	NNS
cord-021637-f5wwn45z	200	17	,	,	,
cord-021637-f5wwn45z	200	18	including	include	VBG
cord-021637-f5wwn45z	200	19	:	:	:
cord-021637-f5wwn45z	200	20	1	1	CD
cord-021637-f5wwn45z	200	21	.	.	.
cord-021637-f5wwn45z	201	1	The	the	DT
cord-021637-f5wwn45z	201	2	absence	absence	NN
cord-021637-f5wwn45z	201	3	of	of	IN
cord-021637-f5wwn45z	201	4	a	a	DT
cord-021637-f5wwn45z	201	5	regulatory	regulatory	JJ
cord-021637-f5wwn45z	201	6	pathway	pathway	NN
cord-021637-f5wwn45z	201	7	for	for	IN
cord-021637-f5wwn45z	201	8	generic	generic	JJ
cord-021637-f5wwn45z	201	9	vaccines	vaccine	NNS
cord-021637-f5wwn45z	201	10	deters	deter	VBZ
cord-021637-f5wwn45z	201	11	potential	potential	JJ
cord-021637-f5wwn45z	201	12	entrants	entrant	NNS
cord-021637-f5wwn45z	201	13	from	from	IN
cord-021637-f5wwn45z	201	14	engaging	engage	VBG
cord-021637-f5wwn45z	201	15	in	in	IN
cord-021637-f5wwn45z	201	16	a	a	DT
cord-021637-f5wwn45z	201	17	complex	complex	JJ
cord-021637-f5wwn45z	201	18	and	and	CC
cord-021637-f5wwn45z	201	19	expensive	expensive	JJ
cord-021637-f5wwn45z	201	20	approval	approval	NN
cord-021637-f5wwn45z	201	21	process	process	NN
cord-021637-f5wwn45z	201	22	.	.	.
cord-021637-f5wwn45z	202	1	2	2	LS
cord-021637-f5wwn45z	202	2	.	.	.
cord-021637-f5wwn45z	203	1	In	in	IN
cord-021637-f5wwn45z	203	2	most	most	JJS
cord-021637-f5wwn45z	203	3	cases	case	NNS
cord-021637-f5wwn45z	203	4	,	,	,
cord-021637-f5wwn45z	203	5	access	access	NN
cord-021637-f5wwn45z	203	6	to	to	IN
cord-021637-f5wwn45z	203	7	knowhow	knowhow	NN
cord-021637-f5wwn45z	203	8	,	,	,
cord-021637-f5wwn45z	203	9	such	such	JJ
cord-021637-f5wwn45z	203	10	as	as	IN
cord-021637-f5wwn45z	203	11	proprietary	proprietary	JJ
cord-021637-f5wwn45z	203	12	cell	cell	NN
cord-021637-f5wwn45z	203	13	lines	line	NNS
cord-021637-f5wwn45z	203	14	,	,	,
cord-021637-f5wwn45z	203	15	virus	virus	NN
cord-021637-f5wwn45z	203	16	strains	strain	NNS
cord-021637-f5wwn45z	203	17	,	,	,
cord-021637-f5wwn45z	203	18	and	and	CC
cord-021637-f5wwn45z	203	19	internally	internally	RB
cord-021637-f5wwn45z	203	20	developed	develop	VBN
cord-021637-f5wwn45z	203	21	processes	process	NNS
cord-021637-f5wwn45z	203	22	,	,	,
cord-021637-f5wwn45z	203	23	is	be	VBZ
cord-021637-f5wwn45z	203	24	far	far	RB
cord-021637-f5wwn45z	203	25	more	more	RBR
cord-021637-f5wwn45z	203	26	valuable	valuable	JJ
cord-021637-f5wwn45z	203	27	than	than	IN
cord-021637-f5wwn45z	203	28	patent	patent	NN
cord-021637-f5wwn45z	203	29	protection	protection	NN
cord-021637-f5wwn45z	203	30	.	.	.
cord-021637-f5wwn45z	204	1	3	3	LS
cord-021637-f5wwn45z	204	2	.	.	.
cord-021637-f5wwn45z	205	1	The	the	DT
cord-021637-f5wwn45z	205	2	birth	birth	NN
cord-021637-f5wwn45z	205	3	cohort	cohort	NN
cord-021637-f5wwn45z	205	4	is	be	VBZ
cord-021637-f5wwn45z	205	5	renewable	renewable	JJ
cord-021637-f5wwn45z	205	6	,	,	,
cord-021637-f5wwn45z	205	7	providing	provide	VBG
cord-021637-f5wwn45z	205	8	an	an	DT
cord-021637-f5wwn45z	205	9	ongoing	ongoing	JJ
cord-021637-f5wwn45z	205	10	unmet	unmet	JJ
cord-021637-f5wwn45z	205	11	need	need	NN
cord-021637-f5wwn45z	205	12	for	for	IN
cord-021637-f5wwn45z	205	13	vaccines	vaccine	NNS
cord-021637-f5wwn45z	205	14	.	.	.
cord-021637-f5wwn45z	206	1	As	as	IN
cord-021637-f5wwn45z	206	2	a	a	DT
cord-021637-f5wwn45z	206	3	result	result	NN
cord-021637-f5wwn45z	206	4	,	,	,
cord-021637-f5wwn45z	206	5	sole	sole	NN
cord-021637-f5wwn45z	206	6	-	-	HYPH
cord-021637-f5wwn45z	206	7	sourced	source	VBN
cord-021637-f5wwn45z	206	8	vaccines	vaccine	NNS
cord-021637-f5wwn45z	206	9	,	,	,
cord-021637-f5wwn45z	206	10	manufactured	manufacture	VBN
cord-021637-f5wwn45z	206	11	in	in	IN
cord-021637-f5wwn45z	206	12	fully	fully	RB
cord-021637-f5wwn45z	206	13	depreciated	depreciate	VBN
cord-021637-f5wwn45z	206	14	assets	asset	NNS
cord-021637-f5wwn45z	206	15	,	,	,
cord-021637-f5wwn45z	206	16	are	be	VBP
cord-021637-f5wwn45z	206	17	profitable	profitable	JJ
cord-021637-f5wwn45z	206	18	for	for	IN
cord-021637-f5wwn45z	206	19	pharmaceutical	pharmaceutical	JJ
cord-021637-f5wwn45z	206	20	companies	company	NNS
cord-021637-f5wwn45z	206	21	.	.	.
cord-021637-f5wwn45z	207	1	One	one	CD
cord-021637-f5wwn45z	207	2	such	such	JJ
cord-021637-f5wwn45z	207	3	example	example	NN
cord-021637-f5wwn45z	207	4	is	be	VBZ
cord-021637-f5wwn45z	207	5	the	the	DT
cord-021637-f5wwn45z	207	6	MMR	MMR	NNP
cord-021637-f5wwn45z	207	7	vaccine	vaccine	NN
cord-021637-f5wwn45z	207	8	,	,	,
cord-021637-f5wwn45z	207	9	which	which	WDT
cord-021637-f5wwn45z	207	10	after	after	IN
cord-021637-f5wwn45z	207	11	40	40	CD
cord-021637-f5wwn45z	207	12	years	year	NNS
cord-021637-f5wwn45z	207	13	still	still	RB
cord-021637-f5wwn45z	207	14	has	have	VBZ
cord-021637-f5wwn45z	207	15	no	no	DT
cord-021637-f5wwn45z	207	16	competition	competition	NN
cord-021637-f5wwn45z	207	17	in	in	IN
cord-021637-f5wwn45z	207	18	the	the	DT
cord-021637-f5wwn45z	207	19	United	United	NNP
cord-021637-f5wwn45z	207	20	States	States	NNP
cord-021637-f5wwn45z	207	21	.	.	.
cord-021637-f5wwn45z	208	1	A	a	DT
cord-021637-f5wwn45z	208	2	typical	typical	JJ
cord-021637-f5wwn45z	208	3	vaccine	vaccine	NN
cord-021637-f5wwn45z	208	4	company	company	NN
cord-021637-f5wwn45z	208	5	will	will	MD
cord-021637-f5wwn45z	208	6	have	have	VB
cord-021637-f5wwn45z	208	7	several	several	JJ
cord-021637-f5wwn45z	208	8	vaccine	vaccine	NN
cord-021637-f5wwn45z	208	9	candidates	candidate	NNS
cord-021637-f5wwn45z	208	10	in	in	IN
cord-021637-f5wwn45z	208	11	early	early	JJ
cord-021637-f5wwn45z	208	12	development	development	NN
cord-021637-f5wwn45z	208	13	,	,	,
cord-021637-f5wwn45z	208	14	defined	define	VBN
cord-021637-f5wwn45z	208	15	as	as	IN
cord-021637-f5wwn45z	208	16	all	all	DT
cord-021637-f5wwn45z	208	17	R&D	r&d	NN
cord-021637-f5wwn45z	208	18	through	through	IN
cord-021637-f5wwn45z	208	19	Phase	phase	NN
cord-021637-f5wwn45z	208	20	I	-PRON-	PRP
cord-021637-f5wwn45z	208	21	clinical	clinical	JJ
cord-021637-f5wwn45z	208	22	testing	testing	NN
cord-021637-f5wwn45z	208	23	(	(	-LRB-
cord-021637-f5wwn45z	208	24	Table	table	NN
cord-021637-f5wwn45z	208	25	4	4	CD
cord-021637-f5wwn45z	208	26	.6	.6	CD
cord-021637-f5wwn45z	208	27	)	)	-RRB-
cord-021637-f5wwn45z	208	28	.	.	.
cord-021637-f5wwn45z	209	1	[	[	-LRB-
cord-021637-f5wwn45z	209	2	14	14	CD
cord-021637-f5wwn45z	209	3	]	]	-RRB-
cord-021637-f5wwn45z	209	4	[	[	-LRB-
cord-021637-f5wwn45z	209	5	15	15	CD
cord-021637-f5wwn45z	209	6	]	]	-RRB-
cord-021637-f5wwn45z	209	7	[	[	-LRB-
cord-021637-f5wwn45z	209	8	16	16	CD
cord-021637-f5wwn45z	209	9	]	]	-RRB-
cord-021637-f5wwn45z	210	1	[	[	-LRB-
cord-021637-f5wwn45z	210	2	17	17	CD
cord-021637-f5wwn45z	210	3	]	]	-RRB-
cord-021637-f5wwn45z	211	1	Those	those	DT
cord-021637-f5wwn45z	211	2	that	that	WDT
cord-021637-f5wwn45z	211	3	are	be	VBP
cord-021637-f5wwn45z	211	4	most	most	RBS
cord-021637-f5wwn45z	211	5	promising	promising	JJ
cord-021637-f5wwn45z	211	6	Tuberculosis	tuberculosis	NN
cord-021637-f5wwn45z	211	7	productivity	productivity	NN
cord-021637-f5wwn45z	211	8	estimated	estimate	VBN
cord-021637-f5wwn45z	211	9	at	at	IN
cord-021637-f5wwn45z	211	10	10-to	10-to	CD
cord-021637-f5wwn45z	211	11	20-fold	20-fold	CD
cord-021637-f5wwn45z	211	12	higher	high	JJR
cord-021637-f5wwn45z	211	13	than	than	IN
cord-021637-f5wwn45z	211	14	the	the	DT
cord-021637-f5wwn45z	211	15	measles	measle	NNS
cord-021637-f5wwn45z	211	16	vaccines	vaccine	NNS
cord-021637-f5wwn45z	211	17	made	make	VBN
cord-021637-f5wwn45z	211	18	by	by	IN
cord-021637-f5wwn45z	211	19	Merck	Merck	NNP
cord-021637-f5wwn45z	211	20	and	and	CC
cord-021637-f5wwn45z	211	21	GlaxoSmithKline	GlaxoSmithKline	NNP
cord-021637-f5wwn45z	211	22	.	.	.
cord-021637-f5wwn45z	212	1	This	this	DT
cord-021637-f5wwn45z	212	2	privately	privately	RB
cord-021637-f5wwn45z	212	3	held	hold	VBN
cord-021637-f5wwn45z	212	4	vaccine	vaccine	NN
cord-021637-f5wwn45z	212	5	company	company	NN
cord-021637-f5wwn45z	212	6	has	have	VBZ
cord-021637-f5wwn45z	212	7	relentlessly	relentlessly	RB
cord-021637-f5wwn45z	212	8	invested	invest	VBN
cord-021637-f5wwn45z	212	9	in	in	IN
cord-021637-f5wwn45z	212	10	production	production	NN
cord-021637-f5wwn45z	212	11	facilities	facility	NNS
cord-021637-f5wwn45z	212	12	/	/	SYM
cord-021637-f5wwn45z	212	13	infrastructure	infrastructure	NN
cord-021637-f5wwn45z	212	14	that	that	WDT
cord-021637-f5wwn45z	212	15	surpasses	surpass	VBZ
cord-021637-f5wwn45z	212	16	some	some	DT
cord-021637-f5wwn45z	212	17	of	of	IN
cord-021637-f5wwn45z	212	18	the	the	DT
cord-021637-f5wwn45z	212	19	best	good	JJS
cord-021637-f5wwn45z	212	20	biotech	biotech	JJ
cord-021637-f5wwn45z	212	21	manufacturing	manufacturing	NN
cord-021637-f5wwn45z	212	22	facilities	facility	NNS
cord-021637-f5wwn45z	212	23	in	in	IN
cord-021637-f5wwn45z	212	24	the	the	DT
cord-021637-f5wwn45z	212	25	United	United	NNP
cord-021637-f5wwn45z	212	26	States	States	NNP
cord-021637-f5wwn45z	212	27	.	.	.
cord-021637-f5wwn45z	213	1	So	so	RB
cord-021637-f5wwn45z	213	2	powerful	powerful	JJ
cord-021637-f5wwn45z	213	3	has	have	VBZ
cord-021637-f5wwn45z	213	4	its	-PRON-	PRP$
cord-021637-f5wwn45z	213	5	growth	growth	NN
cord-021637-f5wwn45z	213	6	been	be	VBN
cord-021637-f5wwn45z	213	7	that	that	IN
cord-021637-f5wwn45z	213	8	one	one	CD
cord-021637-f5wwn45z	213	9	out	out	IN
cord-021637-f5wwn45z	213	10	of	of	IN
cord-021637-f5wwn45z	213	11	every	every	DT
cord-021637-f5wwn45z	213	12	two	two	CD
cord-021637-f5wwn45z	213	13	children	child	NNS
cord-021637-f5wwn45z	213	14	immunized	immunize	VBN
cord-021637-f5wwn45z	213	15	worldwide	worldwide	RB
cord-021637-f5wwn45z	213	16	get	get	VBP
cord-021637-f5wwn45z	213	17	at	at	RB
cord-021637-f5wwn45z	213	18	least	least	RBS
cord-021637-f5wwn45z	213	19	one	one	CD
cord-021637-f5wwn45z	213	20	vaccine	vaccine	NN
cord-021637-f5wwn45z	213	21	produced	produce	VBN
cord-021637-f5wwn45z	213	22	by	by	IN
cord-021637-f5wwn45z	213	23	the	the	DT
cord-021637-f5wwn45z	213	24	Serum	Serum	NNP
cord-021637-f5wwn45z	213	25	Institute	Institute	NNP
cord-021637-f5wwn45z	213	26	.	.	.
cord-021637-f5wwn45z	214	1	Vaccines	vaccine	NNS
cord-021637-f5wwn45z	214	2	recently	recently	RB
cord-021637-f5wwn45z	214	3	developed	develop	VBN
cord-021637-f5wwn45z	214	4	by	by	IN
cord-021637-f5wwn45z	214	5	the	the	DT
cord-021637-f5wwn45z	214	6	Serum	Serum	NNP
cord-021637-f5wwn45z	214	7	Institute	Institute	NNP
cord-021637-f5wwn45z	214	8	are	be	VBP
cord-021637-f5wwn45z	214	9	Nasovac	Nasovac	NNP
cord-021637-f5wwn45z	214	10	(	(	-LRB-
cord-021637-f5wwn45z	214	11	live	live	JJ
cord-021637-f5wwn45z	214	12	attenuated	attenuated	JJ
cord-021637-f5wwn45z	214	13	trivalent	trivalent	JJ
cord-021637-f5wwn45z	214	14	influenza	influenza	NN
cord-021637-f5wwn45z	214	15	vaccine	vaccine	NN
cord-021637-f5wwn45z	214	16	)	)	-RRB-
cord-021637-f5wwn45z	214	17	,	,	,
cord-021637-f5wwn45z	214	18	MenAf	MenAf	NNP
cord-021637-f5wwn45z	214	19	-	-	HYPH
cord-021637-f5wwn45z	214	20	riVac	riVac	NNP
cord-021637-f5wwn45z	214	21	(	(	-LRB-
cord-021637-f5wwn45z	214	22	meningococcal	meningococcal	JJ
cord-021637-f5wwn45z	214	23	A	a	DT
cord-021637-f5wwn45z	214	24	conjugate	conjugate	JJ
cord-021637-f5wwn45z	214	25	vaccine	vaccine	NN
cord-021637-f5wwn45z	214	26	)	)	-RRB-
cord-021637-f5wwn45z	214	27	,	,	,
cord-021637-f5wwn45z	214	28	Pentavac	Pentavac	NNP
cord-021637-f5wwn45z	214	29	(	(	-LRB-
cord-021637-f5wwn45z	214	30	DTP	DTP	NNP
cord-021637-f5wwn45z	214	31	Hepatitis	Hepatitis	NNP
cord-021637-f5wwn45z	214	32	B	B	NNP
cord-021637-f5wwn45z	214	33	-	-	HYPH
cord-021637-f5wwn45z	214	34	Hib	Hib	NNP
cord-021637-f5wwn45z	214	35	vaccine	vaccine	NN
cord-021637-f5wwn45z	214	36	)	)	-RRB-
cord-021637-f5wwn45z	214	37	,	,	,
cord-021637-f5wwn45z	214	38	and	and	CC
cord-021637-f5wwn45z	214	39	inactivated	inactivate	VBN
cord-021637-f5wwn45z	214	40	polio	polio	NN
cord-021637-f5wwn45z	214	41	vaccine	vaccine	NN
cord-021637-f5wwn45z	214	42	.	.	.
cord-021637-f5wwn45z	215	1	The	the	DT
cord-021637-f5wwn45z	215	2	Institute	Institute	NNP
cord-021637-f5wwn45z	215	3	continues	continue	VBZ
cord-021637-f5wwn45z	215	4	to	to	TO
cord-021637-f5wwn45z	215	5	invest	invest	VB
cord-021637-f5wwn45z	215	6	in	in	IN
cord-021637-f5wwn45z	215	7	R&D	r&d	NN
cord-021637-f5wwn45z	215	8	and	and	CC
cord-021637-f5wwn45z	215	9	is	be	VBZ
cord-021637-f5wwn45z	215	10	currently	currently	RB
cord-021637-f5wwn45z	215	11	working	work	VBG
cord-021637-f5wwn45z	215	12	on	on	IN
cord-021637-f5wwn45z	215	13	a	a	DT
cord-021637-f5wwn45z	215	14	rotavirus	rotavirus	JJ
cord-021637-f5wwn45z	215	15	vaccine	vaccine	NN
cord-021637-f5wwn45z	215	16	,	,	,
cord-021637-f5wwn45z	215	17	a	a	DT
cord-021637-f5wwn45z	215	18	polyvalent	polyvalent	JJ
cord-021637-f5wwn45z	215	19	meningococcal	meningococcal	JJ
cord-021637-f5wwn45z	215	20	conjugate	conjugate	JJ
cord-021637-f5wwn45z	215	21	vaccine	vaccine	NN
cord-021637-f5wwn45z	215	22	,	,	,
cord-021637-f5wwn45z	215	23	a	a	DT
cord-021637-f5wwn45z	215	24	pneumococcal	pneumococcal	JJ
cord-021637-f5wwn45z	215	25	conjugate	conjugate	NN
cord-021637-f5wwn45z	215	26	vaccine	vaccine	NN
cord-021637-f5wwn45z	215	27	,	,	,
cord-021637-f5wwn45z	215	28	and	and	CC
cord-021637-f5wwn45z	215	29	HPV	HPV	NNP
cord-021637-f5wwn45z	215	30	Vaccine	Vaccine	NNP
cord-021637-f5wwn45z	215	31	,	,	,
cord-021637-f5wwn45z	215	32	combination	combination	NN
cord-021637-f5wwn45z	215	33	vaccines	vaccine	NNS
cord-021637-f5wwn45z	215	34	containing	contain	VBG
cord-021637-f5wwn45z	215	35	acellular	acellular	JJ
cord-021637-f5wwn45z	215	36	pertussis	pertussis	NN
cord-021637-f5wwn45z	215	37	,	,	,
cord-021637-f5wwn45z	215	38	and	and	CC
cord-021637-f5wwn45z	215	39	others	other	NNS
cord-021637-f5wwn45z	215	40	.	.	.
cord-021637-f5wwn45z	216	1	China	China	NNP
cord-021637-f5wwn45z	216	2	ranks	rank	VBZ
cord-021637-f5wwn45z	216	3	as	as	IN
cord-021637-f5wwn45z	216	4	the	the	DT
cord-021637-f5wwn45z	216	5	world	world	NN
cord-021637-f5wwn45z	216	6	's	's	POS
cord-021637-f5wwn45z	216	7	largest	large	JJS
cord-021637-f5wwn45z	216	8	vaccine	vaccine	NN
cord-021637-f5wwn45z	216	9	consuming	consume	VBG
cord-021637-f5wwn45z	216	10	and	and	CC
cord-021637-f5wwn45z	216	11	manufacturing	manufacture	VBG
cord-021637-f5wwn45z	216	12	country	country	NN
cord-021637-f5wwn45z	216	13	,	,	,
cord-021637-f5wwn45z	216	14	with	with	IN
cord-021637-f5wwn45z	216	15	an	an	DT
cord-021637-f5wwn45z	216	16	estimated	estimate	VBN
cord-021637-f5wwn45z	216	17	annual	annual	JJ
cord-021637-f5wwn45z	216	18	output	output	NN
cord-021637-f5wwn45z	216	19	of	of	IN
cord-021637-f5wwn45z	216	20	1	1	CD
cord-021637-f5wwn45z	216	21	billion	billion	CD
cord-021637-f5wwn45z	216	22	doses	dose	NNS
cord-021637-f5wwn45z	216	23	.	.	.
cord-021637-f5wwn45z	217	1	21	21	CD
cord-021637-f5wwn45z	218	1	The	the	DT
cord-021637-f5wwn45z	218	2	original	original	JJ
cord-021637-f5wwn45z	218	3	six	six	CD
cord-021637-f5wwn45z	218	4	government	government	NN
cord-021637-f5wwn45z	218	5	-	-	HYPH
cord-021637-f5wwn45z	218	6	owned	own	VBN
cord-021637-f5wwn45z	218	7	regional	regional	JJ
cord-021637-f5wwn45z	218	8	biological	biological	JJ
cord-021637-f5wwn45z	218	9	institutes	institute	NNS
cord-021637-f5wwn45z	218	10	are	be	VBP
cord-021637-f5wwn45z	218	11	now	now	RB
cord-021637-f5wwn45z	218	12	part	part	NN
cord-021637-f5wwn45z	218	13	of	of	IN
cord-021637-f5wwn45z	218	14	the	the	DT
cord-021637-f5wwn45z	218	15	China	China	NNP
cord-021637-f5wwn45z	218	16	National	National	NNP
cord-021637-f5wwn45z	218	17	Biotec	Biotec	NNP
cord-021637-f5wwn45z	218	18	Group	Group	NNP
cord-021637-f5wwn45z	218	19	(	(	-LRB-
cord-021637-f5wwn45z	218	20	CNBG	CNBG	NNP
cord-021637-f5wwn45z	218	21	)	)	-RRB-
cord-021637-f5wwn45z	218	22	consolidated	consolidate	VBN
cord-021637-f5wwn45z	218	23	under	under	IN
cord-021637-f5wwn45z	218	24	the	the	DT
cord-021637-f5wwn45z	218	25	China	China	NNP
cord-021637-f5wwn45z	218	26	National	National	NNP
cord-021637-f5wwn45z	218	27	Pharmaceutical	Pharmaceutical	NNP
cord-021637-f5wwn45z	218	28	Group	Group	NNP
cord-021637-f5wwn45z	218	29	Corporation	Corporation	NNP
cord-021637-f5wwn45z	219	1	(	(	-LRB-
cord-021637-f5wwn45z	219	2	Sinopharm	Sinopharm	NNP
cord-021637-f5wwn45z	219	3	Group	Group	NNP
cord-021637-f5wwn45z	219	4	Co.	Co.	NNP
cord-021637-f5wwn45z	219	5	,	,	,
cord-021637-f5wwn45z	219	6	Ltd.	Ltd.	NNP
cord-021637-f5wwn45z	219	7	)	)	-RRB-
cord-021637-f5wwn45z	219	8	.	.	.
cord-021637-f5wwn45z	220	1	CNBG	CNBG	NNP
cord-021637-f5wwn45z	220	2	has	have	VBZ
cord-021637-f5wwn45z	220	3	a	a	DT
cord-021637-f5wwn45z	220	4	large	large	JJ
cord-021637-f5wwn45z	220	5	R&D	r&d	NN
cord-021637-f5wwn45z	220	6	center	center	NN
cord-021637-f5wwn45z	220	7	in	in	IN
cord-021637-f5wwn45z	220	8	Beijing	Beijing	NNP
cord-021637-f5wwn45z	220	9	that	that	WDT
cord-021637-f5wwn45z	220	10	maximizes	maximize	VBZ
cord-021637-f5wwn45z	220	11	the	the	DT
cord-021637-f5wwn45z	220	12	synergies	synergy	NNS
cord-021637-f5wwn45z	220	13	of	of	IN
cord-021637-f5wwn45z	220	14	the	the	DT
cord-021637-f5wwn45z	220	15	six	six	CD
cord-021637-f5wwn45z	220	16	affiliated	affiliate	VBN
cord-021637-f5wwn45z	220	17	institutions	institution	NNS
cord-021637-f5wwn45z	220	18	.	.	.
cord-021637-f5wwn45z	221	1	Today	today	NN
cord-021637-f5wwn45z	221	2	,	,	,
cord-021637-f5wwn45z	221	3	CNBG/	CNBG/	NNP
cord-021637-f5wwn45z	221	4	Sinopharm	Sinopharm	NNP
cord-021637-f5wwn45z	221	5	supplies	supply	VBZ
cord-021637-f5wwn45z	221	6	85	85	CD
cord-021637-f5wwn45z	221	7	%	%	NN
cord-021637-f5wwn45z	221	8	of	of	IN
cord-021637-f5wwn45z	221	9	the	the	DT
cord-021637-f5wwn45z	221	10	doses	dose	NNS
cord-021637-f5wwn45z	221	11	of	of	IN
cord-021637-f5wwn45z	221	12	the	the	DT
cord-021637-f5wwn45z	221	13	14	14	CD
cord-021637-f5wwn45z	221	14	Chinese	Chinese	NNP
cord-021637-f5wwn45z	221	15	National	National	NNP
cord-021637-f5wwn45z	221	16	Immunization	Immunization	NNP
cord-021637-f5wwn45z	221	17	Program	Program	NNP
cord-021637-f5wwn45z	221	18	vaccines	vaccine	NNS
cord-021637-f5wwn45z	221	19	.	.	.
cord-021637-f5wwn45z	222	1	China	China	NNP
cord-021637-f5wwn45z	222	2	's	's	POS
cord-021637-f5wwn45z	222	3	vaccine	vaccine	NN
cord-021637-f5wwn45z	222	4	manufacturing	manufacturing	NN
cord-021637-f5wwn45z	222	5	capabilities	capability	NNS
cord-021637-f5wwn45z	222	6	are	be	VBP
cord-021637-f5wwn45z	222	7	currently	currently	RB
cord-021637-f5wwn45z	222	8	intensely	intensely	RB
cord-021637-f5wwn45z	222	9	focused	focused	JJ
cord-021637-f5wwn45z	222	10	on	on	IN
cord-021637-f5wwn45z	222	11	supplying	supply	VBG
cord-021637-f5wwn45z	222	12	their	-PRON-	PRP$
cord-021637-f5wwn45z	222	13	own	own	JJ
cord-021637-f5wwn45z	222	14	domestic	domestic	JJ
cord-021637-f5wwn45z	222	15	needs	need	NNS
cord-021637-f5wwn45z	222	16	for	for	IN
cord-021637-f5wwn45z	222	17	the	the	DT
cord-021637-f5wwn45z	222	18	pediatric	pediatric	JJ
cord-021637-f5wwn45z	222	19	birth	birth	NN
cord-021637-f5wwn45z	222	20	cohort	cohort	NN
cord-021637-f5wwn45z	222	21	of	of	IN
cord-021637-f5wwn45z	222	22	17	17	CD
cord-021637-f5wwn45z	222	23	million	million	CD
cord-021637-f5wwn45z	222	24	newborns	newborn	NNS
cord-021637-f5wwn45z	222	25	annually	annually	RB
cord-021637-f5wwn45z	222	26	.	.	.
cord-021637-f5wwn45z	223	1	There	there	EX
cord-021637-f5wwn45z	223	2	are	be	VBP
cord-021637-f5wwn45z	223	3	46	46	CD
cord-021637-f5wwn45z	223	4	registered	register	VBN
cord-021637-f5wwn45z	223	5	vaccine	vaccine	NN
cord-021637-f5wwn45z	223	6	manufacturers	manufacturer	NNS
cord-021637-f5wwn45z	223	7	in	in	IN
cord-021637-f5wwn45z	223	8	China	China	NNP
cord-021637-f5wwn45z	223	9	and	and	CC
cord-021637-f5wwn45z	223	10	24	24	CD
cord-021637-f5wwn45z	223	11	licensed	license	VBN
cord-021637-f5wwn45z	223	12	vaccines	vaccine	NNS
cord-021637-f5wwn45z	223	13	.	.	.
cord-021637-f5wwn45z	224	1	Several	several	JJ
cord-021637-f5wwn45z	224	2	of	of	IN
cord-021637-f5wwn45z	224	3	the	the	DT
cord-021637-f5wwn45z	224	4	manufacturers	manufacturer	NNS
cord-021637-f5wwn45z	224	5	are	be	VBP
cord-021637-f5wwn45z	224	6	members	member	NNS
cord-021637-f5wwn45z	224	7	of	of	IN
cord-021637-f5wwn45z	224	8	the	the	DT
cord-021637-f5wwn45z	224	9	Developing	Developing	NNP
cord-021637-f5wwn45z	224	10	Countries	Countries	NNPS
cord-021637-f5wwn45z	224	11	Vaccine	Vaccine	NNP
cord-021637-f5wwn45z	224	12	Manufacturers	Manufacturers	NNP
cord-021637-f5wwn45z	224	13	'	'	POS
cord-021637-f5wwn45z	224	14	Network	Network	NNP
cord-021637-f5wwn45z	224	15	(	(	-LRB-
cord-021637-f5wwn45z	224	16	DCVMN	DCVMN	NNP
cord-021637-f5wwn45z	224	17	)	)	-RRB-
cord-021637-f5wwn45z	224	18	.	.	.
cord-021637-f5wwn45z	225	1	In	in	IN
cord-021637-f5wwn45z	225	2	2013	2013	CD
cord-021637-f5wwn45z	225	3	,	,	,
cord-021637-f5wwn45z	225	4	the	the	DT
cord-021637-f5wwn45z	225	5	World	World	NNP
cord-021637-f5wwn45z	225	6	Health	Health	NNP
cord-021637-f5wwn45z	225	7	Organization	Organization	NNP
cord-021637-f5wwn45z	225	8	prequalified	prequalifie	VBD
cord-021637-f5wwn45z	225	9	the	the	DT
cord-021637-f5wwn45z	225	10	Chinese	Chinese	NNPS
cord-021637-f5wwn45z	225	11	-	-	HYPH
cord-021637-f5wwn45z	225	12	made	make	VBN
cord-021637-f5wwn45z	225	13	Japanese	japanese	JJ
cord-021637-f5wwn45z	225	14	encephalitis	encephalitis	JJ
cord-021637-f5wwn45z	225	15	virus	virus	NN
cord-021637-f5wwn45z	225	16	vaccine	vaccine	NN
cord-021637-f5wwn45z	225	17	made	make	VBN
cord-021637-f5wwn45z	225	18	by	by	IN
cord-021637-f5wwn45z	225	19	the	the	DT
cord-021637-f5wwn45z	225	20	Chengdu	Chengdu	NNP
cord-021637-f5wwn45z	225	21	Institute	Institute	NNP
cord-021637-f5wwn45z	225	22	for	for	IN
cord-021637-f5wwn45z	225	23	Biological	Biological	NNP
cord-021637-f5wwn45z	225	24	Products	Products	NNPS
cord-021637-f5wwn45z	225	25	in	in	IN
cord-021637-f5wwn45z	225	26	collaboration	collaboration	NN
cord-021637-f5wwn45z	225	27	with	with	IN
cord-021637-f5wwn45z	225	28	PATH	path	NN
cord-021637-f5wwn45z	225	29	.	.	.
cord-021637-f5wwn45z	226	1	22	22	CD
cord-021637-f5wwn45z	227	1	China	China	NNP
cord-021637-f5wwn45z	227	2	became	become	VBD
cord-021637-f5wwn45z	227	3	the	the	DT
cord-021637-f5wwn45z	227	4	first	first	JJ
cord-021637-f5wwn45z	227	5	country	country	NN
cord-021637-f5wwn45z	227	6	ever	ever	RB
cord-021637-f5wwn45z	227	7	a	a	DT
cord-021637-f5wwn45z	227	8	year	year	NN
cord-021637-f5wwn45z	227	9	;	;	:
cord-021637-f5wwn45z	227	10	its	-PRON-	PRP$
cord-021637-f5wwn45z	227	11	products	product	NNS
cord-021637-f5wwn45z	227	12	are	be	VBP
cord-021637-f5wwn45z	227	13	used	use	VBN
cord-021637-f5wwn45z	227	14	in	in	IN
cord-021637-f5wwn45z	227	15	more	more	JJR
cord-021637-f5wwn45z	227	16	than	than	IN
cord-021637-f5wwn45z	227	17	140	140	CD
cord-021637-f5wwn45z	227	18	countries	country	NNS
cord-021637-f5wwn45z	227	19	.	.	.
cord-021637-f5wwn45z	228	1	Serum	Serum	NNP
cord-021637-f5wwn45z	228	2	Institute	Institute	NNP
cord-021637-f5wwn45z	228	3	is	be	VBZ
cord-021637-f5wwn45z	228	4	also	also	RB
cord-021637-f5wwn45z	228	5	one	one	CD
cord-021637-f5wwn45z	228	6	of	of	IN
cord-021637-f5wwn45z	228	7	the	the	DT
cord-021637-f5wwn45z	228	8	largest	large	JJS
cord-021637-f5wwn45z	228	9	suppliers	supplier	NNS
cord-021637-f5wwn45z	228	10	of	of	IN
cord-021637-f5wwn45z	228	11	measlescontaining	measlescontaine	VBG
cord-021637-f5wwn45z	228	12	vaccines	vaccine	NNS
cord-021637-f5wwn45z	228	13	and	and	CC
cord-021637-f5wwn45z	228	14	the	the	DT
cord-021637-f5wwn45z	228	15	diphtheria	diphtheria	NN
cord-021637-f5wwn45z	228	16	-	-	HYPH
cord-021637-f5wwn45z	228	17	tetanus	tetanus	NN
cord-021637-f5wwn45z	228	18	-	-	HYPH
cord-021637-f5wwn45z	228	19	pertussis	pertussis	NN
cord-021637-f5wwn45z	228	20	(	(	-LRB-
cord-021637-f5wwn45z	228	21	DTP	DTP	NNP
cord-021637-f5wwn45z	228	22	)	)	-RRB-
cord-021637-f5wwn45z	228	23	vaccines	vaccine	NNS
cord-021637-f5wwn45z	228	24	to	to	IN
cord-021637-f5wwn45z	228	25	U.N.	U.N.	NNP
cord-021637-f5wwn45z	228	26	agencies	agency	NNS
cord-021637-f5wwn45z	228	27	(	(	-LRB-
cord-021637-f5wwn45z	228	28	UNICEF	UNICEF	NNP
cord-021637-f5wwn45z	228	29	and	and	CC
cord-021637-f5wwn45z	228	30	Pan	Pan	NNP
cord-021637-f5wwn45z	228	31	American	American	NNP
cord-021637-f5wwn45z	228	32	Health	Health	NNP
cord-021637-f5wwn45z	228	33	Organization	Organization	NNP
cord-021637-f5wwn45z	228	34	[	[	-LRB-
cord-021637-f5wwn45z	228	35	PAHO	PAHO	NNP
cord-021637-f5wwn45z	228	36	]	]	-RRB-
cord-021637-f5wwn45z	228	37	)	)	-RRB-
cord-021637-f5wwn45z	228	38	.	.	.
cord-021637-f5wwn45z	229	1	The	the	DT
cord-021637-f5wwn45z	229	2	Institute	Institute	NNP
cord-021637-f5wwn45z	229	3	makes	make	VBZ
cord-021637-f5wwn45z	229	4	its	-PRON-	PRP$
cord-021637-f5wwn45z	229	5	measles	measles	NN
cord-021637-f5wwn45z	229	6	vaccine	vaccine	NN
cord-021637-f5wwn45z	229	7	in	in	IN
cord-021637-f5wwn45z	229	8	MRC-5	MRC-5	NNP
cord-021637-f5wwn45z	229	9	cells	cell	NNS
cord-021637-f5wwn45z	229	10	instead	instead	RB
cord-021637-f5wwn45z	229	11	of	of	IN
cord-021637-f5wwn45z	229	12	chick	chick	NN
cord-021637-f5wwn45z	229	13	embryos	embryo	NNS
cord-021637-f5wwn45z	229	14	and	and	CC
cord-021637-f5wwn45z	229	15	has	have	VBZ
cord-021637-f5wwn45z	229	16	Although	although	IN
cord-021637-f5wwn45z	229	17	the	the	DT
cord-021637-f5wwn45z	229	18	first	first	JJ
cord-021637-f5wwn45z	229	19	two	two	CD
cord-021637-f5wwn45z	229	20	of	of	IN
cord-021637-f5wwn45z	229	21	these	these	DT
cord-021637-f5wwn45z	229	22	factors	factor	NNS
cord-021637-f5wwn45z	229	23	have	have	VBP
cord-021637-f5wwn45z	229	24	been	be	VBN
cord-021637-f5wwn45z	229	25	consistently	consistently	RB
cord-021637-f5wwn45z	229	26	present	present	JJ
cord-021637-f5wwn45z	229	27	in	in	IN
cord-021637-f5wwn45z	229	28	recent	recent	JJ
cord-021637-f5wwn45z	229	29	years	year	NNS
cord-021637-f5wwn45z	229	30	,	,	,
cord-021637-f5wwn45z	229	31	downward	downward	JJ
cord-021637-f5wwn45z	229	32	pressure	pressure	NN
cord-021637-f5wwn45z	229	33	on	on	IN
cord-021637-f5wwn45z	229	34	price	price	NN
cord-021637-f5wwn45z	229	35	is	be	VBZ
cord-021637-f5wwn45z	229	36	a	a	DT
cord-021637-f5wwn45z	229	37	major	major	JJ
cord-021637-f5wwn45z	229	38	threat	threat	NN
cord-021637-f5wwn45z	229	39	to	to	IN
cord-021637-f5wwn45z	229	40	current	current	JJ
cord-021637-f5wwn45z	229	41	companies	company	NNS
cord-021637-f5wwn45z	229	42	and	and	CC
cord-021637-f5wwn45z	229	43	a	a	DT
cord-021637-f5wwn45z	229	44	disincentive	disincentive	NN
cord-021637-f5wwn45z	229	45	to	to	IN
cord-021637-f5wwn45z	229	46	new	new	JJ
cord-021637-f5wwn45z	229	47	companies	company	NNS
cord-021637-f5wwn45z	229	48	.	.	.
cord-021637-f5wwn45z	230	1	Freedom	freedom	NN
cord-021637-f5wwn45z	230	2	to	to	TO
cord-021637-f5wwn45z	230	3	price	price	NN
cord-021637-f5wwn45z	230	4	vaccines	vaccine	NNS
cord-021637-f5wwn45z	230	5	is	be	VBZ
cord-021637-f5wwn45z	230	6	restricted	restrict	VBN
cord-021637-f5wwn45z	230	7	to	to	IN
cord-021637-f5wwn45z	230	8	the	the	DT
cord-021637-f5wwn45z	230	9	private	private	JJ
cord-021637-f5wwn45z	230	10	market	market	NN
cord-021637-f5wwn45z	230	11	.	.	.
cord-021637-f5wwn45z	231	1	Less	Less	JJR
cord-021637-f5wwn45z	231	2	than	than	IN
cord-021637-f5wwn45z	231	3	50	50	CD
cord-021637-f5wwn45z	231	4	%	%	NN
cord-021637-f5wwn45z	231	5	of	of	IN
cord-021637-f5wwn45z	231	6	the	the	DT
cord-021637-f5wwn45z	231	7	vaccines	vaccine	NNS
cord-021637-f5wwn45z	231	8	for	for	IN
cord-021637-f5wwn45z	231	9	children	child	NNS
cord-021637-f5wwn45z	231	10	sold	sell	VBN
cord-021637-f5wwn45z	231	11	in	in	IN
cord-021637-f5wwn45z	231	12	the	the	DT
cord-021637-f5wwn45z	231	13	United	United	NNP
cord-021637-f5wwn45z	231	14	States	States	NNP
cord-021637-f5wwn45z	231	15	are	be	VBP
cord-021637-f5wwn45z	231	16	sold	sell	VBN
cord-021637-f5wwn45z	231	17	in	in	IN
cord-021637-f5wwn45z	231	18	the	the	DT
cord-021637-f5wwn45z	231	19	private	private	JJ
cord-021637-f5wwn45z	231	20	market	market	NN
cord-021637-f5wwn45z	231	21	;	;	:
cord-021637-f5wwn45z	231	22	the	the	DT
cord-021637-f5wwn45z	231	23	rest	rest	NN
cord-021637-f5wwn45z	231	24	are	be	VBP
cord-021637-f5wwn45z	231	25	sold	sell	VBN
cord-021637-f5wwn45z	231	26	to	to	IN
cord-021637-f5wwn45z	231	27	the	the	DT
cord-021637-f5wwn45z	231	28	federal	federal	JJ
cord-021637-f5wwn45z	231	29	or	or	CC
cord-021637-f5wwn45z	231	30	state	state	NN
cord-021637-f5wwn45z	231	31	governments	government	NNS
cord-021637-f5wwn45z	231	32	at	at	IN
cord-021637-f5wwn45z	231	33	reduced	reduced	JJ
cord-021637-f5wwn45z	231	34	prices	price	NNS
cord-021637-f5wwn45z	231	35	.	.	.
cord-021637-f5wwn45z	232	1	Controls	control	NNS
cord-021637-f5wwn45z	232	2	are	be	VBP
cord-021637-f5wwn45z	232	3	even	even	RB
cord-021637-f5wwn45z	232	4	greater	great	JJR
cord-021637-f5wwn45z	232	5	in	in	IN
cord-021637-f5wwn45z	232	6	Western	Western	NNP
cord-021637-f5wwn45z	232	7	Europe	Europe	NNP
cord-021637-f5wwn45z	232	8	and	and	CC
cord-021637-f5wwn45z	232	9	Japan	Japan	NNP
cord-021637-f5wwn45z	232	10	,	,	,
cord-021637-f5wwn45z	232	11	and	and	CC
cord-021637-f5wwn45z	232	12	internationally	internationally	RB
cord-021637-f5wwn45z	232	13	there	there	EX
cord-021637-f5wwn45z	232	14	is	be	VBZ
cord-021637-f5wwn45z	232	15	strong	strong	JJ
cord-021637-f5wwn45z	232	16	downward	downward	JJ
cord-021637-f5wwn45z	232	17	pressure	pressure	NN
cord-021637-f5wwn45z	232	18	on	on	IN
cord-021637-f5wwn45z	232	19	prices	price	NNS
cord-021637-f5wwn45z	232	20	as	as	IN
cord-021637-f5wwn45z	232	21	one	one	CD
cord-021637-f5wwn45z	232	22	moves	move	NNS
cord-021637-f5wwn45z	232	23	from	from	IN
cord-021637-f5wwn45z	232	24	well	well	RB
cord-021637-f5wwn45z	232	25	-	-	HYPH
cord-021637-f5wwn45z	232	26	developed	develop	VBN
cord-021637-f5wwn45z	232	27	to	to	IN
cord-021637-f5wwn45z	232	28	less	less	RBR
cord-021637-f5wwn45z	232	29	-	-	HYPH
cord-021637-f5wwn45z	232	30	developed	develop	VBN
cord-021637-f5wwn45z	232	31	regions	region	NNS
cord-021637-f5wwn45z	232	32	of	of	IN
cord-021637-f5wwn45z	232	33	the	the	DT
cord-021637-f5wwn45z	232	34	world	world	NN
cord-021637-f5wwn45z	232	35	.	.	.
cord-021637-f5wwn45z	233	1	In	in	IN
cord-021637-f5wwn45z	233	2	addition	addition	NN
cord-021637-f5wwn45z	233	3	to	to	IN
cord-021637-f5wwn45z	233	4	the	the	DT
cord-021637-f5wwn45z	233	5	burden	burden	NN
cord-021637-f5wwn45z	233	6	of	of	IN
cord-021637-f5wwn45z	233	7	partial	partial	JJ
cord-021637-f5wwn45z	233	8	price	price	NN
cord-021637-f5wwn45z	233	9	controls	control	NNS
cord-021637-f5wwn45z	233	10	,	,	,
cord-021637-f5wwn45z	233	11	the	the	DT
cord-021637-f5wwn45z	233	12	vaccine	vaccine	NN
cord-021637-f5wwn45z	233	13	industry	industry	NN
cord-021637-f5wwn45z	233	14	is	be	VBZ
cord-021637-f5wwn45z	233	15	subject	subject	JJ
cord-021637-f5wwn45z	233	16	to	to	IN
cord-021637-f5wwn45z	233	17	intense	intense	JJ
cord-021637-f5wwn45z	233	18	regulation	regulation	NN
cord-021637-f5wwn45z	233	19	.	.	.
cord-021637-f5wwn45z	234	1	It	-PRON-	PRP
cord-021637-f5wwn45z	234	2	can	can	MD
cord-021637-f5wwn45z	234	3	not	not	RB
cord-021637-f5wwn45z	234	4	sell	sell	VB
cord-021637-f5wwn45z	234	5	products	product	NNS
cord-021637-f5wwn45z	234	6	until	until	IN
cord-021637-f5wwn45z	234	7	the	the	DT
cord-021637-f5wwn45z	234	8	vaccine	vaccine	NN
cord-021637-f5wwn45z	234	9	and	and	CC
cord-021637-f5wwn45z	234	10	the	the	DT
cord-021637-f5wwn45z	234	11	facility	facility	NN
cord-021637-f5wwn45z	234	12	in	in	IN
cord-021637-f5wwn45z	234	13	which	which	WDT
cord-021637-f5wwn45z	234	14	it	-PRON-	PRP
cord-021637-f5wwn45z	234	15	is	be	VBZ
cord-021637-f5wwn45z	234	16	manufactured	manufacture	VBN
cord-021637-f5wwn45z	234	17	are	be	VBP
cord-021637-f5wwn45z	234	18	approved	approve	VBN
cord-021637-f5wwn45z	234	19	by	by	IN
cord-021637-f5wwn45z	234	20	the	the	DT
cord-021637-f5wwn45z	234	21	FDA	FDA	NNP
cord-021637-f5wwn45z	234	22	or	or	CC
cord-021637-f5wwn45z	234	23	other	other	JJ
cord-021637-f5wwn45z	234	24	regulatory	regulatory	JJ
cord-021637-f5wwn45z	234	25	authorities	authority	NNS
cord-021637-f5wwn45z	234	26	;	;	:
cord-021637-f5wwn45z	234	27	each	each	DT
cord-021637-f5wwn45z	234	28	batch	batch	NN
cord-021637-f5wwn45z	234	29	must	must	MD
cord-021637-f5wwn45z	234	30	be	be	VB
cord-021637-f5wwn45z	234	31	released	release	VBN
cord-021637-f5wwn45z	234	32	by	by	IN
cord-021637-f5wwn45z	234	33	the	the	DT
cord-021637-f5wwn45z	234	34	appropriate	appropriate	JJ
cord-021637-f5wwn45z	234	35	regulatory	regulatory	JJ
cord-021637-f5wwn45z	234	36	agency	agency	NN
cord-021637-f5wwn45z	234	37	;	;	:
cord-021637-f5wwn45z	234	38	and	and	CC
cord-021637-f5wwn45z	234	39	the	the	DT
cord-021637-f5wwn45z	234	40	usage	usage	NN
cord-021637-f5wwn45z	234	41	,	,	,
cord-021637-f5wwn45z	234	42	and	and	CC
cord-021637-f5wwn45z	234	43	therefore	therefore	RB
cord-021637-f5wwn45z	234	44	market	market	NN
cord-021637-f5wwn45z	234	45	size	size	NN
cord-021637-f5wwn45z	234	46	,	,	,
cord-021637-f5wwn45z	234	47	is	be	VBZ
cord-021637-f5wwn45z	234	48	largely	largely	RB
cord-021637-f5wwn45z	234	49	determined	determine	VBN
cord-021637-f5wwn45z	234	50	in	in	IN
cord-021637-f5wwn45z	234	51	the	the	DT
cord-021637-f5wwn45z	234	52	United	United	NNP
cord-021637-f5wwn45z	234	53	States	States	NNP
cord-021637-f5wwn45z	234	54	by	by	IN
cord-021637-f5wwn45z	234	55	the	the	DT
cord-021637-f5wwn45z	234	56	CDC	CDC	NNP
cord-021637-f5wwn45z	234	57	and	and	CC
cord-021637-f5wwn45z	234	58	in	in	IN
cord-021637-f5wwn45z	234	59	Europe	Europe	NNP
cord-021637-f5wwn45z	234	60	by	by	IN
cord-021637-f5wwn45z	234	61	national	national	JJ
cord-021637-f5wwn45z	234	62	regulatory	regulatory	JJ
cord-021637-f5wwn45z	234	63	authorities	authority	NNS
cord-021637-f5wwn45z	234	64	.	.	.
cord-021637-f5wwn45z	235	1	Thus	thus	RB
cord-021637-f5wwn45z	235	2	,	,	,
cord-021637-f5wwn45z	235	3	the	the	DT
cord-021637-f5wwn45z	235	4	vaccine	vaccine	NN
cord-021637-f5wwn45z	235	5	industry	industry	NN
cord-021637-f5wwn45z	235	6	does	do	VBZ
cord-021637-f5wwn45z	235	7	not	not	RB
cord-021637-f5wwn45z	235	8	operate	operate	VB
cord-021637-f5wwn45z	235	9	in	in	IN
cord-021637-f5wwn45z	235	10	a	a	DT
cord-021637-f5wwn45z	235	11	free	free	JJ
cord-021637-f5wwn45z	235	12	-	-	HYPH
cord-021637-f5wwn45z	235	13	market	market	NN
cord-021637-f5wwn45z	235	14	environment	environment	NN
cord-021637-f5wwn45z	235	15	,	,	,
cord-021637-f5wwn45z	235	16	and	and	CC
cord-021637-f5wwn45z	235	17	its	-PRON-	PRP$
cord-021637-f5wwn45z	235	18	behavior	behavior	NN
cord-021637-f5wwn45z	235	19	reflects	reflect	VBZ
cord-021637-f5wwn45z	235	20	these	these	DT
cord-021637-f5wwn45z	235	21	constraints	constraint	NNS
cord-021637-f5wwn45z	235	22	.	.	.
cord-021637-f5wwn45z	236	1	Vaccine	vaccine	NN
cord-021637-f5wwn45z	236	2	business	business	NN
cord-021637-f5wwn45z	236	3	growth	growth	NN
cord-021637-f5wwn45z	236	4	in	in	IN
cord-021637-f5wwn45z	236	5	the	the	DT
cord-021637-f5wwn45z	236	6	future	future	NN
cord-021637-f5wwn45z	236	7	will	will	MD
cord-021637-f5wwn45z	236	8	have	have	VB
cord-021637-f5wwn45z	236	9	three	three	CD
cord-021637-f5wwn45z	236	10	important	important	JJ
cord-021637-f5wwn45z	236	11	drivers	driver	NNS
cord-021637-f5wwn45z	236	12	:	:	:
cord-021637-f5wwn45z	236	13	1	1	CD
cord-021637-f5wwn45z	236	14	.	.	.
cord-021637-f5wwn45z	237	1	New	new	JJ
cord-021637-f5wwn45z	237	2	vaccines	vaccine	NNS
cord-021637-f5wwn45z	237	3	for	for	IN
cord-021637-f5wwn45z	237	4	CMV	CMV	NNP
cord-021637-f5wwn45z	237	5	,	,	,
cord-021637-f5wwn45z	237	6	herpes	herpes	NN
cord-021637-f5wwn45z	237	7	simplex	simplex	NN
cord-021637-f5wwn45z	237	8	virus	virus	NN
cord-021637-f5wwn45z	237	9	(	(	-LRB-
cord-021637-f5wwn45z	237	10	HSV	HSV	NNP
cord-021637-f5wwn45z	237	11	)	)	-RRB-
cord-021637-f5wwn45z	237	12	,	,	,
cord-021637-f5wwn45z	237	13	respiratory	respiratory	JJ
cord-021637-f5wwn45z	237	14	syncytial	syncytial	JJ
cord-021637-f5wwn45z	237	15	virus	virus	NN
cord-021637-f5wwn45z	237	16	(	(	-LRB-
cord-021637-f5wwn45z	237	17	RSV	RSV	NNP
cord-021637-f5wwn45z	237	18	)	)	-RRB-
cord-021637-f5wwn45z	237	19	,	,	,
cord-021637-f5wwn45z	237	20	norovirus	norovirus	NN
cord-021637-f5wwn45z	237	21	,	,	,
cord-021637-f5wwn45z	237	22	Clostridium	clostridium	NN
cord-021637-f5wwn45z	237	23	difficile	difficile	NN
cord-021637-f5wwn45z	237	24	,	,	,
cord-021637-f5wwn45z	237	25	enterotoxigenic	enterotoxigenic	NNP
cord-021637-f5wwn45z	237	26	Escherichia	Escherichia	NNP
cord-021637-f5wwn45z	237	27	coli	coli	NNS
cord-021637-f5wwn45z	237	28	(	(	-LRB-
cord-021637-f5wwn45z	237	29	ETEC	ETEC	NNP
cord-021637-f5wwn45z	237	30	)	)	-RRB-
cord-021637-f5wwn45z	237	31	,	,	,
cord-021637-f5wwn45z	237	32	"	"	''
cord-021637-f5wwn45z	237	33	improved	improve	VBN
cord-021637-f5wwn45z	237	34	influenza	influenza	NN
cord-021637-f5wwn45z	237	35	,	,	,
cord-021637-f5wwn45z	237	36	"	"	''
cord-021637-f5wwn45z	237	37	and	and	CC
cord-021637-f5wwn45z	237	38	others	other	NNS
cord-021637-f5wwn45z	237	39	that	that	WDT
cord-021637-f5wwn45z	237	40	will	will	MD
cord-021637-f5wwn45z	237	41	gradually	gradually	RB
cord-021637-f5wwn45z	237	42	shift	shift	VB
cord-021637-f5wwn45z	237	43	the	the	DT
cord-021637-f5wwn45z	237	44	focal	focal	JJ
cord-021637-f5wwn45z	237	45	point	point	NN
cord-021637-f5wwn45z	237	46	of	of	IN
cord-021637-f5wwn45z	237	47	immunization	immunization	NN
cord-021637-f5wwn45z	237	48	activities	activity	NNS
cord-021637-f5wwn45z	237	49	from	from	IN
cord-021637-f5wwn45z	237	50	the	the	DT
cord-021637-f5wwn45z	237	51	pediatric	pediatric	JJ
cord-021637-f5wwn45z	237	52	sector	sector	NN
cord-021637-f5wwn45z	237	53	to	to	IN
cord-021637-f5wwn45z	237	54	the	the	DT
cord-021637-f5wwn45z	237	55	adolescent	adolescent	JJ
cord-021637-f5wwn45z	237	56	and	and	CC
cord-021637-f5wwn45z	237	57	adult	adult	NN
cord-021637-f5wwn45z	237	58	sectors	sector	NNS
cord-021637-f5wwn45z	237	59	.	.	.
cord-021637-f5wwn45z	238	1	2	2	LS
cord-021637-f5wwn45z	238	2	.	.	.
cord-021637-f5wwn45z	239	1	Private	private	JJ
cord-021637-f5wwn45z	239	2	market	market	NN
cord-021637-f5wwn45z	239	3	expansion	expansion	NN
cord-021637-f5wwn45z	239	4	in	in	IN
cord-021637-f5wwn45z	239	5	India	India	NNP
cord-021637-f5wwn45z	239	6	and	and	CC
cord-021637-f5wwn45z	239	7	China	China	NNP
cord-021637-f5wwn45z	239	8	driven	drive	VBN
cord-021637-f5wwn45z	239	9	by	by	IN
cord-021637-f5wwn45z	239	10	"	"	``
cord-021637-f5wwn45z	239	11	high	high	JJ
cord-021637-f5wwn45z	239	12	-	-	HYPH
cord-021637-f5wwn45z	239	13	income	income	NN
cord-021637-f5wwn45z	239	14	family	family	NN
cord-021637-f5wwn45z	239	15	"	"	''
cord-021637-f5wwn45z	239	16	birth	birth	NN
cord-021637-f5wwn45z	239	17	cohorts	cohort	NNS
cord-021637-f5wwn45z	239	18	of	of	IN
cord-021637-f5wwn45z	239	19	2	2	CD
cord-021637-f5wwn45z	239	20	million	million	CD
cord-021637-f5wwn45z	239	21	and	and	CC
cord-021637-f5wwn45z	239	22	6	6	CD
cord-021637-f5wwn45z	239	23	million	million	CD
cord-021637-f5wwn45z	239	24	,	,	,
cord-021637-f5wwn45z	239	25	respectively	respectively	RB
cord-021637-f5wwn45z	239	26	.	.	.
cord-021637-f5wwn45z	240	1	This	this	DT
cord-021637-f5wwn45z	240	2	birth	birth	NN
cord-021637-f5wwn45z	240	3	cohort	cohort	NN
cord-021637-f5wwn45z	240	4	roughly	roughly	RB
cord-021637-f5wwn45z	240	5	equals	equal	VBZ
cord-021637-f5wwn45z	240	6	the	the	DT
cord-021637-f5wwn45z	240	7	combined	combine	VBN
cord-021637-f5wwn45z	240	8	birth	birth	NN
cord-021637-f5wwn45z	240	9	cohort	cohort	NN
cord-021637-f5wwn45z	240	10	of	of	IN
cord-021637-f5wwn45z	240	11	8	8	CD
cord-021637-f5wwn45z	240	12	million	million	CD
cord-021637-f5wwn45z	240	13	in	in	IN
cord-021637-f5wwn45z	240	14	the	the	DT
cord-021637-f5wwn45z	240	15	United	United	NNP
cord-021637-f5wwn45z	240	16	States	States	NNP
cord-021637-f5wwn45z	240	17	and	and	CC
cord-021637-f5wwn45z	240	18	Europe	Europe	NNP
cord-021637-f5wwn45z	240	19	.	.	.
cord-021637-f5wwn45z	241	1	These	these	DT
cord-021637-f5wwn45z	241	2	high	high	JJ
cord-021637-f5wwn45z	241	3	-	-	:
cord-021637-f5wwn45z	241	4	and	and	CC
cord-021637-f5wwn45z	241	5	even	even	RB
cord-021637-f5wwn45z	241	6	middle	middle	JJ
cord-021637-f5wwn45z	241	7	-	-	HYPH
cord-021637-f5wwn45z	241	8	income	income	NN
cord-021637-f5wwn45z	241	9	individuals	individual	NNS
cord-021637-f5wwn45z	241	10	have	have	VBP
cord-021637-f5wwn45z	241	11	shown	show	VBN
cord-021637-f5wwn45z	241	12	the	the	DT
cord-021637-f5wwn45z	241	13	desire	desire	NN
cord-021637-f5wwn45z	241	14	and	and	CC
cord-021637-f5wwn45z	241	15	ability	ability	NN
cord-021637-f5wwn45z	241	16	to	to	TO
cord-021637-f5wwn45z	241	17	pay	pay	VB
cord-021637-f5wwn45z	241	18	for	for	IN
cord-021637-f5wwn45z	241	19	vaccines	vaccine	NNS
cord-021637-f5wwn45z	241	20	at	at	IN
cord-021637-f5wwn45z	241	21	relatively	relatively	RB
cord-021637-f5wwn45z	241	22	high	high	JJ
cord-021637-f5wwn45z	241	23	prices	price	NNS
cord-021637-f5wwn45z	241	24	in	in	IN
cord-021637-f5wwn45z	241	25	relation	relation	NN
cord-021637-f5wwn45z	241	26	to	to	IN
cord-021637-f5wwn45z	241	27	their	-PRON-	PRP$
cord-021637-f5wwn45z	241	28	incomes	income	NNS
cord-021637-f5wwn45z	241	29	in	in	IN
cord-021637-f5wwn45z	241	30	these	these	DT
cord-021637-f5wwn45z	241	31	and	and	CC
cord-021637-f5wwn45z	241	32	other	other	JJ
cord-021637-f5wwn45z	241	33	countries	country	NNS
cord-021637-f5wwn45z	241	34	.	.	.
cord-021637-f5wwn45z	242	1	to	to	TO
cord-021637-f5wwn45z	242	2	approve	approve	VB
cord-021637-f5wwn45z	242	3	a	a	DT
cord-021637-f5wwn45z	242	4	hepatitis	hepatitis	NN
cord-021637-f5wwn45z	242	5	E	e	NN
cord-021637-f5wwn45z	242	6	vaccine	vaccine	NN
cord-021637-f5wwn45z	242	7	,	,	,
cord-021637-f5wwn45z	242	8	which	which	WDT
cord-021637-f5wwn45z	242	9	was	be	VBD
cord-021637-f5wwn45z	242	10	developed	develop	VBN
cord-021637-f5wwn45z	242	11	by	by	IN
cord-021637-f5wwn45z	242	12	Xiamen	Xiamen	NNP
cord-021637-f5wwn45z	242	13	Innovax	Innovax	NNP
cord-021637-f5wwn45z	242	14	Biotech	Biotech	NNP
cord-021637-f5wwn45z	242	15	.	.	.
cord-021637-f5wwn45z	243	1	Brazil	Brazil	NNP
cord-021637-f5wwn45z	243	2	has	have	VBZ
cord-021637-f5wwn45z	243	3	four	four	CD
cord-021637-f5wwn45z	243	4	notable	notable	JJ
cord-021637-f5wwn45z	243	5	vaccine	vaccine	NN
cord-021637-f5wwn45z	243	6	manufacturing	manufacture	VBG
cord-021637-f5wwn45z	243	7	companies	company	NNS
cord-021637-f5wwn45z	243	8	.	.	.
cord-021637-f5wwn45z	244	1	Bio	Bio	NNP
cord-021637-f5wwn45z	244	2	-	-	HYPH
cord-021637-f5wwn45z	244	3	Manguinhos	Manguinhos	NNP
cord-021637-f5wwn45z	244	4	/	/	SYM
cord-021637-f5wwn45z	244	5	Fiocruz	Fiocruz	NNP
cord-021637-f5wwn45z	244	6	is	be	VBZ
cord-021637-f5wwn45z	244	7	a	a	DT
cord-021637-f5wwn45z	244	8	government	government	NN
cord-021637-f5wwn45z	244	9	-	-	HYPH
cord-021637-f5wwn45z	244	10	owned	own	VBN
cord-021637-f5wwn45z	244	11	entity	entity	NN
cord-021637-f5wwn45z	244	12	that	that	WDT
cord-021637-f5wwn45z	244	13	supplies	supply	VBZ
cord-021637-f5wwn45z	244	14	the	the	DT
cord-021637-f5wwn45z	244	15	full	full	JJ
cord-021637-f5wwn45z	244	16	demand	demand	NN
cord-021637-f5wwn45z	244	17	for	for	IN
cord-021637-f5wwn45z	244	18	most	most	JJS
cord-021637-f5wwn45z	244	19	vaccines	vaccine	NNS
cord-021637-f5wwn45z	244	20	under	under	IN
cord-021637-f5wwn45z	244	21	the	the	DT
cord-021637-f5wwn45z	244	22	Brazilian	Brazilian	NNP
cord-021637-f5wwn45z	244	23	National	National	NNP
cord-021637-f5wwn45z	244	24	Immunization	Immunization	NNP
cord-021637-f5wwn45z	244	25	Program	Program	NNP
cord-021637-f5wwn45z	244	26	(	(	-LRB-
cord-021637-f5wwn45z	244	27	NIP	NIP	NNP
cord-021637-f5wwn45z	244	28	)	)	-RRB-
cord-021637-f5wwn45z	244	29	.	.	.
cord-021637-f5wwn45z	245	1	They	-PRON-	PRP
cord-021637-f5wwn45z	245	2	also	also	RB
cord-021637-f5wwn45z	245	3	have	have	VBP
cord-021637-f5wwn45z	245	4	a	a	DT
cord-021637-f5wwn45z	245	5	R&D	r&d	NN
cord-021637-f5wwn45z	245	6	collaboration	collaboration	NN
cord-021637-f5wwn45z	245	7	with	with	IN
cord-021637-f5wwn45z	245	8	GlaxoSmithKline	GlaxoSmithKline	NNP
cord-021637-f5wwn45z	245	9	for	for	IN
cord-021637-f5wwn45z	245	10	a	a	DT
cord-021637-f5wwn45z	245	11	dengue	dengue	NN
cord-021637-f5wwn45z	245	12	vaccine	vaccine	NN
cord-021637-f5wwn45z	245	13	.	.	.
cord-021637-f5wwn45z	246	1	Butantan	Butantan	NNP
cord-021637-f5wwn45z	246	2	Institute	Institute	NNP
cord-021637-f5wwn45z	246	3	is	be	VBZ
cord-021637-f5wwn45z	246	4	another	another	DT
cord-021637-f5wwn45z	246	5	government	government	NN
cord-021637-f5wwn45z	246	6	-	-	HYPH
cord-021637-f5wwn45z	246	7	owned	own	VBN
cord-021637-f5wwn45z	246	8	institution	institution	NN
cord-021637-f5wwn45z	246	9	that	that	WDT
cord-021637-f5wwn45z	246	10	supplies	supply	VBZ
cord-021637-f5wwn45z	246	11	the	the	DT
cord-021637-f5wwn45z	246	12	full	full	JJ
cord-021637-f5wwn45z	246	13	demand	demand	NN
cord-021637-f5wwn45z	246	14	for	for	IN
cord-021637-f5wwn45z	246	15	a	a	DT
cord-021637-f5wwn45z	246	16	smaller	small	JJR
cord-021637-f5wwn45z	246	17	number	number	NN
cord-021637-f5wwn45z	246	18	of	of	IN
cord-021637-f5wwn45z	246	19	vaccines	vaccine	NNS
cord-021637-f5wwn45z	246	20	under	under	IN
cord-021637-f5wwn45z	246	21	the	the	DT
cord-021637-f5wwn45z	246	22	Brazilian	brazilian	JJ
cord-021637-f5wwn45z	246	23	NIP	nip	NN
cord-021637-f5wwn45z	246	24	.	.	.
cord-021637-f5wwn45z	247	1	Ataulfo	Ataulfo	NNP
cord-021637-f5wwn45z	247	2	de	de	NNP
cord-021637-f5wwn45z	247	3	Paiva	Paiva	NNP
cord-021637-f5wwn45z	247	4	Foundation	Foundation	NNP
cord-021637-f5wwn45z	247	5	is	be	VBZ
cord-021637-f5wwn45z	247	6	nonprofit	nonprofit	JJ
cord-021637-f5wwn45z	247	7	private	private	JJ
cord-021637-f5wwn45z	247	8	institution	institution	NN
cord-021637-f5wwn45z	247	9	that	that	WDT
cord-021637-f5wwn45z	247	10	primarily	primarily	RB
cord-021637-f5wwn45z	247	11	supplies	supply	VBZ
cord-021637-f5wwn45z	247	12	the	the	DT
cord-021637-f5wwn45z	247	13	BCG	BCG	NNP
cord-021637-f5wwn45z	247	14	vaccine	vaccine	NN
cord-021637-f5wwn45z	247	15	for	for	IN
cord-021637-f5wwn45z	247	16	the	the	DT
cord-021637-f5wwn45z	247	17	Brazilian	brazilian	JJ
cord-021637-f5wwn45z	247	18	market	market	NN
cord-021637-f5wwn45z	247	19	.	.	.
cord-021637-f5wwn45z	248	1	Ezequiel	Ezequiel	NNP
cord-021637-f5wwn45z	248	2	Dias	Dias	NNP
cord-021637-f5wwn45z	248	3	Foundation	Foundation	NNP
cord-021637-f5wwn45z	248	4	(	(	-LRB-
cord-021637-f5wwn45z	248	5	FUNED	FUNED	NNP
cord-021637-f5wwn45z	248	6	)	)	-RRB-
cord-021637-f5wwn45z	248	7	is	be	VBZ
cord-021637-f5wwn45z	248	8	a	a	DT
cord-021637-f5wwn45z	248	9	public	public	JJ
cord-021637-f5wwn45z	248	10	institution	institution	NN
cord-021637-f5wwn45z	248	11	and	and	CC
cord-021637-f5wwn45z	248	12	part	part	NN
cord-021637-f5wwn45z	248	13	of	of	IN
cord-021637-f5wwn45z	248	14	Minas	Minas	NNP
cord-021637-f5wwn45z	248	15	Gerais	Gerais	NNP
cord-021637-f5wwn45z	248	16	state	state	NN
cord-021637-f5wwn45z	248	17	.	.	.
cord-021637-f5wwn45z	249	1	Since	since	IN
cord-021637-f5wwn45z	249	2	2009	2009	CD
cord-021637-f5wwn45z	249	3	,	,	,
cord-021637-f5wwn45z	249	4	it	-PRON-	PRP
cord-021637-f5wwn45z	249	5	has	have	VBZ
cord-021637-f5wwn45z	249	6	supplied	supply	VBN
cord-021637-f5wwn45z	249	7	the	the	DT
cord-021637-f5wwn45z	249	8	meningococcal	meningococcal	JJ
cord-021637-f5wwn45z	249	9	conjugate	conjugate	NN
cord-021637-f5wwn45z	249	10	vaccine	vaccine	NN
cord-021637-f5wwn45z	249	11	after	after	IN
cord-021637-f5wwn45z	249	12	transferring	transfer	VBG
cord-021637-f5wwn45z	249	13	the	the	DT
cord-021637-f5wwn45z	249	14	technology	technology	NN
cord-021637-f5wwn45z	249	15	from	from	IN
cord-021637-f5wwn45z	249	16	Novartis	Novartis	NNP
cord-021637-f5wwn45z	249	17	.	.	.
cord-021637-f5wwn45z	250	1	The	the	DT
cord-021637-f5wwn45z	250	2	Indian	indian	JJ
cord-021637-f5wwn45z	250	3	vaccine	vaccine	NN
cord-021637-f5wwn45z	250	4	industry	industry	NN
cord-021637-f5wwn45z	250	5	is	be	VBZ
cord-021637-f5wwn45z	250	6	the	the	DT
cord-021637-f5wwn45z	250	7	most	most	RBS
cord-021637-f5wwn45z	250	8	advanced	advanced	JJ
cord-021637-f5wwn45z	250	9	among	among	IN
cord-021637-f5wwn45z	250	10	these	these	DT
cord-021637-f5wwn45z	250	11	three	three	CD
cord-021637-f5wwn45z	250	12	developing	develop	VBG
cord-021637-f5wwn45z	250	13	countries	country	NNS
cord-021637-f5wwn45z	250	14	,	,	,
cord-021637-f5wwn45z	250	15	and	and	CC
cord-021637-f5wwn45z	250	16	is	be	VBZ
cord-021637-f5wwn45z	250	17	already	already	RB
cord-021637-f5wwn45z	250	18	providing	provide	VBG
cord-021637-f5wwn45z	250	19	a	a	DT
cord-021637-f5wwn45z	250	20	significant	significant	JJ
cord-021637-f5wwn45z	250	21	portion	portion	NN
cord-021637-f5wwn45z	250	22	of	of	IN
cord-021637-f5wwn45z	250	23	the	the	DT
cord-021637-f5wwn45z	250	24	world	world	NN
cord-021637-f5wwn45z	250	25	's	's	POS
cord-021637-f5wwn45z	250	26	vaccine	vaccine	NN
cord-021637-f5wwn45z	250	27	supply	supply	NN
cord-021637-f5wwn45z	250	28	as	as	RB
cord-021637-f5wwn45z	250	29	well	well	RB
cord-021637-f5wwn45z	250	30	as	as	IN
cord-021637-f5wwn45z	250	31	developing	develop	VBG
cord-021637-f5wwn45z	250	32	new	new	JJ
cord-021637-f5wwn45z	250	33	vaccines	vaccine	NNS
cord-021637-f5wwn45z	250	34	.	.	.
cord-021637-f5wwn45z	251	1	China	China	NNP
cord-021637-f5wwn45z	251	2	is	be	VBZ
cord-021637-f5wwn45z	251	3	on	on	IN
cord-021637-f5wwn45z	251	4	the	the	DT
cord-021637-f5wwn45z	251	5	verge	verge	NN
cord-021637-f5wwn45z	251	6	of	of	IN
cord-021637-f5wwn45z	251	7	the	the	DT
cord-021637-f5wwn45z	251	8	transition	transition	NN
cord-021637-f5wwn45z	251	9	from	from	IN
cord-021637-f5wwn45z	251	10	a	a	DT
cord-021637-f5wwn45z	251	11	domestic	domestic	JJ
cord-021637-f5wwn45z	251	12	-	-	HYPH
cord-021637-f5wwn45z	251	13	only	only	JJ
cord-021637-f5wwn45z	251	14	provider	provider	NN
cord-021637-f5wwn45z	251	15	to	to	IN
cord-021637-f5wwn45z	251	16	a	a	DT
cord-021637-f5wwn45z	251	17	vaccine	vaccine	NN
cord-021637-f5wwn45z	251	18	exporter	exporter	NN
cord-021637-f5wwn45z	251	19	,	,	,
cord-021637-f5wwn45z	251	20	and	and	CC
cord-021637-f5wwn45z	251	21	is	be	VBZ
cord-021637-f5wwn45z	251	22	demonstrating	demonstrate	VBG
cord-021637-f5wwn45z	251	23	solid	solid	JJ
cord-021637-f5wwn45z	251	24	progress	progress	NN
cord-021637-f5wwn45z	251	25	in	in	IN
cord-021637-f5wwn45z	251	26	vaccine	vaccine	NN
cord-021637-f5wwn45z	251	27	innovation	innovation	NN
cord-021637-f5wwn45z	251	28	.	.	.
cord-021637-f5wwn45z	252	1	Brazil	Brazil	NNP
cord-021637-f5wwn45z	252	2	is	be	VBZ
cord-021637-f5wwn45z	252	3	approaching	approach	VBG
cord-021637-f5wwn45z	252	4	the	the	DT
cord-021637-f5wwn45z	252	5	point	point	NN
cord-021637-f5wwn45z	252	6	of	of	IN
cord-021637-f5wwn45z	252	7	supplying	supply	VBG
cord-021637-f5wwn45z	252	8	its	-PRON-	PRP$
cord-021637-f5wwn45z	252	9	own	own	JJ
cord-021637-f5wwn45z	252	10	domestic	domestic	JJ
cord-021637-f5wwn45z	252	11	needs	need	NNS
cord-021637-f5wwn45z	252	12	,	,	,
cord-021637-f5wwn45z	252	13	largely	largely	RB
cord-021637-f5wwn45z	252	14	with	with	IN
cord-021637-f5wwn45z	252	15	technology	technology	NN
cord-021637-f5wwn45z	252	16	transferred	transfer	VBN
cord-021637-f5wwn45z	252	17	from	from	IN
cord-021637-f5wwn45z	252	18	the	the	DT
cord-021637-f5wwn45z	252	19	developed	develop	VBN
cord-021637-f5wwn45z	252	20	world	world	NN
cord-021637-f5wwn45z	252	21	.	.	.
cord-021637-f5wwn45z	253	1	Together	together	RB
cord-021637-f5wwn45z	253	2	,	,	,
cord-021637-f5wwn45z	253	3	these	these	DT
cord-021637-f5wwn45z	253	4	emerging	emerge	VBG
cord-021637-f5wwn45z	253	5	players	player	NNS
cord-021637-f5wwn45z	253	6	from	from	IN
cord-021637-f5wwn45z	253	7	middle	middle	JJ
cord-021637-f5wwn45z	253	8	-	-	HYPH
cord-021637-f5wwn45z	253	9	income	income	NN
cord-021637-f5wwn45z	253	10	countries	country	NNS
cord-021637-f5wwn45z	253	11	will	will	MD
cord-021637-f5wwn45z	253	12	have	have	VB
cord-021637-f5wwn45z	253	13	increasing	increase	VBG
cord-021637-f5wwn45z	253	14	influence	influence	NN
cord-021637-f5wwn45z	253	15	in	in	IN
cord-021637-f5wwn45z	253	16	the	the	DT
cord-021637-f5wwn45z	253	17	global	global	JJ
cord-021637-f5wwn45z	253	18	vaccine	vaccine	NN
cord-021637-f5wwn45z	253	19	industry	industry	NN
cord-021637-f5wwn45z	253	20	during	during	IN
cord-021637-f5wwn45z	253	21	the	the	DT
cord-021637-f5wwn45z	253	22	coming	come	VBG
cord-021637-f5wwn45z	253	23	years	year	NNS
cord-021637-f5wwn45z	253	24	.	.	.
cord-021637-f5wwn45z	254	1	Pricing	pricing	NN
cord-021637-f5wwn45z	254	2	is	be	VBZ
cord-021637-f5wwn45z	254	3	a	a	DT
cord-021637-f5wwn45z	254	4	critical	critical	JJ
cord-021637-f5wwn45z	254	5	component	component	NN
cord-021637-f5wwn45z	254	6	of	of	IN
cord-021637-f5wwn45z	254	7	success	success	NN
cord-021637-f5wwn45z	254	8	for	for	IN
cord-021637-f5wwn45z	254	9	large	large	JJ
cord-021637-f5wwn45z	254	10	companies	company	NNS
cord-021637-f5wwn45z	254	11	and	and	CC
cord-021637-f5wwn45z	254	12	for	for	IN
cord-021637-f5wwn45z	254	13	venture	venture	NN
cord-021637-f5wwn45z	254	14	funding	funding	NN
cord-021637-f5wwn45z	254	15	of	of	IN
cord-021637-f5wwn45z	254	16	small	small	JJ
cord-021637-f5wwn45z	254	17	companies	company	NNS
cord-021637-f5wwn45z	254	18	since	since	IN
cord-021637-f5wwn45z	254	19	potential	potential	JJ
cord-021637-f5wwn45z	254	20	sales	sale	NNS
cord-021637-f5wwn45z	254	21	determine	determine	VBP
cord-021637-f5wwn45z	254	22	the	the	DT
cord-021637-f5wwn45z	254	23	desirability	desirability	NN
cord-021637-f5wwn45z	254	24	of	of	IN
cord-021637-f5wwn45z	254	25	an	an	DT
cord-021637-f5wwn45z	254	26	investment	investment	NN
cord-021637-f5wwn45z	254	27	decision	decision	NN
cord-021637-f5wwn45z	254	28	.	.	.
cord-021637-f5wwn45z	255	1	The	the	DT
cord-021637-f5wwn45z	255	2	public	public	JJ
cord-021637-f5wwn45z	255	3	expectation	expectation	NN
cord-021637-f5wwn45z	255	4	is	be	VBZ
cord-021637-f5wwn45z	255	5	for	for	IN
cord-021637-f5wwn45z	255	6	low	low	JJ
cord-021637-f5wwn45z	255	7	vaccine	vaccine	NN
cord-021637-f5wwn45z	255	8	prices	price	NNS
cord-021637-f5wwn45z	255	9	,	,	,
cord-021637-f5wwn45z	255	10	although	although	IN
cord-021637-f5wwn45z	255	11	this	this	DT
cord-021637-f5wwn45z	255	12	has	have	VBZ
cord-021637-f5wwn45z	255	13	changed	change	VBN
cord-021637-f5wwn45z	255	14	somewhat	somewhat	RB
cord-021637-f5wwn45z	255	15	in	in	IN
cord-021637-f5wwn45z	255	16	recent	recent	JJ
cord-021637-f5wwn45z	255	17	years	year	NNS
cord-021637-f5wwn45z	255	18	with	with	IN
cord-021637-f5wwn45z	255	19	the	the	DT
cord-021637-f5wwn45z	255	20	introduction	introduction	NN
cord-021637-f5wwn45z	255	21	of	of	IN
cord-021637-f5wwn45z	255	22	several	several	JJ
cord-021637-f5wwn45z	255	23	new	new	JJ
cord-021637-f5wwn45z	255	24	,	,	,
cord-021637-f5wwn45z	255	25	higher	high	JJR
cord-021637-f5wwn45z	255	26	priced	price	VBN
cord-021637-f5wwn45z	255	27	vaccines	vaccine	NNS
cord-021637-f5wwn45z	255	28	,	,	,
cord-021637-f5wwn45z	255	29	such	such	JJ
cord-021637-f5wwn45z	255	30	as	as	IN
cord-021637-f5wwn45z	255	31	varicella	varicella	NN
cord-021637-f5wwn45z	255	32	,	,	,
cord-021637-f5wwn45z	255	33	rotavirus	rotavirus	NN
cord-021637-f5wwn45z	255	34	,	,	,
cord-021637-f5wwn45z	255	35	pneumococcal	pneumococcal	JJ
cord-021637-f5wwn45z	255	36	conjugate	conjugate	NN
cord-021637-f5wwn45z	255	37	vaccine	vaccine	NN
cord-021637-f5wwn45z	255	38	,	,	,
cord-021637-f5wwn45z	255	39	zoster	zoster	NN
cord-021637-f5wwn45z	255	40	vaccine	vaccine	NN
cord-021637-f5wwn45z	255	41	,	,	,
cord-021637-f5wwn45z	255	42	and	and	CC
cord-021637-f5wwn45z	255	43	HPV	HPV	NNP
cord-021637-f5wwn45z	255	44	vaccine	vaccine	NN
cord-021637-f5wwn45z	255	45	(	(	-LRB-
cord-021637-f5wwn45z	255	46	Fig	Fig	NNP
cord-021637-f5wwn45z	255	47	.	.	.
cord-021637-f5wwn45z	255	48	4.3	4.3	CD
cord-021637-f5wwn45z	255	49	)	)	-RRB-
cord-021637-f5wwn45z	255	50	.	.	.
cord-021637-f5wwn45z	256	1	Large	large	JJ
cord-021637-f5wwn45z	256	2	companies	company	NNS
cord-021637-f5wwn45z	256	3	believe	believe	VBP
cord-021637-f5wwn45z	256	4	that	that	IN
cord-021637-f5wwn45z	256	5	vaccines	vaccine	NNS
cord-021637-f5wwn45z	256	6	should	should	MD
cord-021637-f5wwn45z	256	7	be	be	VB
cord-021637-f5wwn45z	256	8	priced	price	VBN
cord-021637-f5wwn45z	256	9	according	accord	VBG
cord-021637-f5wwn45z	256	10	to	to	IN
cord-021637-f5wwn45z	256	11	value	value	NN
cord-021637-f5wwn45z	256	12	to	to	IN
cord-021637-f5wwn45z	256	13	society	society	NN
cord-021637-f5wwn45z	256	14	such	such	JJ
cord-021637-f5wwn45z	256	15	as	as	IN
cord-021637-f5wwn45z	256	16	reduction	reduction	NN
cord-021637-f5wwn45z	256	17	in	in	IN
cord-021637-f5wwn45z	256	18	health	health	NN
cord-021637-f5wwn45z	256	19	care	care	NN
cord-021637-f5wwn45z	256	20	and	and	CC
cord-021637-f5wwn45z	256	21	related	related	JJ
cord-021637-f5wwn45z	256	22	costs	cost	NNS
cord-021637-f5wwn45z	256	23	,	,	,
cord-021637-f5wwn45z	256	24	relief	relief	NN
cord-021637-f5wwn45z	256	25	from	from	IN
cord-021637-f5wwn45z	256	26	pain	pain	NN
cord-021637-f5wwn45z	256	27	and	and	CC
cord-021637-f5wwn45z	256	28	suffering	suffering	NN
cord-021637-f5wwn45z	256	29	,	,	,
cord-021637-f5wwn45z	256	30	and/or	and/or	CC
cord-021637-f5wwn45z	256	31	prevention	prevention	NN
cord-021637-f5wwn45z	256	32	of	of	IN
cord-021637-f5wwn45z	256	33	death	death	NN
cord-021637-f5wwn45z	256	34	,	,	,
cord-021637-f5wwn45z	256	35	and	and	CC
cord-021637-f5wwn45z	256	36	that	that	IN
cord-021637-f5wwn45z	256	37	they	-PRON-	PRP
cord-021637-f5wwn45z	256	38	should	should	MD
cord-021637-f5wwn45z	256	39	be	be	VB
cord-021637-f5wwn45z	256	40	rewarded	reward	VBN
cord-021637-f5wwn45z	256	41	for	for	IN
cord-021637-f5wwn45z	256	42	taking	take	VBG
cord-021637-f5wwn45z	256	43	the	the	DT
cord-021637-f5wwn45z	256	44	enormous	enormous	JJ
cord-021637-f5wwn45z	256	45	risks	risk	NNS
cord-021637-f5wwn45z	256	46	inherent	inherent	JJ
cord-021637-f5wwn45z	256	47	in	in	IN
cord-021637-f5wwn45z	256	48	early	early	JJ
cord-021637-f5wwn45z	256	49	vaccine	vaccine	NN
cord-021637-f5wwn45z	256	50	development	development	NN
cord-021637-f5wwn45z	256	51	.	.	.
cord-021637-f5wwn45z	257	1	Such	such	JJ
cord-021637-f5wwn45z	257	2	prices	price	NNS
cord-021637-f5wwn45z	257	3	far	far	RB
cord-021637-f5wwn45z	257	4	exceed	exceed	VBP
cord-021637-f5wwn45z	257	5	manufacturing	manufacturing	NN
cord-021637-f5wwn45z	257	6	costs	cost	NNS
cord-021637-f5wwn45z	257	7	,	,	,
cord-021637-f5wwn45z	257	8	but	but	CC
cord-021637-f5wwn45z	257	9	are	be	VBP
cord-021637-f5wwn45z	257	10	essential	essential	JJ
cord-021637-f5wwn45z	257	11	to	to	TO
cord-021637-f5wwn45z	257	12	produce	produce	VB
cord-021637-f5wwn45z	257	13	the	the	DT
cord-021637-f5wwn45z	257	14	revenue	revenue	NN
cord-021637-f5wwn45z	257	15	streams	stream	NNS
cord-021637-f5wwn45z	257	16	that	that	WDT
cord-021637-f5wwn45z	257	17	allow	allow	VBP
cord-021637-f5wwn45z	257	18	vaccines	vaccine	NNS
cord-021637-f5wwn45z	257	19	to	to	TO
cord-021637-f5wwn45z	257	20	be	be	VB
cord-021637-f5wwn45z	257	21	competitive	competitive	JJ
cord-021637-f5wwn45z	257	22	for	for	IN
cord-021637-f5wwn45z	257	23	R&D	r&d	NN
cord-021637-f5wwn45z	257	24	and	and	CC
cord-021637-f5wwn45z	257	25	manufacturing	manufacturing	NN
cord-021637-f5wwn45z	257	26	resources	resource	NNS
cord-021637-f5wwn45z	257	27	within	within	IN
cord-021637-f5wwn45z	257	28	large	large	JJ
cord-021637-f5wwn45z	257	29	pharmaceutical	pharmaceutical	JJ
cord-021637-f5wwn45z	257	30	companies	company	NNS
cord-021637-f5wwn45z	257	31	or	or	CC
cord-021637-f5wwn45z	257	32	that	that	WDT
cord-021637-f5wwn45z	257	33	make	make	VBP
cord-021637-f5wwn45z	257	34	biotech	biotech	JJ
cord-021637-f5wwn45z	257	35	companies	company	NNS
cord-021637-f5wwn45z	257	36	attractive	attractive	JJ
cord-021637-f5wwn45z	257	37	investment	investment	NN
cord-021637-f5wwn45z	257	38	opportunities	opportunity	NNS
cord-021637-f5wwn45z	257	39	.	.	.
cord-021637-f5wwn45z	258	1	In	in	IN
cord-021637-f5wwn45z	258	2	general	general	JJ
cord-021637-f5wwn45z	258	3	,	,	,
cord-021637-f5wwn45z	258	4	vaccine	vaccine	NN
cord-021637-f5wwn45z	258	5	prices	price	NNS
cord-021637-f5wwn45z	258	6	have	have	VBP
cord-021637-f5wwn45z	258	7	declined	decline	VBN
cord-021637-f5wwn45z	258	8	when	when	WRB
cord-021637-f5wwn45z	258	9	more	more	JJR
cord-021637-f5wwn45z	258	10	than	than	IN
cord-021637-f5wwn45z	258	11	two	two	CD
cord-021637-f5wwn45z	258	12	companies	company	NNS
cord-021637-f5wwn45z	258	13	have	have	VBP
cord-021637-f5wwn45z	258	14	competed	compete	VBN
cord-021637-f5wwn45z	258	15	in	in	IN
cord-021637-f5wwn45z	258	16	a	a	DT
cord-021637-f5wwn45z	258	17	single	single	JJ
cord-021637-f5wwn45z	258	18	vaccine	vaccine	NN
cord-021637-f5wwn45z	258	19	market	market	NN
cord-021637-f5wwn45z	258	20	and	and	CC
cord-021637-f5wwn45z	258	21	profitability	profitability	NN
cord-021637-f5wwn45z	258	22	has	have	VBZ
cord-021637-f5wwn45z	258	23	fallen	fall	VBN
cord-021637-f5wwn45z	258	24	sharply	sharply	RB
cord-021637-f5wwn45z	258	25	.	.	.
cord-021637-f5wwn45z	259	1	The	the	DT
cord-021637-f5wwn45z	259	2	influenza	influenza	NN
cord-021637-f5wwn45z	259	3	vaccine	vaccine	NN
cord-021637-f5wwn45z	259	4	market	market	NN
cord-021637-f5wwn45z	259	5	highlights	highlight	VBZ
cord-021637-f5wwn45z	259	6	this	this	DT
cord-021637-f5wwn45z	259	7	cyclical	cyclical	JJ
cord-021637-f5wwn45z	259	8	ebb	ebb	NN
cord-021637-f5wwn45z	259	9	and	and	CC
cord-021637-f5wwn45z	259	10	flow	flow	NN
cord-021637-f5wwn45z	259	11	of	of	IN
cord-021637-f5wwn45z	259	12	competitors	competitor	NNS
cord-021637-f5wwn45z	259	13	,	,	,
cord-021637-f5wwn45z	259	14	most	most	RBS
cord-021637-f5wwn45z	259	15	recently	recently	RB
cord-021637-f5wwn45z	259	16	with	with	IN
cord-021637-f5wwn45z	259	17	the	the	DT
cord-021637-f5wwn45z	259	18	H1N1	H1N1	NNP
cord-021637-f5wwn45z	259	19	outbreak	outbreak	NN
cord-021637-f5wwn45z	259	20	and	and	CC
cord-021637-f5wwn45z	259	21	shortages	shortage	NNS
cord-021637-f5wwn45z	259	22	in	in	IN
cord-021637-f5wwn45z	259	23	2009	2009	CD
cord-021637-f5wwn45z	259	24	leading	lead	VBG
cord-021637-f5wwn45z	259	25	to	to	IN
cord-021637-f5wwn45z	259	26	expanded	expand	VBN
cord-021637-f5wwn45z	259	27	competition	competition	NN
cord-021637-f5wwn45z	259	28	and	and	CC
cord-021637-f5wwn45z	259	29	a	a	DT
cord-021637-f5wwn45z	259	30	vaccine	vaccine	NN
cord-021637-f5wwn45z	259	31	surplus	surplus	NN
cord-021637-f5wwn45z	259	32	,	,	,
cord-021637-f5wwn45z	259	33	followed	follow	VBN
cord-021637-f5wwn45z	259	34	by	by	IN
cord-021637-f5wwn45z	259	35	lower	low	JJR
cord-021637-f5wwn45z	259	36	prices	price	NNS
cord-021637-f5wwn45z	259	37	in	in	IN
cord-021637-f5wwn45z	259	38	2010	2010	CD
cord-021637-f5wwn45z	259	39	.	.	.
cord-021637-f5wwn45z	260	1	A	a	DT
cord-021637-f5wwn45z	260	2	vigorous	vigorous	JJ
cord-021637-f5wwn45z	260	3	large	large	JJ
cord-021637-f5wwn45z	260	4	-	-	HYPH
cord-021637-f5wwn45z	260	5	company	company	NN
cord-021637-f5wwn45z	260	6	vaccine	vaccine	NN
cord-021637-f5wwn45z	260	7	industry	industry	NN
cord-021637-f5wwn45z	260	8	is	be	VBZ
cord-021637-f5wwn45z	260	9	dependent	dependent	JJ
cord-021637-f5wwn45z	260	10	upon	upon	IN
cord-021637-f5wwn45z	260	11	several	several	JJ
cord-021637-f5wwn45z	260	12	factors	factor	NNS
cord-021637-f5wwn45z	260	13	:	:	:
cord-021637-f5wwn45z	261	1	1	1	LS
cord-021637-f5wwn45z	261	2	.	.	.
cord-021637-f5wwn45z	262	1	A	a	DT
cord-021637-f5wwn45z	262	2	rich	rich	JJ
cord-021637-f5wwn45z	262	3	research	research	NN
cord-021637-f5wwn45z	262	4	environment	environment	NN
cord-021637-f5wwn45z	262	5	sponsored	sponsor	VBN
cord-021637-f5wwn45z	262	6	largely	largely	RB
cord-021637-f5wwn45z	262	7	by	by	IN
cord-021637-f5wwn45z	262	8	the	the	DT
cord-021637-f5wwn45z	262	9	NIH	NIH	NNP
cord-021637-f5wwn45z	262	10	and	and	CC
cord-021637-f5wwn45z	262	11	mostly	mostly	RB
cord-021637-f5wwn45z	262	12	carried	carry	VBN
cord-021637-f5wwn45z	262	13	out	out	RP
cord-021637-f5wwn45z	262	14	in	in	IN
cord-021637-f5wwn45z	262	15	academia	academia	NN
cord-021637-f5wwn45z	262	16	,	,	,
cord-021637-f5wwn45z	262	17	as	as	IN
cord-021637-f5wwn45z	262	18	the	the	DT
cord-021637-f5wwn45z	262	19	source	source	NN
cord-021637-f5wwn45z	262	20	for	for	IN
cord-021637-f5wwn45z	262	21	new	new	JJ
cord-021637-f5wwn45z	262	22	creative	creative	JJ
cord-021637-f5wwn45z	262	23	ideas	idea	NNS
cord-021637-f5wwn45z	262	24	.	.	.
cord-021637-f5wwn45z	263	1	2	2	LS
cord-021637-f5wwn45z	263	2	.	.	.
cord-021637-f5wwn45z	264	1	Strong	strong	JJ
cord-021637-f5wwn45z	264	2	patent	patent	NN
cord-021637-f5wwn45z	264	3	laws	law	NNS
cord-021637-f5wwn45z	264	4	and	and	CC
cord-021637-f5wwn45z	264	5	protection	protection	NN
cord-021637-f5wwn45z	264	6	of	of	IN
cord-021637-f5wwn45z	264	7	intellectual	intellectual	JJ
cord-021637-f5wwn45z	264	8	property	property	NN
cord-021637-f5wwn45z	264	9	.	.	.
cord-021637-f5wwn45z	265	1	3	3	LS
cord-021637-f5wwn45z	265	2	.	.	.
cord-021637-f5wwn45z	266	1	Freedom	freedom	NN
cord-021637-f5wwn45z	266	2	to	to	IN
cord-021637-f5wwn45z	266	3	price	price	NN
cord-021637-f5wwn45z	266	4	products	product	NNS
cord-021637-f5wwn45z	266	5	at	at	IN
cord-021637-f5wwn45z	266	6	fair	fair	JJ
cord-021637-f5wwn45z	266	7	levels	level	NNS
cord-021637-f5wwn45z	266	8	related	relate	VBN
cord-021637-f5wwn45z	266	9	to	to	IN
cord-021637-f5wwn45z	266	10	value	value	NN
cord-021637-f5wwn45z	266	11	of	of	IN
cord-021637-f5wwn45z	266	12	product	product	NN
cord-021637-f5wwn45z	266	13	to	to	IN
cord-021637-f5wwn45z	266	14	society	society	NN
cord-021637-f5wwn45z	266	15	.	.	.
cord-021637-f5wwn45z	267	1	4	4	LS
cord-021637-f5wwn45z	267	2	.	.	.
cord-021637-f5wwn45z	268	1	Well	well	RB
cord-021637-f5wwn45z	268	2	-	-	HYPH
cord-021637-f5wwn45z	268	3	implemented	implement	VBN
cord-021637-f5wwn45z	268	4	immunization	immunization	NN
cord-021637-f5wwn45z	268	5	practices	practice	NNS
cord-021637-f5wwn45z	268	6	.	.	.
cord-021637-f5wwn45z	269	1	U.S.	U.S.	NNP
cord-021637-f5wwn45z	269	2	vaccine	vaccine	NN
cord-021637-f5wwn45z	269	3	price	price	NN
cord-021637-f5wwn45z	269	4	evolution	evolution	NN
cord-021637-f5wwn45z	269	5	polio	polio	NN
cord-021637-f5wwn45z	269	6	vaccine	vaccine	NN
cord-021637-f5wwn45z	269	7	grows	grow	VBZ
cord-021637-f5wwn45z	269	8	in	in	IN
cord-021637-f5wwn45z	269	9	developing	develop	VBG
cord-021637-f5wwn45z	269	10	countries	country	NNS
cord-021637-f5wwn45z	269	11	,	,	,
cord-021637-f5wwn45z	269	12	alternative	alternative	JJ
cord-021637-f5wwn45z	269	13	approaches	approach	NNS
cord-021637-f5wwn45z	269	14	for	for	IN
cord-021637-f5wwn45z	269	15	local	local	JJ
cord-021637-f5wwn45z	269	16	production	production	NN
cord-021637-f5wwn45z	269	17	will	will	MD
cord-021637-f5wwn45z	269	18	be	be	VB
cord-021637-f5wwn45z	269	19	explored	explore	VBN
cord-021637-f5wwn45z	269	20	,	,	,
cord-021637-f5wwn45z	269	21	including	include	VBG
cord-021637-f5wwn45z	269	22	access	access	NN
cord-021637-f5wwn45z	269	23	to	to	IN
cord-021637-f5wwn45z	269	24	bulk	bulk	JJ
cord-021637-f5wwn45z	269	25	injected	inject	VBN
cord-021637-f5wwn45z	269	26	polio	polio	NN
cord-021637-f5wwn45z	269	27	vaccine	vaccine	NN
cord-021637-f5wwn45z	269	28	,	,	,
cord-021637-f5wwn45z	269	29	tech	tech	NN
cord-021637-f5wwn45z	269	30	transfer	transfer	NN
cord-021637-f5wwn45z	269	31	by	by	IN
cord-021637-f5wwn45z	269	32	big	big	JJ
cord-021637-f5wwn45z	269	33	pharma	pharma	NNS
cord-021637-f5wwn45z	269	34	as	as	IN
cord-021637-f5wwn45z	269	35	a	a	DT
cord-021637-f5wwn45z	269	36	part	part	NN
cord-021637-f5wwn45z	269	37	of	of	IN
cord-021637-f5wwn45z	269	38	their	-PRON-	PRP$
cord-021637-f5wwn45z	269	39	strategic	strategic	JJ
cord-021637-f5wwn45z	269	40	alliances	alliance	NNS
cord-021637-f5wwn45z	269	41	in	in	IN
cord-021637-f5wwn45z	269	42	developing	develop	VBG
cord-021637-f5wwn45z	269	43	markets	market	NNS
cord-021637-f5wwn45z	269	44	,	,	,
cord-021637-f5wwn45z	269	45	and	and	CC
cord-021637-f5wwn45z	269	46	potential	potential	JJ
cord-021637-f5wwn45z	269	47	introduction	introduction	NN
cord-021637-f5wwn45z	269	48	of	of	IN
cord-021637-f5wwn45z	269	49	alternative	alternative	JJ
cord-021637-f5wwn45z	269	50	injected	inject	VBN
cord-021637-f5wwn45z	269	51	polio	polio	NN
cord-021637-f5wwn45z	269	52	vaccine	vaccine	NN
cord-021637-f5wwn45z	269	53	strains	strain	NNS
cord-021637-f5wwn45z	269	54	such	such	JJ
cord-021637-f5wwn45z	269	55	as	as	IN
cord-021637-f5wwn45z	269	56	the	the	DT
cord-021637-f5wwn45z	269	57	Sabin	Sabin	NNP
cord-021637-f5wwn45z	269	58	strain	strain	NN
cord-021637-f5wwn45z	269	59	.	.	.
cord-021637-f5wwn45z	270	1	Another	another	DT
cord-021637-f5wwn45z	270	2	key	key	JJ
cord-021637-f5wwn45z	270	3	driver	driver	NN
cord-021637-f5wwn45z	270	4	will	will	MD
cord-021637-f5wwn45z	270	5	be	be	VB
cord-021637-f5wwn45z	270	6	the	the	DT
cord-021637-f5wwn45z	270	7	expansion	expansion	NN
cord-021637-f5wwn45z	270	8	of	of	IN
cord-021637-f5wwn45z	270	9	vaccine	vaccine	NN
cord-021637-f5wwn45z	270	10	markets	market	NNS
cord-021637-f5wwn45z	270	11	in	in	IN
cord-021637-f5wwn45z	270	12	India	India	NNP
cord-021637-f5wwn45z	270	13	,	,	,
cord-021637-f5wwn45z	270	14	China	China	NNP
cord-021637-f5wwn45z	270	15	,	,	,
cord-021637-f5wwn45z	270	16	and	and	CC
cord-021637-f5wwn45z	270	17	Brazil	Brazil	NNP
cord-021637-f5wwn45z	270	18	.	.	.
cord-021637-f5wwn45z	271	1	Vaccine	vaccine	NN
cord-021637-f5wwn45z	271	2	uptake	uptake	NN
cord-021637-f5wwn45z	271	3	rates	rate	NNS
cord-021637-f5wwn45z	271	4	in	in	IN
cord-021637-f5wwn45z	271	5	India	India	NNP
cord-021637-f5wwn45z	271	6	,	,	,
cord-021637-f5wwn45z	271	7	China	China	NNP
cord-021637-f5wwn45z	271	8	and	and	CC
cord-021637-f5wwn45z	271	9	Brazil	Brazil	NNP
cord-021637-f5wwn45z	271	10	are	be	VBP
cord-021637-f5wwn45z	271	11	still	still	RB
cord-021637-f5wwn45z	271	12	low	low	JJ
cord-021637-f5wwn45z	271	13	compared	compare	VBN
cord-021637-f5wwn45z	271	14	with	with	IN
cord-021637-f5wwn45z	271	15	western	western	JJ
cord-021637-f5wwn45z	271	16	countries	country	NNS
cord-021637-f5wwn45z	271	17	(	(	-LRB-
cord-021637-f5wwn45z	271	18	e.g.	e.g.	RB
cord-021637-f5wwn45z	271	19	,	,	,
cord-021637-f5wwn45z	271	20	India	India	NNP
cord-021637-f5wwn45z	271	21	's	's	POS
cord-021637-f5wwn45z	271	22	flu	flu	NN
cord-021637-f5wwn45z	271	23	vaccine	vaccine	NN
cord-021637-f5wwn45z	271	24	uptake	uptake	NN
cord-021637-f5wwn45z	271	25	in	in	IN
cord-021637-f5wwn45z	271	26	2014	2014	CD
cord-021637-f5wwn45z	271	27	was	be	VBD
cord-021637-f5wwn45z	271	28	1.0	1.0	CD
cord-021637-f5wwn45z	271	29	million	million	CD
cord-021637-f5wwn45z	271	30	doses	dose	NNS
cord-021637-f5wwn45z	271	31	vs.	vs.	IN
cord-021637-f5wwn45z	271	32	140	140	CD
cord-021637-f5wwn45z	271	33	million	million	CD
cord-021637-f5wwn45z	271	34	doses	dose	NNS
cord-021637-f5wwn45z	271	35	in	in	IN
cord-021637-f5wwn45z	271	36	the	the	DT
cord-021637-f5wwn45z	271	37	United	United	NNP
cord-021637-f5wwn45z	271	38	States	States	NNP
cord-021637-f5wwn45z	271	39	)	)	-RRB-
cord-021637-f5wwn45z	271	40	.	.	.
cord-021637-f5wwn45z	272	1	23	23	CD
cord-021637-f5wwn45z	272	2	,	,	,
cord-021637-f5wwn45z	272	3	24	24	CD
cord-021637-f5wwn45z	272	4	The	the	DT
cord-021637-f5wwn45z	272	5	immunization	immunization	NN
cord-021637-f5wwn45z	272	6	rates	rate	NNS
cord-021637-f5wwn45z	272	7	are	be	VBP
cord-021637-f5wwn45z	272	8	also	also	RB
cord-021637-f5wwn45z	272	9	expected	expect	VBN
cord-021637-f5wwn45z	272	10	to	to	TO
cord-021637-f5wwn45z	272	11	increase	increase	VB
cord-021637-f5wwn45z	272	12	in	in	IN
cord-021637-f5wwn45z	272	13	other	other	JJ
cord-021637-f5wwn45z	272	14	low	low	JJ
cord-021637-f5wwn45z	272	15	-	-	HYPH
cord-021637-f5wwn45z	272	16	income	income	NN
cord-021637-f5wwn45z	272	17	countries	country	NNS
cord-021637-f5wwn45z	272	18	,	,	,
cord-021637-f5wwn45z	272	19	which	which	WDT
cord-021637-f5wwn45z	272	20	will	will	MD
cord-021637-f5wwn45z	272	21	increase	increase	VB
cord-021637-f5wwn45z	272	22	vaccine	vaccine	NN
cord-021637-f5wwn45z	272	23	dose	dose	NN
cord-021637-f5wwn45z	272	24	requirements	requirement	NNS
cord-021637-f5wwn45z	272	25	substantially	substantially	RB
cord-021637-f5wwn45z	272	26	.	.	.
cord-021637-f5wwn45z	273	1	Most	Most	JJS
cord-021637-f5wwn45z	273	2	of	of	IN
cord-021637-f5wwn45z	273	3	this	this	DT
cord-021637-f5wwn45z	273	4	demand	demand	NN
cord-021637-f5wwn45z	273	5	in	in	IN
cord-021637-f5wwn45z	273	6	low	low	JJ
cord-021637-f5wwn45z	273	7	-	-	HYPH
cord-021637-f5wwn45z	273	8	income	income	NN
cord-021637-f5wwn45z	273	9	countries	country	NNS
cord-021637-f5wwn45z	273	10	is	be	VBZ
cord-021637-f5wwn45z	273	11	expected	expect	VBN
cord-021637-f5wwn45z	273	12	to	to	TO
cord-021637-f5wwn45z	273	13	be	be	VB
cord-021637-f5wwn45z	273	14	met	meet	VBN
cord-021637-f5wwn45z	273	15	by	by	IN
cord-021637-f5wwn45z	273	16	manufacturers	manufacturer	NNS
cord-021637-f5wwn45z	273	17	of	of	IN
cord-021637-f5wwn45z	273	18	DCVMN	DCVMN	NNP
cord-021637-f5wwn45z	273	19	network	network	NN
cord-021637-f5wwn45z	273	20	.	.	.
cord-021637-f5wwn45z	274	1	As	as	IN
cord-021637-f5wwn45z	274	2	the	the	DT
cord-021637-f5wwn45z	274	3	DCVMN	DCVMN	NNP
cord-021637-f5wwn45z	274	4	expands	expand	VBZ
cord-021637-f5wwn45z	274	5	its	-PRON-	PRP$
cord-021637-f5wwn45z	274	6	role	role	NN
cord-021637-f5wwn45z	274	7	,	,	,
cord-021637-f5wwn45z	274	8	one	one	PRP
cord-021637-f5wwn45z	274	9	would	would	MD
cord-021637-f5wwn45z	274	10	expect	expect	VB
cord-021637-f5wwn45z	274	11	significant	significant	JJ
cord-021637-f5wwn45z	274	12	downward	downward	JJ
cord-021637-f5wwn45z	274	13	pressure	pressure	NN
cord-021637-f5wwn45z	274	14	on	on	IN
cord-021637-f5wwn45z	274	15	vaccine	vaccine	NN
cord-021637-f5wwn45z	274	16	prices	price	NNS
cord-021637-f5wwn45z	274	17	.	.	.
cord-021637-f5wwn45z	275	1	The	the	DT
cord-021637-f5wwn45z	275	2	delicate	delicate	JJ
cord-021637-f5wwn45z	275	3	balance	balance	NN
cord-021637-f5wwn45z	275	4	between	between	IN
cord-021637-f5wwn45z	275	5	innovation	innovation	NN
cord-021637-f5wwn45z	275	6	,	,	,
cord-021637-f5wwn45z	275	7	government	government	NN
cord-021637-f5wwn45z	275	8	support	support	NN
cord-021637-f5wwn45z	275	9	,	,	,
cord-021637-f5wwn45z	275	10	industrial	industrial	JJ
cord-021637-f5wwn45z	275	11	expertise	expertise	NN
cord-021637-f5wwn45z	275	12	,	,	,
cord-021637-f5wwn45z	275	13	and	and	CC
cord-021637-f5wwn45z	275	14	market	market	NN
cord-021637-f5wwn45z	275	15	forces	force	NNS
cord-021637-f5wwn45z	275	16	has	have	VBZ
cord-021637-f5wwn45z	275	17	led	lead	VBN
cord-021637-f5wwn45z	275	18	to	to	IN
cord-021637-f5wwn45z	275	19	the	the	DT
cord-021637-f5wwn45z	275	20	establishment	establishment	NN
cord-021637-f5wwn45z	275	21	of	of	IN
cord-021637-f5wwn45z	275	22	a	a	DT
cord-021637-f5wwn45z	275	23	robust	robust	JJ
cord-021637-f5wwn45z	275	24	vaccine	vaccine	NN
cord-021637-f5wwn45z	275	25	industry	industry	NN
cord-021637-f5wwn45z	275	26	that	that	WDT
cord-021637-f5wwn45z	275	27	will	will	MD
cord-021637-f5wwn45z	275	28	continue	continue	VB
cord-021637-f5wwn45z	275	29	into	into	IN
cord-021637-f5wwn45z	275	30	the	the	DT
cord-021637-f5wwn45z	275	31	future	future	NN
cord-021637-f5wwn45z	275	32	.	.	.
cord-021637-f5wwn45z	276	1	The	the	DT
cord-021637-f5wwn45z	276	2	industry	industry	NN
cord-021637-f5wwn45z	276	3	is	be	VBZ
cord-021637-f5wwn45z	276	4	changing	change	VBG
cord-021637-f5wwn45z	276	5	,	,	,
cord-021637-f5wwn45z	276	6	however	however	RB
cord-021637-f5wwn45z	276	7	,	,	,
cord-021637-f5wwn45z	276	8	with	with	IN
cord-021637-f5wwn45z	276	9	the	the	DT
cord-021637-f5wwn45z	276	10	growth	growth	NN
cord-021637-f5wwn45z	276	11	of	of	IN
cord-021637-f5wwn45z	276	12	new	new	JJ
cord-021637-f5wwn45z	276	13	markets	market	NNS
cord-021637-f5wwn45z	276	14	in	in	IN
cord-021637-f5wwn45z	276	15	emerging	emerge	VBG
cord-021637-f5wwn45z	276	16	economies	economy	NNS
cord-021637-f5wwn45z	276	17	and	and	CC
cord-021637-f5wwn45z	276	18	with	with	IN
cord-021637-f5wwn45z	276	19	the	the	DT
cord-021637-f5wwn45z	276	20	pressing	press	VBG
cord-021637-f5wwn45z	276	21	need	need	NN
cord-021637-f5wwn45z	276	22	for	for	IN
cord-021637-f5wwn45z	276	23	new	new	JJ
cord-021637-f5wwn45z	276	24	vaccines	vaccine	NNS
cord-021637-f5wwn45z	276	25	for	for	IN
cord-021637-f5wwn45z	276	26	the	the	DT
cord-021637-f5wwn45z	276	27	developing	develop	VBG
cord-021637-f5wwn45z	276	28	world	world	NN
cord-021637-f5wwn45z	276	29	.	.	.
cord-021637-f5wwn45z	277	1	The	the	DT
cord-021637-f5wwn45z	277	2	current	current	JJ
cord-021637-f5wwn45z	277	3	efforts	effort	NNS
cord-021637-f5wwn45z	277	4	of	of	IN
cord-021637-f5wwn45z	277	5	PDPs	pdp	NNS
cord-021637-f5wwn45z	277	6	and	and	CC
cord-021637-f5wwn45z	277	7	public	public	JJ
cord-021637-f5wwn45z	277	8	creation	creation	NN
cord-021637-f5wwn45z	277	9	of	of	IN
cord-021637-f5wwn45z	277	10	markets	market	NNS
cord-021637-f5wwn45z	277	11	in	in	IN
cord-021637-f5wwn45z	277	12	response	response	NN
cord-021637-f5wwn45z	277	13	to	to	IN
cord-021637-f5wwn45z	277	14	this	this	DT
cord-021637-f5wwn45z	277	15	need	need	NN
cord-021637-f5wwn45z	277	16	will	will	MD
cord-021637-f5wwn45z	277	17	be	be	VB
cord-021637-f5wwn45z	277	18	successful	successful	JJ
cord-021637-f5wwn45z	277	19	if	if	IN
cord-021637-f5wwn45z	277	20	lessons	lesson	NNS
cord-021637-f5wwn45z	277	21	learned	learn	VBN
cord-021637-f5wwn45z	277	22	from	from	IN
cord-021637-f5wwn45z	277	23	the	the	DT
cord-021637-f5wwn45z	277	24	industrial	industrial	JJ
cord-021637-f5wwn45z	277	25	vaccine	vaccine	NN
cord-021637-f5wwn45z	277	26	effort	effort	NN
cord-021637-f5wwn45z	277	27	are	be	VBP
cord-021637-f5wwn45z	277	28	incorporated	incorporate	VBN
cord-021637-f5wwn45z	277	29	into	into	IN
cord-021637-f5wwn45z	277	30	these	these	DT
cord-021637-f5wwn45z	277	31	government	government	NN
cord-021637-f5wwn45z	277	32	and	and	CC
cord-021637-f5wwn45z	277	33	philanthropically	philanthropically	RB
cord-021637-f5wwn45z	277	34	driven	drive	VBN
cord-021637-f5wwn45z	277	35	expectations	expectation	NNS
cord-021637-f5wwn45z	277	36	.	.	.
cord-021637-f5wwn45z	278	1	Estimates	estimate	NNS
cord-021637-f5wwn45z	278	2	of	of	IN
cord-021637-f5wwn45z	278	3	the	the	DT
cord-021637-f5wwn45z	278	4	total	total	JJ
cord-021637-f5wwn45z	278	5	worldwide	worldwide	JJ
cord-021637-f5wwn45z	278	6	vaccine	vaccine	NN
cord-021637-f5wwn45z	278	7	market	market	NN
cord-021637-f5wwn45z	278	8	revenue	revenue	NN
cord-021637-f5wwn45z	278	9	are	be	VBP
cord-021637-f5wwn45z	278	10	$	$	$
cord-021637-f5wwn45z	278	11	25	25	CD
cord-021637-f5wwn45z	278	12	billion	billion	CD
cord-021637-f5wwn45z	278	13	.	.	.
cord-021637-f5wwn45z	279	1	The	the	DT
cord-021637-f5wwn45z	279	2	top	top	JJ
cord-021637-f5wwn45z	279	3	four	four	CD
cord-021637-f5wwn45z	279	4	Western	western	JJ
cord-021637-f5wwn45z	279	5	suppliers	supplier	NNS
cord-021637-f5wwn45z	279	6	(	(	-LRB-
cord-021637-f5wwn45z	279	7	see	see	VB
cord-021637-f5wwn45z	279	8	Table	table	NN
cord-021637-f5wwn45z	279	9	4	4	CD
cord-021637-f5wwn45z	279	10	.1	.1	CD
cord-021637-f5wwn45z	279	11	)	)	-RRB-
cord-021637-f5wwn45z	280	1	account	account	VBP
cord-021637-f5wwn45z	280	2	for	for	IN
cord-021637-f5wwn45z	280	3	approximately	approximately	RB
cord-021637-f5wwn45z	280	4	85	85	CD
cord-021637-f5wwn45z	280	5	%	%	NN
cord-021637-f5wwn45z	280	6	of	of	IN
cord-021637-f5wwn45z	280	7	these	these	DT
cord-021637-f5wwn45z	280	8	sales	sale	NNS
cord-021637-f5wwn45z	280	9	;	;	:
cord-021637-f5wwn45z	280	10	the	the	DT
cord-021637-f5wwn45z	280	11	remainder	remainder	NN
cord-021637-f5wwn45z	280	12	comes	come	VBZ
cord-021637-f5wwn45z	280	13	from	from	IN
cord-021637-f5wwn45z	280	14	regional	regional	JJ
cord-021637-f5wwn45z	280	15	vaccine	vaccine	NN
cord-021637-f5wwn45z	280	16	companies	company	NNS
cord-021637-f5wwn45z	280	17	,	,	,
cord-021637-f5wwn45z	280	18	the	the	DT
cord-021637-f5wwn45z	280	19	largest	large	JJS
cord-021637-f5wwn45z	280	20	of	of	IN
cord-021637-f5wwn45z	280	21	which	which	WDT
cord-021637-f5wwn45z	280	22	are	be	VBP
cord-021637-f5wwn45z	280	23	located	locate	VBN
cord-021637-f5wwn45z	280	24	in	in	IN
cord-021637-f5wwn45z	280	25	middle	middle	JJ
cord-021637-f5wwn45z	280	26	-	-	HYPH
cord-021637-f5wwn45z	280	27	income	income	NN
cord-021637-f5wwn45z	280	28	countries	country	NNS
cord-021637-f5wwn45z	280	29	such	such	JJ
cord-021637-f5wwn45z	280	30	as	as	IN
cord-021637-f5wwn45z	280	31	India	India	NNP
cord-021637-f5wwn45z	280	32	,	,	,
cord-021637-f5wwn45z	280	33	China	China	NNP
cord-021637-f5wwn45z	280	34	,	,	,
cord-021637-f5wwn45z	280	35	and	and	CC
cord-021637-f5wwn45z	280	36	Brazil	Brazil	NNP
cord-021637-f5wwn45z	280	37	(	(	-LRB-
cord-021637-f5wwn45z	280	38	see	see	UH
cord-021637-f5wwn45z	280	39	Table	table	NN
cord-021637-f5wwn45z	280	40	4	4	CD
cord-021637-f5wwn45z	280	41	.5	.5	CD
cord-021637-f5wwn45z	280	42	)	)	-RRB-
cord-021637-f5wwn45z	280	43	.	.	.
cord-021637-f5wwn45z	281	1	The	the	DT
cord-021637-f5wwn45z	281	2	top	top	JJ
cord-021637-f5wwn45z	281	3	four	four	CD
cord-021637-f5wwn45z	281	4	companies	company	NNS
cord-021637-f5wwn45z	281	5	are	be	VBP
cord-021637-f5wwn45z	281	6	slowly	slowly	RB
cord-021637-f5wwn45z	281	7	losing	lose	VBG
cord-021637-f5wwn45z	281	8	market	market	NN
cord-021637-f5wwn45z	281	9	share	share	NN
cord-021637-f5wwn45z	281	10	in	in	IN
cord-021637-f5wwn45z	281	11	doses	dose	NNS
cord-021637-f5wwn45z	281	12	to	to	IN
cord-021637-f5wwn45z	281	13	the	the	DT
cord-021637-f5wwn45z	281	14	DCVMN	DCVMN	NNP
cord-021637-f5wwn45z	281	15	sourced	source	VBN
cord-021637-f5wwn45z	281	16	doses	dose	NNS
cord-021637-f5wwn45z	281	17	and	and	CC
cord-021637-f5wwn45z	281	18	when	when	WRB
cord-021637-f5wwn45z	281	19	polio	polio	NN
cord-021637-f5wwn45z	281	20	eradication	eradication	NN
cord-021637-f5wwn45z	281	21	is	be	VBZ
cord-021637-f5wwn45z	281	22	achieved	achieve	VBN
cord-021637-f5wwn45z	281	23	their	-PRON-	PRP$
cord-021637-f5wwn45z	281	24	dose	dose	NN
cord-021637-f5wwn45z	281	25	share	share	NN
cord-021637-f5wwn45z	281	26	will	will	MD
cord-021637-f5wwn45z	281	27	drop	drop	VB
cord-021637-f5wwn45z	281	28	to	to	IN
cord-021637-f5wwn45z	281	29	less	less	JJR
cord-021637-f5wwn45z	281	30	than	than	IN
cord-021637-f5wwn45z	281	31	20	20	CD
cord-021637-f5wwn45z	281	32	%	%	NN
cord-021637-f5wwn45z	281	33	of	of	IN
cord-021637-f5wwn45z	281	34	worldwide	worldwide	JJ
cord-021637-f5wwn45z	281	35	dose	dose	NN
cord-021637-f5wwn45z	281	36	volume	volume	NN
cord-021637-f5wwn45z	281	37	.	.	.
cord-021637-f5wwn45z	282	1	In	in	IN
cord-021637-f5wwn45z	282	2	the	the	DT
cord-021637-f5wwn45z	282	3	coming	come	VBG
cord-021637-f5wwn45z	282	4	years	year	NNS
cord-021637-f5wwn45z	282	5	,	,	,
cord-021637-f5wwn45z	282	6	as	as	IN
cord-021637-f5wwn45z	282	7	the	the	DT
cord-021637-f5wwn45z	282	8	eradication	eradication	NN
cord-021637-f5wwn45z	282	9	of	of	IN
cord-021637-f5wwn45z	282	10	polio	polio	NN
cord-021637-f5wwn45z	282	11	becomes	become	VBZ
cord-021637-f5wwn45z	282	12	a	a	DT
cord-021637-f5wwn45z	282	13	reality	reality	NN
cord-021637-f5wwn45z	282	14	,	,	,
cord-021637-f5wwn45z	282	15	the	the	DT
cord-021637-f5wwn45z	282	16	developing	develop	VBG
cord-021637-f5wwn45z	282	17	country	country	NN
cord-021637-f5wwn45z	282	18	manufacturers	manufacturer	NNS
cord-021637-f5wwn45z	282	19	will	will	MD
cord-021637-f5wwn45z	282	20	phase	phase	VB
cord-021637-f5wwn45z	282	21	out	out	RP
cord-021637-f5wwn45z	282	22	their	-PRON-	PRP$
cord-021637-f5wwn45z	282	23	oral	oral	JJ
cord-021637-f5wwn45z	282	24	polio	polio	NN
cord-021637-f5wwn45z	282	25	vaccine	vaccine	NN
cord-021637-f5wwn45z	282	26	production	production	NN
cord-021637-f5wwn45z	282	27	.	.	.
cord-021637-f5wwn45z	283	1	However	however	RB
cord-021637-f5wwn45z	283	2	,	,	,
cord-021637-f5wwn45z	283	3	the	the	DT
cord-021637-f5wwn45z	283	4	need	need	NN
cord-021637-f5wwn45z	283	5	for	for	IN
cord-021637-f5wwn45z	283	6	inactivated	inactivate	VBN
cord-021637-f5wwn45z	283	7	polio	polio	NN
cord-021637-f5wwn45z	283	8	vaccine	vaccine	NN
cord-021637-f5wwn45z	283	9	will	will	MD
cord-021637-f5wwn45z	283	10	grow	grow	VB
cord-021637-f5wwn45z	283	11	as	as	IN
cord-021637-f5wwn45z	283	12	developing	develop	VBG
cord-021637-f5wwn45z	283	13	countries	country	NNS
cord-021637-f5wwn45z	283	14	adopt	adopt	VBP
cord-021637-f5wwn45z	283	15	it	-PRON-	PRP
cord-021637-f5wwn45z	283	16	into	into	IN
cord-021637-f5wwn45z	283	17	their	-PRON-	PRP$
cord-021637-f5wwn45z	283	18	pediatric	pediatric	JJ
cord-021637-f5wwn45z	283	19	immunization	immunization	NN
cord-021637-f5wwn45z	283	20	plans	plan	NNS
cord-021637-f5wwn45z	283	21	.	.	.
cord-021637-f5wwn45z	284	1	As	as	IN
cord-021637-f5wwn45z	284	2	the	the	DT
cord-021637-f5wwn45z	284	3	demand	demand	NN
cord-021637-f5wwn45z	284	4	for	for	IN
cord-021637-f5wwn45z	284	5	injected	inject	VBN
cord-021637-f5wwn45z	284	6	Assuming	assume	VBG
cord-021637-f5wwn45z	284	7	such	such	JJ
cord-021637-f5wwn45z	284	8	vaccines	vaccine	NNS
cord-021637-f5wwn45z	284	9	become	become	VBP
cord-021637-f5wwn45z	284	10	reality	reality	NN
cord-021637-f5wwn45z	284	11	,	,	,
cord-021637-f5wwn45z	284	12	there	there	EX
cord-021637-f5wwn45z	284	13	is	be	VBZ
cord-021637-f5wwn45z	284	14	little	little	JJ
cord-021637-f5wwn45z	284	15	doubt	doubt	NN
cord-021637-f5wwn45z	284	16	that	that	IN
cord-021637-f5wwn45z	284	17	the	the	DT
cord-021637-f5wwn45z	284	18	international	international	JJ
cord-021637-f5wwn45z	284	19	donor	donor	NN
cord-021637-f5wwn45z	284	20	community	community	NN
cord-021637-f5wwn45z	284	21	,	,	,
cord-021637-f5wwn45z	284	22	working	work	VBG
cord-021637-f5wwn45z	284	23	through	through	IN
cord-021637-f5wwn45z	284	24	organizations	organization	NNS
cord-021637-f5wwn45z	284	25	such	such	JJ
cord-021637-f5wwn45z	284	26	as	as	IN
cord-021637-f5wwn45z	284	27	the	the	DT
cord-021637-f5wwn45z	284	28	Global	Global	NNP
cord-021637-f5wwn45z	284	29	Alliance	Alliance	NNP
cord-021637-f5wwn45z	284	30	for	for	IN
cord-021637-f5wwn45z	284	31	Vaccines	Vaccines	NNPS
cord-021637-f5wwn45z	284	32	and	and	CC
cord-021637-f5wwn45z	284	33	Immunization	Immunization	NNP
cord-021637-f5wwn45z	284	34	,	,	,
cord-021637-f5wwn45z	284	35	will	will	MD
cord-021637-f5wwn45z	284	36	provide	provide	VB
cord-021637-f5wwn45z	284	37	adequate	adequate	JJ
cord-021637-f5wwn45z	284	38	funds	fund	NNS
cord-021637-f5wwn45z	284	39	for	for	IN
cord-021637-f5wwn45z	284	40	purchase	purchase	NN
cord-021637-f5wwn45z	284	41	of	of	IN
cord-021637-f5wwn45z	284	42	effective	effective	JJ
cord-021637-f5wwn45z	284	43	malaria	malaria	NN
cord-021637-f5wwn45z	284	44	,	,	,
cord-021637-f5wwn45z	284	45	HIV	HIV	NNP
cord-021637-f5wwn45z	284	46	,	,	,
cord-021637-f5wwn45z	284	47	and	and	CC
cord-021637-f5wwn45z	284	48	TB	TB	NNP
cord-021637-f5wwn45z	284	49	vaccines	vaccine	NNS
cord-021637-f5wwn45z	284	50	,	,	,
cord-021637-f5wwn45z	284	51	all	all	DT
cord-021637-f5wwn45z	284	52	of	of	IN
cord-021637-f5wwn45z	284	53	which	which	WDT
cord-021637-f5wwn45z	284	54	are	be	VBP
cord-021637-f5wwn45z	284	55	cost	cost	NN
cord-021637-f5wwn45z	284	56	-	-	HYPH
cord-021637-f5wwn45z	284	57	effective	effective	JJ
cord-021637-f5wwn45z	284	58	REFERENCES	reference	NNS
cord-021637-f5wwn45z	284	59	1	1	CD
cord-021637-f5wwn45z	284	60	.	.	.
cord-021637-f5wwn45z	285	1	Company	company	NN
cord-021637-f5wwn45z	285	2	2013	2013	CD
cord-021637-f5wwn45z	285	3	year	year	NN
cord-021637-f5wwn45z	285	4	-	-	HYPH
cord-021637-f5wwn45z	285	5	end	end	NN
cord-021637-f5wwn45z	285	6	earnings	earning	NNS
cord-021637-f5wwn45z	285	7	releases	release	NNS
cord-021637-f5wwn45z	285	8	from	from	IN
cord-021637-f5wwn45z	285	9	Evaluate	evaluate	VB
cord-021637-f5wwn45z	285	10	Pharma	Pharma	NNP
cord-021637-f5wwn45z	285	11	New	new	JJ
cord-021637-f5wwn45z	285	12	scientific	scientific	JJ
cord-021637-f5wwn45z	285	13	opportunities	opportunity	NNS
cord-021637-f5wwn45z	285	14	and	and	CC
cord-021637-f5wwn45z	285	15	old	old	JJ
cord-021637-f5wwn45z	285	16	obstacles	obstacle	NNS
cord-021637-f5wwn45z	285	17	in	in	IN
cord-021637-f5wwn45z	285	18	vaccine	vaccine	NN
cord-021637-f5wwn45z	285	19	development	development	NN
cord-021637-f5wwn45z	285	20	Immunizing	immunize	VBG
cord-021637-f5wwn45z	285	21	children	child	NNS
cord-021637-f5wwn45z	285	22	:	:	:
cord-021637-f5wwn45z	285	23	can	can	MD
cord-021637-f5wwn45z	285	24	one	one	CD
cord-021637-f5wwn45z	285	25	shot	shot	NN
cord-021637-f5wwn45z	285	26	do	do	VB
cord-021637-f5wwn45z	285	27	it	-PRON-	PRP
cord-021637-f5wwn45z	285	28	all	all	DT
cord-021637-f5wwn45z	285	29	?	?	.
cord-021637-f5wwn45z	286	1	In	in	IN
cord-021637-f5wwn45z	286	2	:	:	:
cord-021637-f5wwn45z	286	3	Medical	Medical	NNP
cord-021637-f5wwn45z	286	4	and	and	CC
cord-021637-f5wwn45z	286	5	Health	Health	NNP
cord-021637-f5wwn45z	286	6	Annual	Annual	NNP
cord-021637-f5wwn45z	286	7	Public	Public	NNP
cord-021637-f5wwn45z	286	8	health	health	NN
cord-021637-f5wwn45z	286	9	:	:	:
cord-021637-f5wwn45z	286	10	U.S.	U.S.	NNP
cord-021637-f5wwn45z	286	11	vaccine	vaccine	NN
cord-021637-f5wwn45z	286	12	Supply	Supply	NNP
cord-021637-f5wwn45z	286	13	falls	fall	VBZ
cord-021637-f5wwn45z	286	14	seriously	seriously	RB
cord-021637-f5wwn45z	286	15	short	short	JJ
cord-021637-f5wwn45z	286	16	Lessons	Lessons	NNPS
cord-021637-f5wwn45z	286	17	learned	learn	VBD
cord-021637-f5wwn45z	286	18	from	from	IN
cord-021637-f5wwn45z	286	19	a	a	DT
cord-021637-f5wwn45z	286	20	review	review	NN
cord-021637-f5wwn45z	286	21	of	of	IN
cord-021637-f5wwn45z	286	22	the	the	DT
cord-021637-f5wwn45z	286	23	development	development	NN
cord-021637-f5wwn45z	286	24	of	of	IN
cord-021637-f5wwn45z	286	25	selected	select	VBN
cord-021637-f5wwn45z	286	26	vaccines	vaccine	NNS
cord-021637-f5wwn45z	286	27	.	.	.
cord-021637-f5wwn45z	287	1	National	National	NNP
cord-021637-f5wwn45z	287	2	Vaccine	Vaccine	NNP
cord-021637-f5wwn45z	287	3	Advisory	Advisory	NNP
cord-021637-f5wwn45z	287	4	Committee	Committee	NNP
cord-021637-f5wwn45z	287	5	Vaccine	Vaccine	NNP
cord-021637-f5wwn45z	287	6	development	development	NN
cord-021637-f5wwn45z	287	7	:	:	:
cord-021637-f5wwn45z	287	8	the	the	DT
cord-021637-f5wwn45z	287	9	long	long	JJ
cord-021637-f5wwn45z	287	10	road	road	NN
cord-021637-f5wwn45z	287	11	from	from	IN
cord-021637-f5wwn45z	287	12	initial	initial	JJ
cord-021637-f5wwn45z	287	13	idea	idea	NN
cord-021637-f5wwn45z	287	14	to	to	IN
cord-021637-f5wwn45z	287	15	product	product	NN
cord-021637-f5wwn45z	287	16	licensure	licensure	NN
cord-021637-f5wwn45z	287	17	Cost	cost	NN
cord-021637-f5wwn45z	287	18	of	of	IN
cord-021637-f5wwn45z	287	19	new	new	JJ
cord-021637-f5wwn45z	287	20	drug	drug	NN
cord-021637-f5wwn45z	287	21	development	development	NN
cord-021637-f5wwn45z	287	22	Spending	spend	VBG
cord-021637-f5wwn45z	287	23	on	on	IN
cord-021637-f5wwn45z	287	24	new	new	JJ
cord-021637-f5wwn45z	287	25	drug	drug	NN
cord-021637-f5wwn45z	287	26	development	development	NN
cord-021637-f5wwn45z	288	1	United	United	NNP
cord-021637-f5wwn45z	288	2	States	States	NNP
cord-021637-f5wwn45z	288	3	vaccine	vaccine	NN
cord-021637-f5wwn45z	288	4	research	research	NN
cord-021637-f5wwn45z	288	5	:	:	:
cord-021637-f5wwn45z	288	6	a	a	DT
cord-021637-f5wwn45z	288	7	delicate	delicate	JJ
cord-021637-f5wwn45z	288	8	fabric	fabric	NN
cord-021637-f5wwn45z	288	9	of	of	IN
cord-021637-f5wwn45z	288	10	political	political	JJ
cord-021637-f5wwn45z	288	11	and	and	CC
cord-021637-f5wwn45z	288	12	private	private	JJ
cord-021637-f5wwn45z	288	13	collaboration	collaboration	NN
cord-021637-f5wwn45z	288	14	.	.	.
cord-021637-f5wwn45z	289	1	National	National	NNP
cord-021637-f5wwn45z	289	2	Vaccine	Vaccine	NNP
cord-021637-f5wwn45z	289	3	Advisory	Advisory	NNP
cord-021637-f5wwn45z	289	4	Committee	Committee	NNP
cord-021637-f5wwn45z	289	5	Influenza	Influenza	NNP
cord-021637-f5wwn45z	289	6	vaccine	vaccine	NN
cord-021637-f5wwn45z	289	7	manufacturers	manufacturer	NNS
cord-021637-f5wwn45z	289	8	Testimony	testimony	NN
cord-021637-f5wwn45z	289	9	on	on	IN
cord-021637-f5wwn45z	289	10	vaccine	vaccine	NN
cord-021637-f5wwn45z	289	11	policy	policy	NN
cord-021637-f5wwn45z	289	12	before	before	IN
cord-021637-f5wwn45z	289	13	the	the	DT
cord-021637-f5wwn45z	289	14	U.S.	U.S.	NNP
cord-021637-f5wwn45z	289	15	House	House	NNP
cord-021637-f5wwn45z	289	16	of	of	IN
cord-021637-f5wwn45z	289	17	Representatives	Representatives	NNP
cord-021637-f5wwn45z	289	18	Committee	Committee	NNP
cord-021637-f5wwn45z	289	19	on	on	IN
cord-021637-f5wwn45z	289	20	Commerce	Commerce	NNP
cord-021637-f5wwn45z	289	21	Vaccine	Vaccine	NNP
cord-021637-f5wwn45z	289	22	advance	advance	NN
cord-021637-f5wwn45z	289	23	-	-	HYPH
cord-021637-f5wwn45z	289	24	purchase	purchase	NN
cord-021637-f5wwn45z	289	25	agreements	agreement	NNS
cord-021637-f5wwn45z	289	26	for	for	IN
cord-021637-f5wwn45z	289	27	low	low	JJ
cord-021637-f5wwn45z	289	28	income	income	NN
cord-021637-f5wwn45z	289	29	countries	country	NNS
cord-021637-f5wwn45z	289	30	:	:	:
cord-021637-f5wwn45z	289	31	practical	practical	JJ
cord-021637-f5wwn45z	289	32	issues	issue	NNS
cord-021637-f5wwn45z	290	1	Improving	improve	VBG
cord-021637-f5wwn45z	290	2	vaccine	vaccine	NN
cord-021637-f5wwn45z	290	3	supply	supply	NN
cord-021637-f5wwn45z	290	4	and	and	CC
cord-021637-f5wwn45z	290	5	development	development	NN
cord-021637-f5wwn45z	290	6	:	:	:
cord-021637-f5wwn45z	290	7	who	who	WP
cord-021637-f5wwn45z	290	8	needs	need	VBZ
cord-021637-f5wwn45z	290	9	what	what	WP
cord-021637-f5wwn45z	290	10	?	?	.
cord-021637-f5wwn45z	291	1	Vaccines	vaccine	NNS
cord-021637-f5wwn45z	291	2	Market	Market	NNP
cord-021637-f5wwn45z	291	3	in	in	IN
cord-021637-f5wwn45z	291	4	India	India	NNP
cord-021637-f5wwn45z	291	5	China	China	NNP
cord-021637-f5wwn45z	291	6	's	's	POS
cord-021637-f5wwn45z	291	7	growing	grow	VBG
cord-021637-f5wwn45z	291	8	biomedical	biomedical	JJ
cord-021637-f5wwn45z	291	9	industry	industry	NN
cord-021637-f5wwn45z	291	10	China	China	NNP
cord-021637-f5wwn45z	291	11	's	's	POS
cord-021637-f5wwn45z	291	12	emerging	emerge	VBG
cord-021637-f5wwn45z	291	13	vaccine	vaccine	NN
cord-021637-f5wwn45z	291	14	industry	industry	NN
cord-021637-f5wwn45z	291	15	Special	special	JJ
cord-021637-f5wwn45z	291	16	thanks	thank	NNS
cord-021637-f5wwn45z	291	17	to	to	IN
cord-021637-f5wwn45z	291	18	Andrew	Andrew	NNP
cord-021637-f5wwn45z	291	19	Hopkins	Hopkins	NNP
cord-021637-f5wwn45z	291	20	for	for	IN
cord-021637-f5wwn45z	291	21	compositional	compositional	JJ
cord-021637-f5wwn45z	291	22	support	support	NN
cord-021637-f5wwn45z	291	23	.	.	.